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The synthetic progestogens, medroxyprogesterone acetate (MPA) and norethisterone enanthate (NET-EN), 
are widely used in developing countries as injectable contraceptives, where disease burden is high. 
Levonorgestrel (LNG) is a common progestogen used in oral contraceptives and intrauterine devices. Some 
studies suggest that MPA, unlike NET, increases HIV-1 acquisition in women, while few studies have 
reported on the effects of LNG on HIV-1 acquisition. Whether MPA, NET and LNG differentially affect HIV-1 
infection and the expression of key genes relevant to HIV-1 acquisition via differential molecular 
mechanisms is key to understanding choice of progestogen contraceptive in young women at high risk for 
HIV-1 acquisition.  
 
The central hypothesis of this study is that the differential effects on host gene expression and HIV-1 
replication by the different progestogens is due to their differential selectivity to towards different steroid 
receptors, in particular the glucocorticoid receptor (GR). In order to investigate this hypothesis, the 
regulation of selected genes was investigated in cervical tissue explants from premenopausal, HIV-1 
negative, and contraception negative women and peripheral blood mononuclear cells (PBMCs) from 
women, by real time quantitative PCR, western blotting and Luminex assays, in response to physiologically 
relevant doses of progestogens. Infection assays were performed in the absence and presence of HIV-1 
using HIV-1BAL-RENILLA or HIVpNL4.3 infectious molecular clones (IMCs). The GR antagonist RU486 or GR 
siRNA knockdown was used to determine the role of the GR in modulating ligand-specific effects. 
 
PBMCs and primary cervical explants were chosen as useful models to assess the direct effects of these 
progestogens in both the systemic and in the local mucosal immune environments. In PBMCs, MPA like 
dexamethasone (DEX, a GR specific agonist), showed anti-inflammatory effects, decreasing pro-
inflammatory interleukin (IL) 6, IL8 and regulated upon activation, normal T cell expressed and secreted 
(RANTES) levels and increasing anti-inflammatory glucocorticoid interacting leucine zipper (GILZ) gene 
expression levels, while NET, progesterone (P4) and LNG did not, after 48 hours. In primary ectocervical 
tissue explants, DEX, cortisol, MPA and P4 significantly repressed IL6 while only DEX, cortisol and MPA 
significantly repressed IL8 and increased GILZ gene expression levels after 48 hours. Steroid receptor 
expression was characterised in both PBMCs and ectocervical explants. GR was the only detectable 
steroid receptor protein expressed in PBMCs, while ectocervical explants expressed all the steroid 
receptors. The progesterone and estrogen receptor levels were higher in ectocervical explants from donors 
that were in the follicular phase compared to ectocervical explants from donors in the luteal phase of the 
menstrual cycle. In PBMCs, results suggested that differential gene expression by MPA versus NET and P4 
is mediated via the GR after 48 hours. Furthermore, it was observed that MPA and DEX, unlike NET, LNG 
and P4 increases HIV-1 replication in viable PBMCs, in the majority of donors. The increase in HIV-1 
replication in the MPA treated PBMC samples correlated significantly with an increased in IL6 mRNA levels. 
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Interestingly, IL6 mRNA expression was significantly elevated by MPA in 7 out of 10 of the donor samples, 
in the absence and presence of HIV-1BaL-Renilla after 9 days, in PBMCs. IL6, IL8 and RANTES repression by 
DEX and MPA after 48 hours was lost after 3 – 7 days of hormonal incubation, while GILZ mRNA 
upregulation was maintained in PBMCs. Although the mechanism whereby MPA- and DEX- dependent 
repression of IL6, IL8 and RANTES mRNA expression in PBMCs is lost is yet to be determined, the results 
suggest that time of exposure to MPA could determine whether anti- or pro-inflammatory effects occur.  
 
In primary cervical explants, MPA, but not NET increased HIVpNL4.3 replication in 5 out of 8 donor samples, 
and increased HIV-1BaL-Renilla replication in 3 out 6 donor explant samples. The data suggest that MPA 
exhibits differential and direct effects on HIV-1 replication in primary cervical explants, with the majority of 
donor samples showing an increase in HIV-1 replication with MPA, but not NET, similar in vivo effects 
reported in some observational studies. 
  
The results suggest that MPA, unlike NET and LNG, is likely to exert significant effects on host 
immunomodulatory gene expression and HIV-1 replication, at peak serum concentrations in contraceptive 
users, directly on cells and tissue in both the systemic and local mucosal environments. Collectively, the 
data suggest that NET, unlike MPA, would be a safer choice of injectable progestin contraceptive in young 
women in high risk areas for HIV-1 infection. Additionally, this study suggests that LNG has a lower risk 
profile in comparison to MPA, but similar to NET. The molecular basis for this choice most likely involves 
differential effects of MPA as compared to NET and P4, on transcription of immunomodulatory genes, due 
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The thesis is comprised of six chapters, of which two are results chapters, as well as five appendices. 
Chapter 1: Progestogens, Immunity and HIV-1 infection: The role of progestin contraceptives and 
endogenous P4 on immunomodulatory gene regulation and HIV-1 acquisition. This chapter is a 
literature review and gives a brief overview on the different types progestogens used in contraception and 
their differential mechanisms of actions through different steroid receptors, particularly the glucocorticoid 
receptor (GR). This review focuses on three progestogens, medroxyprogesterone acetate (MPA), 
norethisterone acetate (NET-A) and levonorgestrel (LNG). Furthermore the review focuses on the current 
knowledge of the different progestins and their effects on disease susceptibility, particularly, HIV-1, and 
immune gene function in both the systemic and local genital mucosa immune environments. This chapter 
also outlines the research aims and hypotheses of this current study. 
 
Chapter 2: Methods and Materials. This chapter provides detailed technical methodology used to obtain 
the results in the research chapters. 
 
Chapter 3: MPA, unlike NET, P4 and LNG, regulates immunomodulatory gene expression via the 
GR and increases HIV-1 replication in the majority of primary human PBMCS. This chapter focuses 
on the differential regulation of select immunomodulatory genes by the different progestogens (MPA, P4, 
NET and LNG) and a glucocorticoid (DEX) over time in PBMCs. This chapter also investigates the role of 
the GR in mediating some of these responses. Furthermore, this chapter investigates the direct effects of 
these progestogens on HIV-1 replication in PBMCs. 
 
Chapter 4: The effects of progestogens on immunomodulatory gene expression and HIV-1 
replication ex vivo in human cervical explants. This chapter focuses on the effects of different 
progestogens (MPA, P4, NET and LNG) and glucocorticoids (DEX and CORT) on immune gene expression 
in cervical explants that are models for the local mucosa. This chapter also investigates the role of the 
menstrual cycle on regulating the steroid receptors as well the effects of progestogens on SR mRNA 
expression. Furthermore this chapter investigates the direct effects of the progestins MPA and NET on HIV-
1 replication in tissue explants. 
 
Chapter 5: Conclusions and Future Perspectives. This chapter synthesizes the results from chapters 3 
and 4 and draws conclusions in the context of the field. Suggestions into future research on these topics 
are also discussed. 
 






Appendix A: Supplementary Data. This appendix consists of relevant supplementary data used to 
support the findings in chapters 3 and 4. 
 
Appendix B: Repeated Measure two way ANOVA analysis for ectocervical explant HIV-1 infection 
time course analysis. This appendix contains the statistical output used to analyse the effects of HIV-1 
replication over time in chapter 4. 
 
Appendix C: Donor Information. This appendix provides a table with detailed information on the donors 
used in chapter 4, including hormone levels, age, HSV-1, HSV-2, HIV-1 and HPV status. Additionally the 
table provided the information on what experiments in chapter 4 were performed on each donor’s tissue.  
 
Appendix D: Buffers and Solutions. This appendix provides details for common solutions used 
throughout the study and mentioned in chapter 2. 
 
Appendix E: Optimisation results used to determine the methodology employed in this study. This 
appendix provides information on the steps used to determine the optimal conditions used in this study in 
both chapters 3 and 4. 
 
Appendix F: Research articles. This appendix contains PDF versions of the research articles co-authored 
by the candidate and listed below. 
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Heterosexual transmission of HIV-1 accounts for the majority of infections in women (Padian et al., 1991; 
Padian et al., 1997). In Sub-Saharan Africa, 59% of all those infected are women (World Health 
Organisation, 2011). While vaginal intercourse has a low rate of transmission, it contributes to more new 
cases of HIV than any other type of transmission (Hladik & Hope, 2009). Currently, there is an on-going and 
contentious debate whether hormonal contraceptives may increase HIV-1 acquisition in women. Synthetic 
progestins, such as medroxyprogesterone acetate (MPA) or Depo-Provera and norethisterone enanthate 
(NET-EN) or Nuristerate, are used worldwide as injectable contraceptives. These contraceptives, along with 
other contraceptive methods provide important health benefits and empowerment to women globally (World 
Health Organisation, 2014b). In sub-Saharan Africa, 11 million women use injectable contraceptives 
(United Nations, Department of Economic and Social Affairs, Population Division, 2011), particularly in 
areas with high HIV-1 prevalence (Morrison et al., 2012). Thus identifying whether injectable or other 
hormonal contraception methods increases the risk of HIV-1 acquisition in women is imperative and of 
great public health importance.  
1.1. Progesterone and Progestin Contraceptives  
 
The menstrual cycle is under control of a gonadotropin releasing hormone (GnRH) pulsatile signal from the 
hypothalamus, as part of the hypothalamic-pituitary-gonadal axis (HPG) (Wira et al., 2015). Gonadotropin 
releasing hormone cells of the pituitary, secrete luteinising hormone (LH) and follicle-stimulating hormone 
(FSH) (Chabbert-Buffet & Bouchard, 2002). The menstrual cycle consists of several different phases; the 
follicular, the ovulatory and the luteal phase. The follicular phase refers to the phase of growth of a single 
follicle, governed by FSH stimulation, with increasing amounts of estrogen (E2) being secreted (Wira et al., 
2015). During this phase, the follicle reorganises to become the corpus luteum, and the epithelial cells 
proliferate in the endometrium, under the control of E2 (Wira et al., 2010). Ovulation is triggered by an LH 
surge, which occurs mid-cycle. After ovulation, the corpus luteum secretes E2 and progesterone (P4) under 
the control of LH (Wira et al., 2015), signalling the second phase of the menstrual cycle, known as the luteal 
phase. During this phase, epithelial cells of the endometrium differentiate under the control of P4 into 
secretory cells, also known as the secretory phase (Sitruk-Ware et al., 2013). In the absence of pregnancy, 
the corpus luteum regresses and E2 and P4 secretion decreases. The endometrium sheds leading to 
menstruation, and FSH levels increase, initiating a new cycle (Chabbert-Buffet & Bouchard, 2002). 
Progesterone (P4) is the natural progestin in humans, and is integral for female reproductive function. The 
concentration of P4 will either lead to inhibition of or activation of ovulation (Stanczyk, 2002). A decrease in 
the concentration of progesterone leads to menstruation and endometrial repair, while increased levels lead 
to the inhibition of ovulation during pregnancy (Critchley et al., 2003). It is this quality that makes P4 an 
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ideal contraceptive candidate. However due to progesterone’s short half-life; synthetic progestins were 
designed to provide both the inhibitory effect of progesterone and maintaining a long half-life in vivo 
(Hapgood et al., 2004; Africander et al., 2011). As such, progestins or progestogens (when including both 
synthetic and the natural hormone P4) are defined as compounds that have pro-gestational activity 
(Stanczyk et al., 2013). That is, progestogens are able to maintain pregnancy and transform the 
endometrium to a secretory phase to support gestation (Stanczyk et al., 2013). Progestogens also prevent 
the over-proliferation of the endometrial tissue and are used to counteract the proliferative effects of 
estrogen (Stanczyk et al., 2013; Akison & Robker, 2012). However the extent to which the progestin may 
exert this effect is based on its anti-estrogenic properties, as well as the dose and duration of the treatment 
(Sitruk-Ware, 2006b).  
Over the years, many progestins have been designed. Of interest to this study, are the synthetic progestins 
used most often as injectable contraceptives, medroxyprogesterone acetate (MPA) and norethisterone 
enanthate (NET-EN) and the progestin levonorgestrel (LNG) used in combined oral contraceptives or in 
intrauterine devices (Sitruk-Ware, 2006a). Their structures are depicted in Figure 1.1. 
 
   
 
Figure 1.1: Structures of the progestogens. (A) The natural endogenous hormone, progesterone (P4), 
(B) first generation, progesterone derivative, medroxyprogesterone acetate (MPA), (C) first generation 
testosterone derivative, norethisterone acetate (NET-A) and (D) second generation testosterone derivative, 
levonorgestrel (LNG) (Stanczyk et al., 2013). 
 
MPA, administered for contraception as Depo-MPA (DMPA) or Depo-Provera, is a 150 mg three-monthly 
intramuscular injection that is used by millions of women worldwide (Drey & Darney, 2002), particularly in 
Sub-Saharan Africa with high HIV-1 prevalence (Morrison et al., 2012). MPA is a first generation progestin, 
that is one of the first synthetic progestins synthesised, and is a progesterone derivative belonging to the 
pregnane group of progestins (Stanczyk, 2003). The benefits of MPA as a contraceptive include its high 
efficacy and safety (Drey & Darney, 2002).  
Norethisterone enanthate (NET-EN) is a 200 mg two-monthly injectable that is used less than MPA, 
although its usage is high in some regions of South Africa (Smit & Beksinska, 2013). NET-A is a 
testosterone derivative, belonging to the estrane group of progestins (Stanczyk, 2002). However being a 
derivative of testosterone, it has the ability to exert some androgenic effects via the androgen receptor (AR) 
(Sitruk-Ware & Nath, 2013). However, these effects are reduced due to the chemical modifications 
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performed to make NET-A (Stanczyk et al., 2013). Interestingly, NET-A has been shown to convert to 
ethinyl estradiol (EE) and can exert some estrogenic effects. However this is concentration dependent, as 
the conversion rate is low (Sitruk-Ware & Nath, 2013). This is the only known progestogen that exhibits any 
estrogenic effects (Africander, Verhoog, et al., 2011; Stanczyk et al., 2013). 
Levonorgestrel (LNG) is a second generation testosterone-derived progestin (Stanczyk, 2003) belonging to 
the estrane group having weak androgenic activity. LNG is commonly administered as an oral contraceptive 
with the combination of EE (Sitruk-Ware & Nath, 2011). It is also used as a progestin only contraceptive in 
intrauterine devices, like the Mirena® (Drey & Darney, 2002) or in implants like Norplant® or Jadelle® 
(Sitruk-Ware & Nath, 2011). It is a derivative of NET-A with the replacement of the methyl group at carbon 
14 with an ethyl group (Stanczyk et al., 2013). Due to the local delivery nature of the implants and 
intrauterine devices as well as the daily use oral contraceptives, the concentration of LNG is much lower 
than that administered for the injectable contraceptives (Sitruk-Ware & Nath, 2011). Oral LNG is 
administered at 20 - 50 µg and the intrauterine device is delivered at 20 µg dose per day (Kuhl, 2011). In 
addition, LNG has recently been used in combination microbicide-contraception trials as part of developing 
new disease prevention strategies for women delivered in a Carraguard® vaginal gel (Sitruk-Ware et al., 
2007). 
While these contraceptives have been designed to act as the natural ligand P4 exerting strong 
progestational effects via the progesterone receptor (PR), they have different off-target effects than the 
natural progestin, P4, based on their modifications (see Figure 1.1) (Stanczyk, 2003; Hapgood et al., 2004; 
Stanczyk et al., 2013). The progesterone receptor belongs to the nuclear receptor super-family which 
includes the androgen receptor (AR), the mineralocorticoid receptor (MR), the estrogen receptor (ER) and 
the glucocorticoid receptor (Africander, Verhoog, et al., 2011; Sitruk-Ware, 2006b). There is a high 
conservation amongst this superfamily of structure and function, acting as ligand-activated transcription 
factors (Africander et al., 2011; Stanczyk et al., 2013), which mediate a variety of important physiological 
functions including, stress, reproduction and metabolism (Africander et al., 2011; Hapgood et al., 2004). As 
such, it is unsurprising that progestins may exhibit differential activity from the natural ligand P4 due to their 
interaction and binding with other steroid receptors (Africander et al., 2011; Stanczyk et al., 2013; Sitruk-
Ware, 2004). Indeed, it is well established that these different synthetic progestins exhibit different 
biological effects, in particular their extents of glucocorticoid, androgenic, and mineralocorticoid activities, 
as seen in Table 1.1 (Hapgood et al., 2004; Africander et al., 2011; Africander et al., 2013; Africander et al., 
2014; Stanczyk et al., 2013). Consequently, many of the reported side effects with the synthetic progestins 
are most likely related to their androgenic or glucocorticoid properties (Sitruk-Ware, 2008; Sitruk-Ware et 
al., 2004; Hapgood et al., 2004; Sitruk-Ware & Nath, 2013; Sitruk-Ware, 2006b; Erkkola & Landgren, 2005; 
Kuhl & Stevenson, 2006; Toh et al., 2012). The androgenic qualities of LNG exhibited at high 
concentrations, has been associated with acne, while bloating, weight gain (reviewed in Sitruk-Ware, 
2006b; Hapgood et al., 2004) and loss of bone density (Ishida & Heersche, 2002) have been proposed to 
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be due to the glucocorticoid properties of MPA. As seen in Table 1.1, preclinical studies and binding studies 
show that MPA, NET and LNG all exhibit some binding to the androgen receptor, with P4 exhibiting weak 
anti-androgenic activity (Stanczyk, 2003) and all exhibiting some androgenic activity (Sasagawa et al., 
2008; Africander, et al., 2011). MPA and NET exhibit very little anti-mineralocorticoid activity at 
contraceptive doses (Sasagawa et al., 2008; Africander et al., 2013), unlike some reports for LNG 
(Africander et al., 2011; Africander et al., 2013). However, MPA binds to the GR with an affinity (Kd of 4 nM 
– 11 nM) similar to that of the endogenous glucocorticoid cortisol, and acts as a full to partial agonist for the 
GR (Bamberger et al., 1999; Zhang et al., 2000; Thomas et al., 2006; Koubovec et al., 2004; Ronacher et 
al., 2009; Africander et al., 2011), whereas P4, NET and LNG bind to the GR with about a 50 - 100 fold 
lower affinity and are very weak partial GR agonists with much lower potency and efficacy (Africander et al., 
2011; Koubovec et al., 2004; Koubovec et al., 2005; Ronacher et al., 2009; Govender et al., 2014). Recent 
studies by Africander et al. (2014) suggest that MPA and NET have moderate to high binding affinity 
towards the AR (using competitive binding assays in COS-1 cells) to a similar effect as the natural ligand, 
5ɑ-dihydrotestosterone, as well as exerting differential transcriptional effects via the AR using androgen 
receptor response element promoter-reporter assays (Africander et al., 2014). Similarly, the same lab 
reported that NET-A and MPA had relatively low affinity towards the MR, binding with approximately 100 - 
fold lower affinity than endogenous P4 in competitive binding assays (Africander et al., 2013). As discussed 
by Stanzcyk et al. (2013) and Hapgood et al. (2013), the binding affinities of progestogens towards the 
different steroid receptors may not correlate directly with their bioactivity as determined by bioassays or 
pre-clinical models (such as ovulation inhibition assays in rabbits for progestenic activity and weight gain in 
the prostate of male rats for androgenic activity), which are prone to inherent biological variability and 
methodological limitations (Stanczyk et al., 2013; Hapgood et al., 2013). These differences may be due to 
the presence of other steroid receptors present in the bioassays, unlike the relative bindings assays that 
are performed in steroid receptor negative cell lines (reviewed in Hapgood et al., 2013). Additionally, 
ligands that bind with a strong affinity to a steroid receptor, may have weak to no effects on downstream 
transcriptional effects, such as RU486, a GR/PR steroid receptor antagonist (Hapgood et al., 2013; 
Ronacher et al., 2009; Africander et al., 2014; Africander et al., 2013).  
Some studies have reported the differential biological effects of synthetic progestins using various animal 
models to study androgenic, glucocorticoid, mineralocorticoid, and progestenic activity (Winneker et al., 
2003; Kumar et al., 2000; reviewed in Sitruk-Ware & Nath, 2011; Stanczyk et al., 2013; Africander et al., 
2011; Hapgood et al., 2013). For example, MPA has been shown to have strong progestogenic biological 
activity, weak androgenic activity, full to partial agonist activity via the GR and weak to no MR agonist 
activity in various animal models as reviewed in Table 1.1. NET, like MPA has been shown to have strong 
progestogenic agonist activity, with no anti- mineralocorticoid activity reported (Winneker et al., 2003). 
However, unlike MPA, NET has no glucocorticoid activity, but has partial androgenic effects via the AR. 
Similarly, LNG, like NET, has strong progestogenic activity, partial androgenic activity, no glucocorticoid 
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activity and weak anti-mineralocorticoid activity (Kumar et al., 2000; Stanczyk et al., 2013; Africander et al., 
2011; Hapgood et al., 2013). 
 
Table 1.1: Biological activity of progestogens in preclinical models and relative binding assays. 
 
 

















P4 + 50a 
100a 










MPA ++ 115a 
298a 










NET ++ 75a 
134a 








LNG ++ 150a 
320a 







Table adapted from a progestin review by Africander et al. (2011) and Stanczyk et al. (2013). ++ Strongly effective, + effective, - no 
effect, ± Literature not consistent. Data for these effects were obtained from preclinical studies. “For progestational effects, 
endometrial transformation tests using the McPhail scale, maintenance of pregnancy, inhibition of ovulation and or the assessment 
of gestagenic activity in female rabbits or rats was performed. Androgenic activity was measured by an increase in the weight of the 
ventral prostate or levator castrated male rats, anti-androgenic activity was assessed by treating castrated male rats and measuring 
feminisation-inducing activity thereafter. Glucocorticoid responses were assessed for production of glycogen and tyrosine 
transaminase production in rats. Anti-mineralocorticoid activity was measured by feeding rats a low sodium diet and sodium and 
potassium excretion measured (Africander et al., 2011).” Relative binding assays (RBA) were determined by competitive binding 
assays, and complied by Stanczyk et al. (2013), with additional binding information included for the AR (Africander et al., 2014) and 
MR binding (Africander et al., 2013). “(a) Were based on competitive binding assays using a radiolabelled reference ligand and 
increasing concentrations of unlabelled competitor ligand calculating IC50 values, while Ki (equilibrium dissociation constant for an 
unlabelled competitor or inhibitor ligand competing for the radiolabelled reference ligand to the receptor) values were determined by 
homologous and heterologous displacement using the Cheng-Prusoff equation” (b) (Stanczyk et al., 2013).  
 
The nature and extent to which these steroid hormones exert their biological functions is not only 
dependent on the concentration of the ligand, but the expression of the steroid receptors within the cells 
(Hapgood et al., 2013). Hapgood et al. (2013) addressed the effects of changes in steroid receptor and 
ligand concentrations by modelling the changes in the form of competition binding curves. The authors 
observed in the models, that increasing the concentration of the receptor significantly changed the apparent 
affinity (IC50) of the ligand for the receptor (Hapgood et al., 2013). It has also been observed in several 
studies that some of the steroid receptors exhibit tissue specific regulation. Moreover, it has been observed 
that within each cell type, different ratios of the steroid receptors and the ratios of their respective isoforms 
play an integral role in the site specific gene regulation observed (Lu & Cidlowski, 2006; Beato & Klug, 
2000; Mahita & Cidlowski, 2013; Gruver-Yates & Cidlowski, 2013). For example, it has been established 
that the PR is predominantly expressed in the female reproductive tract, mammary gland, brain and 
pituitary gland (Lu et al., 2006). The PR has two isoforms, the dominant negative PRA and the active form 
PRB (Africander et al., 2011; Akahira et al., 2002; Richer et al., 2002; Conneely et al., 2002; Conneely et 
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al., 2001). These isoforms have been shown to be differentially expressed in different tissue types, (Akahira 
et al., 2002; Tan et al., 2012, Africander 2011, Stanczyk 2013), have differential sub-cellular localisation 
(Lim et al., 1999) and that the isoforms display gene specific regulation (Beato & Klug, 2000). Similarly, the 
ER, AR and MR have been found to be expressed in select tissues (Reviewed in Africander et al., 2011; 
Stanczyk et al., 2013). Like the PR, the ER has two predominant isoforms, ERα and ERβ (Stanczyk et al., 
2013). These isoforms also have tissue specific regulation with the ERα predominantly expressed in 
reproductive tissues while ERβ is predominantly expressed in the ovary (reviewed in Faulds et al., 2012). 
The GR has been found to be expressed in all tissue types (Lu et al., 2006; Mahita & Cidlowski, 2013), and 
expresses several isoforms (Lu & Cidlowski, 2006; Gruver-Yates et al., 2014), each of which have shown 
distinct transcriptional expression patterns in in vitro models (Lu & Cidlowski, 2006; Oakley & Cidlowski, 
2011; Gruver-Yates & Cidlowski, 2013). Thus the context of the cellular environment plays an important role 
in determining the physiological effects exerted by the progestogens, and could be particularly important 
when assessing the effects of the progestogens on gene transcriptional effects. 
Taken together, the nature and extent to which synthetic progestins affect biological functions, other than 
their intended reproductive effects, needs to be carefully considered when assessing the choice of 
contraceptive for women. Moreover, a greater understanding in their underlying mechanism of action needs 
to be investigated if more informed choices are to be made. 
1.1.1. Modes of Action of Steroid Receptors 
At the cellular level, progestogens and steroid hormones mediate their effects via alterations in transcription 
of specific genes via binding to and regulating the activity of steroid receptors (Africander et al., 2011). As 
seen in Figure 1.2, ligands such as the progestogens are able to diffuse though the plasma membrane from 
the blood and enter the cytoplasm of the cell (Mahita & Cidlowski, 2013; Moore et al., 2011). Once inside, 
the ligand is able to bind to its inactive steroid receptor (SR) complexed with chaperones (such as heat 
shock protein 90) (Mahita & Cidlowski, 2013; Wan et al., 2001; Brinkmann et al., 1999). Ligand-binding to 
the inactive SR induces conformational changes of the SR and induces the removal of the chaperone 
complex (Griekspoor et al., 2007). The ligand-bound SR is subsequently hyper-phosphorylated by kinases 
in the cytoplasm as several sites in the SR. The now active SR is then able to translocate to the nucleus 
where it can exert genomic effects on target genes. Ligand-bound SRs are able to dimerise and bind 
directly to specific DNA sequences, known as steroid receptor response elements (Beato & Klug, 2000; 
Mahita & Cidlowski, 2013; De Bosscher et al., 2010; Moore et al., 2011; Claessens & Tilley, 2014; Williams 
& Sigler, 1998; Gruver-Yates et al., 2014). DNA binding is mediated by the DNA-binding domain (DBD) of 
the SR where it recognises specific palindromic sequences associated with the SR (Wan et al., 2001). 
However, due to the similarity in DBDs of the SRs, it is known that some SREs may be recognised by more 
than one type of SR (Wan et al., 2001; Griekspoor et al., 2007; Mahita & Cidlowski, 2013; Moore et al., 
2011; Africander et al., 2011). Once the ligand-bound SR dimer is bound to its cognate SRE, it is able to 
recruit several co-factors, known as co-activators to the promoter site, and increase transcription of the 
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target gene (Moore et al., 2011; Africander et al., 2011; Wu et al., 2005; Brinkmann et al., 1989). This is 
known as transactivation. Steroid receptors are also able to reduce transcription of target genes (Fuller et 
al., 2012; De Bosscher et al., 2003; Africander et al., 2011; Moore et al., 2011). The most common method 
is known as tethering, whereby a ligand-bound SR monomer tethers to other transcription factors, bound to 
their canonical sites in the promoter of target genes, and inhibits the recruitment of transcriptional 
machinery to the promoter, thereby reducing gene transcription (De Bosscher et al., 2003). This is known 
as transrepression. These mechanisms of differential gene transcription by SRs are how these SRs are 
able to exert their distinct biological effects in the body.  
Ligands bound to steroid receptors are also able to mediate rapid differential responses through non-
genomic actions (Norman et al., 2004). These responses are independent of nuclear translocation and 
direct DNA binding of the ligand bound SR to SREs or other transcription factors (Bennett et al., 2010; 
Mahita & Cidlowski, 2013). These rapid effects occur through the activation of protein-kinase cascades to 
regulate biological responses (Norman et al., 2004). This includes post-translational modifications, such as 
phosphorylation, protein-protein interactions with G proteins, second messengers and kinases (reviewed in 
Banerjee et al., 2014; Bennett et al., 2010; Mahita & Cidlowski, 2013; Mueck et al., 2014; Norman et al., 
2004). For example, some studies have found that synthetic progestins bound to membrane-bound PR are 
able to activate protein-kinase cascades and regulate proliferation in breast cancer cell lines (Ruan et al., 
2012; Zhou et al., 2013; reviewed in Mueck et al., 2014). It has also been observed in several studies, that 
ligand bound GR is able to exert non-genomic actions through the mitogen-activated protein kinase (MAPK) 
pathway to affect the cardiovascular, immune and neuroendocrine pathways (Widén et al., 2000; Bruna et 
al., 2003; Solito et al., 2003; reviewed in Mahita & Cidlowski, 2013). Additionally, non-genomic actions via 
ligand bound ER in vascular endothelial cells has been shown to mediate endothelial cell repair via 
activation of endothelial NO synthase (eNOS), in the cytoplasm (Cheng et al., 1999; Florian et al., 2004; 







Figure 1.2: Schematic diagram adapted from Stanczyk et al. (2013) illustrating the different genomic 
actions of progestogens on steroid receptors. As presented in Table 1.1, the different progestogens have 
different biological activities for the different steroid receptors (SRs). Once the progestogens bind to their target 
receptors as well as to other SRs with varying binding affinity (see Table 1.1), they exert differential effects on gene 
transcription. In some cases, the SRs become activated through a series of phosphorylation events performed by 
various kinases (green stars) in the cytoplasm. Once phosphorylated (denoted by the green triangles), the ligand-
bound SR translocates into the nucleus where it can affect changes on gene transcription. Ligand activated SRs can 
bind as dimers to their cognate steroid receptor response elements (SREs), recruit co-activators and increase 
transcription (transactivation). Ligand bound SRs can also bind as monomers to other transcription factors, recruit co-
repressors, and prevent gene transcription (transrepression). Alternatively, the ligand bound SR may prevent SR 
activation and subsequently prevent SR-dependent transcriptional effects (e.g. the anti-mineralocorticoid effects that 
P4 and LNG exert via the MR). P4, unlike the other progestogens, has been found to exhibit both weak androgenic 
and anti-androgenic effects (Table 1.1). Thick grey arrows denote strong biological activity of the progestogen via the 
SR, while dashed grey arrows represent weak biological activity of the progestogen via the SR. Blue arrows indicate 
the order of effects, while blue lines with perpendicular lines at the end represent a blocking effect. 
Taken together the data suggests the different progestins may exert differential biological activity through 
binding to different steroid receptors to different extents, which results in a unique downstream pattern of 
genomic and non-genomic effects. Of interest to this study is the GR, which discriminates between MPA, 




1.1.1.1 Glucocorticoid Receptor Signalling Pathway 
 
Glucocorticoids regulate numerous physiological functions such as growth, development, stress responses 
and immune homeostasis (Cruz-Topete & Cidlowski, 2015; Mahita & Cidlowski, 2013), and their expression 
is under the control of the hypothalamic-pituitary-adrenal (HPA) axis (Zhou & Cidlowski, 2005). 
Glucocorticoids, like cortisol (CORT) or the synthetic GC dexamethasone (DEX), bind to inactive GR in the 
cytoplasm. The GR is a modular protein consisting of several domains, the N-terminal transactivation 
domain, the DNA binding domain and the C-terminal ligand binding domain (Oakley & Cidlowski, 2011). 
The GR remains inactive in the cytoplasm complexed with several chaperone proteins, including heat 
shock proteins and several immunophilins (Baschant & Tuckermann, 2010). Upon ligand binding, several 
conformational changes occur within the GR, resulting in the dissociation of the chaperone complex, and 
subsequent exposure of the nuclear localisation signal (Oakley & Cidlowski, 2011). While in the cytoplasm, 
the ligand bound GR is hyper-phosphorylated at several target serine residues (namely, S203, S211 and 
S226), important in modulating GR activity (Avenant, et al., 2010; Avenant et al., 2010; Beck et al., 2009). 
The ligand bound GR is subsequently translocated into the nucleus, where ligand bound GR can exert 
differential effects on gene transcription (Oakley & Cidlowski, 2011). Ligand bound GR can bind as a dimer 
to target glucocorticoid response elements (GREs) found in the promoter of target genes (Zhou & 
Cidlowski, 2005). The bound GR dimer recruits several co-activators resulting in positive transcriptional 
regulation (Mahita & Cidlowski, 2013; Cruz-Topete & Cidlowski, 2015; Newton, 2000). Further, ligand 
bound GR dimers can bind to negative GREs (nGREs) in promoters of target genes to suppress 
transcription, however this mechanism is not well defined (Zhou & Cidlowski, 2005). One of the most well 
studied mechanisms of transrepression is the GR tethering to other transcription factors. Monomeric ligand-
bound GR can negatively regulate transcription by interfering either directly or indirectly to other DNA bound 
transcription factors, like Nuclear Factor κ B (NFκB), signal transduction and activator of transcription 
(STAT) or activator protein -1 (AP-1) and prevents NFκB, STAT and AP-1 gene dependent transcription 
(Zhou & Cidlowski, 2005; De Bosscher & Haegeman, 2009; De Bosscher et al., 2008). Further it has been 
well established that cross talk between the GR and the tumour necrosis factor (TNF) signalling pathway is 
the major mechanism whereby inflammation is controlled (Van Bogaert et al., 2010; De Bosscher et al., 
2003; De Bosscher et al., 2008). It has also been established that there are cell type specific effects of the 
GR, with glucocorticoids inducing tolergenicity in dendritic cells, and induction of apoptosis in T cells 
(Baschant & Tuckermann, 2010). 
The biochemical evidence and preclinical assays strongly suggest that there are distinct differences in 
steroid receptor affinity and biological effects for the different progestogens (Hapgood et al., 2004; 
Africander et al., 2011; Stanczyk et al., 2013). Of importance is the discrimination for MPA by the GR, 
compared to the other progestogens. This key difference may play a role in the regulation by MPA of 
immune function associated with the GR. It is likely that MPA could exert much more potent and efficacious 
effects on gene promoters involved in immune function than P4, NET or LNG via the GR. 
 
11 
1.2. Identifying useful models to study HIV-1 infection 
 
Blish and Baeton (2010) hypothesised that hormonal contraceptives may increase the risk of HIV-1 
infection by several different mechanisms. As seen in Figure 1.3, the authors proposed that hormonal 
contraceptives may change the local mucosal environment, by increasing susceptibility to other STIs or 
bacterial vaginosis, and/or could change the integrity of the local mucosal epithelial barrier, and/or changing 
systemic and local immune cells (Blish & Baeten, 2010). Indeed, Mestecky (2007) proposed that HIV-1 
infections depend on a number of factors such as transcytosis through the epithelial barrier, and uptake of 
the virus by target cells, such as CD4+ T cells and dendritic cells (Mestecky, 2007). Furthermore, it has 
been suggested that HIV-1 is primarily a mucosal disease, as the majority of HIV-1 infections occurs at a 
mucosal site during vaginal, anal or oral sex encounters (Mestecky, 2007). Upon infection, in the mucosal 
environment, draining lymph nodes become important sites of viral replication, where CD4+ T cell depletion 
occurs (Alimonti et al., 2003). As such, if progestogens affect CD4+ and CD8+ T cell distribution and 
proliferation, they may compromise humoral and cellular responses both in the mucosa and systemically, 
thereby changing the susceptibility profile to HIV-1 infection (Mestecky, 2007). 
 
 
Figure 1.3: Proposed mechanisms whereby hormonal contraceptives may affect HIV-1 
transmission. The schematic diagram was taken from a review by Blish and Baeten (2010) (Blish & Baeten, 2010).  
 
 
HIV-1 entry occurs via binding to CD4+ cells and co-receptor dependent [(C-C chemokine receptor type 5 
(CCR5) or C-X-C chemokine receptor type 4 (CXCR4)] fusion, predominantly expressed on memory T cells, 
dendritic cells and macrophages (McDonald et al., 2002; Murphy et al., 2012). The viral envelope protein 
first binds to the CD4 receptor and undergoes a conformational change to allow it to bind to a second 
receptor (named the co-receptor) (Cullen, 2001). Predominantly, viral infections occur through binding to 
the chemokine co-receptor, CCR5, while a small percentage of infections occur via CXCR4 co-receptor 
binding (Cullen, 2001; Cullen, 2014). The ability of HIV-1 to enter the cell through a specific co-receptor is 
 
12 
known as tropism, and the virus can be defined as being R5-tropic, X4-tropic or dual tropic (Murphy et al., 
2012). Co-receptor binding initiates a second conformational change (Cullen, 2001), where HIV-1 fuses into 
the membrane, where after several events occur. These include virion shedding and reverse transcription 
of the viral RNA to cDNA, and the insertion of the HIV-1 genome into the genome of the cell (Cullen, 2001; 
McDonald et al., 2002) through the aid of the viral protein intergrase (Murphy et al., 2012). It appears as 
though R5-viruses are preferentially transmitted via sexual contact, as the mucosa environment is rich in 
activated CCR5-expressing immune cells that the virus may infect (Murphy et al., 2012).  
The female genital tract (FGT) is a remarkable and intricate environment, consisting of many cell 
types important in the protection against pathogens. The FGT is sensitive to hormonal fluctuations in 
the menstrual cycle that change the levels of cytokines, immunoglobulin (IgG) transport, cell type 
distributions and antigen presentation (reviewed in Wira et al., 2005). The lower female genital tract 
consists of the ectocervix and the vagina (Miller & Shattock, 2003), while the endocervix is the start of the 
upper female genital tract (Wira et al., 2014; Wira et al., 2015). Multi-layered squamous epithelial cells 
cover the ectocervix and the vaginal mucosa and offer mechanical protection against pathogen invasion 
(Hladik & Hope, 2009). The endocervix is composed of mucus-secreting, simple columnar epithelium 
covering the lamina propria (Miller & Shattock, 2003). The zone between the ectocervix and the endocervix 
is a fragile single layered columnar epithelial layer known as the transition or transformation zone, and is 
thought to be the most susceptible to HIV transmission (Hirbod & Broliden, 2007). The FGT produces a 
thick hydrophobic glycoprotein mucosa that acts as a physical barrier preventing pathogen entry into 
cellular targets. Additionally, the FGT produces a plethora of innate antimicrobial peptides and interferons 
that actively inhibit and prevent pathogen infections (Ferreira et al., 2014). Underlying the epithelial layer is 
a dense layer of stromal fibroblast cells that provide support and structure. This layer also contains a 
dynamic distribution of leukocytes (Wira et al., 2015). In order for HIV-1 to establish infection, it must 
evade and overcome mechanical, chemical and biological barriers present in the FGT (Kaushic et al., 
2010). Traversing the epithelial barrier by HIV-1 is in part dependent upon the state of the epithelial barrier 
(Pope & Haase, 2003), which is subject to weakening due to hormonal changes and ageing or through 
ulcerations or infections (Iqbal & Kaul, 2007). In addition, it is possible for HIV-1 to traverse intact epithelial 
layers through mechanisms such as transcytosis (Pope & Haase, 2003; Kaushic, 2011; Ferreira et al., 
2014), uptake of HIV-1 by intraepithelial dendritic cells (Margolis & Shattock, 2006) or through the disruption 
of the tight junctions within the endocervix to allow viral entry (Nazli et al., 2010). Once HIV-1 has passed 
this barrier, it is able to infect and replicate in CD4+ cells found in the submucosae. While it has been found 
that HIV-1 does not actively replicate in epithelial cells (Dezzutti & Hladik, 2012; Ferreira et al., 2014), it has 
been observed in macaques that after initial SIV-1 infection, a small population of resident target cells in the 
submucosae that have been infected undergo viral expansion, before dissemination into the lymphatic 
tissues 5 to 6 days post infection (Miller et al., 2005). Hladik et al. (2007) found that the initial resident viral 
target cells were mainly intraepithelial Langerhan cells (or CD1a+ dendritic cells) and CD4+ T cells in ex 




Pudney et al. (2005) identified cells involved in the cell-mediated immunity in the female genital tract and 
found distinct populations in each region. The authors found that in the patients observed, most 
ectocervical tissue samples contained more CD1a+ dendritic cells, CD4+ T cells and CD8+ T cells than the 
vaginal tissue samples. The authors observed using immunohistochemistry (IHC), that the majority of the 
lymphocytes observed in the ectocervix and the vagina were located along the stroma-epithelium interface. 
The transformation zone contained the highest concentration of macrophages, CD4+ and CD8+ T 
lymphocytes, with CD1a+ dendritic cells located near the ectocervical side of the transformation zone. The 
authors stated that the ectocervix and the transformation zone could be the most susceptible to HIV-1 
infection, due to the abundance of HIV-1 target cells present in these areas. The authors found that the 
endocervix contained the lowest levels of CD4+ and CD8+ T lymphocytes compared to the vagina, 
ectocervix and the transformation zone. In addition, the authors found that macrophages but not CD1a+ 
dendritic cells were observed in the endocervix (Pudney et al., 2005). Interestingly, when inflammation was 
observed in the patients, the distribution of CD8+ lymphocytes in the vagina was different, with more CD8+ 
cells observed within the epithelium and an increase in both CD8+ and CD4+ lymphocytes observed in the 
ectocervix (Pudney et al., 2005). 
The data suggest that it is important to use organ culture, or ex vivo explants, containing tissue from 
regions in the lower female genital tract, as it is reflective of the target site of initial infection in heterosexual 
transmission of HIV-1. Ex vivo explant cultures are powerful tools that allow one to answer key questions in 
HIV-1 infection and potential modulators thereof. Using explants from the ectocervix, endocervix or vagina, 
researchers have been able to establish HIV-1 distribution within these cell types (Collins et al., 2000; 
Greenhead et al., 2000). Collins et al. (2000) found that memory T lymphocytes (CD45RO+), dendritic cells 
and macrophages were present in cervical tissue explants, with memory T cells the most abundant of the 
cell types assayed. The authors also observed that the cell type distributions did not change over the 
duration of the time course (6 days) nor did HIV-1 infection alter the cell type distributions. Greenhead et al. 
(2000) found that that HIV-1 infection (measured by the presence of the viral protein subunit p24) was 
associated with CD14+CD68+ macrophages and CD3+ lymphocytes located in the sub-epithelial mucosa 
of the cervical tissue. Interestingly in this study, the authors observed that no p24 positive cells were 
observed in the epithelium or in epithelial cells (Greenhead et al., 2000). Maher et al. (2005) observed in 
cervical explants that HIV-1 infected cells were detected 3 to 4 days post infection within the submucosa of 
the explant. The authors also found that the cervical mucosa contributed to the complexity of infection, with 
cervical mucous trapping seminal cells (representing cell associated HIV-1) and HIV-1 virions (representing 
cell free virus). When visualised using confocal microscopy, the authors found that HIV-1 virions were able 
to penetrate beneath the cervical epithelium and bind to the epithelial surface, despite cervical mucosal 
trapping of HIV-1 (Maher et al., 2005). 
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Explants obtained from the lower FGT can be further used to explore the role of select cell types in HIV-1 
infection, by digesting the tissue and isolating or purifying different cell types through filtration techniques 
(Hladik et al., 2007) or by isolating different tissue sections through suction blistering (Hladik et al., 2007). 
For example, Hladik et al. (2007), processed vaginal explant tissue using suction blistering and isolated the 
vaginal epithelial sheaths, containing intraepithelial Langerhan and CD4+ T cells. The authors found that 
exposure to HIV-1 of these vaginal epithelial sheaths, resulted in rapid penetration of HIV-1 into 
intraepithelial CD4+ T cells and Langerhan target cells, through CD4 and CCR5 receptor mediated binding 
and endocytosis, respectively (Hladik et al., 2007). Furthermore, utilising purified primary epithelial cells 
from the endocervix of the FGT, researchers have observed that HIV-1 disrupts the tight junctions formed 
within the endocervix (Nazli et al., 2010) and utilises transcytosis to cross the epithelial barrier (Ferreira et 
al., 2014).  
Thus, utilising these techniques in primary cervical explants to determine the effects of progestogens on 
HIV-1 replication in the local genital mucosa will be highly informative and useful. Explant tissue culture is 
an incredibly useful tool in which to assay the safety and efficacy of microbicides on HIV-1 infection 
(Fletcher et al., 2006; Fletcher et al., 2008; Fletcher & Shattock, 2008; Dodou et al., 2014; Harman et al., 
2012) as well as assessing the effects of entry inhibitors on HIV-1 infection (Hu et al., 2004). However, 
tissue explants also present challenges when assaying the effects of HIV-1 infection over time. It has been 
observed that susceptibility to infection may be dependent on the phase of menstrual cycle (Anderson et 
al., 2010; Carias et al., 2013; Saba et al., 2013). Saba et al., 2013 observed that tissue explants harvested 
from women in the luteal phase were more permissible to HIV-1 infection compared to tissue harvested 
from women in the follicular phase (Saba et al., 2013). Thus some tissue explants harvested from donors at 
different stages of the menstrual cycle, may exhibit different levels of HIV-1 infection levels that may 
compound the analysis. Furthermore, explant tissue has been shown to be prone to disintegration over 
time, with the epithelial layer often sloughed within 48 hours of tissue culture (Anderson et al., 2010), that 
may further exacerbate HIV-1 infection within the culture, compared to samples with an intact epithelium. 
Additionally, ex vivo explants may provide limited information on HIV-1 transmission, due to the difficulties 
associated with maintaining an intact and polarised epithelium in the explant (Hladik et al., 2007; Anderson 
et al., 2010; Merbah et al., 2011). Further it is not possible to adequately assess transmission of HIV-1 in 
the mucosa to target cells using explants, as recruitment of these target cells from surrounding vessels 
cannot occur in an isolated ex vivo tissue explant. As such, most explant studies focus on early HIV-1 
infection in this model (Hladik et al., 2007). Lastly, it has been observed that the state of inflammation may 
play a role in HIV-1 infectivity (Roberts et al., 2012; Masson et al., 2014; Masson et al., 2015). Thus patient 
information on sexually transmitted infections (STIs) is important in order to make appropriate conclusions 
about the effect of treatment on HIV-1 infection in ex vivo tissue explants.  
The role of inflammation is an important determinant of HIV-1 susceptibility (Roberts et al., 2012; Masson et 
al., 2014; Masson et al., 2015). Explant tissue is host to multiple cell types, as such, a plethora of cytokines, 
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chemokines and other signalling molecules are expressed (Murphy et al., 2012). Some studies suggest that 
elevated cytokine levels in the local female genital tract may facilitate viral infection, by recruiting key target 
cells, like CD4+ T cells for HIV-1 infection, to the local site of infection (Roberts et al., 2010; Masson et al., 
2014). Indeed, Greenhead et al. (2000) found that explants treated with PHA to facilitate immune activation 
enhanced HIV-1 infection (Greenhead et al., 2000), while Pudney et al. (2005) found that more target cells 
for HIV-1 infection were present in the ectocervix and vaginal biopsy samples from women with 
inflammation (Pudney et al., 2005). Masson et al. (2014) found that an elevated cytokine profile was 
associated with women who were chlamydia or gonorrhoea positive. Interestingly, they found that the 
inflammation was only present in the cervico-vaginal secretions, and did not correlate to the serum cytokine 
levels in the same women (Masson et al., 2014). This study suggests that there may be compartment 
specific effects that change the susceptibility profile of women to HIV-1, and that all of these compartments 
should be assessed in order to elucidate the full effects of progestogens on infection risk in women. 
Masson et al., (2015) also identified that HIV-1 seroconversion was associated with an increased genital 
inflammation. The authors proposed that increased levels in macrophage inflammatory factor (MIP)-1α, 
MIP-1β and interferon-ϒ inducible protein -10 (IP-10) contributed towards this increased association with 
HIV-1 seroconversion (Masson et al., 2015). Interestingly, this increased inflammatory profile in the young 
women assayed was not associated with STIs tested (Masson et al., 2015). While these studies suggest 
that inflammation may be important in increasing HIV-1 infection (Greenhead et al., 2000) or 
seroconversion (Masson et al., 2014; Masson et al., 2015), the role of inflammation to increase HIV-1 
susceptibility has not been fully elucidated. Indeed in a study by Lehman et al. (2014), systemic cytokine 
levels were not associated with HIV-1 acquisition in women (Lehman et al., 2014). 
Upon infection, HIV-1 is disseminated into the lymphatic system through the transport of virus-capturing 
dendritic cells or infected CD4+ T cells from the mucosa. Once in the lymph nodes, memory CD4+ T cells 
are predominantly infected and produce the majority of the virus in vivo (Pope & Haase, 2003). In addition it 
has been found that within this population, activation of these cells plays an important role in propagating 
virus, with activated CD4+ T cells producing 5 fold more virus than resting T cells (Zhang et al., 1999). 
Interestingly, the authors found that resting T cells may provide the initial target of HIV-1 infection, as well 
as the initial target cells for latency. After initial infection of resting T cells, activated T cells are recruited 
through the initiation of immune activation by viral infection, and subsequent viral propagation and 
dissemination of infection (Zhang et al., 1999). Murooka et al. (2012) found using humanised mice models, 
that CD4+ T cells that were infected with HIV-1 had reduced motility, formed syncytia and were able to 
facilitate cell-to-cell virus transfer through the formation of virological synapses. The authors also observed 
two types of populations of infected CD4+ T cells, those located within the lymph nodes to increase local 
viral loads, and those that were re-circulated through the tissues promoting efficient systemic viral spread in 
vivo (Murooka et al., 2012). Collectively, results to date suggest that the systemic immune system plays a 
pivotal role in viral load setup, maintenance of HIV-1 infection and viral dissemination (Pope & Haase, 
2003; Haynes & Shattock, 2008). Joag et al. (2014) assessed the effects of a CCR5-tropic HIV-1 
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pseudovirus on cervical and systemic CD4+ T cells, and found that while viral entry was 3 fold higher in 
cervical CD4 + T cells compared to systemic CD4+ T cells, viral entry was strongly correlated between the 
two compartments for each participant (Joag et al., 2014). The authors suggest that this may indicate that 
there are shared host determinants of viral entry (Joag et al., 2014), which supports the relevance of using 
systemic PBMCs to study HIV-1 infection.  
While CD4+ T cells are important cellular reservoirs for HIV-1, many other cell types contribute to the 
distribution of HIV-1 to other target sites. HIV-1 has been shown to bind to the surface of dendritic cells to a 
C-type lectin known as DC-SIGN, or be internalised by endosomes (Murphy et al., 2012). HIV-1 attached 
dendritic cells are able to move from the submucosa and enter the draining lymph nodes, where they can 
transfer HIV-1 to CD4+ T cells via an immunological synapse (Murphy et al., 2012). Macrophages have 
also been shown to be important viral reservoirs in early macrophage-tropic HIV-1 infection (Shen et al., 
2009) as well as being important in viral dissemination (reviewed in Fantuzzi et al., 2003). Macrophages 
and monocytes are important mediators of cellular immunity and produce large amounts of key cytokines 
such as interleukin (IL) 6, IL8 and tumour necrosis factor (TNF)-ɑ (Fantuzzi et al., 2003), while an increase 
in IL6 and TNF-ɑ expression has been associated with an increase in HIV-1 viral load (Masson et al., 2014; 
Roberts et al., 2012; Birx et al., 1990). Some studies utilise the expression of select signalling molecules as 
markers for cellular activation and function (Huijbregts et al., 2013; Huijbregts et al., 2014; Michel et al., 
2015), as such signalling molecules produced by key immune cells could provide insight into cellular 
activation and function. Roberts et al. (2012) found that a higher viral set point (or viral load) and a 
decrease in CD4+ lymphocytes, was associated with higher expression levels of several pro-inflammatory 
cytokines in women, suggesting that changes in the inflammatory profile could alter the susceptibility to 
infection and disease progression (Roberts et al., 2012). Additionally McKinnon et al. (2015) found that 
early HIV infection was associated with an increase in expression of the chemokines, regulated upon 
activation, normal T cell expressed and secreted (RANTES) and macrophage inflammatory protein (MIP)-
3ɑ (McKinnon et al., 2015).  
Thus, when investigating the effects of progestogens on HIV-1 infection it may be imperative to assay the 
multicellular effects in ex vivo systems from the ectocervix and endocervix as well as in the systemic 
system using peripheral blood mononuclear cells (PBMCs), as both compartments are important in the viral 
infection cycle and the progestogens may have distinct effects on gene expression, cell type regulation and 
HIV-1 replication within these systems. 
1.3. Contraception and HIV-1 
1.3.1. Observational studies 
 
Contraception is a valuable resource in family planning. Contraception use significantly decreases the 
mother and infant morbidity and mortality rate, as well as empowering women in choice of family planning 
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(World Health Organisation, 2014a; World Health Organisation, 2014b). In sub-Saharan Africa, 31 million 
women do not have access to proper family planning or adequate contraceptive choices (World Health 
Organisation, 2014a) The importance of contraception for quality of life, freedom of choice, health and 
economic benefits (Ralph et al., 2015), drives the need to provide safe, cheap and effective contraception 
options for women. As such, many different progestins have been derived over the past 50 years with 
equally as many delivery systems (Stanczyk et al., 2013; Sitruk-Ware et al., 2013). However, as previously 
stated, different progestins administered at different doses via different delivery systems, have different 
unintended side effects (Hapgood et al., 2004). Of particular concern is the observational evidence over the 
past 20 years, focusing on the association between hormonal contraception and HIV-1 risk.  
The observational studies have produced conflicting observations. Some studies report no association 
between hormonal contraception and HIV-1 risk (Kleinschmidt et al., 2007; Myer et al., 2007; Reid et al., 
2010; Morrison et al., 2012; Lutalo et al., 2013), while other studies report significant associations between 
hormonal contraception and HIV-1 risk (Leclerc et al., 2008; Morrison et al., 2010; Heffron et al., 2011; 
Wand & Ramjee, 2012; McCoy et al., 2013). Furthermore, some studies have shown that age and HSV-2 
status may have a significant role in HIV-1 susceptibility in women using DMPA (Morrison et al., 2012; 
Leclerc et al., 2008; Morrison et al., 2010), while others did not (Heffron et al., 2011; McCoy et al., 2013; 
Wand & Ramjee, 2012). Of the studies that were able to differentiate the different types of injectable 
contraceptives used, Myer et al. (2007) found that women on COCs, DMPA and NET-EN had similar 
incidence ratios of HIV-1 infection compared to women not on hormonal contraceptives (Myer et al., 2007). 
Similar observations were also reported in a study by Lutalo et al. (2013), which found no significant 
increased risk in HIV-1 acquisition or transmission for DMPA users or COC users compared to no hormonal 
contraceptive users (Lutalo et al., 2013). In contrast, several other studies have observed an increased risk 
of HIV-1 infection with the injectable contraceptive MPA, (Leclerc et al., 2008; Morrison et al., 2010). 
Heffron et al. (2011) found that injectable contraceptives, in particular DMPA, was associated with a two 
fold increased risk of HIV-1 acquisition. Additionally, the analysis suggested that the rate of transmission 
from female to male increased two fold if the women were using the injectable contraceptives, compared to 
women who did not. In this study, the authors found that age and HSV-2 status did not affect the 
significance of this association (Heffron et al., 2011).  
Taken together, the above data highlights the difficulty in addressing the associative risk of hormonal 
contraception and HIV-1 acquisition. Furthermore, the observational studies to date do not appear to be 
persuasive enough to definitely address whether hormonal contraceptives affect HIV-1 acquisition in 
women. Moreover, the studies to date are not detailed enough to address the differences between the type 
of injectable contraceptives (DMPA and NET-EN), different oral contraceptives (such as progestin-only like 
levonorgestrel, etonorgestrel, or combined oral contraceptives), or other contraceptive methods 
(intrauterine devices). Indeed, most often the observation studies were secondary analyses of data 
obtained to answer other questions, with few that were randomised control trials, specifically designed to 
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address the question. In addition, most of these prospective studies differed in study design, follow up 
times, population size and type, sexual behaviour reporting, analytical methods used, rate of 
discontinuation or switching of contraceptive method and adherence (Smit & Beksinska, 2013; Ralph et al., 
2015; Morrison et al., 2015; Haddad et al., 2014; Polis et al., 2014). In response to these inherent 
differences between the studies, as well as to provide insight into contraceptive choice and HIV-1 risk, 
recent studies have sought to perform systematic review (Polis et al., 2014) or meta-analyses of all the 
observational data over the past twenty years (Ralph et al., 2015; Morrison et al., 2015).  
A panel of WHO experts comprising of epidemiologists, clinicians and basic research scientists, rigorously 
assessed all observational studies performed prior to January 2014 using GRADE criteria (Polis et al., 
2014). The authors identified 9 key studies that were “informative, but with important limitations”. Of these 
nine studies, four studies found that DMPA significantly increased HIV-1 risk (Fig. 1.4). One out of five 
studies that stratified for NET-EN use, found that NET-EN increased HIV-1 acquisition in women (Fig. 1.4). 
One out of eight studies that reported COC use, reported a significant increased risk with COC use (Polis et 
al., 2014). Based on this analysis, the WHO recommendation on contraceptive choice for 2014, places no 
restriction on contraceptive usage, while noting that condoms usage should be highly encouraged for 
women in high risk areas using long-acting progestins (specifically DMPA) (World Health Organisation, 
2014b).  
 
Figure 1.4: The distribution of the adjusted hazard ratios for DMPA and NET-EN use in 9 studies 
identified as “informative but with important limitations” in the Polis et al. (2014) systematic review. 
Red indicates a significant association (p = 0.05). Error bars show 95% confidence intervals (CIs). 
Since the Polis et al. (2014) systematic review, several important observational studies have been 
published. A large prospective study found no association between HIV-1 acquisition and contraceptive 
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use, as well as no association in contraceptive use and transmission from male to female (Wall et al., 
2014b; Wall et al., 2015) or female to male (Wall et al., 2014a; Wall et al., 2015). Crook et al. (2014) 
analysed hormonal contraception and HIV-1 risk from data acquired from the MDP3-1 microbicide trials. 
The authors found, after correcting for sexual behaviour, socio-demographic variables, and laboratory 
findings (HSV-2 status, Neisseria gonorrhoea, Chlamydia trachomatis, Trichomonas vaginalis, syphilis and 
bacterial vaginosis [BV]), DMPA use associated with a significant increase in risk of HIV-1 acquisition 
compared to non HC users, while NET-EN and COCs were not. Interestingly in this cohort study, HSV-2 
status, age, vaginal discharge, chlamydia and BV were all independently associated with an increased risk 
in HIV-1 (Crook et al., 2014). Additionally, a recent study by Noguchi et al., (2015) analysing a cohort from 
the VOICE trials, found that DMPA use was associated with a significant increase in risk in HIV-1 
acquisition compared to NET-EN users. However, the study could not estimate the risk associated with 
either method compared to non-use, due to a lack of a non-hormonal contraception group (Noguchi et al., 
2015). 
In addition to these new studies, two meta analyses have been performed, whereby key studies were 
identified, the data accessed and analysed cumulatively (Ralph et al., 2015; Morrison et al., 2015). In 
Morrison et al. (2015) the authors reviewed and examined individual participant data from several studies. 
This was performed in order to eliminate some of the methodological limitations of aggregated reviews. 
This meta analysis sought to address three questions; first if hormonal contraceptive (HC) method 
increased HIV-1 risk compared to no HC users, second if HSV-2 co-infection had a role in the increase in 
infection and lastly if there were differences in risk between the different contraceptive types (DMPA, NET-
EN and COC users) (Morrison et al., 2015). The grouped data set from 18 studies consisting of 36,973 
women of which 26% were on DMPA, 16% on COC and 9% on NET-EN. Of this grouped cohort, 14% of 
the women discontinued HC between visits, while 13% of the women switched methods multiple times 
throughout the study (Morrison et al., 2015). Using a two-stage random effects meta-analysis correcting for 
multiple covariates (age, condom use, region, marital status) the authors found that there was no 
association with COC and HIV-1 acquisition (aHR 1.03; 95% CI 0.88 - 1.2). DMPA usage had a significant 
association (aHR 1.51; 95% CI 1.24 - 1.8), while NET-EN usage was weakly associated (aHR 1.24; 95% CI 
0.84 - 1.82). The authors found that between-study heterogeneity (that is the differences in study design) 
was mild (Morrison et al., 2015). In a direct comparisons model, the authors found that DMPA was 
associated with an increased risk of HIV-1 acquisition, compared to both COC and NET-EN use. In 
addition, the authors found some evidence to suggest an increased risk of HIV-1 acquisition in NET-EN 
users compared to COC users (however, this association was not significant). The authors found no 
association with HSV-2 infection or age on HIV-1 acquisition and hormonal contraception in this data set. 
Interestingly, the data found stronger associations with DMPA use and increased HIV-1 acquisition in East 
Africa compared to Southern Africa, or South Africa (Morrison et al., 2015). This could be due to the 
population type (at risk population versus general population) utilised within the different trials.  
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Ralph et al. (2015) employed a different strategy in analysing the observational and randomised controlled 
trials (RCT) data. In this meta-analysis, the authors identified 12 studies and employed inverse probability 
of treatment weighted marginal structural models in order to obtain pooled hazard ratios that will give 
insight into the average effect of the treatment on the population (Ralph et al., 2015). Using a series of a 
priori secondary analyses, the authors wanted to identify any studies that disproportionally affected the 
results, as well to identify if there were population differences in risk profile by stratifying the data sets, as 
well as to assess whether condom reporting influenced the risk profile obtained (Ralph et al., 2015). Pooled 
estimates from 10 studies indicated that DMPA increased the risk of HIV-1 acquisition (pooled HR 1.4 95% 
CI 1.16 - 1.69). Interestingly when correcting for population, there was a lower risk associated with DMPA 
use and HIV-1 acquisition in the general population (pooled HR 1.31; 95% CI 1.1 - 1.57). In 2 studies where 
the populations included commercial sex workers and sero-discordant partnerships (that is, the at risk 
population), the pooled HR increased to 1.73 (CI 1.28 - 2.34). However the authors note that the high 
heterogeneity between these population groups contraindicated pooled estimates. Additionally the meta-
analysis indicated that there was no increase in risk comparing no contraception to COC users (pooled HR 
1.0; 95% CI 0.86 - 1.16), or comparing no contraception to NET-EN users (pooled HR 1.1; CI 0.88 - 1.37) 
(Ralph et al., 2015). The authors found that no one study significantly affected the results obtained. The 
authors inferred from the data that within the general population, complete withdrawal of DMPA was not 
warranted. However, the authors strongly support the modelling of regional or geographic and sub-
population differences so that context-specific contraceptive policy can be deployed (Ralph et al., 2015). 
Collectively, a picture is emerging from clinical, studies that the injectable contraceptive, MPA, is likely to 
increase HIV-1 acquisition in women. 
Taken together, the meta-analyses highlight the inherent difficulties and limitations in observational analysis 
and random control trials. Both Morrison et al. (2015) and Ralph et al. (2015), report that the data is prone 
to bias and cannot be used to determine whether the association between HIV-1 risk and HC use is causal. 
Another important factor is that no study has assessed acute HIV-1 infections. This would strengthen the 
confidence in the timing of exposure to HC and subsequent acquisition of HIV in women, and provide a 
more causal link in the association (Ralph et al., 2015). That is, that exposure to HIV-1 and subsequent 
sero-conversion corresponded with HC use. Condom usage may be the greatest confounder in these data 
sets. If underreporting exists in one group compared to the other, the risk could be over-reported or under-
reported (Ralph et al., 2015). In addition it has been reported that women on hormonal contraceptives are 
less likely to report condom usage than women on no contraceptives (Myer, 2012), which may be a 
contribution to the observed risk in contraceptive usage. However in the meta-analysis by Ralph et al. 
(2015) condom use did not greatly affect their outcome (Ralph et al., 2015). In both situations (either under 
or over-reporting of condom use), one may make policy decisions based on mis-reported risk assessment. 
Moreover, the data suggests that there could be both geographic (Morrison et al., 2015) and population 
specific (Ralph et al., 2015) risk factors associated with hormonal contraceptive use. Thus, policy change 
for the general population may be unwarranted (Jones, 2014; Ralph et al., 2015). Indeed, many are 
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cautious over general policy change due the significant benefits hormonal contraception have on the health 
and wellbeing of women (Jain, 2012; Westhoff & Winikoff, 2014; Ralph et al., 2015; Morrison et al., 2015). 
Jain reported in 2012 that if one were to change from DMPA to OC or no contraception, the increase in 
unwanted pregnancies and increase in mother and child mortality and morbidity rates outweigh the number 
of HIV-1 infections prevented in women. Of importance, Jain weighted the analysis so that NET-EN had the 
same profile as oral contraceptives, thus one could assume that the effect would be the same if moving 
from DMPA to NET-EN in this scenario. However, Jain (2012) notes, that there are highly variable 
population effects (different fertility rates in different countries, maternal mortality rates and different 
proportions of contraceptive use) that could affect the cost-benefit ratios. In addition, the author could not 
account for factors such as unsafe abortions, neonatal mortality and effects of pregnancy on HIV-1 
susceptibility in the analysis performed, which may change the cost-benefit ratios presented in this study. 
As such, the author proposes region specific assessments, rather than a general policy shift to remove 
DMPA from the general pool of contraceptives, and promotes individual level planning (Jain, 2012). In line 
with this, Butler et al. (2013) modelled the effects of removing injectable contraceptives from different 
countries and its subsequent effect on maternal and HIV-1 related deaths. In this modelling analysis, the 
authors found that if injectable contraceptives increased HIV-1 incidence with an odds ratio (OR) of 1.2 or 
2.19, removing it from the pool of contraceptives would result in 5000 to 27000 (respectively) fewer deaths 
in South Africa per annum (Butler et al., 2013). However, this was not true for other African and Asian 
countries, which showed either moderate protect effects or a significant increase in maternal and HIV-1 
related deaths per year (Butler et al., 2013). Additionally, the data suggested that injectable contraceptives 
with an OR of 1.2 or 2.19 would result in 13 000 to 59 000 new HIV-1 infections per year in South Africa 
alone (Butler et al., 2013). Thus these analyses together with the recent Morrison et al. (2015) and Ralph et 
al. (2015) meta-analyses are a cause for concern, especially in a South African context, and strongly 
support the reassessment of DMPA as a suitable contraceptive choice. 
Collectively, the data suggest that DMPA more than NET-EN and COCs may increase HIV-1 acquisition in 
women. HSV-2 status and age were also seen to increase risk in some studies (Morrison et al., 2012; 
Leclerc et al., 2008; Day et al., 2014; Ralph et al., 2015; Morrison et al., 2015), but not others (Kleinschmidt 
et al., 2007; Myer et al., 2007; Lutalo et al., 2013). Since the current data from observational studies are not 
considered persuasive enough to recommend using methods of contraception other than DMPA (World 
Health Organisation, 2012), more research is urgently required. One approach is to design a large-scale 
randomised clinical trial. Indeed, some suggest this may provide the clearer picture and provide a more 
direct analysis over the role of HC and HIV-1 acquisition (Morrison et al., 2015; Morrison & Nanda, 2011). 
However, many argue that equipoise needed in a trial may be breached in light of the current observational 
studies, and argue that the funds needed, resources utilised and time taken, may be better utilised in 
broadening contraception availability and providing regional and population specific policies on 
contraception use (Jain, 2012; Westhoff et al., 2007; Hapgood, 2013; Ralph et al., 2013; Ralph et al., 
2015). Indeed, the ethical considerations and methodological approach to a trial are also complex and 
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difficult. Another approach is to understand the basic biological mechanisms underlying the differences in 
HIV-1 acquisition risk with different types of contraceptives. Many state that more basic research is urgently 
needed, as the exact mechanisms are not known. The advantage of basic research on hormonal 
contraception and HIV-1 risk, is that time, dose and direct effects may be measured and assessed in 
appropriate model systems (Hapgood et al., 2013; Michel et al., 2015). 
1.3.2. Associated risks, disease progression and susceptibility profiles 
 
In addition to assessing HIV-1 acquisition rates and hormonal contraception use in women, studies have 
also assessed the effects of hormonal contraception on HIV-1 RNA and DNA shedding, disease 
progression, inflammatory profiles and susceptibility to other infectious diseases, all of which could 
contribute to an increased risk in HIV-1 infection. It has been reported in some studies, that hormonal 
contraceptives (both injectable and combined oral contraceptives) increase HIV-1 DNA shedding in the 
cervix and vagina (Moss et al., 1991; Mostad et al., 1997; Elovitz & Wang, 2004), while two cohort study 
found no significant differences in HIV-1 RNA shedding in the cervix or plasma compared to women not on 
contraception (Richardson et al., 2007; Day et al., 2014). Interestingly, the Mostad et al. 1997 study found 
that both DMPA and combined oral contraceptive use not only increased HIV-1 DNA shedding, but that this 
increase was correlated to an increase in CD4+ T cell count in these HIV-1 positive women (Mostad et al., 
1997). In a study by Lavreys et al. (2004), women on DMPA had a significant increase in viral set points or 
viral loads (Log HIV-1 RNA copies/ml) from time of HIV-1 infection to the end of the study, compared to 
women not on contraceptives. In addition, the authors found that use of DMPA at the time of HIV-1 
infection, was associated with higher levels HIV-1 replication. There was no difference in viral set point, or 
HIV-1 replication levels in women on oral contraceptives compared to women on no contraception (Lavreys 
et al., 2004). This finding was similar to the Heffron et al. 2012 study, where women who become infected 
and on injectable contraceptives, had increased genital HIV-1 RNA levels but not plasma HIV-RNA levels, 
(Heffron et al., 2013). Heffron et al. (2013) suggested that hormonal contraceptives may act to increase 
HIV-1 infectiousness through direct effects on genital mucosal HIV-1 replication (Heffron et al., 2013).  
Several studies to date have found that DMPA use does not increase the rate of disease progression in 
HIV-1 positive women (Richardson et al., 2007) with one study reporting rates of disease progression 
significantly lower in women on injectable contraceptives compared to women not on contraception (Heffron 
et al., 2013). Contrary to these findings, one study has reported that HIV-1 positive women on DMPA or 
oral contraceptives, but not on antiretroviral therapy, were associated with an increased likelihood of 
becoming eligible for ART and meeting the authors disease progression outcome (death or becoming 
eligible for ART) compared to women using an intrauterine device (IUD) (Stringer et al., 2009). Westrich et 
al. (2014) found that there was no difference in progression to cervical disease when comparing DMPA, 
NET-EN and COCs compared to no contraception users in HIV-1 positive women (Westreich et al., 2014). 
Borgdorff et al. (2015) found that OC use was associated with an increase in human papillomavirus (HPV) 
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and Chlamydia trachomatis prevalence, while DMPA use as associated with an increase in HSV-2 
prevalence in women (Borgdorff et al., 2015). DMPA usage has also been associated with an increased 
acquisition of cervical chlamydial and gonococcal infections (Morrison et al., 2004), increased HSV-1 
cervical shedding (Mostad et al., 1997) and an increase in cervical ectopy (Morrison et al., 2004; Bright et 
al., 2011). However, in women who are HIV-1 positive, no differences were observed between STI 
incidence and hormonal contraception (Overton et al., 2008).  
The above data suggest that DMPA and oral contraceptives may have differential HIV-1 infection effects, 
with more differences observed in susceptibility to HIV-1 than to HIV-1 disease progression. The data also 
suggest that there may be compartment specific effects on HIV-1 DNA viral shedding as well as differential 
effects on HIV-1 DNA and RNA shedding within the same compartment, suggesting further complexity on 
the effects of HC in disease progression. During acute phase infections, DMPA but not oral contraceptives, 
may have a more pronounced effect on HIV-1 viral loads and CD4+ T cell counts, while this may not be 
evident in chronically infected women. This data also highlights the lack of information about women on the 
injectable contraceptive, NET-EN, as well as the lack of information on the type of oral contraceptive 
associated with increased HIV-1 DNA viral shedding.  
It is thus of importance that these apparent differences be further investigated so that appropriate 
contraceptive choices may be made by women in high risk areas. As the observational data have 
demonstrated, the inherent confounders may limit observations made. Thus animal studies, ex vivo and 
biochemical studies may provide much needed insight into the differential actions of hormonal 
contraceptives, the difference in HIV-1 susceptibility and the differential mechanisms thereof.  
1.3.3. Animal, ex vivo and biochemical studies 
As outlined below, evidence suggests that hormonal contraceptives may affect epithelial thickness, barrier 
integrity, the inflammatory profile, cellular function and gene expression, however greater clarity is needed 
to determine which hormonal contraceptives have a greater risk profile associated with HIV-1 acquisition. 
Biochemical studies in cell lines and primary cells as well as animal studies have provided significant 
insight into the effects on cellular immune function, epithelial integrity and susceptibility to infections of 
different progestin contraceptives. 
1.3.3.1. Epithelial thickness and mucosal barrier integrity  
Animal models have proven to be useful in studying the effects of contraceptives and HIV risk, to reduce 
the confounders present in observational studies (McNicholl et al., 2014). In a seminal study by Trunova et 
al. (2006), the authors reported a strong association between hormonal contraception and SHIV-1 shedding 
in cervical secretions in rhesus macaques infected with HIV-1 through the vaginal route, with Rhesus 
Macaques treated with DMPA having higher viral loads than the no treatment control group (Trunova et al., 
2006). Additionally the study found that the genetic complexity of the replicating virus was greater in DMPA-
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treated macaques, and that independent of the tropism of the virus (X4 or R5) DMPA treated macaques 
had higher viral loads (Trunova et al., 2006). A similar finding was reported by Jiang et al. (2009) where 
pigtail macaques treated with DMPA had higher mean plasma viral loads after the acute phase of infection, 
and a higher incidence of AIDS-like symptoms compared to the DMPA naive group (Jiang et al., 2009). The 
natural female hormone, Progesterone (P4), has been shown in macaques to increase SIV-1 susceptibility 
in macaques by 7.7 fold by thinning the vaginal epithelium (Marx et al., 1996). In a study comparing rhesus 
macaques with either P4 or estrogen (E2) implants, the authors found that five out of the 6 macaques with 
P4 implants became infected upon several rounds of SIV-1 intra-vaginal challenges, while the E2 group 
remained protected (Smith et al., 2000). Interestingly, when the authors infected the macaques at the sub-
epithelium layer, the authors found that all the E2 treated macaques became infected, suggesting that E2 
blocked infection at the vaginal epithelium or lumen (Smith et al., 2000). Since natural P4 showed similar 
effects to the hormonal contraceptives, several macaque studies have assessed SHIV-1 risk during the 
different phases of the menstrual cycles using pigtail macaques, and found that there was an increased 
susceptibility to SHIV-1 in the luteal phase (high P4) (McNicholl et al., 2014; Vishwanathan et al., 2011; 
Kersh et al., 2014).  
A recent study by Radzio et al. (2014) examined the effects of menstrual cycle and DMPA on SHIV-1 viral 
shedding, epithelial thickness and density of intraepithelial CD3+ cells. The authors found that with 
increasing doses of DMPA, vaginal epithelial thickness decreased by up to 80% compared to the follicular 
phase. Epithelial thickness was reduced in the luteal phase, however it was not significantly reduced 
compared to the follicular phase. In addition, low doses of DMPA (3 mg) decreased epithelial thickness by 
50% for 3 weeks, before returning to similar levels in the follicular phase by week 6. This data suggests that 
DMPA is more efficacious than the natural ligand P4 at reducing epithelial thickness. DMPA treatment also 
significantly increased the amounts of CD3+ cells in the vaginal epithelium compared to both the luteal and 
follicular phase in untreated macaques. Using the low dose of DMPA, which the authors suggest produces 
similar effects of 150 mg dose in humans; they challenged the macaques with SHIV-1. While the authors 
found that DMPA treated macaques had higher odds of virus being detected in the serum, there was no 
significant difference in viral shedding compared to the untreated control group (Radzio et al., 2014). The 
data from this study highlights the importance of dose, and sampling times. The authors only assessed viral 
shedding, and not acquisition, thus the data suggests that DMPA may not affect viral RNA shedding in 
plasma or vaginal secretions after acute infection but it does not provide any information on the likelihood to 
become infected. Interestingly, DMPA treated macaques exhibited different effects compared to P4 (in the 
luteal phase) in macaques, suggesting that MPA, more than the natural hormone P4, could change immune 
parameters and vaginal epithelial thickness to predispose an individual to HIV-1 infection (Radzio et al., 
2014).  
To elucidate some of the mechanistic underpinnings of how mucosal barrier function could play a role in 
mediating HIV-1 infection, Nazli et al. (2010) showed that exposure to HIV-1, for 2 - 4 hours, significantly 
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disrupted the trans-epithelial resistance in primary genital and intestinal epithelial cells. Furthermore in 
primary genital epithelial cells, the authors found that exposure to HIV-1 increased the permeability of the 
cells and increased the expression of pro-inflammatory cytokines (Nazli et al., 2010). Further to this, a 
recent study from Ferreria et al. (2014) suggests that MPA could further exacerbate the risk of HIV-1 
infection, by increasing uptake (via endocytosis) of the virus in primary genital epithelial cells. In addition, 
the authors found that MPA-treated epithelial cells exhibited increased transcytosis of the virus from the 
apical exposed surface to the basolateral layer, and that when co-cultured with T-cells, MPA-treated 
conditions had greater infection levels measured in the T-cells than that of the control, P4 or estrogen 
treated cells (Ferreira et al., 2014). A study in the vaginal epithelial cell line (VK2/E6E7) found that 
treatment with high concentrations of MPA (388 µM) increased syndecan expression in these cells, 
resulting in a greater transfer of HIV-1 to T cells compared to the vehicle control. In addition, using the 
endometrial epithelial HEC-1-A cell line to mimic the epithelial monolayer in the endocervix, MPA treatment 
(77 and 388 µM) decreased the epithelial integrity (as measured by a decrease in barrier resistance), after 
4 days treatment (Irvin & Herold, 2015). The authors also found that this decrease in barrier integrity 
corresponded to an increase in HIV-1 transmission as measured by an increase in p24 expression levels in 
the JT-CCR5 indicator T cell line in the basolateral chamber (Irvin & Herold, 2015). The authors suggest 
that syndecans facilitate the transfer of the virus through the epithelial barrier of the vagina, and could be 
one mechanism of viral entry in the female genital tract, while HIV-1 could disrupt the endothelial barrier to 
increase HIV-1 transmission in the cervix, similar to that observed by Nazli et al. (2010).  
The data suggest that MPA, more so than P4, significantly reduces epithelial barrier thickness in animal 
models (Radzio et al., 2014; Marx et al., 1996). It has also been suggested in several macaque studies that 
the luteal phase may be the most susceptible to SHIV-1 infection (Marx et al., 1996; McNicholl et al., 2014; 
Vishwanathan et al., 2011; Kersh et al., 2014). As such, the role of progestin contraceptives, which mimic 
the luteal phase, in HIV-1 acquisition is concerning (Radzio et al., 2014; Kersh et al., 2014; McNicholl et al., 
2014). Supporting this is the evidence to suggest that MPA treatment may increase both viral load and 
genetic diversity of the virus in macaques (Trunova et al., 2006), as well as increasing viral transport 
mechanisms through the epithelium and into the submucosa, increasing rates of transmission in cell line 
studies (Ferreira et al., 2014; Irvin & Herold, 2015). Taken together, the data highlights that more research 
on the effects of different progestins compared to endogenous P4 on barrier integrity, HIV-1 susceptibility 
and transmission are needed.  
1.3.3.2. Mucosal environment, inflammatory profiles and disease susceptibility 
It has been observed in several studies that the effects of the menstrual cycle could affect disease 
susceptibility by altering immune cell populations and subsequent immune responses (reviewed in (Wira et 
al., 2010; Wira et al., 2014; Wira et al., 2015) and may be in part mediated by the differential levels of P4 
and E2 in the follicular and luteal phase. Some studies have observed that natural killer cells, which are 
important in cell mediated immunity in clearing virus infected cells (Yovel et al., 2001), have higher activity 
 
26 
levels and cell numbers in the follicular phase (high E2, low P4) compared to the luteal phase (high P4, low 
E2) (Souza et al., 2001; Yovel et al., 2001). Other studies have reported that P4 decreases cell mediated 
immunity by increasing the population of T regulatory (T reg) cells (which are tolerogenic) in the luteal 
phase (Weinberg et al., 2011), as well as decreasing the production of Th-1 cytokines (Enomoto et al., 
2007; Kaushic et al., 2003; Gillgrass et al., 2003), altering the ability to mount an immune response upon 
pathogen challenge. It has also been established that the menstrual cycle affects the secretion of 
immunoglobulins (IgA, IgM and IgG) within the female genital tract (FGT), with the highest amounts 
produced 2 - 3 days before ovulation, in the follicular phase (Wira & Sullivan, 1985; Kutteh et al., 1996; 
Franklin & Kutteh, 1999). Furthermore it has been found that the luteal phase has been associated with an 
increase in HIV-1 RNA viral shedding (Benki et al., 2004), an increase in CXCR4 and CCR5 co-receptor 
expression (Cabrera-Muñoz et al., 2012; Wira et al., 2005), and a decrease in antimicrobial peptide 
production (Wira et al., 2015), while pregnancy has been associated with an increase in susceptibility to 
HIV-1 (Borgdorff et al., 2015; Morrison et al., 2014). Thus it has been proposed, that high progesterone 
may increase disease susceptibility, including the use of progestogens (Kaushic et al., 2011; Wira et al., 
2015). 
In order to address the question of how progestogens may alter the genital mucosa in women, several 
studies have investigated the changes in immune function in the mucosal environment within the female 
genital tract of animals subjected to progestogen treatment. One study in rhesus macaques suggests that 
DMPA increases the availability of select HIV-1 target cells and increases the expression of the intergrin 
α4β7 receptor in these memory CD4+ T cells and dendritic cells (DCs). These cells, with high  α4β7 
expression are reported to be highly susceptible to HIV-1 infection (Goode et al., 2014). Additionally the 
authors observed in the endocervix of rhesus macaques, that DMPA treatment altered the expression of 
Th-1 and Th-2 cytokines, increasing interferon (IFN) – γ, chemokine (C-C motif) ligand (CCL) 4, CCL21 
protein expression and decreasing IL6 and IL8 compared to untreated controls (Goode et al., 2014). 
Interestingly in this study, the authors found that treatment with estrogen (E2) selectively repressed select 
cytokine expression in the endocervix, while only DMPA had effects on cytokine levels in the plasma 
(Goode et al., 2014). The authors also reported that the levels of HIV-1 target co-receptor CCR5 were 
elevated in several cell types upon treatment with DMPA compared to the untreated control (Goode et al., 
2014). Importantly, this study suggests that E2 and the synthetic progestin MPA exert differential effects on 
target cells in a compartment specific manner, and that it is a combination of these factors that alter the 
susceptibility to infections (Goode et al., 2014).  
In mice studies HSV-2 infection was increased by 100 fold in DMPA treated mice while P4 treatment lead to 
a 10 fold increase. In addition, mice in the estrus phase (high E2), were fully protected against HSV-2 
infection (Kaushic et al., 2003). The authors found that several cell types as well as IgA and IgG levels were 
altered in response to DMPA treatment (Kaushic et al., 2003). Another study found that prolonged DMPA 
treatment in mice, compared to short treatment, altered the response to effective immunisation to HSV-2, 
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with long term treatment reducing the ability to mount an effective response to HSV-2 treatment (Gillgrass 
et al., 2003). The authors found that DMPA decreased the induction of a protective immune response, with 
a reduction in IFN-ɣ production (Gillgrass et al., 2003). Following this, Miguel et al. 2012, found that DMPA 
treatment in mice impaired the initial expansion of virus-specific and memory precursor T cells, and 
dampened the expression select co-stimulatory molecules by dendritic cells necessary to clear the viral 
infection. The authors also found that these effects were site specific, with most of the observed effects 
occurring at the mucosal site of infection (Miguel et al., 2012). 
Some of these observations on immune function in animal models have been corroborated in prospective 
cohort studies, when studying the associative risks of HIV-1 acquisition and contraceptive use. Morrison et 
al. (2014) assessed if certain biomarkers of cervical inflammation in women on contraception, not on 
contraception or pregnant, were associated with an increased risk of HIV-1 infection. When comparing 
women who became infected to those that remained uninfected, the authors found that women who 
became infected had increased levels of regulated upon activation, normal T cell expressed and secreted 
(RANTES) and beta-defensin (BD)-2 and decreased levels of secretory leukocyte proteinase inhibitor 
(SLPI). When stratifying for contraceptive use, the authors found that there were distinct patterns of 
inflammatory markers upregulated in women on COCs compared to women on DMPA. Additionally, the 
authors found that DMPA use was associated with an increase in RANTES and a decrease in BD-2 levels. 
While the authors could not stratify between DMPA users who became infected to those that remained 
uninfected, they suggest that increased RANTES and decreased BD-2 expression levels could explain why 
they observed an increase in infection in women on DMPA compared to no contraception (Morrison et al., 
2012; Morrison et al., 2014). Similarly, Guthrie et al. (2015) assessed the effects of hormonal contraception 
on changes in anti-viral peptides associated with HIV-1 infection in the female genital tract. The authors 
found that women on DMPA had higher levels of human neutrophil peptide (HNP)-1-3, human cathelicidin 
(LL-37) and lactoferrin, compared to women not on contraception. In addition, the authors found an 
increase in SLPI in COC users compared to women not on contraception, and an increased expression 
levels in LL-37 and lactoferrin in implant users. HNP-1-3 and LL-37 have been shown to increase HIV-1 
replication in vitro, by recruiting CD4+ target cells, thus the authors suggest that women on DMPA may 
have an increased risk in HIV-1 acquisition due to increased levels of HNP-1-3 and LL-37 (Guthrie et al., 
2015). Ngcapu et al. (2015) measured secretory protein levels found in the CVL of women who were on 
injectable contraceptives and found that these women had significantly lower levels of several cytokines 
(eotaxin, MCP-1, MDC, IL-15), a growth factor (PDGF-AA) and a metalloproteinase (TIMP-2) compared to 
women not on hormonal contraception (Ngcapu et al., 2015). The authors suggest that women on injectable 
contraceptives may have a immunosuppressive profile compared to women not on contraception (Ngcapu 
et al., 2015). However in this study DMPA and NET-EN users were not separated. 
In an ex vivo study by Chandra et al. (2013), DMPA use significantly increased the number of select 
activation markers (HLA-DR and CCR5) and receptors (CD45, CD3, CD68) in leukocytes obtained from the 
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vaginal mucosa 12 weeks post administration, compared to the same women when in the follicular phase 
and luteal phase. In addition DMPA treatment increased the density of vaginal immune cells (CD3+, CD8+, 
CCR5+ and HLA-DR+ cells) compared to the luteal phase, and significantly compared to the follicular 
phase. In this study, the authors found a decrease in vaginal epithelial thickness and a reduction in the 
number of cell layers upon DMPA treatment compared to both the follicular and luteal phase (Chandra et 
al., 2013), similar to that observed in macaques (Radzio et al., 2014). In a study by Prakash et al. (2002), 
CCR5 expression was significantly increased in T cells (both CD4+ and CD8+) isolated from cytobrush 
samples of women on oral contraceptives compared to women not on contraceptives (Prakash et al., 
2002). This study suggests that COCs may increase the risk in HIV-1 acquisition (Prakash et al., 2002). 
However, since both studies only compare one type of contraception to no contraception, it is not possible 
to assess if there may be differences between DMPA, COC or other types of contraception (NET-EN, 
implants, copper IUD). Additionally, in a longitudinal study assessing the effects of DMPA use after one 
year, DMPA users had a non-significant reduction in vaginal epithelium, and a significant reduction in CD3+ 
T cells infiltrating the epithelium over the time course evaluated (Mitchell et al., 2014). Interestingly, in this 
study, CCR5 expression was maintained over time in all groups, unlike that observed by Prakash et al. 
(2002) and in a macaque study (Goode et al., 2014).  
Collectively both animal and observational studies in women, suggest that progestins have significant 
effects on immune cell function and cell type expression. However the extent to which different progestins 
at different doses over time affect immune function is still to be determined. Importantly, it must be noted 
that these studies differ significantly in their time points where they assayed the effects of DMPA on key 
host responses and functions. In macaques, some studies were assayed at 3 - 5 weeks post injection with 
DMPA (Goode et al., 2014; Trunova et al., 2006), while for the observational studies in women, samples 
were taken from 12 weeks post injection (Chandra et al., 2013) to 3 - 12 months (Morrison et al., 2014). 
Furthermore the differences between the immune response and composition of the FGT in animal models 
compared to human studies must be taken into consideration when investigating the effects of progestins 
on immune function. As discussed by McNicholl et al. (2014), rhesus macaques are seasonal breeders with 
a keratinised lower FGT, as such the effects of progestins may be different in these models compared to 
women (McNicholl et al., 2014). 
Thus, the literature presents an incomplete assessment on the changes in mucosal immune parameters in 
women and in animal studies upon treatment with DMPA. Since DMPA treatment has peak serum 
concentrations a few days after injection, before plateauing for 2 - 3 months, it will be of importance to 
assess changes in HIV-1 susceptibility at the different concentrations throughout the period of DMPA 
treatment in women, rather than assessing at the end point only. The effects of different concentrations is 
more feasible to investigate in ex vivo and cell line models, where one does not have to repeatedly sample 
women or animals over a short period of time. In addition, no reported animal studies have compared the 
different progestins used in contraceptives for the effects on susceptibility to HIV-1 acquisition, nor have 
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any reports compared changes in humoral and cellular immune parameters thereof. Few of these 
observational studies in women have compared the effects of different contraceptives in HIV-1 susceptibility 
(Morrison et al., 2014; Guthrie et al., 2015). However, inclusion of too many types of contraceptives in 
clinical studies could compromise the power of the study, as observed in the Guthrie et al. (2015) study 
where the small group of women on oral contraceptives or the implant (Jadelle) prevented the authors from 
making associations between changes in cationic peptides involved in anti-viral activity and contraceptive 
use (Guthrie et al., 2015). Lastly, the observational studies are unable to provide a conclusive correlation 
between changes in immune parameters by progestin contraceptives and HIV-1 acquisition, nor evidence 
for direct effects on target cells (Morrison et al., 2014; Guthrie et al., 2015) making ex vivo studies attractive 
models in which to assay direct effects of these progestins on various immunological parameters and HIV-1 
infection. 
1.3.3.3. Differential effects of progestogens on cellular immune function and gene 
expression 
 
Given that MPA, unlike other progestins, acts as a relatively potent full to partial agonist for the GR, MPA is 
likely to exert much more potent and efficacious effects on gene promoters involved in immune function 
than P4 or NET via the GR (Koubovec et al., 2004; Koubovec et al., 2005; Africander et al., 2011). 
Hapgood et al. (2004) proposed in 2004 that due to the differential activity of MPA versus NET via the GR, 
MPA is likely to exert different effects on immune function and hence modulate susceptibility to infections 
like HIV-1 (Hapgood et al., 2004). As mentioned previously, progestins exert their effects via steroid 
receptors. Koubovec et al. (2004) investigated the effects of MPA, P4 and the synthetic glucocorticoid DEX 
on GR binding and transcriptional responses. Using L929sA cells (a mouse fibroblast cell line), the authors 
found that MPA like DEX, repressed TNF-α induced IL6 protein secretion and IL6 and IL8 transcriptional 
activity, and increased GRE-driven promoter-reporter construct in a dose dependent manner, and that 
these effects were modulated in part by the GR. Interestingly, both MPA and P4 also appeared to act as 
partial GR agonists in the transrepression experiments, while P4 had weaker effects on transactivation. The 
authors also found that MPA induced recruitment of the GR to the nucleus similar to DEX (Koubovec et al., 
2004). Following this, the authors investigated the ligand-selective profiles of the different progestins 
towards the GR. Using HEK293 cells, the authors performed competitive binding assays and found that 
MPA had a higher RBA for the GR than P4 and NET (Ki of 10.8 nM for MPA compared to 270 and 215 nM 
for P4 and NET-A respectively). In addition, the authors found that MPA had greater transactivation agonist 
potency than NET-A or P4, similar to DEX. Similarly MPA, like DEX had greater agonist potency for 
transrepression than NET-A or P4. The authors also found that MPA induced the phosphorylation of the GR 
at serine residue 211 (a marker for GR activation) to a much greater extent compared to NET-A and P4 
(Koubovec et al., 2005). These two studies show that MPA, unlike NET-A and P4 differentially regulates 
select GR-target genes via the GR in a concentration dependent manner. This was confirmed in a study by 
Avenant et al. (2010) investigating the effects of MPA and NET-A on GR phosphorylation at serine (S) 226 
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and S211, GR half-life and on GR transcriptional responses. The authors found that MPA induced GR S226 
and S211 phosphorylation, while NET had minimal effects on phosphorylation. Additionally, MPA induced 
GR turnover, while NET did not. These results show that MPA, unlike NET, has glucocorticoid-like 
properties and is able to activate the GR to elicit downstream transcriptional effects (Avenant et al., 2010). 
Furthermore, it has been established that the effects of the progestins on GR-target genes are dependent 
on the concentration of the progestin and the nature of the promoter in target genes. Ronacher et al. (2009) 
found that there were ligand-selective differences in potency and efficacy for each promoter, as well as for 
a particular progestin between the promoters assayed. The authors found that in COS-1 cells, MPA 
behaved as a partial agonist for transactivation, compared to DEX, and a full agonist for transrepression. 
NET had no activity on any of the constructs tested. In addition, the study found that MPA was more 
efficacious in transrepression on an AP-1 promoter than an NFκB promoter. In order to further distinguish 
between the different transcriptional activities exerted by the different ligands, the authors investigated co-
factor recruitment. Using a mammalian two-hybrid assay in U2OS cells, the authors found that the co-
activators tested, interacted with the GR in a ligand specific manner. MPA increased recruitment of 
glucocorticoid receptor interacting protein 1 (GRIP-1), steroid receptor co-activator 1  (SRC-1) A, nuclear 
receptor co-repressor (NCoR)-receptor interacting domain (RID) and silencing mediator for retinoid or 
thyroid-hormone receptor (SMRT)-RID, while NET weakly recruited these co-activators and co-repressors. 
The results suggest that NET and MPA have differential effects on co-factor recruitment and supports the 
idea of differential gene regulation by these ligands on host genes (Ronacher et al., 2009). 
Differential gene regulation effects by MPA and NET have been reported in several cell types on 
endogenous genes. Africander et al. (2011) investigated the relative effects of 1 μM P4, MPA and NET-A 
on cytokine gene expression in the female genital tract, using two epithelial cell lines (vaginal: Vk2/E6E7 
and ectocervical: Ect1/E6E7). The authors found after 24 hours of incubation, that P4 increased TNF-α 
induced IL6 mRNA expression levels in both cell lines, while MPA and NET had no effect. TNF-α induced 
IL8 mRNA expression was significantly unregulated by P4 and MPA, but not NET-A in ectocervical cells, 
while the ligands had no effect on IL8 mRNA expression in vaginal cells. Interestingly, MPA significantly 
decreased TNF-α induced RANTES mRNA expression levels in ectocervical cells, while P4 significantly 
increased expression. In vaginal cells, MPA had no effect on RANTES levels, while P4 increased 
expression. In both cell lines, NET-A had no effect on RANTES mRNA expression levels (Africander et al., 
2011). Hadley et al. (2011) found that MPA but not P4 or NET-A, significantly increased glucocorticoid 
interacting leucine zipper (GILZ) mRNA expression in a lung epithelial cell line (A549), and that MPA 
significantly recruited the GR to the promoter region of GILZ (Hadley et al., 2011). Irvin and Herold (2015) 
also observed similar pro-inflammatory effects (in the absence of TNF-ɑ) in the vaginal cell line Vk2/E6/E7 
by MPA. The authors found that MPA at high concentrations, dose dependently increased TNF-ɑ, GM-CSF, 
IL6, IL8, CCL3 and CCL4 mRNA expression levels after five days, and dose dependently increased TNF- ɑ, 
granulocyte macrophage - colony stimulating factor (GM-CSF), IL6, IL8, CCL3, CCL4 and CCL5 protein 
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expression levels after 5 days. Interestingly, some cytokines were more sensitive to MPA treatment, with 
CCL5 expression increasing at lower concentrations of MPA, while increases in CCL4 and CCL3 protein 
levels were only apparent at the highest concentration of MPA (Irvin & Herold, 2015). Govender et al. 
(2014) investigated the differential effects, molecular mechanisms of action and the steroid receptor 
involvement in gene expression by the synthetic progestins MPA and NET compared to the endogenous 
hormone, P4 in an endocervical cell line model (End1/E6E7). The authors found that 100 nM MPA, unlike 
NET-A and P4, increased mRNA expression of the anti-inflammatory GILZ and IκBα genes in End1/E6E7 
and HeLa cells after 24 hours. Similarly, MPA unlike NET-A, decreased basal mRNA expression of the pro- 
inflammatory IL6, IL8 and RANTES genes in both cell lines. In these cell lines, MPA behaved as a full to 
partial GR agonist compared to DEX. In addition, the authors found that after 24 hours of treatment, MPA 
like DEX, repressed IL6, IL8, RANTES and up regulated GILZ mRNA expression dose dependently, while 
NET-A like P4 had no effect on gene transcription at any concentration. The authors also found that these 
responses were mediated via the GR, and that MPA, like DEX recruited the GR to the promoter elements of 
the genes tested (Govender et al., 2014). Further identifying the role of the progestins in the local mucosa, 
Louw-du Toit et al. (2014) investigated the regulation of the pro-inflammatory cytokine, interleukin (IL)-12, 
and the anti-inflammatory cytokine IL-10, by MPA and P4, in Ect1/E6E7 cell lines as a model of the female 
ectocervical environment. The authors found that MPA and P4 significantly increased the TNF-ɑ induced 
mRNA expression of IL12p40 and IL-12p35 in a dose dependent manner, and to similar extents. In 
addition, both P4 and MPA decreased IL10 mRNA expression dose-dependently. Using two different types 
of siRNA targeting the GR, the authors established that these effects on gene regulation were GR 
dependent. In addition, the authors found that these GR-dependent effects by MPA and P4 recruited 
different co-factors to mediate the responses observed (Louw-du Toit et al., 2014a).  
These results highlight that the different progestogens, MPA, NET and P4, have differential effects on 
immune gene expression at different concentrations in different cellular systems. Furthermore, some 
studies have found that MPA and to a lesser extent, P4, mediate some of their gene specific effects via the 
GR. Taken together, dose, length of treatment time and cellular compartment have important and significant 
impact on gene regulation exerted by MPA via the GR. Thus dose, model and time must be carefully 
considered in the experimental design in order to fully address the effects of progestins on HIV-1 
susceptibility. 
Few studies have identified the effects of progestins in primary cell models. Tomasicchio et al. (2013) found 
that MPA, unlike NET and P4, exhibited differential regulation of apoptotic genes and dose-dependently 
enhanced HIV-1 mediated apoptosis in primary human CD4+ T cells via a GR-dependent mechanism 
(Tomasicchio et al., 2013). Huijbregts et al. (2013) found that MPA, to a greater extent than P4, suppressed 
ex vivo the production of key regulators of cellular and humoral immunity involved in orchestrating the 
immune response to invading pathogens such as HIV-1 in peripheral blood mononuclear cells (PBMCs) 
and vaginal mononuclear cells (VMMCs). In addition the authors found that some of the responses were 
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mediated most likely via the GR, using the antagonist RU486 (Huijbregts et al., 2013). In addition, the 
authors found that MPA like DEX increased CCR5 and CXCR4 protein expression in CD4+ and CD8+ T 
cells (Huijbregts et al., 2013). Hughes et al. (2008) found that plasmacytoid dendritic cells (pDCs) were 
present in both cervical tissue and in systemic PBMCs. pDCs are key immune sentinels in the anti-viral 
response, producing large amounts of interferon (IFN)-ɣ that initiate the anti-viral response. When the 
authors assessed the ability of these cells to produce IFN-ɣ in the presence of the contraceptive MPA and 
the natural ligand P4, the authors found that DMPA treatment drastically reduced IFN-ɣ expression in pDCs 
(Hughes et al., 2008). This study suggests that DMPA is able to exert important physiological effects in cell 
types important in both the local mucosa and in the systemic environment. This was confirmed in Huijbregts 
et al. (2014) where the authors found that DMPA, but not LNG or NET suppressed IFN-ɣ expression in 
pDCs (Huijbregts et al., 2014). Further to this, the authors found that MPA, but not NET or LNG, inhibited 
cytokine production in activated T cells. In addition, MPA but not NET or LNG inhibited the IFN-ɑ and TNF-
ɑ induction in pDCs upon exposure to inactivated HIV-1 or CpG (a ligand for the anti-viral response), 
suggesting that MPA may disrupt the response to infections (Huijbregts et al., 2014). Kleynhans et al. 
(2011) reported that women using MPA had decreased cytokine protein expression profiles compared to 
women not on MPA in BCG-stimulated peripheral blood mononuclear cells (PBMCs). In addition, the 
authors suggest that their findings suggest that MPA affects the systemic immune environment and not just 
the local mucosal environment (Kleynhans et al., 2011). Following this study, Kleynhans et al. (2013) found 
that MPA significantly decreased the expression of select cytokines, and that following challenge with BCG 
in C57BL/6 mice, mice treated with MPA at doses similar to serum concentration in women had higher 
bacterial loads in their lungs (Kleynhans et al., 2013).  
Taken together, these studies show that MPA has significant effects on key immune modulators in both 
systemic (Huijbregts et al., 2013; Huijbregts et al., 2014; Tomasicchio et al., 2013; Hughes et al., 2008) and 
local immune environments (Africander et al., 2011; Louw-du Toit et al., 2014b; Govender et al., 2014; 
Kleynhans et al., 2011; Kleynhans et al., 2013), and has been shown to increase the susceptibility to 
infections in both mice models (Kleynhans et al., 2011; Kleynhans et al., 2013) and human PBMCs 
(Huijbregts et al., 2014; Hughes et al., 2008) by modulating or delaying the immune response. However, the 
extent to which effects of MPA compared to P4, NET and LNG modulate host immune system as well as 






1.4. Aims of this study 
 
The aims of this study are to understand the molecular mechanisms underpinning the differential effects by 
progestogens on select immune gene function in relevant models for systemic and local immunity. In 
addition, this project aims to elucidate whether different progestogens have differential effects on HIV-1 
infection in these relevant biological systems. As mentioned, both local mucosal and systemic immune 
systems are pivotal in HIV-1 infection, with some progestogens shown to affect immune parameters in both 
systems. Utilising peripheral blood mononuclear cells from healthy HIV-1 negative individuals representing 
key targets for HIV-1 infection and replication, as well as ex vivo primary cervical explants from women who 
have undergone hysterectomies for benign reasons representing a key site for transmission, we aim to 
elucidate mechanisms of differential gene regulation exerted by the progestogens in the different 
compartments important in HIV-1 infection, and the effects of these progestogens on HIV-1 infection. 
This study has focused on three contraceptives used in South Africa, namely the injectable contraceptives 
MPA and NET, and the progestin used in combined oral contraceptives and implants, LNG. In order to 
make a persuasive argument to support the reassessment of select progestins used in contraception for 
women, control ligands are needed to elucidate whether the effects observed by each progestin are 
different or similar to the natural ligand P4. In addition, since the literature has shown that MPA is a partial 
glucocorticoid (Bamberger et al., 1999; Koubovec et al., 2004; Koubovec et al., 2005; Ronacher et al., 
2009), the synthetic glucocorticoid, dexamethasone (DEX) will be used to infer glucocorticoid effects in 
these systems. To date, there is little literature comparing progestogens used in contraceptives on immune 
function in different compartments. This is important, because as Jain (2012) reported, removing a 
contraceptive from the usable pool, may increase mother and child mortality and morbidity rates (Jain, 
2012). As such, it is necessary to compare progestogens so that one can make informed choices over 
which progestin contraceptive to utilise in areas where HIV-1 acquisition is high.  
In order to assess the effects of the progestogens and glucocorticoids on immune function in peripheral 
blood mononuclear cells (PBMCs) and ex vivo cervical explants, the project focused primarily on 4 key 
immunomodulatory genes namely, GILZ, IL6, IL8 and RANTES. GILZ is an anti-inflammatory protein that 
inhibits the activation of pro-inflammatory transcription factors, nuclear factor κB (NFκB) (Di Marco et al., 
2007) and activator protein 1 (AP-1) (Eddleston et al., 2007). GILZ is constitutively expressed in many 
human tissues, including T cells, epithelial cells and mesenchymal cells, and its expression is rapidly up-
regulated in response to GCs (Ayroldi & Riccardi, 2009). It has been found that GILZ mediates anti-
inflammatory responses similar to that of the anti-inflammatory cytokine IL10 (Berrebi, 2002) and has been 
found to play a role in the regulation of T helper cell differentiation and dendritic cell function (Ayroldi & 
Riccardi, 2009). IL6 is an important cytokine involved in mediating T-cell activation, growth and 
differentiation, and is secreted mainly by dendritic cells and macrophages in response to the activation of 
pattern recognition receptors (Murphy et al., 2012). Additionally, IL6 is a key cytokine involved in cytotoxic 
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immunity involved in immune responses directed against virus-infected cells (Borish & Steinke, 2003). It 
has been observed in two studies that IL6 expression has been associated with an increased risk in HIV-1 
susceptibility in women (Roberts et al., 2012; Masson et al., 2014), while one study has indicated that 
decreased IL6 expression levels were moderately associated with HIV-1 acquisition (Lehman et al., 2014). 
It has also been found that IL6 protein expression is induced by HIV-1 replication, several days after 
infection in monocytes and that this correlated with increased viral replication in monocytes (Birx et al., 
1990). IL8 is a chemokine that is highly expressed in mononuclear, epithelial, endothelial, macrophages 
and monocytes (Murphy et al., 2012) and T cells in response to virus-infected cells (Borish & Steinke, 
2003). IL8 is a chemotactic factor that recruits neutrophils, basophils and T cells to the sites of infection 
(Murphy et al., 2012). Additionally, IL8 induces neutrophils to migrate out into the surrounding infected 
tissue from the blood, making it an important local immunity protein (Murphy et al., 2012). Additionally it has 
been observed that an increase in IL8 protein levels decreases HIV-1 infection in PBMCs and ectocervical 
explants (Rollenhagen & Asin, 2010). RANTES (CCL5) is a CC chemokine that is involved in the 
recruitment of mononuclear cells to sites of chronic inflammation (Charo & Ransohoff, 2006), and is 
produced predominantly by T cells and endothelial cells (Murphy et al., 2012). RANTES is a chemokine and 
a ligand for the HIV co-receptor, CCR5 (Cocchi et al., 1995). RANTES protein expression has been shown 
to directly promote the development of IFN-γ producing Th-1 lymphocytes (Borish & Steinke, 2003), while a 
decline in RANTES protein levels has been associated with an increase in HIV-1 disease progression 
(Aukrust et al., 1998). Additionally, RANTES expression has been shown to interfere with the spread of 
HIV-1 by competitive binding to CCR5, a receptor integral to HIV-1 entry (Cocchi et al., 1995). Some 
reports have stated that increasing levels of RANTES may lead to an increased outcompeting for the CCR5 
co-receptor, thereby reducing HIV-1 infection (Lane et al., 1999). Consequently, it has been found that an 
increase in RANTES gene expression has been associated with decreasing HIV-1 replication and infection 
in peripheral blood monocytes (PBMs) (Lane et al., 1999). Interestingly, it has also been found that high 
protein levels of RANTES has been associated with HIV-1 seroconversion in women and an increased risk 
in HIV-1 acquisition in women using DMPA (Morrison et al., 2014). In conjunction with mRNA expression 
studies investigating these genes, select protein expression studies using commercial cytokine Luminex 
panels will be employed to investigate the effects of these progestogens on key cytokines and chemokines 
in the inflammatory response. 
Additionally, previous research on the biological effects of progestins and P4 has been hampered by a lack 
of understanding of the significance doses have in determination of physiologically relevant responses 
(Hapgood et al., 2013; Hapgood, 2013). Unfortunately there is also a lack of information about serum 
concentrations of progestins in contraception users, which show high inter-individual variability, as well as 
concentrations in tissues at target sites, which may not mimic serum concentrations (Halpern et al., 2014; 
Hapgood, 2013). As such, this study aims to elucidate whether the observed effects of MPA, NET and P4 
are relevant to the physiological doses of these ligands (Africander et al., 2011; Stanczyk et al., 2013) by 
dose response analysis to determine potencies and efficacies (Hapgood et al., 2013). It is known that 
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endogenous P4 serum concentrations vary substantially during the menstrual cycle in premenopausal 
women and are low during the follicular phase (0.65 nM), rising to about 80 nM during the luteal phase, with 
higher concentrations of about 600 nM during pregnancy (Africander et al., 2011). MPA serum 
concentrations are reported to be in the range 2.5 to 65 nM a few days after injection in injectable users 
(Ortiz et al., 1977; Mishell, 1996; Hiroi et al., 1975; Mathrubutham & Fotherby, 1981) and to plateau at 
about 2.6 nM for about three months (Africander et al., 2011), while serum concentrations of NET-EN are 
reported to be in the range 1.5–59 nM (Fotherby, 1981; Africander et al., 2011; Stanczyk et al., 2013). LNG 
at a 50 µg dose, administered orally, reaches a max serum concentration of 6.4 nM within an hour, before it 
declines (Sitruk-Ware, 2008). LNG administered in intrauterine devices, reach a serum concentration of 1.6 
nM after 6 and 12 months post insertion (Kuhl, 2011), while implant users have peak serum concentration 
levels of 2.47 nM for the first month before declining to 0.89 nM after 3 years (Sivin et al., 2002). Therefore 
understanding the effects of the progestogens at relevant concentrations will provide insight into the effects 
that may occur in vivo, and will inform better contraceptive choice by examining the doses at which 
contraceptives are administered.  
A key question remains as to how do different progestins affect expression of key genes involved in 
immune function in primary cells relevant to HIV-1 pathogenesis. The Hapgood group proposed in 2004 
that due to the differential activity of MPA versus NET via the GR, MPA is likely to exert different effects on 
immune function and hence modulate susceptibility to infections like HIV-1 (Hapgood et al., 2004). In this 
study, the aim is to investigate GR involvement in mediating the effects of the progestogens on immune 
gene modulation in peripheral blood mononuclear cells utilising both antagonist and small interfering RNA 
(siRNA) techniques. 
Lastly, more evidence is needed that compares the effects of the different progestogens on HIV-1 infection 
in relevant models. Observational (Morrison et al., 2015; Ralph et al., 2015), animal (Trunova et al., 2006; 
Kaushic et al., 2003) cell line data and some primary PBMCs (Tomasicchio et al., 2013; Huijbregts et al., 
2013; Kleynhans et al., 2011; Kleynhans et al., 2013) data has not as yet been persuasive enough to 
inform policy change in contraceptive use. In addition, these studies have been limited in their choice of 
progestogens and have not provided clear differential and comparative effects of these progestins on HIV-1 
acquisition. As such, the current study seeks to compare the differential effects of HIV-1 infection by the 
progestogens in both PBMCs and primary cervical explants. Using laboratory strains of X4 and R5 viruses 
(HIV-1BaL_Renilla and HIV-1pNL4.3 respectively) the project aims to understand effects on HIV-1 replication by 
MPA, NET, LNG and P4 in primary ex vivo explants and primary PBMCs (HIV-1BaL_Renilla only). In addition 
this study aims to understand how these progestins modulate immune gene function over time, and if HIV-1 
infection alters the expression of these genes to favour HIV-1 replication in these systems. As has 
previously been mentioned, inflammation is thought to play a major role in initial infection (Roberts et al., 
2012; Masson et al., 2014). As such the effects of progestogens over time on key pro-inflammatory genes 
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(IL6, IL8 and RANTES) and the anti-inflammatory gene (GILZ) may provide some molecular insight into the 
relative risks of progestogen use over time, and how this may affect susceptibility to HIV-1 infection.  
It is essential to provide clarity around the associative risks of progestin contraceptives on HIV-1 acquisition 
obtained from observational, animal and biochemical data. As such this study seeks to provide such 
evidence using relevant models (PBMCs and primary cervical explants) showing that MPA, unlike other 
progestins and P4 differentially and dose dependently, modulates immune function genes and differentially 
modulates HIV-1 infection in these systems. In addition the data seeks to provide clarity over the apparent 
discrepancies in the observational data, whereby MPA is seen to increase HIV-1 acquisition in some 
cohorts, while not in others (Ralph et al., 2015). It is imperative that there be more effort into providing 
evidence on contraceptive use and HIV-1 risk. It is important and necessary when one considers that if the 
observational data is correct, a woman in a high risk area for HIV-1 infection may have a 1.4 increased risk 
in HIV-1 acquisition (Hapgood, 2013; Ralph et al., 2015). Thus, urgency exists to make informed choices on 
contraceptives use in high risk areas, and that choice of progestin used in contraception is vital. It may be 
five years before any data from the ECHO trial (Rees, 2014) is released, in the interim, studies such as this, 
as well as studies in animal, observational and biochemical data are needed to help make more informed 
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Work undertaken in this project was approved by the Science Faculty Biological Safety Committee, The 
University of Cape Town, South Africa (approval number: BSC021_2014), which included the use of 
Hazardous Biological Agents and/or Genetically Modified Organisms.  
Cell line work was performed under P2 conditions, while primary cell work including PBMC and primary 
cervical explant experiments and experiments using HIV-1 infectious molecular clones, were performed 
under P2+ conditions in the Department of Molecular and Cell Biology (The University of Cape Town, South 
Africa). 
2.2. Test compounds, reagents and antibodies 
 
(11b,16a)-9-fluoro-11,17,21- trihydroxy-16-methylpregna-1,4-diene-3,20-dione (dexamethasone; DEX, 
D4902), 17-hydroxycorticosterone (cortisol; CORT, H0888),  6α-methyl-17α-hydroxy-progesterone acetate 
(medroxyprogesterone acetate; MPA, D4902), 4-pregnene-3,20-dione (progesterone; P4, P0130), 117α-
ethynyl-19-nortestosterone 17β- acetate (norethisterone acetate; NET-A, N6127), 17α-ethynyl-19-
nortestosterone (norethisterone; NET, N4128), 13β-ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one 
(levonorgestrel; LNG, N2260), and 11β-(4-dimethylamino)phenyl-17β-hydroxy-17-(1-propynyl)estra-4,9-
dien-3-one (Mifepristone; RU486, M8046) were purchased from Sigma-Aldrich, South Africa. In vivo, both 
NET-EN and NET-A under go hydrolysis and are converted to NET and its metabolites (Stanczyk & Roy, 
1990).  
Phytohaemoagglutinin (PHA, L1668) and cycloheximide (CHX, C7698) were purchased from Sigma-Aldrich 
(South Africa) and interleukin 2 (IL2) was obtained through the AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 
M5655) was purchased from Sigma-Aldrich, South Africa. 
Antibodies to glucocorticoid receptor (GR) (H-300, sc-8992), androgen receptor (AR) (441, sc-7305), 
mineralocorticoid receptor (MR) (H-300, sc-11412), estrogen receptor alpha (ERα) (MC-20, sc-542), IκB⍺ 
(C-21, sc-371) and GAPDH (0411; sc-47724) were obtained from Santa Cruz Biotechnology, USA. 
Antibodies to the progesterone receptor (PR) (NCL-LPGR-312) were purchased from Leica Biosystems 
(Novocastra, United Kingdom). Secondary antibodies for primary detection were purchased from Santa 
Cruz Biotechnology, USA, and include anti-mouse (sc-2005) and anti-rabbit (sc-2313). Antibodies for 
CD4+, (CD4-FITC, 555346) CD14+ (CD14-APC, 345787), IL-6 (IL6-PE, 340527), GILZ (GILZ-PE, 12-4033) 
for flow cytometry were purchased from Becton Dickinson (BD) Sciences, USA. Isotype controls, anti-
mouse IgG (APC, 555751) and anti-rat IgG (PE, 12-4321), were also purchased from BD Sciences, USA.  
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2.2.1. Incubation with test compounds  
 
All test compounds were made at a stock concentration of 10-2 M in absolute ethanol (EtOH; Merck, South 
Africa), with concentrations confirmed using the respective extinction co-efficient for each test compound in 
ethanol, where available, and if not the extinction co-efficient of the compound in methanol was used. For 
dose response experiments, stock concentrations were serially diluted 1:10 in absolute EtOH from 10-2 M to 
10-6 M. All test compounds and vehicle control (absolute EtOH), were added to cells or explant tissue 
samples at a final concentration of 0.1% (v/v), unless stated otherwise. Test compounds were incubated 
with cells or explants for a variety of time points depending on the experimental question.  
2.3. Plasmids 
 
The human MR expression vector, pRShMR, was a kind gift from Ronald Evans (Howard Hughes Medical 
Institute, La Jolla, USA) and previously described (Arriza et al., 1987) while the human AR expression 
vector, pSVARo (Brinkmann et al., 1999) was obtained from Frank Claessens (University of Leuven, 
Leuven, Belgium). The expression vector for the human PR isoform B, pSG5hPR-B (Kastner et al., 1990), 
was obtained from Stoney Simons Jr (NIH, Bethesda, USA) and the wild type HA-tagged human GR 
(pCMV-HA-human GR) was a kind gift from Prof. M. J. Garabedian (New York School of Medicine, New 
York). The expression vector for the human ERα, pSG5-hERα (Denger et al., 2001) was a gift from F. 
Gannon (European Molecular Biology Laboratory, Germany). An X4 tropic infectious molecular clone (IMC), 
pNL4-3, was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH, from Dr. Malcolm Martin (Adachi et al., 1986), and named HIV-1pNL4.3 in this study. An R5 
infectious molecular clone, HIV-1BaL, that had a luciferase gene inserted adjacent to the env gene in the 
HIV-1 NL4-3 backbone known as NL–LucR.T2A–BaL.ecto, was kindly gifted to us by Dr. Christina 
Ochsenbauer (Edmonds et al., 2010). For the purposes of this study, the clone was named HIV-1BaL_Renilla.  
2.3.1. Transformation of bacterial cells and plasmid preparation 
 
Plasmids were transformed into Escherichia coli DH5α cells by heat shock transformations according to 
Sambrook and Russell, (2006) (Sambrook & Russell, 2006). Ten nanograms of plasmid DNA was 
incubated with 100 µl of competent E. coli cells. The mixture was incubated on ice for 30 min, followed by 2 
min incubation at 42°C and 2 min incubation on ice (Sambrook & Russell, 2006). Immediately after 
transformation, cells were mixed with 900 µl Luria broth (LB) (1% (w/v) tryptone, 0.5% (w/v) yeast extract, 
0.5% (w/v) NaCl) and incubated for 1 h at 37°C while shaking at 200 rpm. Cells were subsequently plated 
out on LB agar plates (1% (w/v) tryptone, 0.5% yeast extract, 1% NaCl and 1.5% agar) with 100 µg/ml final 
concentration of ampicillin (Sigma-Aldrich, South Africa) and allowed to grow overnight at 37°C. The 
following day, 5 ml LB starter cultures with ampicillin (100 µg/mL, final concentration) were inoculated with 
single colonies for 8 h at 37°C with shaking. For glycerol stocks 500 µl 70% (v/v) glycerol was mixed with 
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500 µl of the cell suspension and stored at -80°C. For plasmid preparations, 200 µl of the starter culture 
was inoculated into 200 ml LB with ampicillin (final concentration of 100 µg/mL) and incubated at 37°C with 
shaking for 16 hours. The next day the plasmid DNA was purified from the transformed cells, using the 
PUREYIELD plasmid maxiprep kit (Promega, Madison, WI, USA), according to the manufacturer’s protocol. 
The yield, purity and integrity of the plasmid prep were determined using a spectrophotometer (NanoDrop®, 
ND-1000 Spectrophotometer, NanoDrop Technologies), followed by gel electrophoresis. Additionally, 
confirmation of plasmid type was tested by restriction enzyme digestion (Fermentas, Thermo Scientific, 
USA) followed by agarose gel electrophoresis. One microgram of purified plasmid DNA was digested with 
restriction enzymes (Fermentas, Thermo Scientific, USA) for 10 minutes, using the FastDigest™ system 
with a universal buffer with sample application dye, at 37℃, with a corresponding undigested control. Five 
hundred nanograms of the undigested and digested DNA was electrophoresed on a 0.8% 1 X TRIS acetate 
EDTA (TAE) agarose gel (see Appendix D), with 10 µg/ml ethidium bromide (Sigma-Aldrich, South Africa) 
for 1 hr at 60 V. The gel was visualised at 256 nM on a Syngene, G:Box (Vacutec, England) and images 
acquired using GeneSnap from synGene, version 7.08 (SynGene, England), where plasmid DNA 
integrity (supercoiled) and confirmation of the plasmid type was determined. HIV-1pNL4-3 and HIV-1BaL-Renilla 
plasmids were transformed into E. coli and cultured as described above with the addition of carbenicillin 
(100 µg/ml final concentration; C1389, Sigma-Aldrich, South Africa).  
2.4. Cell Culture  
2.4.1. COS-1, HEK293T and TZM-bl cell lines 
COS-1 (African green monkey kidney fibroblast) cells and human embryonic kidney cells (HEK293T) were 
purchased from America Type Culture Collection (ATCC, USA). Human cervical TZM-bl cells, were 
procured from the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr. John C. Kappes, Dr. 
Xiaoyun Wu and Tranzyme Inc. (ARP, NIH, USA). The TZM-bl cell line is a HeLa cell line that has been 
modified to stably express CD4 and CCR5 receptors and contains separate integrated copies of the 
luciferase and β-galactosidase genes under the control of the HIV-1 promoter (LTR). Cells were cultured in 
75 cm2 flasks (Greiner Bio-one International, Austria) in Dulbecco’s modified Eagle’s medium [(DMEM) 
(Sigma-Aldrich, South Africa) supplemented with 1 mM sodium pyruvate (58636, Sigma-Aldrich, South 
Africa), 44 mM sodium bicarbonate (Sigma-Aldrich, South Africa), 10% (v/v) foetal bovine serum (Thermo 
Scientific, South Africa) 100 IU/ml penicillin and 100 mg/ml streptomycin (P4333, Sigma-Aldrich, South 
Africa); full DMEM]. All cells were maintained at 37℃ in a water jacket incubator (90% humidity and 5% 
CO2). Cells were passaged twice a week, with 0.25% (w/v) trypsin/ 0.1% (w/v) EDTA in PBS (Highveld 
Biological, South Africa). Trypsinisation was terminated with neutralisation medium (full DMEM). The cell 
lines were regularly tested for mycoplasma infection by means of Hoechst staining (Freshney, 1987), and 




2.4.2. PBMC Isolation 
Buffy packs were obtained from healthy donors who were negative for HIV-1, syphilis and hepatitis B and C 
from the Western Province Blood Transfusion Services. Ethics for this study was approved by the Human 
Research Ethics Committee at The University of Cape Town (approval number: HREC 210/2011). PBMCs 
were isolated using Histopaque (H1077 Hybri-MaxTM; Sigma-Aldrich, South Africa) density centrifugation 
with Leucosep tubes (Greiner Bio-One, Germany) according to the manufacturer’s instructions (Thorsby & 
Bratlie, 1970). Briefly, 15 ml Histopaque was loaded onto a Leucosep tube and centrifuged 
(ThermoScientific, swing-bucket centrifuge) for 1 minute at 2500 rpm at room temperature. Whole blood 
was diluted 1/3 with 50% Roswell Park Memorial Institute medium (RPMI) 1640 (BE12-7012, Lonza, 
Switzerland), with no supplementation, and 50% phosphate buffered saline (PBS; Sigma-Aldrich, South 
Africa) and 30 ml of the diluted blood was placed onto the 50 ml Leucosep tube with Histopaque. The 
sample was centrifuged at 2500 rpm for 15 minutes at room temperature, with the brakes set to 3. After 
centrifugation, the peripheral blood mononuclear cells separate into a clean white buffy coat, separate from 
the red blood cells (now present in the Histopaque). The buffy coat was removed with a Pasteur pipette, 
and washed twice with PBS supplemented with 1% (v/v) charcoal-stripped foetal calf serum (c-s FCS) 
(Thermo Scientific, South Africa). After each wash the samples were centrifuged for 5 minutes at 1200 rpm. 
During the second wash, 10 µl of the PBMC sample in PBS was added to 90 µl trypan blue (Lonza, 
Switzerland) and counted on a Haemocytometer to determine cell number and viability. PBMCs were 
subsequently cultured in high glucose (4.5 g/ml) RPMI 1640 (Lonza, Switzerland) with 10% (v/v) charcoal-
stripped foetal calf serum (c-s FCS) (Thermo Scientific, South Africa), 2 mM L-glutamine (G7513, Sigma-
Aldrich, South Africa), 100 IU/ml penicillin and 100 mg/ml streptomycin (Sigma-Aldrich, South Africa) at 
37℃ in a water-jacket incubator (90% humidity and 5% CO2).  
2.4.2.1 Time course and dose response experiments 
20 million PBMCs were seeded into sterile 50 ml V-bottomed tubes (Griener, Germany) at a concentration 
of 2 million/ml in full RPMI, and stimulated with either saturating conditions of ligands or with increasing 
doses and the tubes placed upright in an incubator, with the lids loosely attached for the duration of the 
experiment.  
For the shorter time course experiments, samples were harvested at 4, 24 and 48 hours. Samples were 
centrifuged for 5 minutes at room temperature at 400 X g, after which the supernatant was discarded, and 
the pellet was resuspended in 400 µl TriReagent® (Sigma-Aldrich, South Africa) for subsequent RNA 
isolation (see section 2.5 for RNA isolation method). For the dose response experiments samples were 
harvested 48 hours after stimulation and 1 ml of the supernatant from each condition was harvested after 
centrifugation and stored in 2 ml cryovials (Nunc, Germany) at -80℃ for subsequent secreted protein 




For the longer time course experiments, 20 million PBMCs were seeded into sterile 50 ml V-bottomed tubes 
(Griener, Germany) at a concentration of 2 million/ml in full RPMI containing IL2 at a final concentration of 
30 U/ml. PBMCs were stimulated with 100 nM of ligand and tubes were placed upright in an incubator, with 
the lids loosely attached for the duration of the experiment. Samples were harvested at days 2, 3, 4, 5, 6 
and 7 post stimulation, with a half media exchange (containing 100 nM of the appropriate ligand) at days 3 
and 6. At each day of harvesting, PBMCs were resuspended through gentle agitation where 300 µl of each 
sample was removed and used in an MTT viability assay. The remainder of each sample was divided into 
two new 50 ml tubes, and centrifuged at room temperature for 5 minutes at 400 X g. The supernatant from 
both conditions was discarded and one tube was processed for RNA as described above, while the other 
tube was processed for protein isolation. For the protein isolation, the pellet was gently resuspended in 1 ml 
ice cold 1 X PBS and the cell suspension was placed into a new sterile 1.5 ml microfuge tube (Eppendorf, 
USA) and centrifuged at room temperature for 5 minutes at 400 X g. The supernatant was gently removed 
and the pellet was stored at -80℃ until protein isolation (see section 2.6.1). 
For the MTT viability assay, 100 µl of the PBMCs was aliquoted into a 96 well plate in triplicate. 5 mg/ml 
MTT was added to the PBMCs to a final concentration of 0.5 mg/ml MTT. PBMCs were incubated for 2 
hours at 37℃ in a water jacket incubator. The plate was centrifuged for 5 minutes at 400 X g, the 
supernatant removed and 100 µl of 0.1 N HCl in isopropanol was added to each well and incubated for 10 
minutes to ensure complete cellular lysis. The plate was read on a spectrophotometer (Thermo Scientific, 
USA) at 520 nm and 695 nm (secondary background absorbance). Cellular viability was determined by 
normalising each sample OD/ml reading to the average vehicle control MTT (OD/ml).  
2.4.2.2. Inhibitor and RNA interference experiments 
In order to determine GR involvement in ligand-dependent gene regulation, a selective PR/GR antagonist, 
RU486 and selective GR siRNA knockdown strategies were employed. For antagonist experiments, 20 
million PBMCs were seeded at a density of 2 million cells/ml in 50 ml tubes (Greiner, Germany) in full 
RPMI. PBMCs were treated with vehicle (EtOH), 100 nM DEX or 100 nM MPA in the absence or presence 
of 1 µM RU486. PBMCs were incubated for 48 hours at 37℃ in a water jacket incubator, before harvesting 
in 400 µl TriReagent®, and stored at -80℃ for RNA isolation. 
For siRNA knockdown of the GR in PBMCs, 100 million PBMCs were seeded in sterile 50 ml   V-bottomed 
tubes (Griener, Germany) at a concentration of 2 million/ml in 50 ml tubes (Greiner, Germany) and rested 
overnight at 37℃. The following day, PBMCs were washed once in 1 X PBS and counted, and 15 million 
cells per condition were used. PBMCs were pelleted and resuspended in 100 µl P3 buffer (Amaxa™ P3 
Primary Cell 4D-Nucleofector™ X Kit L, Lonza, Switzerland). Three hundred nanomolar GR5 (GR specific 
siRNA, Qiagen, Netherlands), or non-silencing control (NSC, Qiagen, Netherlands) was added per 
condition. Each mix was subsequently aliquoted into an electroporation cuvette (Amaxa™ P3 Primary Cell 
4D-Nucleofector™ X Kit L, Lonza, Switzerland) and all air bubbles were disrupted with gentle tapping. 
 
44 
Nucleofection was performed on a Nucelofector 4-D (Lonza, Switzerland) using the Monocyte, human 
(code EA100) program (Nucleofection occurred at the SUN Immunology Research Group, University of 
Stellenbosch, South Africa). After nucleofection, 500 µl full RPMI was added to each cuvette. Using Pasteur 
pipettes, the nucleofected PBMCs were gently transferred to 50 ml tubes (Griener, Germany) and a further 
4.5 ml full RPMI was added to each condition. PBMCs were rested for 1 hour, before transporting back to 
the Molecular and Cell Biology Department, at the University of Cape Town, South Africa. Upon arrival, 
nucleofected PBMCs were rested overnight at 37℃ in a water jacket incubator. The following day, 
nucleofected PBMCs were stimulated with 100 nM ligands or vehicle for 48 hours at 37℃. In order to 
confirm GR knockdown, PBMC control samples were harvested 24 hours later and pellets stored at -80℃ 
for protein isolation. After 48 hours, PBMCs were harvested in 400 µl TriReagent and stored at -80℃ for 
subsequent RNA isolation. Initial pilot experiments by members in the Hapgood laboratory, found that 
samples harvested 48 hours post nucleofection had the greatest knockdown visible, compared to 24 hours 
post infection, as determined by western blot. As such, in these experiments, confirmation of knockdown 
was achieved by harvesting two controls (NSC and GR5) to be analysed via western blot at 48 hours post 
nucleofection, but 24 hours post stimulation with ligands. 
2.4.2.3 Cycloheximide experiments 
Twenty million PBMCs were seeded into 50 ml culture tubes (Griener, Germany) at a concentration of 2 
million cells/ml in full RPMI. Optimisation experiments were performed to elucidate the concentration of 
cycloheximide needed to inhibit de novo protein synthesis, while maintaining cell viability (as assessed by 
western blot) over 48 hours (data not shown). PBMCs were incubated in the absence and presence of 10 
µg/ml cycloheximide (Sigma-Aldrich, South Africa), a de novo protein synthesis inhibitor, for 15 minutes at 
37℃ before the addition of 100 nM DEX, 100 nM MPA or vehicle (EtOH) for 48 hours at 37℃. 10 million 
PBMCs were harvested in 400 µl TriReagent® (Sigma-Aldrich, South Africa) for subsequent RNA isolation, 
and the remaining PBMCs were processed as previously described for subsequent protein isolation, and 
stored at -80℃. 
2.4.3. Primary Cervical Explants 
Female Genital Tissue (FGT) was obtained from HIV-1 negative, normal Pap smear, pre-menopausal 
women undergoing hysterectomies for benign reasons, after informed consent. Ethics was obtained from 
the Human Research Ethics Committee (The University of Cape Town, South Africa) for the duration of this 
study (HREC 210/2011). Fresh tissue was supplied from two sites in the Western Cape, South Africa, 
namely Groote Schuur Hospital (under Professor Zephne Van Der Spuy) and Tygerberg Hospital (under Dr. 
Hennie Botha). Patient consent was obtained before the operation and blood samples and Pap smear 
information were obtained. Blood samples were sent to the National Laboratory Health services (NHLS, 
Groote Schuur Hospital, South Africa) to determine HIV-1 and HSV 2 status by serum antibody testing. 
Additionally, serum luteinising hormone (LH), follicle stimulating hormone (FSH), progesterone (P4) and 
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estrogen (E2) levels, were obtained to determine phase of menstrual cycle. Menstrual cycle was 
determined using the guidelines given by the NHLS (South Africa). Most women were older pre-
menopausal donors, with most not on any form of contraception at the time of surgery. All of the women 
were HIV-1 negative and HPV negative (as determined by a normal pap smear), with the majority of the 
women being HSV-1 positive. Table 2.1 below indicates the average age, HSV-1, HSV-2, HIV-1 status and 
phase of menstrual cycle. For further donor information, appendix C contains individual donor information 
including which experiment each piece of tissue was used in. 
 
Table 2.1. The donor information collected during this study. 
 
n = 35 Patient Profile 
	 	
Average age (in years) 44.1 ± 4.3 





Serum ELISA antibody 
detection: 
	
HSV-1 Positive 94% 
HSV-2 Positive 34.3% 
 
Explant tissue containing the ectocervix and/or the endocervix was processed under P2+ conditions, 
between 1 to 3 hours post procedure (see Figure 2.1), and processed according to methodology reported in 
the literature (Greenhead et al., 2000; Fletcher et al., 2006; Richardson-Harman et al., 2009; Fletcher et al., 
2005), with a few modifications. The fresh tissue was processed with the epithelial cell layer facing 
upwards, in the lid of a sterile 15 cm2 dish with warm full RPMI just covering the tissue, and using a 
stainless steel punch, 3 mm3 pieces of tissue were obtained. Pieces were randomly chosen and each tissue 
explant was placed into 96 well round bottomed plate (Cell Star, Greiner, Germany) using sterile forceps 
(soaked in 70% EtOH). The explants in these experiments were not polarised or placed onto any gel-foam 
raft for support. Explants were cultured in 200 μl RPMI (Lonza, Switzerland) supplemented with 10% (v/v) 
charcoal-stripped foetal calf serum (c-s FCS) (Thermo Scientific, USA), 2 mM L-glutamine (Sigma-Aldrich, 
South Africa), 10 µg/ml Fungizone (Sigma-Aldrich, South Africa), 100 IU/ml penicillin and 100 mg/ml 
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streptomycin (Sigma-Aldrich, South Africa) and incubated at 37℃ in a water jacket incubator (90% humidity 
and 5% CO2). For each piece of tissue processed, one 3 X 3 mm piece was immediately placed into a 2 ml 
cryovial (Nunc, Germany) with 200 µl All-Protect® (Qiagen, Netherlands) at -20℃ for future protein 
isolation. Pilot experiments indicated that 80% cell viability was lost if tissue was frozen and thawed before 
use (data not shown), as such all experiments in this study was performed on fresh tissue. 
After 24 hours in culture, migratory cells such as dendritic cells and Langerhan cells, spontaneously migrate 
out of the tissue explant, and remain within the 96-well chamber throughout the duration of the experiment. 
Additionally, it has been observed within the literature, as well as within the duration of this study, that the 
epithelial sheath detaches from the stroma after 36 – 48 hours after processing (Anderson et al., 2010). 
However, it was not observed for all tissue explants within an experiment, and the detachment of the 
epithelial sheath from the stroma appeared to be random.  
Three replicates per treatment were used for all cervical explant experiments to ensure reproducibility within 
an experiment. In addition a cellular viability assay (MTT assay), where possible, was performed upon 
processing to ensure that the tissue was viable at the time of the experiment. Briefly, 5 mg/ml MTT in 
phenol free RPMI (Sigma-Aldrich, South Africa) was added to the tissue explant at 10% (v/v) final culture 
volume. The sample was incubated for 2 hours at 37℃ in a water jacket incubator. The tissue was 
removed using sterile forceps, excess liquid was removed (by gently dabbing the explant onto tissue paper) 
and the explant tissue was weighed to determine the mass (mg). The tissue explant was subsequently 
incubated overnight in 200 µl of 0.1 N HCl  (Merck, South Africa) in isopropanol (Merck, South Africa) in a 
cryovial (Nunc, Germany). 100 µl of the solution was measured on a 96-well microtitre plate on a 
spectrophotometer (Thermo Scientific, USA) at 570 nm and 695 nm (background absorbance). Viability 
was assessed by calculating the OD/mg of tissue. This process was repeated for experiments with long 
incubation times (more than 48 hours), to ensure tissue viability was maintained for the duration of the 
experiment (see appendix A Fig. A.5.1).  
2.4.2.1. Progestin treatment and dose response experiments 
After processing, ectocervical or endocervical tissue explants were treated in triplicate with 100 nM of the 
ligands (CORT, DEX, MPA, P4, NET or LNG) or with increasing concentrations of MPA with a vehicle 
control for each experiment (0.1% (v/v) EtOH), for 48 hours. This time point was chosen based on the 
optimisation experiments performed in PBMCs where MPA exerted maximal repressive effects on select 
mRNA gene expression after 48 hours post incubation (see chapter 3, Figure 3.1). After 48 hours, the 
supernatant was harvested, into a new round bottomed 96-well plate, and centrifuged for 5 minutes at 400 
X g. The supernatant was removed and stored in a flat bottomed 96-well plate, sealed, and stored at -80°C 
for future use. For subsequent RNA isolation, individual explant pieces were placed into new 2 ml cryovial 
tubes (Nunc, Germany), where 600 μl TriReagent® (Sigma-Aldrich, South Africa) was added into each 
tube. Additionally 200 μl TriReagent® was added into each well and incubated for 5 minutes at room 
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temperature. Thereafter, the lysate was removed and added to into each corresponding cryovial tube, to 
ensure that migratory cells present in the well were harvested for RNA. Samples were stored at -80°C until 
processed for RNA. 
 
 
Figure 2.1: Diagram representing the culturing of a piece of ectocervical tissue in a 96-well for 
experimental purposes. Premenopausal tissue was processed under P2+ conditions using a sterile punch to 
produce 3 X 3 mm pieces of tissue that contained both the upper epithelial layer and the underlying stroma. Each 
tissue piece was placed into a single well of a 96-well plate and cultured in 200 µl of media (full RPMI with Fungizone 
and IL2). While the diagram depicts the tissue explant with the epithelial side up, this was not mimicked in culture 
experiments, where pieces were randomly placed into each well. 
 
2.5. Infectious Molecular Clones (IMCs) 
Initial viral stocks were prepared according to Pear et al. (1993) with a few modifications (Pear et al., 1993). 
HEK293T cells were seeded at a density of 4 X 105 cells/well in a 10 cm2-well plate in high glucose (1 g/ml) 
full DMEM at 37℃ in a water jacket incubator (90% humidity and 5% CO2). The next day, media was 
changed to full phenol red-free DMEM and the cells were transfected with 20 µg HIV-1pNL4.3, HIV-1BaL-Renilla 
or a control (DMEM) using X-tremeGENE 9 DNA transfection reagent (Roche Applied Science, South 
Africa) according to the manufacturer’s specifications. Cells were incubated for 60 hours at 37℃, the 
medium was passed through a 0.22 µM filter and charcoal- stripped (c-s) FCS (Thermo Scientific, USA) 
was added to a final concentration of 40%. The viral stocks were aliquoted and stored at -80℃ until use.  
Virus titres were determined using the TZM-bl assay as described in Edmonds et al. (2010), with a few 
modifications (Edmonds et al., 2010). Briefly, TZM-bl cells were seeded at a concentration of 1 X 105 
cells/ml into a 96-well plate in full DMEM. The next day, virus was serially diluted 1 in 5 in full phenol-red 
free DMEM (Sigma-Aldrich, South Africa) for 8 dilutions, with a no virus control. The media was aspirated 
from the TZM-bl cells, and cells were washed once with PBS. Thereafter 200 µl of the serially diluted virus 
in full phenol-red free DMEM was added. Cells were harvested 72 hours later with 120 µl Bright-Glo 
luciferase lysis buffer (Promega, USA). To ensure complete cellular lysis, cells were incubated in the dark 
for 5 minutes before the supernatant was removed and added into a while 96-well luminometer plate 
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(Griener, Germany). Fluorescence was determined on a luminometer (Modulus Microplane, Promega, 
USA), where relative light units were measured for each well. Each dilution was performed in quadruplicate. 
The titre of the virus stock was determined using the Reed Muench method and expressed as log infectious 
units (IU)/ml (Reed & Muench, 1938). Initial viral titres between 100 – 500 IU/ml were routinely produced for 
both viruses. 
Higher titre viral stocks were prepared according to methods learned at Imperial College, London in 2011 
(from Professor Robin Shattock’s laboratory) with a few modifications. In order to produce high titre viral 
stocks for all subsequent virus experiments, 50 million PBMCs at a concentration of 2 million cells/ml in full 
RPMI were activated 2 ways to ensure maximum cellular activation. PBMCs were stimulated with either 5 
µg/ml (final concentration) Phytohaemoagglutinin (PHA) and 30 U/ml (final concentration) interleukin-2 (IL2) 
or with or 0.5 µg/ml PHA and 30 U/ml IL2 in 50 ml tubes (Griener, Germany) and incubated upright at 37℃ 
in a water-jacket incubator. After 3 days, cells from each condition were washed 4 times with 1 X PBS. Cell 
numbers were subsequently determined and PBMCs from each condition were pooled equally (20 million 
cells form each activation condition). Pooled PBMCs were centrifuged for 5 minutes at 1200 rpm and 20 ml 
of full RPMI with 30 U/ml (final concentration) IL2 was added so that PBMCs were at a concentration of 2 
million cells/ml. One hundred infectious units per ml seed virus was used to infect activated PBMCs for 2 
hours, before washing 4 times with 1 X PBS and replacing media. PBMCs were incubated for 7 days at 
37℃ in a water jacket incubator. The supernatant containing the virus was collected into a new 50 ml tube 
and centrifuged for 5 minutes at 1200 rpm at room temperature. The supernatant (~20 ml) was 
subsequently collected and passed through a 0.22 µM filter disk into a new 50 ml tube where c-s FCS 
(Thermo Scientific, USA) was added to a final concentration of 40%. The viral stocks were aliquoted into 2 
ml cryovials (Nunc, Germany) and stored at -80℃ until use. Viral titres were determined as previously 
described using the TZM-bl assay, where viral titres between 1000 – 2500 IU/ml were routinely produced. A 
control group of PBMCs (RPMI only) was included for every batch of virus produced and mock infected with 
the DMEM control obtained from the initial HEK293T virus preparation and processed in the same manner 
described above.  
2.5.1. Infection experiments in PBMCs 
One hundred million PBMCs at a concentration of 2 million cells/ml were activated with either 5 or 0.5 µg/ml 
PHA for 24 hours in T75 culture flask (Griener, Germany), as previously described above. After activation, 
PBMCs were, aliquoted into 50 ml tubes (Griener, Germany) and washed once with 1 X PBS (Sigma-
Aldrich, South Africa) supplemented with 1% cs-FCS (Thermo Scientific, USA). Cell number was 
determined by adding 10 μl of the PBMC in PBS solution to 90 μl trypan blue solution (Lonza, Belgium) in a 
1.5 ml microfuge tube (Eppendorf, USA). Thereafter, 10 μl of the solution was added to a haemocytometer, 
and cell number calculated by counting the trypan blue negative cells under a light microscope at a 10X 
objective lens magnification. PBMCs were centrifuged at room temperature for 5 minutes at 400 X g and re-
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suspended in full RMPI with a final concentration of 30 U/ml IL2. In order to pool the activated PBMCs, 40 
million cells from each activation condition was added into a new T75 flask (Griener, Germany), where full 
RMPI with 30 U/ml IL2 was added to a final concentration of 1 million cells/ml.  
 
For each condition, 5 million cells in 5 ml media was incubated in 12 ml culture tubes (Griener, Germany), 
upright with loose lids, with the appropriate ligand, for 48 hours at 37℃ in a water jacket incubator. For 
these experiments, 100 nM concentrations of ligands were used, with the dilution such that the final 
concentration of ethanol was 0.01%. This was performed as optimisation experiments indicated a slight 
ethanol effect at 0.1% (v/v) on renilla luciferase readings compared to a no treatment control. After 48 
hours, PBMCs were infected with 10 IU/ml HIV-1BaL-Renilla or with a mock infection control (RPMI only) for 2 
hours at 37℃. PBMCs were washed 4 times with 1 X PBS supplemented with 1% cs-FCS. Thereafter, full 
RPMI with IL2, containing ligands at the indicated concentrations was added PBMCs were incubated for a 
further 7 days at 37℃, with half media exchange at day 3 and day 5 post infection. Briefly, 2.5 ml media 
was removed, and replaced with 2.5 ml full RPMI with IL2 and the appropriate concentration (100 nM) of 
ligand for each condition. PBMCs were harvested at day 7 post-infection for renilla luciferase expression, 
cell viability using MTT and RNA isolation. Optimisation experiments were performed where it was 
observed that reproducible and measurable levels of renilla (RLU) were detected at day 7 post infection 
compared to day 5 post infection (see appendix E, Fig. E.1.2 B and C). In addition it was found that cell 
viability decreased over this time course, but differences between day 5 and 7 post infection were negligible 
(see appendix E, Fig. E.1.2 A). Thus in these experiments, day 7 post infection was chosen as the harvest 
time point. Additionally, pilot infection experiments were performed in the absence and presence of IL2. 
However, low levels were detected at day 7 post infection in the absence of IL2 (see appendix E, Fig. 
E.1.1). Thus all the experiments were performed in the presence of IL2. 
PBMCs from each condition were re-suspended by gentle agitation; where after 1200 µl was removed for 
the renilla luciferase and MTT viability assay. For detection of renilla luciferase expression, 200 µl of the 
PBMCs was aliquoted into round bottomed 96 well plates (Griener, Germany). Each condition was 
aliquoted out in triplicate, and the 96 well plate centrifuged at room temperature for 5 minutes at 400 X g to 
pellet the cells. The supernatant was removed and discarded, and 100 µl of 1 X reporter lysis buffer with 
renilla luciferin (Promega, USA) was added to each well, and incubated in the dark for 10 minutes at room 
temperature to ensure complete cellular lysis (this was confirmed by visually examining under a light 
microscope). Samples were added to a white luminometer plate (Qiagen, Netherlands) and read on a 
luminometer (Microplate Modulus, Promega, USA) to determine the relative light units (RLU). For the MTT 
viability assay, 200 µl of the PBMCs were aliquoted into a round-bottomed 96 well plate in triplicate where 5 
mg/ml MTT was added to the PBMCs to a final concentration of 0.5 mg/ml MTT into each well. PBMCs 
were incubated for 2 hours at 37℃ in a water jacket incubator. The plate was centrifuged for at room 
temperature for 5 minutes at 400 X g, the supernatant removed and 100 µl of 0.1 N HCl in isopropanol was 
added to each well and incubated for 10 minutes to ensure complete cellular lysis. The plate was read on a 
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spectrophotometer (Thermo Scientific, USA) at 520 nm and 695 nm (background absorbance). Infection 
was calculated by dividing the RLU obtained for each sample by the average MTT (OD/ml) for that sample 
group. This was performed to account for the changes in cellular viability over time exerted by the different 
ligands on the PBMCs. Once these values were obtained, relative infection was calculated by setting 
vehicle control (EtOH) to 100% infection. 
The remainder of the PBMCs in each tube was centrifuged at room temperature for 5 minutes at 400 X g, 
the supernatant removed, and 400 µl TriReagent® (Sigma-Aldrich, South Africa) was added. Samples were 
stored at -80℃ until RNA isolation was performed. 
2.5.2. Infection experiments in primary cervical explants 
Primary ectocervical tissue was processed as described in section 2.3.3 and incubated in 200 µl full RMPI 
with 10 U/ml IL2 (final concentration) with 100 nM final concentration of ligands (section 2.1.1) in a round 
bottomed 96 well plate (Griener, Germany). The infection experiments were performed according to 
Arakelyan et al. (2013), with a few modifications (Arakelyan et al., 2013). Samples were incubated for 48 
hours, before being exposed in a non-polarised manner with either HIV-1BaL-Renilla or HIV-1pNL4.3 at 500 IU/ml 
at 37℃ in a water jacket incubator. Briefly, each tissue explant, was removed using sterile forceps, and 
added to a 24 well plate (Griener, Germany). Each triplicate group was added to one well in the 24-well 
plate. HIV-1BaL-Renilla or HIV-1pNL4.3 with a mock infected group (RPMI only) was added to a final 
concentration of 500 IU/ml in a final volume of 500 µl, with the remainder of the volume made up with the 
media, containing ligands that the explants were incubated in for the 48 hours previously. To ensure 
reproducibility between infection experiments, virus stocks were diluted to the same concentration (in full 
RMPI) so that the amount of media added was constant (and thus the same concentration of cytokine 
milieu present per infection). Explants were washed 4 X with 1 X PBS (with 1% (v/v) cs-FCS) at room 
temperature in the 48 well plate and each explant was subsequently added back to the 96-well plate using 
sterile forceps (dipped in 70% EtOH between each treatment group, and used after EtOH was evaporated). 
A final wash with 1 X PBS (with 1% (v/v) cs-FCS) was performed in the 96-well plate. Thereafter, 200 µl per 
well of full media with the appropriate concentration of ligand and IL2 was added to each well and explants 
were incubated for a further 10 days post infection. Half of the media (100 µl) was removed at days 3, 5 and 
7 post infection, and replaced with 100 µl of new media containing IL2 and 100 nM final concentration of the 
appropriate ligand for each treatment group. Media harvested at days 0, 3, 5, 7 and 10 post infection was 
aliquoted into a flat bottomed 96 well plate (Griener, Germany) and incubated with 5% (v/v) Empigen® (B13 
Detergent, 45165, Sigma-Aldrich, South Africa) in 1 X PBS (D8537, Sigma-Aldrich, South Africa) for an 
hour at room temperature, to ensure viral inactivation. Thereafter, the supernatants were sealed with plate 
sealers and stored at -80℃. Culture supernatants were subsequently assayed for HIV-1 p24Gag release 
using a sensitive p24 ELISA assay (Innotest, Innogenetics, Belgium). Briefly, culture samples inactivated 
with a 5% (v/v) Empigen® (Sigma-Aldrich, South Africa) solution, were further diluted 1:10 with a buffer 
supplied by the ELISA kit (Matrix Buffer, Innogenetics), before proceeding with the ELISA. Samples were 
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read on a spectrophotometer (Thermo Scientific, USA) at 420 nM and 595 nM (background absorbance). 
p24 concentrations were calculated using the equation generated by the standard curve, and relative 
infection was calculated by setting vehicle control at day 3 post infection (EtOH) to 100%. After 10 days 
post infection, the tissue explants were harvested in 800 µl TriReagent® in 2 ml cryovials and stored at -
80℃ for subsequent RNA isolation. Where possible, an MTT assay (described in section 2.3.3) was 
performed on a single piece of tissue (not infected with HIV-1) to determine cellular viability at the end of 
the experiment (see appendix A, Fig A.6.1). 
Optimisation experiments found that infecting the explants in a larger volume and concentration of HIV-1 
yielded more reproducible results (see appendix E. Fig E.2.2 B). Additionally, due to the high amount of 
starting virus needed to productively infect the cervical explants tissue, it was not possible to individually 
infect each tissue sample with the viral titres (1000 – 2000 IU/ml) produced throughout this study. Thus the 
approach as described above was taken for the virus experiments to reduce variability as far as possible. 
2.6. RNA Isolation, cDNA synthesis and PCR 
2.6.1. RNA isolation 
 
PBMCs harvested in 400 µl TriReagent® (T9424, Sigma-Aldrich, South Africa), were processed for RNA 
according to the manufacturer’s instructions. Briefly, PBMCs in TriReagent® were incubated at room 
temperature for 5 minutes, before centrifugation at 12 000 X g (4℃) to pellet cellular debris. The 
supernatant was transferred into a new microfuge tube. Two hundred microlitres of chloroform per 1 ml 
TriReagent® was added to each sample and vortexed for 30 seconds. Samples were centrifuged for 15 
minutes at 20 000 X g at 4℃. The aqueous phase was carefully removed and transferred into a new 
microfuge tube. Where less than 10 million cells/ml were used per incubation, 1 µl of RNAse-free glycogen 
(Roche Applied Science, South Africa) was used to precipitate the RNA from the aqueous phase to better 
identify the RNA pellets. Five hundred microlitres isopropanol (Merck, South Africa) per 1 ml of 
TriReagent® used (200 µl), was added to the samples and gently mixed by inversion. Samples were 
incubated for 10 minutes at room temperature to precipitate the RNA. Samples were subsequently 
centrifuged at 20 000 X g for 10 minutes at 4℃ to pellet the RNA. The supernatant was removed, and the 
pellet was washed once in 70% EtOH (in DEPC-treated H2O). Samples were centrifuged at 20 000 X g for 
5 minutes at 4℃ and the supernatant was carefully removed to ensure that the majority of the EtOH had 
been removed. Samples were air dried for 5 minutes and the pellets were resuspended in 10 µl RNase-free 
DEPC treated H2O and stored at -80℃.  
 
Primary cervical explants in 800 µl TriReagent® in 2 ml cryovial tubes (Nunc, Germany) were homogenised 
using a hand-held homogeniser (TissueRuptor®, Qiagen, Netherlands) with disposable probes 
(TissueRuptor Probes, Qiagen, Netherlands). Samples were homogenised for 20 second pulses, for up to 1 
minute on ice. Homogenates were transferred to new microfuge tubes and incubated for 5 minutes at room 
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temperature and centrifuged at 12 000 X g for 10 minutes at 4℃. The remainder of the procedure was 
followed as described above for PBMC RNA isolation, including the addition of RNase-free glycogen for 
maximal RNA pellet visibility. Several RNA isolation kits were used in the initial optimisation experiments for 
RNA isolation (Qiagen Allprep RNA/DNA/Protein, Qiagen RNeasy Nano Kit, and Machery Nagel XS-RNA 
isolation kit). However, no kit produced sufficient RNA yields for subsequent downstream applications (see 
appendix E).  
RNA was assessed for quantity and quality on a spectrophotometer (Nanodrop, Thermo Scientific). RNA 
was assessed for integrity using denaturing formaldehyde agarose gel electrophoresis (Sambrook & 
Russell, 2006). Sample loading buffer (see Appendix D) was added at a ratio of 3:1 (v/v) to 250 ng RNA for 
tissue samples and 500 ng RNA for PBMC samples. The samples were analysed by gel electrophoresis on 
a 1% agarose formaldehyde gel (see Appendix D) and electrophoresed for 25 minutes at 65 V in 1 X 
Morpholinopropanesulfonic acid (MOPS) buffer (see Appendix D) (Sambrook & Russell, 2006) and 
visualised on a Syngene, G:Box (Vacutec, England) and images acquired using GeneSnap from 
synGene, version 7.08 (SynGene, England).  
2.6.2. cDNA synthesis  
Total RNA was reverse-transcribed using the Transcriptor First Strand Synthesis cDNA kit (Roche Applied 
Science, South Africa) according to the manufacturer’s instructions. Briefly, 250 ng (primary explant 
samples) or 500 ng (PBMC samples) RNA was reverse-transcribed using anchored oligo (dT) priming in a 
final volume of 10 µl. cDNA samples were stored at -80℃ until use in subsequent real time qPCR 
reactions.  
2.6.3. Conventional PCR  
Conventional PCR was performed using GoTaq DNA polymerase (Promega, USA, M3001) with the steroid 
receptor specific primers (Table 2.1) according to the manufacturer’s specifications. The cycling parameters 
for 40 cycles are shown in Table 2.1. PCR samples were electrophoresed on a 1.5% agarose 1 X TAE gel 
(See Appendix D) at 70 V for 1.5 hours and visualised on a Syngene, G:Box (Vacutec, England) and 
images acquired using GeneSnap from synGene, version 7.08 (SynGene, England).  
2.6.4. Real Time quantitative PCR 
Real-time quantitative PCR (qPCR) was performed using the Bioline SensiMix™ SYBR® no ROX kit 
(QT650-05, Bioline USA) on a RotorGene 3000 (Qiagen, Netherlands) real time qPCR machine, according 
to manufacturer’s instructions. Each 20 µl reaction in a 0.1 ml strip-tube (SSI, USA), contained 1 X Bioline 
SensiMix™(Bioline, Germany), forward and reverse primers (see Table 2.2 for primer sequences and 
concentrations), RNase free H2O and 1 µl template cDNA. The qPCR profiles was established by Verhoog 
et al. (2011) for IL6, IL8, RANTES and GAPDH, while the steroid receptor primers were optimised for this 
study and described in Tomasicchio et al. (2013). Each profile contained a standard initial denaturation at 
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95℃ for 5 minutes followed by 40 cycles of 95℃ for 8 sec, annealing for 10 sec and 72℃ for 8 sec, a final 
elongation step at 72℃. A melt curve analysis was performed after the endpoint (1℃ increase/5 sec from 
65℃ to 95℃). Annealing temperatures can be found in Table 2.2. Data was acquired using the RotorGene 
Software (version 1.7) with melting curve analysis to confirm the amplicon generated in each sample. In 
addition, real time qPCR samples were electrophoresed on a 2% agarose (1 X TAE) gel at 70 V for 1.5 
hours and visualised on a Syngene, G: Box (Vacutec, England) and images acquired using GeneSnap 
from synGene, version 7.08 (SynGene, England), to confirm product sizes. Standard curves for efficiency 
determination were performed for each primer set, with pooled cDNA. Pooled cDNA was serially diluted 1 in 
2, five times, and the dilutions used in triplicate reactions for subsequent standard curve determination. 
Standard curves that had efficiencies (E) between 1.9 - 2.1, slopes (M) between -3.4 and -3.8 and R2 
values between 0.95 and 1 were deemed acceptable. Relative transcript levels were determined using the 
“Fit Points” method described by Pfaffl et al. 2001 and were normalised to relative GAPDH transcript levels 
(Pfaffl, 2001). 
Primers for the steroid receptors were designed using the Primer-BLAST function on the NCBI BLAST 
platform (www,ncbi.nlm.nih.gov/BLAST). Primers were designed to be intron spanning, to produce product 
sizes between 150 – 300 bp, have low self and inter-complementarity and to have an annealing (TA) 
temperature between 50-65℃. Forward and reverse primers were designed towards the following 
sequences obtained from the NCBI database: GR: NM_000176.2, AR: NM_000044.2, ER: NM_000125.3, 
MR: NM_000901.4 and PR: NM_001202474.1. All other primers used in this study were also intron 
spanning, and confirmed with the Primer-BLAST platform using sequences obtained from the NCBI 




















GILZ Quantitect Primer QT00091035 2 3 1 X  60℃ 69 Qiagen, Netherlands 
IL6 F: 5’ - TCTCCACAAGCGCCTTCG - 3’ R: 5’ - CTCAGGGCTGAGATGCCG - 3’ 1,2 2 
250 
nM 60℃ 193 
(Wolf et al., 
2002) 
IL8 F: 5’ - TGCCAAGGAGTGCTAAAG - 3’ R: 5’ - CTCCACAACCCTCTGCAC - 3’ 2 3 
250 
nM 60℃  197 
(Wolf et al., 
2002) 
RANTES F: 5’ - TACCATGAAGGTCTCCGC - 3’ R: 5’ - GACAAAGACGACTGCTGG - 3’ 1 2,3 
250 
nM 60℃  199 
(Wolf et al., 
2002) 
GAPDH F: 5’- TGAACGGGAAGCTCACTGG-3’    R: 5’-TGTCAGTTGATAAAACCGCTGCC-3’  8 9 
200 
nM 60℃  307 
(Ishibashi et 
al., 2003) 
GR⍺ F: 5’- TGCTGTGTTTTGCTCCTGATCTG-3’    R: 5’-TGTCAGTTGATAAAACCGCTGCC-3’  9 10 
250 
nM 53℃  299 This study 
PR A and 
B 
F: 5’- GTGCTCAAGGAGGGCCTGCCG-3’   
R: 5’- TGTGCTGCCCTTCCATTGCCC-3’ 2 3 
250 
nM 65℃  214 This study 
MR F: 5’- GAGCAGTGGAAGGGCAACAC-3’  R: 5’- TGGCTGCTCCTCGTGAATCC-3’ 4 5 
250 
nM 60℃  182 This study 
ER⍺ F: 5’- TCGACGCCAGGGTGGCAGAG-3’  R: 5’- TGGTGCACTGGTTGGTGGCTGG-3’  7 8 
250 
nM 60℃  218 This study 
AR F:5’-CAGGAAAGCGACTTCACCGCACC-3’   R: 5’ATCAGGCAGGTCTTCTGGGGTGG-3’ 3 4 
250 
nM 60℃  209 This study 
 
2.7. Western Blotting 
2.7.1. PBMC Protein Isolation  
Protein isolation was performed according to Tomasicchio et al. (2013) with a few modifications. Briefly, 
PBMCs (8 million) were centrifuged at room temperature for 5 minutes at 400 X g, and pellets stored for 30 
minutes at -80℃. Pellets were incubated on ice with 24 µl 1 X N-[TRIS (hydroxymethyl)methyl]-3-
aminopropanesulfonic acid (TAPS) buffer (0.1 M TAPS, pH 9.5) lysis buffer [1 X TAPS buffer with 1 mM 
(final concentration) PMSF, 5 µg/ml Leupeptin (Roche Applied Science, South Africa), 2 µg/ml Aproptinin 
(Roche Applied Science, South Africa) and 1 X completeMini protease inhibitor tablet (1 tablet/ 10 ml buffer; 
Roche Applied Science, South Africa)], was added to each pellet. Samples were mixed by vortexing every 
10 minutes for a total incubation time of one hour, before centrifugation at 12 000 X g for 15 minutes at 4℃. 
Supernatant was collected into a new microfuge tube, where 5 X protein sample buffer (100 mM TRIS-HCl 
pH 6.8, 5% (w/v) SDS, 20% (v/v) glycerol, 2% β-mercaptoethanol and 0.1% (w/v) bromophenol blue), was 
added to a final concentration of 1 X (v/v) to each sample. Samples were incubated at 100℃ for 7 minutes, 
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stored on ice for 1 minute, and the full volume collected by brief centrifugation. Samples were stored at -
20℃ until use. 
2.7.2. Explant Protein Isolation 
Individual primary cervical explants were harvested in either 1 X Qiagen buffer RLT (All Prep, Qiagen, 
Netherlands) or in 800 µl TriReagent® (Sigma-Aldrich, South Africa). The isolation methods were optimised 
in this study (appendix E, E.2, Table E.2). The following methods produced the best quality protein. 
Samples were homogenised on ice using a tissue rotor-homogeniser at full speed (TissueRuptor, Qiagen, 
Netherlands) for 20 seconds (for up to an accumulated time of 1 minute, dependent on tissue).  
Samples in Qiagen buffer RLT, were processed for protein isolation according to the manufacturer’s 
instructions using the Qiagen AllPrep isolation kit (Qiagen, Netherlands). Samples were resuspended in 80 
µl 1 X reporter lysis buffer (E397A, Promega, USA) with 20 µl 1N NaOH, and incubated at 50℃ for 10 
minutes. Samples were subsequently vortexed for an hour at 4℃ to ensure complete pellet resuspension. 
After pellet resuspension, samples were analysed for total protein concentration using the Bradford method 
of protein quantitation. Samples were stored at -20℃ until use. Before SDS-PAGE gel electrophoresis, 20 
µg total protein per sample was removed and aliquoted into a new 1.5 ml microfuge tube after which 5 X 
protein sample application buffer was added to a final concentration of 1 X. Samples were subsequently 
incubated at 100℃ for 7 minutes and stored on ice for 1 minute, before use in SDS-PAGE gel 
electrophoresis. 
Samples that had been processed for RNA (section 2.6.1) were subsequently processed for protein 
extraction, using the phenol fraction of the isolation, according to the manufacture’s instructions 
(TriReagent, Sigma-Aldrich, South Africa). Briefly, protein samples from the TriReagent fraction, were 
washed 4 times in 0.1 M guanidium hydrochloride (Merck, South Africa) in 95% EtOH, resuspended in 40 µl 
1 X reporter lysis buffer (E397A, Promega, USA), and incubated at 50℃ for 10 minutes to ensure complete 
resuspension. Ten microlitres of 5 X protein sample application buffer was added, to a final concentration of 
1 X, samples incubated at 100℃ for 7 minutes before being stored on ice for 1 minute, and the full volume 
collected by brief centrifugation. Samples were stored at -20℃ until use. 
2.7.3. Generation of Positive Controls 
For the generation of AR, ER⍺, MR, GR⍺ and PR B positive controls for western blotting, COS-1 cells were 
seeded at a density of 1 X 105 cells/ml in a 6 well plate in full DMEM for 24 hours at 37℃ in a water jacket 
incubator (90% humidity and 5% CO2). Cells were transiently transfected with 1 µg of a nuclear receptor 
expression vector using X-tremeGENE 9 (06365809001, Roche Applied Science, South Africa) according 
to the manufacturer’s instructions. After 24 hours incubation, cells were harvested in 50 µl of 2 X protein 
sample buffer, and incubated at 100℃ for 7 minutes. Samples were subsequently stored on ice for a 
minute, and the full volume recovered by centrifugation. Positive controls were confirmed by western 
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blotting using the appropriate nuclear receptor specific primary antibodies. Samples were stored at -20℃ 
until use. 
2.7.4. Western Blotting Protocol 
Western blotting was performed according to Avenant et al., (2010). Protein samples were separated by 
SDS-PAGE at 75 V for 20 minutes followed by 120 V for 1 hour at room temperature in 1 X running buffer 
[25 mM TRIS-HCl, 250 mM glycine and 0,1% (v/v) SDS, pH 8,4 (Sambrook & Russell, 2006)], using a Bio-
Rad Mini Protean II electrophoresis set (Bio-Rad, South Africa). Proteins were subsequently electroblotted 
onto Hybond-ECL (AEC Amersham Biosciences, South Africa) nitrocellulose membrane for 1 hour at 4°C in 
transfer buffer (25 mM TRIS, 200 mM glycine, 10% (v/v) methanol) at 180 milliamps. Membranes were 
subsequently incubated in 4% (w/v) ECL advance blocking powder (AEC Amersham Biosciences, South 
Africa) in 1 X TRIS-buffered saline (50 mM TRIS, 150 mM NaCl; TBS) containing 0.1% (v/v) Tween (TBS-
Tween) for 1 hour at room temperature, on a shaker at 65 rpm. Primary antibody was diluted (see Table 2.3 
for specific dilutions) in 4% (w/v) ECL in 1 X TBS-Tween was added overnight at 4°C on a shaker at 65 
rpm. Three 5 minutes washes with 1 X TBS-tween were performed to remove non-specific primary antibody 
binding. Blots were subsequently incubated with the corresponding secondary antibody (see Table 1 for 
specific pairings and dilutions) for 1 hour in 5% (w/v) skim milk powder in 1 X TBS-Tween at room 
temperature. Washes were repeated as before with 1 X TBS-tween, followed by one 5 minute wash in 1 X 
TBS. Membranes were incubated in ECL-chemiluminescent substrate (Thermo Scientific, USA) for 1 
minute before being visualised using autoradiography, with varying exposure times (see figure legends for 
length of exposure). Autoradiography and ECL visualisation were performed with Amersham Hyperfilm™ 
MP high performance autoradiography film. Autoradiograms were scanned for quantification at 600 dpi in 
grayscale on a flatbed scanner (Hewlett Packard, USA). Autoradiograms were quantified using 
AlphaEaseFC™ Software, version 3.1.2 (Alpha Innotech, USA). 
For consecutive detection steps, membranes were stripped in stripping buffer (100 mM β-mercaptoethanol, 
2% (v/v) SDS, 62.5 mM TRIS-Cl, pH 6.7, (Sambrook & Russell, 2006)) for 30 min at 65℃, washed 2 X 10 
min at room temperature with TBS-Tween and blocked for 1 h in 4% blocking solution at room temperature 




Table 2.3: Dilutions of antibodies used in western blot analysis 
 




GR⍺ 95 1: 2000 Rabbit (1: 10 000) 
PRB/PRA 114/94  1: 500 Mouse (1: 4000) 
AR 110 1:1000 Rabbit (1: 10 000) 
ER⍺ 68 1:500 Rabbit (1: 10 000) 
GAPDH 37 1:15 000 Mouse (1: 4000) 
I𝛋B⍺ 55 1: 500 Rabbit (1: 10 000) 
 
2.8. Fluorescence activated cell sorting (FACS) by Flow Cytometry 
Flow cytometry was performed as described in Tomasicchio et al. (2013) with a few modifications. Five 
hundred thousand PBMCs (at a concentration of 2 million/ml) in full RPMI were placed into 5 ml Becton-
Dickinson Falcon tubes (BD Scientific, South Africa). PBMCs were subsequently stimulated with ligands or 
vehicle for 48 hours, and tubes were placed upright, at 37℃ in a water jacket incubator. In order to 
measure secreted cytokines intracellularly, Brifaldin A (Sigma-Aldrich, South Africa), a secretion inhibitor, 
was added to the PBMCs at a final concentration 10 µg/ml 6 hours prior to processing the samples (Baran 
et al., 2001). Compensation and antibody titrations were performed by Dr. Michele Tomasicchio in the 
Hapgood Laboratory (Tomasicchio et al., 2013). After treatment, PBMCs were surface stained with 20 
µl/million cells anti-CD4 fluorescein isothiocyanate (FITC) (Becton-Dickinson, USA, 555346), 20 µl/million 
cells and anti-CD14 allophycocyanin (APC) (Becton-Dickinson, USA, 555399) antibodies per ml PBS, in 
order to discriminate between cellular populations in PBMCs, at room temperature for 20 minutes in the 
dark. In addition, cells were incubated with a viability marker, 7-AAD (Becton-Dickinson, USA), and only 
viable populations were examined for protein expression. After surface staining, PBMCs were 
permeabilised in 1 X permeabilisation solution (Becton-Dickinson, USA) for 15 minutes at room temperature 
in the dark, and washed twice with 1 X perm wash solution (Becton-Dickinson, USA). PBMCs were 
subsequently stained with either 1.25 µl/million cells GILZ-PE (Becton-Dickinson, USA) with a 
corresponding isotope control (anti-rat IgG-PE) or IL-6 (Becton-Dickinson, USA) with a corresponding 
isotope control (anti-rat IgG-PE), and incubated for 30 minutes at room temperature in the dark. PBMCs 
were washed once with 1 X perm wash solution (Becton-Dickinson, USA), and resuspended in 500 µl 1 X 
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Cell Fix solution (Becton-Dickinson, USA). Samples were acquired using a Becton-Dickinson FACS Calibur 
flow cytometer (Becton-Dickinson, USA) and analysed using Flo Jo software (version 7.1, Treestar, Inc, 
Ashland, Ore). Relative fold change in expression levels was calculated by setting vehicle control (EtOH) 
expression to 1.  
2.9. MSD® ELISA and Luminex® 
Supernatants obtained from PBMC and explant samples incubated for 48 hours with ligands, were stored at 
-80℃. PBMC dose response supernatants were individually stored in cryovials and sent to Harvard 
University (Brigham & Women’s Hospital, Boston, USA), to Professor Raina Fichorova’s laboratory, where 
Meso Scale Delivery (MSD®) ELISA was performed. Relative fold expression of IL-8, IL-10, TNF⍺ and 
VEGF was obtained by setting vehicle control (EtOH) to 1. Supernatants obtained from primary ectocervical 
explants and PBMCs, were processed for cytokine and chemokine secretion using a Bio-Rad Pro™ Human 
Cytokine Group 1 panel (27-plex) Luminex (Bio-Rad, Germany), according to the manufacturer’s 
instructions. Data was obtained on a Luminex 200 pro (Bio-Rad, Germany) at the SUN Immunology 
Research Group, University of Stellenbosch (South Africa) or at the Centre for Proteomics and Genomics 
Research (CPGR; Western Cape, South Africa), that had been validated and calibrated prior to the 
analysis. Sample concentrations were determined using the equation generated for each individual cytokine 
or chemokine. Relative fold change expression was determined by setting vehicle control (EtOH) to 1. 
Analytes included: IL-1β, IL-1ra, IL2, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL12(p70), IL13, IL15, IL17, basic 
FGF, eotaxin, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNFα and 
VEGF. 
2.10. Statistical Analysis 
Results were analysed using GraphPad PRISM (version 6, for MAC) software from GraphPad Software Inc 
(La Jolla California, USA). Data were tested for normalcy before parametric tests were performed using the 
D’Agostino-Pearson omnibus normality test for large data sets and the Kolmogorov-Smirnov test with 
Dallal-Wilkonson-Lille for P value for small data sets (n < 6). Where samples were treated with ligands at 
one time point, a one-way ANOVA, with either a Dunnet’s or Tukey’s post-test (comparing each group to 
control), was performed. For experiments that had different treatments at different time points, a two-way 
ANOVA was performed with a multiple comparison’s Tukey’s post test (either comparing all groups to each 
other or to a control). For comparison between two samples, an unpaired student’s t-test was performed. 
Data were expressed as mean ± SEM on histograms or XY scatter charts, with n values represented in 
each Figure legend. For dose response curves, data was analysed with vehicle control set to 100%, and a 
non-linear regression model was employed using log agonist vs. Response (variable slope - 4 parameters) 
curve. When correlation studies were performed, a Pearsons r correlation test was performed. For infection 
data in the primary cervical explants, repeated measures two-way ANOVA was performed, with post-hoc 
Tukey tests to assess significance between the treatments at each time point assayed. For data that was 
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non-parametric, a Wilcoxon singed-rank test was performed, with the hypothetical value set to the vehicle 
control to determine the effect of a treatment to the control. When comparing two treatment groups to each 
other a Wilcoxon paired-rank sign test was performed. In order to establish productive infection in the 
primary ectocervical explant experiments, the relative infection values of the vehicle control over time were 
analysed for a linear trend using a one-way ANOVA with a post-test for a linear trend (see appendix E, Fig 
E.2.3 for more details). Where statistical significance of difference was determined relative to a single 
control statistical significance is denoted by *, **, ***, or **** to indicate p<0.05, p<0.01, p<0.001, or 
p<0.0001 respectively. Where two values are compared to each other, statistical significance of difference 
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The effects of different progestogens in peripheral blood mononuclear cells (PBMCs) are not well 
understood. In a study by Huijbregts et al. (2013), the authors found that MPA compared to P4 differentially 
regulated key cytokines and chemokines in a dose dependent manner (Huijbregts et al., 2013). The effects 
of the progestogens MPA, P4, NET and LNG on their ability to modulate immune gene mRNA and protein 
expression have not yet been fully elucidated, nor have there been many comparative studies of these 
progestogens on gene expression. Indeed, while it has been established that MPA behaves as a partial 
agonist for the glucocorticoid receptor in cell lines (Koubovec et al., 2004; Koubovec et al., 2005; Ronacher 
et al., 2009; Govender et al., 2014), this has not been established in primary PBMCs.  
It has been observed In a Jurkat T cell line, that MPA (250 nM) after 8 hours, but not P4, was able to 
decrease expression of an IL-2 promoter reporter construct, similar to the synthetic GC agonist, DEX 
(Bamberger et al., 1999). Furthermore, the study observed that IL1, IL2 and IL6 protein levels were reduced 
by MPA, but not P4 and that this mechanism was most likely via the GR, as the authors did not detect PR 
or AR protein expression in normal human lymphocytes ( Bamberger et al., 1999). Kontula et al. (1983) 
using competitive binding assays in human mononuclear leukocytes, observed that MPA had a 42% 
relative binding affinity for the GR, compared to the natural glucocorticoid, cortisol, that had a relative 
binding affinity of 25% for the GR (Kontula et al., 1983). Huijbregts et al. (2013) reported that MPA, more 
than P4 and E2, repressed select cytokine protein expression in a dose dependent manner after 24 hours 
incubation (Huijbregts et al., 2013). It has also been found that that MPA may dysregulate immune priming 
in human pDCs that delays the normal immune response and increases HIV-1 infection risk (Hughes et al., 
2008; Huijbregts et al., 2014; Michel et al., 2015). In addition Huijbregts et al. (2013) have found that after 
five days stimulation with MPA and P4, HIV-1 replication in primary human CD8+ and CD4+ cells increased 
more than the vehicle control (Huijbregts et al., 2013) and that MPA but not P4 increased CCR5 and 
CXCR4 co-receptor expression in these cell types (Huijbregts et al., 2013). Subsequent to the current 
study, Sampah et al. (2015) found that MPA increased HIV-1 infection levels in un-stimulated human 
CD3+CD8+ T cells after three days using an R5 and an X4-tropic HIV-1 pseudovirus. Additionally the 
authors found that this increase in infection was reduced if CD14+ monocytes were removed from the 
sample population of cells (Sampah et al., 2015). However, the extent to which these progestogens may 
affect HIV-1 replication in comparison to NET and LNG has not been explored, nor have the effects of 





The specific aims of this chapter were to: 
 
1.) Identify whether differential gene regulation occurred (both mRNA expression and protein 
expression) by the progestogens and glucocorticoids on key immune response genes, IL6, IL8, 
RANTES and GILZ. 
Using PBMCs isolated from healthy female donors, varying concentrations of DEX, MPA, P4 and NET were 
used to stimulate the PBMCs, after which RNA was isolated and converted to cDNA and mRNA 
transcriptional responses determined using real time qPCR. In addition, the effects of these ligands on 
protein expression and secretion were determined using a combination of flow cytometry, multiplex 
Luminex and MSD ELISA assays on either cells or supernatants. The immune response genes, IL6, IL8, 
RANTES and GILZ were chosen based on their previously established robust responses to glucocorticoids 
and MPA via the GR (Koubovec et al., 2004; Koubovec et al., 2005; Ronacher et al., 2009; Verhoog et al., 
2011; Hadley et al., 2011; Africander et al., 2011; Govender et al., 2014). Additionally, these genes were 
chosen as they have established roles in the regulation of the immune response (Borish & Steinke, 2003; 
Commins et al., 2010; Ayroldi & Riccardi, 2009; Murphy et al., 2012) as well as some of the genes having 
implicated roles in the susceptibility to HIV-1 infection (Birx et al., 1990; Rollenhagen & Asin, 2010; Roberts 
et al., 2012; Lehman et al., 2014; Aukrust et al., 1998; Lane et al., 2001; Lane et al., 1999; Morrison et al., 
2014). 
2.) Determine the steroid receptor profile of PBMCs, and if the GR is involved in mediating the 
differential gene expression by the different progestogens using the selective GR/PR antagonist 
RU486 and GR specific siRNA knockdown by nucleofection in PBMCs. 
Using PBMCs from healthy female donors, GR involvement in transcriptional effects will be determined 
using the selective GR/PR antagonist RU486. In order to support a role for the GR, the GR-specific ligand 
DEX was used as a reference agonist in which to compare the effects. In addition the steroid receptor 
content of PBMCs was analysed in order to aid in determination of whether the activity of RU486 is via the 
GR and/or the PR present in PBMCS. siRNA targeted GR knockdown was used as another method to 
confirm the GR involvement in mediating gene transcription. Using the nucleofection technique, whereby 
the siRNA is electroporated into PBMCs, mRNA expression analysis was performed, 72 hours post 
knockdown, and 48 hours post stimulation with DEX, MPA, P4 or NET. 
3.) Determine the effects of progestogens on HIV-1 replication in PBMCs, and the effects of HIV-1 
on mRNA expression levels of IL6, IL8, RANTES and GILZ in combination with the different 
progestogens. 
PBMCs from healthy female donors were stimulated with CORT, DEX, MPA, P4, NET or LNG for 48 hours, 
before being infected with a luciferase tagged HIV-1BaL_Renilla IMC for 2 hours. Infection was assessed by 
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measuring resultant luciferase activity, and normalised to MTT activity within each condition to account for 
the effects of CORT and DEX on cell viability. In addition, expression of IL6, IL8, RANTES and GILZ mRNA 
was assessed in the absence and presence of HIV-1. 
4.) Determine the effects of longer term incubation with MPA on gene regulation in PBMCs and 
what factors may be involved in mediating the effects of this response. 
PBMCs were treated with either MPA or DEX with effects on mRNA expression of IL6, IL8, RANTES and 
GILZ determined over time. In addition, the effects on cellular viability, using the MTT assay and effects on 





MPA unlike NET-A differentially and dose dependently modulates key immunomodulatory 
gene expression in primary PBMCs 
It was necessary to establish the conditions in order to study the immunomodulatory effects of the 
progestogens, P4, MPA and NET, and the glucocorticoid, DEX on IL6, IL8, RANTES and GILZ mRNA 
expression levels. PBMCs were isolated from the blood of healthy females obtained from the Western 
Province Blood Transfusion Services (WPBTS), South Africa. All blood used in this study was STI free, as 
verified by the WPBTS, South Africa. As such, a time course experiment was performed with saturating 
concentrations of ligand, assessing the transcriptional responses at 4, 24 and 48 hours by the ligands. 
Saturating conditions of ligands were used so that maximal effects on gene transcription could be 
observed. These concentrations were determined by using 10 X concentrations of their potencies or EC50 
values reported in binding studies for the GR (Koubovec et al., 2005; Ronacher et al., 2009). For these 
shorter term incubation experiments, PBMCs were not activated with PHA or incubated in the presence of 
IL2.  
Figure 3.1 shows that of the times investigated, the strongest repressive effects exerted by DEX and MPA 
on IL6, IL8 and RANTES repression were after 48 hours incubation with the ligands. Interestingly, MPA only 
exerted significant repressive effects at 48 hours on IL6 and IL8 mRNA expression, while having no 
significant regulatory effects after 4 or 24 hours post incubation (Figure 3.1 A and B). However MPA 
exerted repressive effects on RANTES mRNA expression after 24 hours post incubation (Fig. 3.1 C). DEX 
had significant and greater repressive effects on IL6 and IL8 and RANTES mRNA expression than MPA. 
However repression was only observed after 24 hours incubation on IL8 expression. The results suggest 
that there could be different regulatory mechanisms involved in mediating the repressive effects observed 
between MPA and DEX, and that time is a factor in this. P4 and NET had no effects on IL6 or IL8 mRNA 
expression at any of the time points assayed (Fig 3.1 A and B). Interestingly, P4 has repressive effects on 
RANTES mRNA expression at 48 hours (Fig. 3.1 C). Both DEX and MPA increased GILZ mRNA 
expression, with DEX exerting stronger transcriptional effects than MPA, at all the time points assayed (Fig. 





Figure 3.1: DEX and MPA, significantly regulates IL6, IL8, RANTES and GILZ mRNA levels in 
primary PBMCs in a time dependent manner. PBMCs were stimulated with saturating concentrations of DEX 
(100 nM), MPA (100 nM), P4 (1 µM), NET-A (10 µM) or vehicle (0,1% EtOH) for 4, 24 or 48 hours. Samples were 
harvested in TriReagent® and subsequently processed for RNA. 500 ng RNA was reversed transcribed to cDNA 
(Roche, South Africa), where it was used in subsequent real time qPCR as template to determine differential mRNA 
expression levels. Relative levels of IL6 (A), IL8 (B), RANTES (C) and GILZ (D) mRNA expression levels were 
normalised to GAPDH mRNA expression levels. Relative fold change in mRNA expression was determined by setting 
vehicle treatment (EtOH) to 1. Histograms represent pooled data from four independent experiments from female 
donors plotted as mean ± SEM. Statistical significance was determined by one-way ANOVA with a post hoc Dunnett’s 
test or unpaired student t-tests comparing each sample to the vehicle control (EtOH) with *, **, ***, **** denoting 
p<0.05, p<0.01, p<0.0001 and p<0.001respectively. 
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Having established that 48 hours incubation with the progestogens exerted the greatest effects on 
transcriptional regulation on the genes tested, the next step was to establish the effects of concentration on 
mRNA expression levels. PBMCs were stimulated with increasing concentrations of DEX, MPA, P4 or NET-
A for 48 hours; followed by RNA isolation, reverse transcription and real time qPCR. DEX served as the 
control for glucocorticoid effects, while P4 the natural ligand served as the control for progestogenic effects.  
The results indicate that MPA, like DEX dose dependently decreased mRNA expression of IL6 and IL8 after 
48 hours stimulation, while P4 and NET-A did not (Fig. 3.2 A and B). In addition MPA, like DEX dose 
dependently increased GILZ mRNA expression at 48 hours, while P4 and NET-A did not (Fig. 3.2 D). Only 
DEX was able to significantly repress RANTES mRNA expression dose dependently under these conditions 
(Fig. 3.2 C), while MPA appeared to reduce RANTES mRNA expression levels at 100 nM and 1 µM. 
Interestingly, this dose response indicated that MPA exerted its most significant differential effects at 100 
nM and 1 µM, with weak effects at 10 nM (Fig. 3.2). Additionally, it appeared that MPA increased GILZ 
mRNA expression at 10 nM (Fig. 3.2 D), suggesting that at low concentrations, MPA is more efficacious in 





Figure 3.2: DEX and MPA, dose-dependently and significantly regulate IL6, IL8, and GILZ mRNA 
levels, while only DEX appears to significantly regulate RANTES mRNA expression in primary 
PBMCs. PBMCs were stimulated with increasing amounts of DEX, MPA, P4, NET-A or vehicle (0,1% EtOH) for 48 
hours. Samples were harvested in TriReagent® and subsequently processed for RNA. 500 ng RNA was reversed 
transcribed to cDNA (Roche, South Africa), where it was used in subsequent real time qPCR as template to determine 
differential mRNA expression levels. Relative levels of IL6 (A), IL8 (B), RANTES (C) and GILZ (D) mRNA expression 
levels were normalised to GAPDH mRNA expression levels with vehicle treatment (EtOH) set to 1. Histograms 
represent pooled data from four independent experiments from female donors plotted as mean ± SEM. Statistical 
significance was determined by one-way ANOVA with a post hoc Dunnett’s test or unpaired student t-tests comparing 
each sample to the vehicle control (EtOH) with *, **, *** denoting p<0.05, p<0.01 and p<0.001 respectively. 
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To more accurately determine whether MPA compared to NET, at concentrations similar to serum 
concentrations, differentially modulate gene expression in a smaller sample set, PBMCs were stimulated 
with 10 nM DEX, MPA, P4 or NET-A for 48 hours, followed by RNA isolation, reverse transcription and real 
time qPCR. Similar to the results in the dose response analyses (Fig. 3.3), only DEX was able to exert 
significant changes in mRNA expression levels, reducing IL6 mRNA expression levels (Fig. 3.3 A) and 
increase GILZ mRNA expression levels (Fig. 3.3 D). MPA appeared to exert a small repressive effect on 
IL6 mRNA expression, and had weak transactivation effects on GILZ mRNA expression levels, although 
significance of these effects could not be established (Fig. 3.3 A and D). Interestingly, while P4 and NET-A 
had no statistically significant effects on mRNA gene expression levels, the mRNA expression levels 
appeared to be elevated compared to basal for IL6, IL8 and RANTES mRNA expression levels (Fig. 3.3 A - 
C). In addition these results highlight the differential sensitivities of the genes to these ligands, with DEX 
having stronger effects on IL6 and GILZ mRNA expression and weaker effects on IL8 and RANTES mRNA 
expression levels, and MPA appearing to follow this trend.  
 
 
Figure 3.3: Low concentrations DEX and MPA, show weak to no effect on IL6, IL8, RANTES and 
GILZ mRNA expression levels in primary PBMCs. PBMCs were stimulated with 10 nM DEX, MPA, P4, NET-A 
or vehicle (0,1% EtOH) for 48 hours. Samples were harvested in TriReagent® and subsequently processed for RNA. 
500 ng RNA was reversed transcribed to cDNA (Roche, South Africa), where it was used in subsequent real time 
qPCR as template to determine the differential expression levels. Relative mRNA expression levels of IL 6 (A), IL 8 
(B), RANTES (C) and GILZ (D) were normalised to GAPDH mRNA expression, with vehicle treatment set to 1. 
Histograms represent pooled data from four independent experiments from female donors plotted as mean ± SEM.  
Statistical significance was determined by one-way ANOVA with a Dunnett’s post-test or unpaired student t-tests 





In order to assess differential gene regulation by MPA and NET-A at a protein expression level, 
supernatants from the dose response experiments were harvested after 48 hours and measured for 
differential levels of secreted proteins using a 4-plex MSD ELISA and a 27-plex Luminex assay. Concurrent 
with the mRNA expression level data (Fig. 3.2 B), relative IL8 protein expression measured by MSD ELISA 
(Fig. 3.4 A) was significantly repressed by DEX and MPA, while P4 and NET-A had no effect at 100 nM 
concentrations. In addition, 100 nM MPA, like DEX, significantly repressed IL-1β protein expression (Fig. 
3.4 B), while P4 and NET, at the same concentration had no effect. DEX significantly repressed IL-10 
protein expression, while MPA appeared to reduce expression of IL-10 at 100 nM (Fig. 3.4 D), while P4 and 
NET at 100 nM had no effect. DEX appeared to reduce TNF-ɑ protein expression at 100 nM (Fig. 3.4 C), 
while MPA had no effect. Interestingly P4 and NET had no effect on any of the proteins measured by MSD 






Figure 3.4: DEX dose-dependently regulates IL8, IL-1β, TNF-ɑ and IL-10 basal protein expression 
levels, while MPA appears to exhibit a similar trend in regulating IL8 and IL-1β expression in 
primary PBMCs. PBMCs were stimulated with increasing amounts of DEX, MPA, P4, NET-A or vehicle (0,1% 
EtOH) for 48 hours. Supernatants were harvested and processed for differential protein expression using MSD ELISA 
(Harvard University, Brigham & Women’s Hospital, Boston, USA). Relative fold change protein expression levels of 
IL8 (A), IL-1β (B), TNF-ɑ (C) and IL-10 (D) were normalised to vehicle control (EtOH) set to 1. Histograms represent 
pooled data from four independent experiments from female donors plotted as mean ± SEM. Statistical significance 
was determined by one-way ANOVA with a post hoc Dunnett’s test or unpaired student t-tests comparing each sample 
to the vehicle control (EtOH) with * and ** denoting p<0.05 and p<0.001 respectively. 
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Following the MSD ELISA, a Luminex assay on the same supernatant samples was performed, and 27 
cytokines expression levels assessed. As with the MSD ELISA, IL-1β expression was significantly reduced 
upon stimulation with DEX (10 and 100 nM) and MPA (100 nM) (Appendix A, Fig A.1.1). DEX significantly 
reduced the protein expression levels of IL-1ra, VEGF, IL-17, IL-12 (p70), and TNF-ɑ (Fig. 3.5 A-E), while 
MPA significantly reduced IL-1ra at 100 nM, and appeared to reduce the apparent expression levels of 
these proteins at 100 nM (Fig. 3.5 A-E). Unlike the mRNA expression data, RANTES did not appear to be 
repressed by either DEX or MPA (Fig. 3.5 F). This could be due to selective degradation of sensitive 
cytokines in the supernatant that had been freeze/thawed twice, however the exact reason is not known. 
Protein determination for IL6, MIP-1ɑ, MIP-1β and MCP-1 was not possible due to the fluorescent values 
being out of range (too high) for most samples in the Luminex assay. In addition to the protein expression 
levels affected by both DEX and MPA, several protein expression levels were significantly reduced by DEX, 
but not MPA (Appendix A, Fig. A.1.1). These results highlight that DEX and MPA may selectively regulate 
key host genes in a concentration dependent manner, and are consistent with the literature, that MPA is a 
partial GR agonist. Additionally the data from Fig. 3.4 and Fig.3.5 suggest that at 100 nM, MPA is more 






Figure 3.5: DEX and MPA dose-dependently regulate select cytokine and chemokine basal protein 
expression levels in primary PBMCs. PBMCs were stimulated with increasing amounts of DEX, MPA, P4, NET-
A or vehicle (0,1% EtOH) for 48 hours. Supernatants were harvested and processed for differential protein expression 
using the Bio-Rad 27-plex Human cytokine and chemokine panel (Bio-Rad, Germany) on a Bio-plex 200 (Bio-Rad, 
Germany). Relative protein expression levels of IL-1ra (A), VEGF (B), IL-7 (C), IL-12 (p70) (D), TNF-ɑ (E) and 
RANTES (F) levels were normalised to vehicle control (EtOH) set to 1. Histograms represent pooled data from four 
independent experiments from female donors plotted as mean ± SEM. Statistical significance was determined by one-
way ANOVA with a post hoc Dunnett’s test or unpaired student t-tests comparing each sample to the vehicle control 





In order to establish whether the progestins differentially regulated protein expression of IL6 and GILZ in 
different cellular populations, protein expression analysis using FACS was performed. PBMCs were 
stimulated with saturating conditions of ligand for 48 hours, before staining cells with surface antibody 
markers (CD4+ and CD14+) followed by GILZ antibody or IL6 intracellular antibody staining for protein 
expression (Figure 3.6).  
MPA (100 nM), like DEX (100 nM), significantly repressed IL6 protein expression after 48 hours while P4 (1 
μM), NET-A (10 μM), NET (10 μM and LNG (10 μM) did not affect basal expression in CD14+ monocytes 
(Fig. 3.6 A). Interestingly, IL6 expression was not readily detected in CD4+ T cells (data not shown), 
indicating that under these conditions IL6 is predominantly expressed in CD14+ monocytes.  
DEX and MPA significantly increased GILZ protein expression levels in CD4+ T cells, after 48 hours. P4, 
NET, NET-A and LNG did not affect GILZ protein expression levels (Fig. 3.6 B). GILZ expression was 
detected in CD14+ monocytes, however no differential expression levels were observed in the cell type 




Figure 3.6: DEX and MPA, but not NET-A or P4, significantly decrease IL6 and increase GILZ protein 
expression in primary human CD14+ Monocytes and CD4+ T cells respectively. Cells were treated with 
100 nM DEX, 100 nM MPA, 1 µM P4, 10 µM NET-A, 10 µM NET, 10 µM LNG or vehicle control (ETOH) for 48 hrs. 
Thereafter cells were stained with surface antibody markers (CD4+ and CD14+) followed by IL6 or GILZ intracellular 
antibody staining for protein expression. Protein expression was measured using a Becton-Dickinson FACsCalibur 
flow cytometer and analysed using FlowJo (software version 7.1, Treestar Inc., Ashland, Ore). Gating strategy in 
Appendix A (Fig.A.2.1 and A.2.2). (A) Relative IL6 protein expression in CD14+ monocytes and (B) relative GILZ 
expression in CD4+ T cells were normalised to vehicle (EtOH) control set to 1. Histograms represent pooled results 
from five independent experiments from female donors plotted as mean ± SEM. Statistical significance was 
determined by one-way ANOVA with a Dunnet’s post-test or with an unpaired student t-test, comparing the sample to 




MPA and DEX mRNA gene expression effects are mediated via the glucocorticoid receptor 
(GR) in primary PBMCs 
 
PBMCs appear to express the GR, ER and MR mRNA, with no AR or PR mRNA being detectable (Fig. 3.7 
A). Western blotting shows that only the GR protein was detectable in PBMCs (Fig. 3.7 B), suggesting that 
the effects of DEX and MPA are most likely to be via the GR. Due to the cross-reactivity of the MR antibody 
used in this study, MR protein expression by western blot could not be determined. There have been a few 
studies that have detected the PR in PBMCs, however detection was low suggesting that the PR may be 




Figure 3.7: The steroid receptor profile shows that ER, GR and MR mRNA are present, while only 
GR was detectable via western blotting in PBMCs. (A) Conventional PCR of cDNA prepared from human 
PBMCs using primers specific for the relevant steroid receptor (see Chapter 2). The controls were prepared by PCR 
amplification of the relative steroid receptor cDNA from plasmid DNA from two female donors (denoted as #1 and #2). 
GAPDH served as a control for mRNA levels. PRAB has two positive controls, with the first positive control showing 
results using PRB plasmid DNA and the second representing PRA. MW: molecular weight; NTC: no template control. 
Products were visualised at 256 nM using a Syngene, G:Box (Vacutec, England) and images acquired using 
GeneSnap from synGene, version 7.08 (SynGene, England). (B) Protein samples isolated from two donors (#1 and 
#2) using TAPS buffer, were electrophoresed on an 8% SDS-PAGE gel before being electroblotted onto a 
nitrocellulose membrane and probed for GR⍺, PRAB, ER⍺ and AR and GAPDH. Nitrocellulose blots were incubated 
for 1 minute in ECL-chemiluminescent substrate before being visualised by audio-radiography. Positive controls 
(donated as +) for each of the steroid receptors were included in each western blot to confirm the product of the donor 
samples. 
 
To investigate the role of the GR in mediating the DEX and MPA effects on mRNA gene expression, 
PBMCs were treated with DEX and MPA in the absence and presence of RU486, a selective GR/PR 
antagonist for 48 hours. Although RU486 can also antagonise the PR, we have recently shown that PBMCs 
under our conditions express no detectable PR mRNA or protein [(Tomasicchio et al., 2013) and Fig 3.7]. 
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Thus, the RU486 results will support a role for the GR in mediating these anti-inflammatory effects in 
PBMCs. In Figure 3.8, IL6, IL8 mRNA expression was significantly repressed by DEX and MPA. In the 
presence of the antagonist RU486, the repressive effects exerted by DEX and MPA was lifted (Fig. 3.8 A 
and B). Similarly, DEX significantly repressed RANTES mRNA expression, while MPA appeared to reduce 
basal expression. In the presence of RU486, the repressive effects exerted by DEX were lifted, while 
RANTES mRNA expression remained the same in the MPA/RU486 treated samples (Fig. 3.8 C). 
Additionally, both DEX and MPA appeared to induce GILZ mRNA expression levels, an effect which was 
lost when co-stimulated with RU486 (Fig. 3.8 D). In Fig 3.8 A, DEX and MPA repression on IL6 appears to 
be more efficacious than on IL8 (Fig. 3.8 B) and RANTES (Fig. 3.8 C), with partial DEX repression still 




Figure 3.8: DEX- and MPA-mediated regulation of GILZ, IL6, IL8 and RANTES mRNA is reversed 
upon RU486 treatment. PBMCs were stimulated with 100 nM DEX and MPA in the presence and absence of 1 µM 
RU486 for 48 hours. Samples were harvested in TriReagent® and harvested for RNA isolation. 500 ng RNA was 
reversed transcribed to cDNA (Roche, South Africa), and used in subsequent real time qPCR as template to 
determine differential mRNA expression levels. Relative mRNA expression levels of IL6 (A), IL8 (B), RANTES (C) and 
GILZ (D) were normalised to GAPDH. Relative fold change in mRNA expression was determined by setting vehicle 
treatment (EtOH) to 1. Histograms show pooled results from three independent experiments plotted as mean ± SEM. 
Statistical significance was determined by one-way ANOVA with Dunnet’s post-test or unpaired student t-tests, with p 
< 0.05 denoted as * and p < 0.0001 denoted as ****. 
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To confirm the effects of the antagonist experiment, PBMCs were electroporated with GR specific siRNA 
and assessed for GR knockdown and resultant mRNA expression. Under these conditions, the repressive 
effects of DEX and MPA on IL6, IL8 and RANTES were muted in the NSC conditions (Fig. 3.9 A-C), as 
compared to the repression observed in Figs. 3.1, 3.2 and 3.8, where 100 nM DEX significantly repressed 
IL6, IL8 and RANTES and MPA significantly repressed IL6 and IL8 mRNA expression after 48 hours 
stimulation. However, the apparent repressive effects appeared to be lifted under knockdown conditions 
(Fig. 3.9 A-C). Indeed, DEX and MPA responses on IL6 increased from a mean of 0.51 fold and 0.75 fold to 
a mean of 0.72 fold and 2.32 fold respectively (Fig. 3.9 A), suggesting that the GR is involved in mediating 
the repression of IL6 in PBMCs. A similar trend was observed for IL8 mRNA expression, where DEX and 
MPA responses were lifted under knockdown conditions. DEX and MPA responses increased from a mean 
response of 0.37 fold and 0.64 fold response under NSC conditions to a mean response of 0.64 fold and 
1.51 fold respectively under knockdown conditions (Fig. 3.9 B). RANTES mRNA expression was 
significantly repressed by DEX under NSC conditions, and appeared to be less repressed when the GR 
was knockdown (Fig. 3.9 C). Similarly MPA appeared to weakly repress RANTES under NSC conditions, 
which was lifted under knockdown conditions (a mean of 0.60 fold under NSC conditions to 0.92 fold under 
knockdown conditions). GILZ transactivation by DEX and MPA was observed under NSC conditions. 
However, under knockdown conditions, only DEX treated responses were muted, while MPA transactivation 
appeared to be maintained (Fig. 3.9 D). In the presence of the knockdown conditions basal levels of IL6 
modestly increased, as well as in P4 and NET conditions. This result suggests that the GR may be involved 
in regulating the basal mRNA expression levels of IL6 (Fig. 3.9 A). A similar trend was observed in the IL8 
knockdown conditions, where NET treatment appeared to elevate IL8 mRNA expression levels (Fig. 3.9 B). 
The apparent pro-inflammation effects may be due to the involvement of the unliganded GR, that may 
regulate basal transcription of pro-inflammatory genes, similar to what Verhoog et al. (2011) observed in an 
epithelial cell line (Verhoog et al., 2011).  
The partial repression maintained on some of the genes by DEX (IL6, IL8 and RANTES) as well as the 
maintenance of GILZ transactivation by MPA, may be due to a relatively low knockdown level (40%) 
achieved under these conditions (Fig. 3.9 E), suggesting that there was sufficient GR under the knockdown 
conditions to exert repressive or transactivating effects on the select panel of genes tested. These results 
suggest that GR is involved in modulating DEX and MPA effects on select gene expression. Furthermore, 
these experiments support the RU486 experiments for a role of the GR in mediating DEX and MPA 







Figure 3.9: DEX- mediated regulation of GILZ mRNA requires the presence of the GR, while MPA- 
mediated repression of IL6, IL8 and RANTES also appears to require the presence of the GR in 
primary human PBMCs. PBMCs were electroporated using a Nucleofector (Lonza) with 20 nM GR5 (Qiagen) 
siRNA or control siRNA and after 24 hours stimulated with 100 nM DEX, MPA, NET or progesterone (P4) for a further 
48 hours. Samples were harvested for RNA isolation followed by reverse transcription of 500 ng RNA to cDNA. 
Relative mRNA expression levels of IL6 (A), IL8 (B), RANTES (C) and GILZ (D) were determined by real time qPCR, 
normalised to GAPDH. Relative fold change in mRNA expression was determined by setting vehicle treatment (EtOH) 
to 1. For each experiment, an untreated NSC and GR5 sample was harvested at 48 hrs post nucleofection for protein 
isolation using TAPS buffer. Samples were electrophoresed on an 8% SDS-PAGE gel before being electroblotted onto 
a nitrocellulose membrane and probed for GRα and GAPDH. Nitrocellulose blots were incubated for 1 minute in ECL-
chemiluminescent substrate before being visualised by audio-radiography. (E) Average knockdown as a percentage of 
NSC GR was determined by densometric analysis (AlphaEC™, Alpha Innotech, version 3.1.) setting NSC GR levels to 
100%. Histograms (A - E) are pooled results from representative of four independent experiments, plotted at mean ± 
SEM, while the western blot in E is representative of one donor. Statistical significance was determined by a one way 





In order to establish whether the effects exerted by MPA on mRNA levels required new protein synthesis, 
cycloheximide (CHX) experiments were performed (Fig. 3.10). CHX prevents de novo protein synthesis 
Thus, if the repression is lost in the presence of CHX, it suggests that new proteins, other than those 
present, are necessary to produce the effects on the mRNA levels assayed.  
Results suggest that in the presence of CHX, DEX and MPA repression of IL6 mRNA is lost after 48 hours 
(Fig. 3.10 A). Further DEX repression of IL8 and RANTES mRNA expression was also lost in the presence 
of CHX (Fig. 3.10 B and C). While MPA repression was not significant on IL8 or RANTES mRNA 
expression after 48 hours in this study, in the presence of CHX, IL8 and RANTES mRNA expression levels 
appeared to be elevated (Fig. 3.10 B and C). These results suggest that repression by DEX, and MPA may 
be indirect. In this experiment, GILZ mRNA appeared to be elevated by DEX and MPA (Fig. 3.10 D). 
Further, in the presence of CHX, GILZ mRNA expression remained elevated with DEX and MPA, 
suggesting that the increase in GILZ mRNA expression may be through direct effects.  
Taken together, the results are consistent with a direct transcriptional effect of the GR in up-regulating GILZ 






Figure 3.10: DEX- mediated regulation of IL6, IL8 and RANTES and MPA-mediated regulation of IL6, 
appears to require additional protein synthesis to exert the repressive effects via the GR, unlike for 
GILZ, in primary human PBMCs. PBMCS were treated with 100 nM DEX, MPA or with a vehicle control (0.1% 
EtOH) in the absence and presence of 10 µg/ml cycloheximide (CHX) for 48 hours. PBMCs were harvested in parallel 
for RNA isolation or subsequent protein isolation. 250 ng of the RNA samples were reverse transcribed, and used in 
subsequent real time qPCR. Relative mRNA expression levels of IL6 (A), IL8 (B), RANTES (C) and GILZ (D) were 
determined by real time qPCR, normalised to GAPDH. Relative fold change in mRNA expression was determined by 
setting vehicle treatment (EtOH) in each condition (± CHX) to 1. Histograms are pooled results from representative of 
four independent experiments, plotted at mean ± SEM. Statistical significance was determined by a one way ANOVA, 




Progestogens and glucocorticoids, differentially modulate immunomodulatory genes in 
PBMCs and variably modulate HIV-1 replication in primary PBMCs after long term exposure 
 
Having established that MPA, like DEX, regulates select key immune response genes via the GR, in a 
manner unlike that of NET and LNG and P4, it was next determined whether these ligands affect HIV-1 
replication in PBMCs. For this set of experiments, initial pilot experiments suggested that it was necessary 
to culture activated PBMCs in 30 U/ml IL2 to obtain reproducible and measureable HIV-1 infection levels 
(appendix E, Fig. E.1.1). Further pilot experiments found that measuring HIV-1 replication levels via 
luminescence at day 7 post infection was optimal, and that cell viability was not significantly effected with 
0.01% EtOH (appendix E, Fig. E.1.2). As such, PBMCs isolated from healthy female donors, were activated 
for one day and subsequently stimulated with 100 nM of each ligand; cortisol (a natural GR ligand), DEX, 
MPA, P4, NET and LNG or vehicle control (0.01% EtOH). After 48 hours, samples were infected with 10 
IU/ml HIV-1BaL_Renilla and incubated for a further 7 days. PBMCs were harvested for RNA, luciferase activity 
and MTT at day 7 post infection. Cell viability as measured by MTT was assessed, in order to normalise the 
luciferase readings to viable cells. This was necessary as incubations times were long (9 days) and it has 
been reported that both DEX and MPA increase GR dependent apoptosis in PBMCs (Tomasicchio et al., 
2013).  
Seven days after infection with HIV-1BaL_Renilla, the level of renilla activity in the PBMCs from 10 different 
donors varied substantially in all treatment groups (Fig. 3.11 A), suggesting that HIV-1 infection and 
replication levels are dependent upon the donor. It could be that the relative concentrations and states of 
activation of different cell types between donors may vary. However, this remains to be confirmed. In 5 out 
10 donor PBMCs, CORT treatment increased HIV-1 viral replication, while appeared to be protective (i.e. 
less infectious) for the other donors. Similarly, 4 out of 10 DEX treated donor PBMCs had in increase in 
viral replication. Similarly to the glucocorticoids, the progestogens P4 and LNG treated PBMCs increased 
viral replication in 5 out of the 10 patient PBMC samples. In contrast to this variability, in MPA treated 
samples, 7 out of 10 donor PBMCs exhibited an increase in HIV-1 replication, while 8 out of 10 NET-treated 
samples had little to protective effects on HIV-1 replication (Fig 3.11 A). MTT viability analysis indicated that 
cell viability decreased significantly in CORT and DEX treated samples, while MPA showed a slight 
reduction in cell viability (Fig. 3.11 B). P4, NET and LNG had no effect on cellular proliferation in the 
absence or presence of HIV-1. Indeed, the presence of HIV-1 did not appear to further alter viability for any 






Figure 3.11: HIV-1 infection levels are highly varied within each treatment group, while it appears 
that CORT, DEX and MPA reduce viability of PBMCs compared to P4, NET or LNG in primary 
PBMCs. PHA activated PBMCs were pre-treated with 100 nM Cortisol (CORT), DEX, MPA, P4, NET and LNG or 
vehicle control, (0.01% (v/v) EtOH) for 48 hours. Pre-treated PBMCs were infected with 10 IU/ml HIV-1BaL-Renilla IMC for 
2 hours, washed 4 times with 1 X PBS and media with the respective ligands was added. Media was replaced every 
second day. PBMCs were harvested 7 days post infection and MTT viability and luciferase activity were measured. (A) 
Renilla luciferase was measured with the Promega Renilla-Glo™ kit using a luminometer (Modulus Microplate, 
Glomax, Promega) and values were normalised against corresponding MTT values, and normalised to vehicle set to 
100% relative infection. (B) MTT activity was detected with a multiplate reader (Thermo Scientific) using a MTT cell 
viability kit (Sigma.) Values were normalised to vehicle, which was set to 1. Histograms (A-B) show pooled results of 
ten independent experiments, with ten donors and plotted as mean ± SEM. Statistical analysis was carried out using 
GraphPad Prism™ software, using a one-way ANOVA with student t-tests. Statistical significance is denoted by *** or 





When assessing relative mRNA expression of IL6, IL8, RANTES and GILZ after infection, CORT, DEX and 
MPA treatment did not repress IL6 or RANTES mRNA expression in both the absence and presence of 
HIV-1 7 days post infection (Fig. 3.12 A and C). Repression of IL8 mRNA expression by CORT, DEX and 
MPA was maintained in the absence of HIV-1 but lost in the presence of HIV-1 (Fig. 3.12 B). Relative IL6 
mRNA expression in the presence of HIV-1 by CORT, DEX and MPA was no longer repressive, as 
previously observed in this study, while relative IL8 mRNA expression varied in the presence of HIV-1 
infection. RANTES mRNA expression levels in CORT, DEX and MPA treated samples in the absence and 
presence of HIV-1 were no longer repressed (Fig. 3.12 C). In contrast, transactivation of GILZ mRNA 
expression by CORT, DEX and MPA was maintained after 7 days post infection (Fig. 3.12 D). Interestingly, 
DEX treatment elevated GILZ mRNA expression to a greater extent in the presence of HIV-1, compared to 
the no virus control (Fig. 3.12 D). P4, NET and LNG had no significant effect on IL6, IL8, RANTES and 
GILZ mRNA expression levels, and the presence of HIV-1 did not alter this expression profile (Fig. 3.12 A-
D). However it did appear that NET and LNG, more so than P4, appeared to elevate IL6, IL8 and RANTES 
mRNA expression levels in the absence of HIV-1, while this was not evident in the presences of HIV-1 (Fig. 
3.12 A-C). Basal expression mRNA expression levels of IL6, IL8, RANTES and GILZ did not change in the 







Figure 3.12: mRNA levels of select immunomodulatory genes after 9 days in the presence of 
ligands and after 7 days in the absence and presence of HIV-1BaL-Renilla. PHA activated PBMCs were pre-
treated with 100 nM Cortisol (CORT), DEX, MPA, P4, NET or LNG, with vehicle control (0.01% EtOH), for 48 hours. 
Pre-treated PBMCs were infected with 10 IU/ml HIV-1BaL-Renilla IMC for 2 hours, washed extensively and the media 
replaced.  Media with the respective ligands was replaced every second day. PBMCs were harvested at 7 days post 
infection in TriReagent® and subsequently processed for RNA. 250 ng RNA was reversed transcribed to cDNA 
(Roche Applied Science, South Africa), where it was used in subsequent real time qPCR as template to determine the 
differential expression levels. Relative mRNA expression levels of IL6 (A) and IL8 (B) were normalised to GAPDH 
mRNA expression levels. Relative fold change expression was determined by setting the vehicle treatment (EtOH) to 
1. Histograms represent pooled data from ten independent experiments from ten female donors plotted as mean ± 
SEM.  Statistical significance was determined by a non-parametric Wilcoxon signed-rank test with the hypothetical 
values set to the vehicle control comparing each sample to the vehicle control (EtOH) with * and ** denoting p<0.05 




Figure 3.12 continued: mRNA levels of select immunomodulatory genes after 9 days in the 
presence of ligands and after 7 days in the absence and presence of HIV-1BaL-Renilla. PHA activated 
PBMCs were pre-treated with 100 nM Cortisol (CORT), DEX, MPA, P4, NET or LNG, with vehicle control (0.01% 
EtOH), for 48 hours. Pre-treated PBMCs were infected with 10 IU/ml HIV-1BaL-Renilla IMC for 2 hours, washed 
extensively and the media replaced. Media with the respective ligands was replaced every second day. PBMCs were 
harvested at 7 days post infection in TriReagent® and subsequently processed for RNA. 250 ng RNA was reversed 
transcribed to cDNA (Roche Applied Science, South Africa), where it was used in subsequent real time qPCR as 
template to determine the differential expression levels. Relative mRNA expression levels of RANTES (C) and GILZ 
(D) were normalised to GAPDH mRNA expression levels. Relative fold change expression was determined by setting 
the vehicle treatment (EtOH) to 1. Histograms represent pooled data from ten independent experiments from ten 
female donors plotted as mean ± SEM. Statistical significance was determined by a non-parametric Wilcoxon signed-
rank test with the hypothetical values set to the vehicle control or a paired Wilcoxon matched-pairs signed rank test 
comparing each sample to the vehicle control (EtOH) with *, and *** denoting p<0.05 and p<0.001 respectively. 
 
MPA induced increase in HIV-1 replication correlates with an increase in IL6 mRNA 
expression level in primary PBMCs 
 
The differential effects of the progestogens on HIV-1 replication and mRNA gene expression after 9 days, 
suggested that there may be a correlation between effects on expression of immunomodulatory genes and 
HIV-1 replication Thus the differential effects of the different ligands on HIV-1 replication after 9 days, may 
be, in part, due to their differential effects on select immunomodulatory gene expression. Upon analysis of 
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the infection data, it was evident that in the MPA treated samples; three donor samples exhibited a 
decrease in HIV-1 replication, while seven donor samples exhibited an increase in HIV-1 replication. In 
addition, the loss of IL6 mRNA repression by MPA (Fig. 3.12) suggested that there may be a relationship 
between IL6 expression levels and HIV-1 replication. As such, the data was analysed to determine whether 
there was any correlation between HIV-1 replication and gene expression. When mean relative infection 
levels were correlated with their matched relative IL6 mRNA expression levels, there was a significant 
positive association between MPA IL6 mRNA expression and relative MPA infection levels (Pearsons r 
0.7826, p value 0.0074; Fig. 3.13 A). That is, low relative infection levels correlated with low relative IL6 
mRNA expression levels, while high relative infection levels were associated with high relative IL6 mRNA 
expression levels after 9 days, as seen in Figure 3.13 B. In addition there was a weak positive correlation 
between DEX IL6 mRNA expression and HIV-1 replication (Pearsons r 0.6939, p value = 0.0381; see 
Appendix A, Fig. A.3.1), while CORT, P4, NET and LNG had no correlation between IL6 mRNA expression 
levels and HIV-1 replication (data not shown).  
  
Figure 3.13: Higher MPA infection levels positively correlate with higher IL6 mRNA expression 
levels. (A) Relative MPA infection levels, normalised to vehicle treatment (EtOH) were plotted against matching 
relative IL6 mRNA expression levels, normalised to vehicle treatment (EtOH). Relative IL6 mRNA transcript levels 
were determined by comparing C(t) values to a standard curve derived from a serial dilution of pooled cDNA (from the 
experimental repeats) with a known concentration. An XY scatter plot represents 10 individuals with mean infection 
levels on the Y-axis and IL6 relative mRNA expression on the X-axis. A Pearsons correlation analysis (comparing r for 
X vs. Every Y data set) was performed with a two-tailed post-test t-test analysis. (B) MPA infection levels were 
grouped according to low relative IL6 mRNA expression levels or high relative IL6 mRNA expression levels. Relative 
infection data from Fig. 3.10 was used to plot (B), with vehicle control (EtOH) set to 100%. The histogram is 
representative of 3 (low IL6) and 7 (high IL6) biological repeats plotted as mean ± SEM. Statistical significance was 
determined by an unpaired student t-tests comparing the two groups, with * denoting p<0.05 (actual p value = 0.0279). 
 
Figure 3.14 shows the results for the pooled data of the 7 out of 10 donor samples in which an increase in 
HIV-1 replication was observed upon stimulation with 100 nM MPA after 9 days. For donors where relative 
IL6 mRNA expression was elevated relative to the vehicle control (Fig. 3.14 A), HIV-1 replication (Fig. 3.14 
B) appears to be elevated in CORT and DEX (4 out of 7 donors) samples, while HIV-1 replication is 
significantly up-regulated in all MPA treated samples (174% mean relative infection levels). This was 
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confirmed, with DEX treated samples also exhibiting a positive correlation with relative IL6 mRNA 
expression levels and HIV-1 replication (Appendix A, Fig. A.3.1), while CORT had no correlative effect. In 
Fig. 3.14 A, CORT, DEX and MPA samples, IL6 mRNA expression levels are elevated in the uninfected 
group, and appear to further increase in the HIV-1 infected group, while P4, NET and LNG have no effect 
on IL6 mRNA gene expression. Both P4 and LNG responses are still varied in this grouping with an 
increase of HIV-1 replication observed in 3 out of 7 samples. Interestingly, NET treated samples appear to 
have no change in HIV-1 replication (92% mean relative infection levels) compared to the vehicle control 
(EtOH). 
 
Figure 3.14: MPA only increases HIV-1 infection in primary PBMCs when IL6 mRNA repression by 
MPA is lost. (A) A loss of IL6 mRNA repression in the presence of HIV-1 correlated with (B) Increased MPA induced 
relative infection levels. Histograms represent pooled data of seven independent experiments from seven female 
donors plotted as mean ± SEM. Statistical significance was determined with a non-parametric Wilcoxon signed-rank 
test with the hypothetical value set to the vehicle control or with a paired Wilcoxon matched-pairs signed rank test 




Interestingly when relative IL6 mRNA expression was low in the HIV-1 infected group (Fig. 3.15 A), HIV-1 
replication was low in all conditions (Fig. 3.15 B). Indeed, CORT, DEX and MPA appear to be protective in 
the group compared to P4, NET and LNG that have similar infection levels to the vehicle control. The 
relative IL6 mRNA expression patterns appear to be similar between HIV-1 uninfected and infected groups. 
In Fig. 3.15 A, CORT, DEX significantly repressed IL6 mRNA expression levels compared to the vehicle 
control, while MPA appeared to have no effect on IL6 mRNA expression levels compared to the vehicle 
control in the presence of HIV-1, which is mimicked in the HIV-1 infected group. Interestingly in the HIV-1 
negative control, only DEX repression was maintained similar to the HIV-1 infected group, while this was 
not true for the CORT and MPA treated samples.  
  
Figure 3.15: DEX and MPA decrease HIV-1 infection when IL6 mRNA repression is maintained in the 
presence of HIV-1. (A) Maintenance of IL6 mRNA repression by DEX and MPA in the presence of HIV-1 
corresponded with (B) a decrease in HIV-1 replication. Histograms represent pooled data from three independent 
experiments from three female donors plotted as mean ± SEM. Statistical significance was determined with a non-
parametric Wilcoxon signed-rank test with the hypothetical value set to the vehicle control or unpaired student t-tests 
(for the parametric MPA group) comparing each sample to the vehicle control (EtOH) with *,denoting p<0.05. 
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The data suggest that responses to MPA treatment over time may vary, and could be population 
dependent. In one population (7/10 donors) MPA is no longer able to repress IL6 mRNA gene expression 
and increase HIV-1 infection, while in the other population (3/10 donors), repression is maintained on IL6 
mRNA gene expression and HIV-1 replication is similar to reduced, compared to the control treatment. 
Additionally, it appears that the population that is able to maintain relative repression of IL6 mRNA levels is 
smaller than those that lose the ability to repress IL6 mRNA levels. When assessing the effects on gene 
expression of IL8, RANTES and GILZ between these groups, it was found that IL8 and RANTES mRNA 
levels were not repressed in the high HIV-1 replication group (Appendix A, Fig. A.4.1), while CORT and 
DEX appeared to repress IL8 mRNA levels in the group that had low HIV-1 replication levels, MPA had no 
effect (Appendix A, Fig. A.4.2). Interestingly it appeared that MPA increased RANTES expression in the 
group that had low HIV-1 viral replication (Appendix A, Fig. A.4.2). GILZ transactivation was maintained in 
both groups (Appendix A, Fig. A.4.1 and A.4.2), showing that the differential effects on pro-inflammatory 
genes are unlikely to be due to factors such as loss of GR activity or RNA degradation. Despite the 
interesting results, IL8, RANTES and GILZ mRNA expression did not correlate with HIV-1 relative infection 
levels (data not shown). 
DEX and MPA repression on IL6, IL8 and RANTES is time dependent 
Comparing the 48 hour gene expression data, with DEX and MPA treatment in the absence of HIV-1 and 
PBMC activation (Fig. 3.1), to the gene expression data after 9 days treatment with DEX or MPA (Fig. 
3.12), suggested that there may be a potential switch from repression to no repression of relative IL6 
mRNA expression. As such, it was hypothesised that the differential regulation mediated by DEX and MPA 
on immunomodulatory gene expression may be time dependent. In order to address this question, PBMCs 
were stimulated with 100 nM DEX or MPA and samples were harvested every day from day 2 to day 7, 
where viability was assessed by MTT, RNA was harvested for gene expression studies, and protein was 
harvested for western blot analysis. IL6 mRNA gene expression analysis indicated (Fig. 3.16 A) that DEX 
repressed mRNA levels at days 2, 3 and 4, but that this repression was lost at days 5, 6 and 7. Similarly 
MPA significantly repressed IL6 mRNA levels at day 2, with expression levels reduced at days 3 and 4, 
while IL6 mRNA levels at days 5, 6 and 7 were elevated. DEX and MPA exerted similar regulatory patterns 
on relative IL8 mRNA levels (Fig. 3.16 B). However, unlike the relative IL6 mRNA levels, IL8 mRNA levels 
were variable throughout the time course, maintaining reduced or similar mRNA levels compared to the 
control treatment at days 5, 6 and 7. RANTES mRNA levels were modulated by DEX and MPA in a similar 
manner to IL8 mRNA levels (Fig. 3.16 C), with DEX having stronger repressive effects on mRNA 
expression at days 2, 3 and 4 compared to MPA that only exhibited significant repressive effects at day 2. 
DEX and MPA no longer exerted any repressive effects at days 5, 6 and 7 (Fig. 3.16 C). Interestingly GILZ 
transactivation by DEX and MPA was maintained throughout the duration of the time course (Fig. 3.16 D), 
with DEX having stronger transactivation effects than MPA, suggesting that as for the previous section, 
factors such as loss of RNA or receptor integrity are not involved. Interestingly, basal expression levels of 
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IL6 and IL8 decreased over time more so than RANTES, while GILZ mRNA levels remained similar to basal 
conditions (EtOH) at day 2 (Appendix A, Fig. A.5.2).   
  
 
Figure 3.16: DEX and MPA-mediated repressive effects on select genes is lost over time, while 
transactivation effects are maintained. PHA activated PBMCs were pre-treated with 100 nM DEX, MPA or 
0.1% (v/v) vehicle control (EtOH) for 7 days with half media exchange at day 3 and 6. Samples were harvested every 
day from day 2 to day 7 for RNA isolation. 250 ng RNA was reverse transcribed to cDNA and used as template in 
subsequent real time qPCR. Relative mRNA expression levels of IL6 (A) and IL8 (B) were normalised to GAPDH 
mRNA expression levels. Relative fold change in expression was determined by setting vehicle treatment (EtOH) at 
each day to 1. Histograms represent pooled data from four independent experiments from four female donors plotted 
as mean ± SEM. Statistical significance was determined by one-way ANOVA with a Dunnett’s post-test or unpaired 
student t-tests comparing each sample to the vehicle control (EtOH) with *, **, *** and **** denoting p<0.05, p<0.01, 





Figure 3.16 continued: DEX and MPA-mediated repressive effects on select genes is lost over time, 
while transactivation effects are maintained. PHA activated PBMCs were pre-treated with 100 nM DEX, MPA 
or 0.1% (v/v) vehicle control (EtOH) for 7 days with half media exchange at day 3 and 6. Samples were harvested 
every day from day 2 to day 7 for RNA isolation. 250 ng RNA was reverse transcribed to cDNA and used as template 
in subsequent real time qPCR. Relative mRNA expression levels of RANTES (C) and GILZ (D) were normalised to 
GAPDH mRNA expression levels. Relative fold change in expression was determined by setting vehicle treatment 
(EtOH) at each day to 1. Histograms represent pooled data from four independent experiments from four female 
donors plotted as mean ± SEM. Statistical significance was determined by one-way ANOVA with a Dunnett’s post-test 
or unpaired student t-tests comparing each sample to the vehicle control (EtOH) with * and, ** denoting p<0.05, and 
p<0.01 respectively.  
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In order to elucidate the mechanism of this loss of IL6 mRNA repression over time, cell viability and steroid 
receptor expression levels were analysed. Cell viability as assessed by MTT, indicated that cell viability 
significantly decreased over time (Fig. 3.17 A). DEX treatment resulted in a 50% loss of cell viability, while 
MPA treatment resulted in a 20% loss in cell viability at the end of the time course. It could be that the loss 
of viability could affect gene expression, however GILZ transactivation by DEX and MPA was maintained 
over the time course (Fig. 3.17 D).  
The effects on gene expression may not only be as a result in loss of cell viability, but a change in the 
relative expression levels of other transcription factors. Since it has been established that DEX and MPA 
mediate their effects via steroid receptors, AR, ER, MR, PR and GR levels were assessed in order to 
elucidate whether changes in their expression levels correlated with the changes in mRNA levels. DEX and 
MPA are partial agonists for the MR (Africander et al., 2011) and the AR (Africander et al., 2014). MPA is a 
full agonist for the PR and partial agonist for the GR, while DEX is a full agonist for the GR with no PR 
activity (Africander et al., 2011). Additionally, it has been shown in some studies that steroids are known to 
regulated the expression of other steroid receptor genes (Acconcia & Kumar, 2006; Mesiano et al., 2002; 
De Amicis et al., 2009). As such, receptor levels were assessed by western blot for the AR, GR and PR. 
Several MR antibodies were used in duration of this study, however the antibodies used were either non-
specific or did not produce convincing western blots. Thus real time qPCR was also performed to 
investigate MR mRNA levels. In the DEX treated samples, MR mRNA levels are slightly elevated over time, 
with more MR mRNA levels at days 5, 6 and 7 (Fig 3.17 B). However, MR mRNA expression levels remain 
unchanged in the MPA treatment of samples throughout the time course, and at similar expression levels 
compared to the control treated samples (Fig. 3.17 B). Neither the AR nor the PR protein were detectable 
via western blot at any of the time points tested (data not shown), suggesting that the AR and PR are not 
involved in this loss of repression effect. GR was detected by western blotting at all the time points in this 
experimental sample set (Fig. 3.17 D). DEX-mediated turnover of the GR protein remained constant over 
the duration of the experiment (Fig. 3.17 C and D) while MPA treated samples did not appear to cause 
turnover of the GR (Fig. 3.17 C and D). Taken together the data highlight that the repressive effects on 
mRNA gene expression by DEX and MPA is time dependent and that cell viability decreases concomitantly 
with a loss of the repression observed. Additionally, the data indicate that GR, PR and AR receptor levels 





Figure 3.17: Cell viability, MR mRNA expression levels or GR protein levels do not change or 
correlate with the loss of DEX and MPA-mediated effects over time. PHA activated PBMCs were pre-
treated with 100 nM DEX or MPA or 0.1% (v/v) vehicle control (EtOH) for 7 days with half media exchange at day 3 
and 6. (A) MTT assays were performed every day from day 2 to day 7 and cell viability was measured 
spectrophotometrically. Samples were harvested every day from day 2 to day 7 for RNA and protein isolation. 250 ng 
RNA was reverse transcribed to cDNA and used as template in subsequent real time qPCR. Relative mRNA 
expression levels of MR (B) were normalised to GAPDH mRNA expression levels and relative fold change in 
expression was determined by setting vehicle treatment (EtOH) at each day to 1. Histograms represent pooled data 
from four independent experiments from four female donors plotted as mean ± SEM. Statistical significance was 
determined by one-way ANOVA with a Dunnett’s post-test or unpaired student t-tests comparing each sample to the 






Figure 3.17 continued: Cell viability, MR mRNA expression levels or GR protein levels do not 
change or correlate with the loss of DEX and MPA-mediated effects over time. PHA activated PBMCs 
were pre-treated with 100 nM DEX or MPA or 0.1% (v/v) vehicle control (EtOH) for 7 days with half media exchange at 
day 3 and 6. Protein samples, isolated using TAPS buffer, were electrophoresed on an 8% SDS-PAGE gel before 
being electroblotted onto a nitrocellulose membrane and probed for GRα and GAPDH. Nitrocellulose blots were 
incubated for 1 minute in ECL-chemiluminescent substrate before being visualised by audio-radiography. (C) 
Represents the average GR protein expression normalised to GAPDH at each day, determined by densometric 
analysis (AlphaEC™, Alpha Innotech) with (D) a representative western blot used in the analysis. Histograms 
represent pooled data from four independent experiments from four female donors plotted as mean ± SEM. Statistical 
significance was determined by one-way ANOVA with a Dunnett’s post-test or unpaired student t-tests comparing 







PBMCs are important mediators in the systemic immunity, and contain an array of immune cells including 
monocytes, macrophages and T cells. These cells respond to numerous stimuli to orchestrate an effective 
immune response (Murphy et al., 2012). As such, PBMCs are a relevant model in which to elucidate the 
effects of progestogens on systemic immune function. Additionally, PBMCs consist of important target cells 
for HIV-1 infection, and are thus a useful model in which to study the effects of HIV-1 infection and viral 
dissemination (Pope & Haase, 2003; Haynes & Shattock, 2008).  
The relative composition of cell types within PBMCs is variable from donor to donor. As such a caveat of 
PBMC research is the high variability of responses between donors, which could potentially mask 
significant effects. Several papers have used different strategies in which to address the high variability 
within PBMCs. One approach would be to measure responses from individual cell types like Huijbregts et 
al. (2013). The authors separated PBMCs into different cell types and analysed the effects of MPA and 
DEX on gene expression and HIV-1 infection (Huijbregts et al., 2013). A second approach would be to 
choose a donor that is representative of the effects observed, like Asin et al. (2008). The authors reported 
on the effects of HIV-1 replication to differing concentrations P4 and E2 in PBMCs and reported their data 
using one patient’s responses as a representative of their experiments (Asin et al., 2008). The third 
approach would be to pool data together from samples in which a particular response was observed. For 
example, Kleynhans et al. (2011) presented only pooled donors that responded to BCG in their figures 
(Kleynhans et al., 2011). For this current study, no donors were excluded from the analysis and where 
possible, flow cytometry was performed. Additionally, where appropriate responses were grouped to assess 
biological differences.  
The effects of progestogens on gene regulation in PBMCs 
This study shows that DEX and MPA have immunosuppressive effects in modulating both mRNA and 
protein expression levels of key immunomodulatory genes, while P4 and NET-A have little-to-no repressive 
effects on these genes in PBMCs, upon incubation up to 2 days. The results from this study show for the 
first time that MPA, unlike NET and P4, dose (Fig. 3.2) and time (Fig. 3.1) dependently decrease IL6, IL8, 
RANTES (to a lesser extent) and increase anti-inflammatory GILZ mRNA expression in primary un-
stimulated PBMCs. Furthermore this study indicated that IL6 protein was predominantly expressed in the 
CD14+ monocytes, where at 100 nM, MPA significantly repressed IL6 protein expression, while NET, P4 
and LNG had no effect after 48 hours (Fig. 3.6). Birx et al. (1990) also observed that IL6 expression was 
predominantly from CD14+ monocytes (Birx et al., 1990), supporting the observation in this study.  
Similarly, MPA, like DEX, increased GILZ protein expression in CD4+ T cells, while P4, NET and LNG had 
no effect (Fig. 3.6). These findings are supported by several studies from the Hapgood laboratory that show 
that MPA compared to NET and P4 differentially affects immunomodulatory genes. Africander et al., (2011) 
reported that IL6 expression was down-regulated at the mRNA level in ectocervical and vaginal cell lines 
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treated with 1 μM MPA compared to 1 μM NET or P4 after 24 hours (Africander et al., 2011). Similarly, 
Govender et al. (2014) found that MPA but not NET-A or P4 decreased IL6, IL8 and RANTES, and 
increased GILZ mRNA and protein expression levels in an endocervical cell line after 24 hours in a dose 
dependent manner (1 nM – 1000 nM) (Govender et al., 2014). These results are similar to what was 
reported in Fig. 3.1. However, in PBMCs, the greatest repressive effect on mRNA gene expression by MPA 
was exerted after 48 hours (Fig 3.1), suggesting that different cell types may respond differentially to 
progestogens at different times. Similar to what was reported in this study, Kurebayshi et al. (2003) 
observed that IL6 protein secretion levels were significantly reduced in a thyroid cancer cell line after 48 
hours stimulation with MPA at 10, 100 and 1000 nM (Kurebayashi et al., 2003). Additionally, Vazques-Tello 
et al. (2012) observed that DEX increased GILZ and decreased IL6 mRNA expression levels in PBMCs 
from asthmatic patients (Vazquez-Tello et al., 2012), consistent with the results observed in this study by 
DEX on gene expression (Fig.3.1, 3.2, 3.3, 3.6 and 3.8). 
The results from this study also show that at 100 nM, MPA like DEX, significantly decreased protein 
expression levels of IL8, IL-1β (Fig. 3.4) and IL-1ra (Fig. 3.5) and appeared to reduce IL10 protein levels 
after 48 hours (Fig. 3.5 and appendix A, Fig. A1). Additionally, Figure 3.5 shows that DEX had greater 
effects on protein expression than MPA. DEX treatment significantly and dose dependently (at 10 and 100 
nM) decreased expression levels of IL-1ra, VEGF, IL7, IL12 (p70), TNF-ɑ and RANTES compared to the 
vehicle control. Like the mRNA expression data, P4 and NET had no effect on protein expression levels 
(Fig. 3.4, 3.5 and appendix A Fig A.1) with the exception of IL12, which was decreased with 10 nM NET 
compared to the vehicle control (Fig. 3.5). The results from the present study are in agreement with 
Huijbregts et al. (2013), where MPA, but not P4 dose dependently decreased IL6, IL-1β and IL-1ra (at 100 
and 1000 nM) after 24 hours (Huijbregts et al., 2013). Interestingly, in the Huijbregts et al. (2013) paper, the 
authors observed no significant repression on IL8 with MPA treatment after 24 hours unlike the results from 
this study (Fig. 3.2 and 3.4), which found significant repressive effects by MPA on IL8 mRNA and protein 
expression after 48 hours. This could be due to the different time point between the studies, where 
repressive effects on IL8 repression were only observed after 48 hours (Fig. 3.1.). Enomoto et al. (2007) 
found in PBMCs that DEX (0.3 nM), unlike P4 (1 nM) and E2 (1 pM) significantly reduced Th1 cytokine 
production after 72 hours, reducing IL2, IFN-ɣ and IL12 protein secretion, while E2 and P4 treatment had 
no effect. In addition, DEX, but not E2 or P4, treatment significantly reduced select pro-inflammatory 
cytokines (IL-1β, IL6 and GM-CSF) and Th2 cytokine responses (IL10 and IL4, with no effect on TGF-β) 
(Enomoto et al., 2007). Kleynhans et al. (2011) reported that PBMCs from women using MPA had 
decreased IL10 and IL12 cytokine protein expression profiles compared to women not on MPA in response 
to BCG stimulation. In addition the authors observed in BCG-stimulated PBMCs, that MPA to a similar 
extent as cortisol (CORT) repressed IL6, TNFα, IL-1ra, IL-13 and GM-CSF after 6 days post infection at 
concentrations within the serum contraceptive range (1 nM – 100 nM) (Kleynhans et al., 2011).  
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The gene expression data in this study (Fig. 3.1, 3.2 and 3.3) suggest that MPA is likely to exert anti-
inflammatory immunosuppressive effects via GILZ gene expression within the range of concentrations 
found in the serum of injectable contraceptive users (1-100 nM), as well as possibly on IL6 and IL8, 
particularly shortly after injection. However, the current study suggests that the immunosuppressive effects 
of NET-EN on PBMCs via the GR are likely to be negligible, even shortly after injection, while P4 is unlikely 
to exert immunosuppressive effects in PBMCs even during pregnancy (highest P4 levels) via these genes. 
Interestingly, the Hapgood laboratory have recently shown that the GR may also play a key role in PBMCs 
in discriminating between apoptotic effects by DEX and MPA, unlike NET and P4, at doses within the 
contraceptive range, in the absence and presence of HIV-1 infection (Tomasicchio et al., 2013). The 
physiological consequences of immunosuppressive and apoptotic effects of MPA on PBMCs could include 
a wide range of effects that are beneficial to the virus. These could include compromising the ability of the 
host to mount effective innate and adaptive immune responses, as well as increasing binding of HIV-1 to 
CCR5 co-receptors. Interestingly, mRNA expression data (Fig 3.3) suggest that MPA has slight to no 
effects on mRNA expression levels at 10 nM, weakly transactivating GILZ mRNA expression, and slightly 
reducing IL6 mRNA expression. Strikingly, this experiment shows that P4 and NET treatment may elevate 
the mRNA expression levels of IL6, IL8 and RANTES (although not significant), in a manner similar to 
Africander et al. (2011), which found some pro-inflammatory effects with P4 on IL6 and IL8 gene 
expression in TNF-ɑ treated Ect1/E6E7 and Vk2/E6/E7 cell lines (Africander et al., 2011). While MPA at 10 
nM does not greatly affect mRNA expression levels, its expression patterns are different to P4 and NET, 
indicating that even at low serum concentrations, MPA and NET might modulate gene expression 
differentially. In addition to concentration, the results of this study suggest that time has an important role 
on the immunosuppressive effects of MPA in PBMCs (Fig. 3.1), with little to no repression observed at 4 
and 24 hours, and significant repressive effects at 48 hours post incubation. This could be due to changes 
in expression levels of other proteins involved in the responses, or changes in the relative cellular 
population or in their activation state over time.  
The data in this study suggest that DEX, more so than MPA, has greater effects on immune gene 
expression than P4 or NET. The Hapgood laboratory has shown previously that MPA exhibits partial GR 
agonist properties, as well as exhibiting differential effects on gene repression in a promoter specific 
manner (Ronacher et al., 2009; Koubovec et al., 2004; Koubovec et al., 2005; Govender et al., 2014). In 
addition the authors provided evidence whereby ligand-selective interaction between the GR and different 
co-activators and co-repressors GRIP-1, SRC-1A, NCoR and SMRT was a major determinant of ligand-
selective and promoter-specific differences in potency and efficacy, for both transactivation and 
transrepression (Ronacher et al., 2009). Thus, MPA may differentially regulate cytokine gene expression, in 
a promoter-specific manner, having greater effects on IL6, IL8 and GILZ mRNA and protein expression 
than on RANTES mRNA and protein expression, like the data in this study suggest (Fig. 3.2, 3.4, 3.5 and 
3.6). In addition MPA, in the same manner, may repress IL-1ra (Fig. 3.5) and IL-1β (Fig. 3.4) protein 
expression more effectively than IL10 (Fig. 3.4), VEGF, IL7, IL12 and TNF-ɑ expression (Fig 3.5). It is 
 
97 
apparent from this study as well as others that MPA, like DEX has strong immunomodulatory effects, and 
that the extent of repression depends not only on the concentration of MPA, but also on its selective 
potency towards target genes. This has been observed by Govender et al. (2014) where the authors found 
that MPA had differential potencies for different target genes in the same cell line (Govender et al., 2014). It 
has also been observed that MPA, unlike NET increases arterial thrombosis in ovarectomised 
apolpoprotein E-deficient mice. Transcriptome analysis indicated that MPA had a distinct and different 
transcriptional profile compared to NET treated mice (Freudenberger et al., 2014). 
Taken together the results from this study are supported by the findings in the literature, and highlight that 
dose and time have significant implications on the effects observed by the different progestogens. 
Furthermore the results from this study show for the first time that MPA unlike the progestogens P4, NET 
and LNG differentially modulates immune gene expression in a manner similar to the glucocorticoid DEX, 
and these effects are more pronounced at concentrations in the range of the peak serum concentration in 
MPA users in PBMCs. 
The repressive effects on gene expression by MPA are mediated by the GR 
In order to determine the role of the glucocorticoid receptor in mediating cytokine gene repression, PBMCs 
were treated with 100 nM DEX or MPA in the absence and presence of RU486, a known GR/PR 
antagonist. In Figure 3.8, IL 6, IL 8 and RANTES repression by DEX and MPA was lifted in the presence of 
RU486, while DEX and MPA induction of GILZ was lifted by RU486 (Fig. 3.8 A-D). These results indicate 
that the GR is involved in the regulation of these cytokine genes. Similarly Huijbregts et al., (2013) found 
that RU486 treatment with MPA, lifted the MPA-mediated repression of IFN-γ protein expression in PBMCs 
and CD3+ cells. The data suggest that MPA exerts its repressive effects through the GR, and that this 
affects both mRNA (Figure 3.8), and protein expression (Huijbregts et al. 2013). Similar to what was 
observed in this current study on a GR transactivation gene, GILZ, Thomas et al. (2006) observed in a 
canine kidney C7 cell line that MPA, like DEX, increased SGK-1 gene expression via the GR, and that this 
increase in expression was lost using the GR/PR selective antagonist RU486, but not with the PR selective 
antagonist Org31710 (Thomas et al., 2006).  
While the data from this study suggest GR involvement, RU486 is also known to antagonise the PR. 
However, it has been shown by Tomasicchio et al. (2013) and in this study (Fig. 3.7), that PBMCs do not 
express the PR. In addition, Bamberger et al. (1999) found no detectable expression of the PR (both mRNA 
and protein) in the primary T lymphocytes, while were able to readily detect the GR (Bamberger et al., 
1999), in agreement with the results seen in Figure 3.7 and those observed in Tomasicchio et al. (2013). 
Thus it is most likely that the effects observed on gene expression in the presence of DEX and MPA were 
mediated via the GR. To further support this finding, PBMCs were nucleofected with GR-specific siRNA, to 
reduce the expression of the GR. The effects of reduced GR levels on mRNA transcription levels were 
assessed by real time qPCR (Fig. 3.9). While only moderate GR knockdown was observed in this 
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experiment, we show for the first time in PBMCs, that the GR knockdown supports the finding that the GR is 
involved in DEX and MPA mediated repression of IL6, IL8 and RANTES mRNA expression (Fig. 3.9). This 
data is in agreement with Govender et al. (2014) who found that upon GR knockdown in the endocervical 
cell line End1/E6E7, MPA and DEX repression on IL6, IL8 and RANTES was mediated by the GR at both 
the mRNA and protein expression levels of IL6 and IL8 (Govender et al., 2014). In addition, their results, 
like those obtained in this study, found that P4 and NET gene regulation were not affected by GR 
knockdown (Govender et al., 2014). Interestingly, a study in human myometrial cells, found that MPA at 1 
μM, reduced the expression of an IL-1β-driven gene, COX-2, and that this repression was mediated via the 
GR even in the presence of overexpressed human PRB. Using both RU486 and a specific PR antagonist 
Org31710, the authors also found that P4 (at 10 μM) exerted this repression via the GR (Lei et al., 2012). 
This study suggests that P4 is able to exert some of its repressive functions via the GR, consistent with the 
findings observed by Koubovec et al. (2004), and that the concentration of the progestogen is important 
when considering the effects of these progestogens on immune function. Nevertheless, the data in this 
study suggests that P4 at 100 nM, had no effect via the GR (Fig. 3.9) and may be due to the fact that lower 
concentrations were used. 
To further explore the role of the GR in regulating gene transcription, cycloheximide experiments were 
performed in this study (Fig 3.10). Cycloheximide inhibits de novo protein synthesis, as such one is able to 
determine whether the effects are due to direct effects by proteins already present, or if they require 
additional proteins for the response, that is, indirect effects. Govender et al. (2014) found that in an 
endocervical cell line, MPA-mediated effects on IL8, GILZ and RANTES mRNA levels were mediated at 
least in part via the GR, but required the addition of new proteins in which to fully exert the repressive 
effects. The authors observed that the effects on GILZ and IL6 mRNA levels were due to direct effects 
mediated via the GR. Additionally the chromatin immuno-precipitation (ChIP) results found that the GR was 
directly recruited to target sites within the promoters of IL6 and GILZ, consistent with the direct effects of the 
GR on transcription (Govender et al., 2014). GILZ mRNA expression in PBMCs appeared to be modulated 
via direct effects (Fig. 3.10), with increased levels of mRNA expression observed in both DEX and MPA 
treated samples, and was similarly observed in Govender et al. (2014). Interestingly, GILZ expression has 
been found to be involved in inhibiting T cell receptor induced IL2 receptor expression and NFκB activity 
(Ayroldi, 2001). In addition, it has been found that GILZ prevents NFκB translocation into the nucleus, and 
transcription through direct interaction with the p65 subunit in T cells (Ayroldi & Riccardi, 2009; Di Marco et 
al., 2007), and that overexpression of GILZ in lung epithelial cells (BEAS-2B) prevents NFκB activation by 
LPS, IL-1β and poly I:C (polyinosinic:polycytidylic acid) (Eddleston et al., 2007). Thus, it could be that MPA-
driven repression on IL6, IL8 and RANTES could, in part, be due to the effects of GILZ protein interference 
on NFκB-driven genes, supporting the cycloheximide data for indirect effects modulating gene transcription 
in PBMCs (Fig.3.10).  
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The results from this study strongly support the hypothesis proposed by Hapgood et al. (2004) that MPA, at 
serum contraceptive concentrations, modulates key immune genes via the GR, while P4 and NET do not. 
This study is the first to report that the differential effects of gene expression by MPA compared to P4 and 
NET is via the GR in primary PBMCs.  
Dose is critically important in assessing the differential effects on gene expression  
The data from this study highlight the importance of dose and concentration of the progestogens. When 
considering contraceptive usage, MPA and NET are administered at relatively high concentrations, with 
MPA reaching peak serum concentrations between 2.5 - 65 nM a few days after intramuscular injection 
(Mishell, 1996; Mathrubutham & Fotherby, 1981; Ortiz et al., 1977; Halpern et al., 2014; Africander et al., 
2011), and NET reaching a peak of 1.5 - 59 nM after injection (Africander et al., 2011; Stanczyk et al., 
2013). LNG is administered at very low doses, with peak daily serum concentrations reaching 6.4 nM in oral 
contraceptive users, 1.6 nM in intrauterine devices (Kuhl, 2011) and 2.47 nM in implant users (Sivin et al., 
2002). While 100 nM MPA and NET concentrations used in this study are close to peak serum 
concentrations, LNG is well above any concentration likely to be achieved in vivo. Endogenous P4 levels 
are governed by the phase of the menstrual cycle and pregnancy. P4 serum concentration levels range 
from 15 – 32 nM (Wira et al., 2015) during the menstrual cycle, with peak P4 levels reached in pregnancy, 
up to 600 nM (Africander et al., 2011). It has been reported that peak serum concentrations of MPA are 
prone to inter-individual variability, with some women having much higher serum concentrations than others 
(Mishell, 1996; Shelton & Halpern, 2014; Halpern et al., 2014; Fotherby, 1981). Thus using a range of 
concentrations of the different progestogens may help to elucidate the effects of the injectable 
contraceptives relevant to the serum concentrations. 
The data from this study suggest that MPA, P4 and NET at physiological concentrations have differential 
effects on immune gene expression (Fig. 3.2, 3.4, 3.5, 3.6). At near-peak serum concentrations, the 
differential effects of MPA compared to P4 and NET on gene expression requires the GR (Fig. 3.8 and 3.9). 
Further this study has observed that MPA and NET at near peak serum concentrations differentially 
modulate immune gene expression after long term exposure (Fig. 3.12 and 3.16) and differentially affect 
HIV-1 replication in PBMCs (Fig. 3.14 and 3.15). P4 and LNG even at higher than peak serum 
concentrations (100 nM), had little effect on gene expression, while the LNG and P4 had no overall effect 
on HIV-1 replication compared to the control and individual responses were highly varied.  
 
Additionally the data at lower concentrations suggest that MPA may have more selective effects on gene 
expression. In the dose response, MPA appeared to decrease IL6 mRNA levels at 10 nM, but had no effect 
on IL8 and RANTES mRNA levels after 48 hours (Fig. 3.2). Further, MPA significantly increased GILZ 
mRNA levels in this experiment (Fig. 3.2). P4 and NET had no effect on gene expression in the dose 
response experiment at 10 nM (Fig. 3.2). Interestingly, when only 10 nM concentrations of the different 
ligands (Fig. 3.3), it was found that while MPA had no significant effects on gene expression, while it 
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appeared that P4 and NET had elevated expression levels of IL6 and IL8 mRNA levels (Fig. 3.3). 
Interestingly, in both of these experiments MPA at 10 nM was more similar to DEX than to the other 
progestogens (Fig. 3.2 and 3.3). The data at low concentrations suggest that MPA has different effects on 
select genes compared to P4 and NET, which have no or slightly proinflammatory effects at 10 nM after 48 
hours. Thus the dynamic changes in concentration and time could greatly affect the changes in gene 
expression by the different ligands.  
Taken together the data from this study supports the hypothesis that MPA but not NET, P4 and LNG 
differentially modulates immune gene expression and HIV-1 replication in PBMCs at physiologically 
relevant concentrations.  
Progestogens exert differential effects on HIV-1 infection and gene expression in primary 
PBMCs, with MPA, unlike NET, increasing HIV-1 replication in the majority of donors  
This study is the first to report differences in HIV-1 replication by the different progestogens in parallel 
experiments. The results for DEX and CORT treatment were prone to inter-individual variability, with 4 to 5 
out of the 10 donor samples exhibiting an increase in HIV-1 replication (Fig. 3.11). P4, and LNG were also 
prone to variability, with 5 out of 10 samples exhibiting an increase in viral replication to different extents in 
each donor (Fig. 3.11). Interestingly, NET was the only progestin that exhibited no effects on HIV-1 
replication for most of the donor samples (Fig. 3.11), while for MPA, 7 out of 10 donor samples exhibited an 
increase in HIV-1 replication compared to the vehicle control.  
The variable effects of P4 and LNG on HIV-1 replication, unlike the results for NET, suggest that these 
progestogens behave differently, despite their similar steroid receptor selectivity profiles (Africander et al., 
2011; Stanczyk et al., 2013). Although few other studies have addressed the effects of P4 on HIV-1 
replication in PBMCs, results from Asin et al., (2008) from a single donor, showed that P4 (1 nM) and E2 
(100 pM) at concentrations, mimicking the mid-follicular phase, increased HIV-1 replication in female 
PBMCs, whereas P4 (100 nM) and E2 (1 nM), mimicking the mid-luteal phase, decreased HIV-1 replication, 
while P4 and E2 alone had no effect on HIV-1 replication compared to the vehicle control (Asin et al., 
2008). Further the authors suggest that these differences were modulated through differential HIV-1 LTR 
activity, based on results using a TZM-bl assay (Asin et al., 2008). The results from the current study 
suggest that treatment with 100 nM P4 alone decreases HIV-1 replication levels in 50% of the donors 
compared to the vehicle control. While results from the current study appear contrary to that reported in 
Asin et al. (2008), the results reported in their study are representative of only one donor. However, the 
variability in HIV-1 replication in the presence of P4 and LNG could also be due to differences in cell type 
activation. It has been observed that P4 at high concentrations (6.3 – 63 μM), decreases pDC function by 
decreasing IFN-α production upon stimulation with a TLR9 agonist, to mimic a viral response (Hughes et 
al., 2008). Thus, it could be that at lower concentrations, P4 may have moderate to no effect on select 
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target cells, depending on the relative abundance of pDCs within a population of PBMCs, that may 
subsequently produce variable effects on HIV-1 replication. 
There may several factors involved in changing the susceptibility of an individual to HIV-1 replication, such 
as the different relative distribution of cell type populations, different levels of endogenous GR levels, the 
different levels of co-factors needed to drive transcription or the differing levels of endogenous HIV-1 co-
receptors present on target cells. Huijbregts et al. (2013) observed that treatment with MPA and DEX (at 
100 nM and I μM) significantly increased HIV-1 replication in PBMCs depleted of CD8+ T cells, but 
decreased (DEX) or had no effect (MPA) on HIV-1 replication in CD4+ T cells depleted of CD14+ T cells 
(Huijbregts et al., 2013). Further supporting this hypothesis, Hanley and Viglianti (2011) found that DEX 
treatment for 24 hours, dose dependently decreased HIV-1 pseudovirus replication in monocyte derived 
macrophages (MDMs) and CD4+ T cells (Hanley & Viglianti, 2011). Further, the authors assessed steroid 
receptor involvement and found that when MDMs were co-incubated with the selective GR antagonist NEA, 
DEX repression of HIV-1 replication was lost (Hanley & Viglianti, 2011). Taken together, it could be that the 
differential effects observed in the present study on HIV-1 replication for the DEX, CORT and MPA treated 
samples may be in part due to GR involvement as well as the different effects these ligands have on 
different cell types that may be present at different levels in each donor.  
The pooled results from this study suggest that there are variable effects on HIV-1 replication in PBMCs 
with the different ligands (Fig. 3.11). However, there appeared to be distinct differential effects within the 
MPA treated group on both HIV-1 replication and IL6 mRNA levels (Fig. 3.11 and 3.12). When analysing 
the sample set comparing IL6 mRNA levels with HIV-1 replication in the MPA treated group, there was a 
significant and positive correlation observed (Fig 3.13). That is, with an increase in IL6 mRNA expression, 
increased HIV-1 replication was observed (Fig. 3.14). A similar finding was reported by Birx et al. (1990) 
where high IL6 protein levels were associated with increased HIV-1 viral loads in monocytes (Birx et al., 
1990). The results from the MPA treated group were separated into those with low IL6 mRNA levels and 
those with high IL6 mRNA levels. Three out of ten donor samples showed low relative mRNA levels (Fig. 
3.15 A) and this corresponded to lower levels in HIV-1 replication (Fig 3.15 B). Additionally, in samples 
where MPA increased IL6 mRNA levels (Fig. 3.14 A), HIV-1 replication was significantly higher compared 
to the vehicle control (Fig 3.14 B). Furthermore, the majority of donor samples (7 out of 10) were found to 
have an increase in HIV-1 replication with MPA treatment. Most strikingly in the current study was the 
observation that IL6 repression observed after 48 hours was lost in 7 out of 10 donor PBMCs, and that this 
effect was independent of HIV-1 infection (Fig.3.14 A), after prolonged incubation for 9 days with MPA at 
100 nM in activated PBMCs. Interestingly, DEX treated samples also exhibited a positive correlation 
between relative IL6 mRNA levels and HIV-1 replication (Appendix A, Fig. A.3.1) suggesting that these 
effects could be due to the glucocorticoid effects of MPA. However, no correlation was observed with CORT 
treatment, suggesting that the endogenous glucocorticoid acts differently to the synthetic and partial 
glucocorticoid agonists. IL8, RANTES and GILZ mRNA expression did not correlate with HIV-1 replication 
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(data not shown), for any of the ligands tested. Interestingly a recent study by Sampah et al. (2015) 
observed that MPA as physiological serum concentrations, dose dependently increased HIV-1 infection in 
un-stimulated CD3+CD8+ T cells, and that this increase in infection required the presence of CD14+ 
monocytes (Sampah et al., 2015). Thus it could be that MPA increases infection in CD3+CD8+ T cells, and 
that CD14+ monocytes could contribute to this increase in infection through an increase in IL6 expression.  
The data from this study suggest that in 70% of the donor samples, MPA increases HIV-1 replication 
compared to the vehicle control. This may have important implications for initial viral replication and viral 
dissemination into the lymphatic system, and supports the hypothesis that MPA may increase disease 
progression in individuals. The effects of MPA on disease progression have not been fully explored. 
Several studies have reported that MPA has no effect on disease progression in HIV-1 positive women 
(Richardson et al., 2007; Heffron et al., 2013), while Stringer et al. (2009) reported that women on DMPA 
were more likely to qualify for anti-retroviral treatment or progress to AIDS than women not on 
contraception (Stringer et al., 2009). Roberts et al. (2010) reported that an increase in pro-inflammatory 
cytokines found in the plasma during the acute phase of HIV-1 infection could be used as a predictor of 
progression to AIDS, with IL7 and IL-1α levels associated with an increase in viral plasma load in women 
(Roberts et al., 2010). While IL6 was not significantly associated as a predictor of HIV-1 viral load and 
subsequent disease progression in the Roberts et al. (2010) study, it supports the finding in this current 
study, that suggests that the change in gene expression by MPA after prolonged exposure has significant 
effects on HIV-1 replication. Furthermore the results from this study support the observations by Stringer et 
al. (2009) that DMPA use could be associated with an increase in HIV-1 disease progression. 
This is also the first study to assess the effects of prolonged exposure by different ligands on HIV-1 
replication and mRNA gene expression in parallel. DEX, CORT and MPA appeared to repress IL8 mRNA 
expression after 9 days compared to the vehicle control. However, this repression was lost in the presence 
of HIV-1 infection (Fig. 3.12). Both RANTES and IL6 mRNA expression were elevated compared to the 
vehicle control in the absence and presence of HIV-1 after 9 days treatment with CORT, DEX or MPA (Fig 
3.12). Interestingly, P4, NET and LNG had no effect on IL6, IL8, RANTES or GILZ mRNA levels compared 
to the vehicle control (Fig 3.11). GILZ mRNA expression levels increased in CORT, DEX and MPA treated 
samples and appeared to be further elevated in the presence of HIV-1 (Fig. 3.12). However this was only 
significant for DEX. It has been previously observed that the viral protein R (VpR) acts as a co-activator for 
the GR (Kino et al., 2002; Hapgood & Tomasicchio, 2010), and has been found to increase the apoptotic 
effects of DEX and MPA in PBMCs (Tomasicchio et al., 2013). Thus it could be that the significant increase 
in GILZ transactivation by DEX in the presence compared to the absence of HIV-1 could be due to VpR 
acting as a co-activator for the GR, increasing the transcriptional response. While CORT and MPA had 
smaller, non-significant increases in GILZ transactivation in the presence of HIV-1, it could be due to the 
lower potencies of these ligands on GILZ transcription. Consistent with this hypothesis, it has been 
observed by Ronacher et al. (2009) and Hadley et al. (2011), that there are ligand specific effects that drive 
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transactivation efficacy, GR translocation into the nucleus and subsequent GR recruitment to the promoter 
region of the GILZ gene, with DEX having greater effects on these factors than MPA and CORT (Ronacher 
et al., 2009; Hadley et al., 2011).  
The results from this study found that CORT, DEX and MPA decreased PBMC viability, while P4, NET and 
LNG did not (Fig. 3.11 B). MPA decreased cell viability by ~ 20%. However this effect was not statistically 
significant, while CORT and DEX had more pronounced effects on cellular viability (~35% and ~50% 
respectively). Interestingly, it appeared that the effects of CORT, DEX and MPA on cellular viability were 
independent of the presence of HIV-1 (Fig. 3.11 B). Enomoto et al. (2007) found that DEX significantly 
reduced PBMC proliferation (Enomoto et al., 2007), suggesting that the results in this study may be due to 
a reduction of proliferation by DEX and MPA (Fig 3.11 B and Fig 3.17 A). The reduction of proliferation 
could be due to an increase in apoptosis, as the authors found that DEX increased the expression of the 
Fas ligand CD178 and the Fas death receptor CD95 in CD8+ and CD14+ cells (Enomoto et al., 
2007).Tomasicchio et al. (2013) found that DEX and MPA significantly increased apoptosis in CD4+ T cells, 
and that this effect was exacerbated by the presence of HIV-1 or the HIV-1 viral accessory protein R (VpR) 
(Tomasicchio et al., 2013). While the current study did not detect any differences in cellular viability when 
treated with MPA, the MTT assay is not specific enough to detect the effects of apoptosis, but rather gives 
an indication on total cellular metabolism within the multicellular population. Thus it could be that the effects 
of HIV-1 on increasing DEX and MPA induced apoptosis may only be prevalent in select cell types. It could 
also be that changing the relative types of immune cells present, through targeted apoptosis by MPA may 
also contribute to differences in HIV-1 replication.  
Collectively, the results from this study suggest that MPA, unlike NET, increases HIV-1 replication in the 
majority of donor PBMCs. Furthermore the results show that the increase in HIV-1 replication correlates 
with increased levels of IL6 mRNA levels in MPA treated PBMCs. While DEX was similar to MPA, the 
effects on viral replication and IL6 mRNA levels were more consistent in MPA treated samples. While IL6 
mRNA expression correlated with HIV-1 replication in MPA treated samples, IL8, RANTES and GILZ mRNA 
expression did not. Interestingly, mRNA levels after 9 days exposure to CORT, DEX and MPA were 
different to the observations previously reported after 48 hours (Fig. 3.1, 3.2, 3.3 and 3.4), suggesting that 
length of time of incubation has important consequences on gene expression. P4, NET and LNG had 
similar effects on IL6, IL8, RANTES and GILZ mRNA expression levels. However, while NET had no effect 
on viral replication, LNG and P4 treatment resulted in highly varied HIV-1 replication levels. Interestingly, of 








The immunosuppressive effects of MPA are time dependent in PBMCs 
 
The effects on cell mediated immunity and gene expression by the different progestogens and 
glucocorticoids could also depend on the concentration of the ligand and the length of time of exposure to 
the ligands. The data from this study suggests that duration of exposure to the progestogens at a constant 
concentration may influence the immunomodulatory effects. The early time course experiments indicated 
that MPA, like DEX repressed maximally at 48 hours post treatment (Fig. 3.1), and that this was dose 
dependent (Fig. 3.2), while gene expression data from the HIV-1 infection studies, found that after 9 days of 
treatment, DEX, CORT and MPA repression of IL6, IL8 and RANTES mRNA was lost (Fig. 3.12). This 
interesting observation led to the hypothesis that the repressive effects of DEX and MPA on select 
immunomodulatory effects may be time dependent. As such, activated PBMCs were stimulated with 100 
nM DEX or MPA in the presence of 30U/ml IL2 to mimic the HIV-1 infection conditions and sampled every 
24 hours from 48 hours (peak repression) to 168 hours (7 days). The data presented indicate that DEX 
exhibited strong repressive effects on IL6, IL8 and RANTES mRNA expression at days 2, 3 and 4, and less 
to no repression on the mRNA expression levels of these genes at days 5, 6 and 7 (Fig. 3.16). MPA had 
similar effects, however the repressive effects on gene expression were less effective than DEX, with loss 
of repression observed from day 3 onwards (Fig. 3.16). Additionally, the ability of DEX and MPA to increase 
GILZ mRNA expression was maintained throughout the duration of the experiment, indicating that the 
transactivation mechanism was consistently activated (Fig. 3.16 D). This is the first study to report these 
effects by MPA in PBMCs over a prolonged time course, and suggest that DEX and MPA exert similar 
effects on these cell types. A study in the Vk2/E6E7 vaginal cell line assayed the effects of MPA on mRNA 
expression levels and protein expression levels of immunomodulatory genes (Irvin & Herold, 2015). After 5 
days in the presence of increasing concentrations of MPA, TNF-ɑ, GM-CSF, IL6, IL8, CCL3 and CCL4 
mRNA expression levels were significantly elevated above the vehicle control. Irvin and Herold (2015) used 
between 38 nM - 388 µM of MPA, and only observed significant increase in expression levels at 3.8 µM and 
above (Irvin & Herold, 2015). Kleynhans et al. (2011) found that in female PBMCs stimulated with 
exogenous BCG, IL6 protein expression was repressed with 10 µM MPA after 6 days, while MPA had no 
effect on IL8 protein expression, which was similar to the BCG control after 6 days (Kleynhans et al., 2011). 
While Kleynhans et al. (2011) reported that IL6 protein expression was reduced after 6 days, this was in the 
presence of BCG, suggesting that these effects may be specific for a bacterial response. The results from 
this current study are from PBMCs activated for one day with PHA, using 100 nM concentrations of MPA. 
Thus the results from the current study are the first to show, that at peak contraceptive doses of MPA and 
in the absence of an exogenous bacterial stress, that IL6, IL8 and RANTES mRNA expression changes 
over time (Fig. 3.16), and the first study to observe these effects in primary PBMCs. 
To elucidate the possible mechanisms underpinning the loss of transrepression, steroid receptor 
expression was examined to determine whether the switch could be explained due changes in SR 
expression levels. It has been established that MPA is a partial agonist for the AR and weak agonist for the 
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MR (Africander et al., 2014; Africander et al., 2013). Additionally, Africander et al. (2011) observed that the 
TNF-ɑ induced IL6 mRNA expression was elevated by MPA in ectocervical cell lines, and that this effect 
was partially modulated via the AR (Africander et al., 2011). Thus it was hypothesised that the AR could be 
involved in the pro-inflammatory responses after prolonged exposure to MPA. However AR protein 
expression was not observed at any of the time points assayed in any of the treatment groups suggesting 
that the AR may not be involved in this switch mechanism. Furthermore the results from this study suggest 
that the regulation of, PR or GR protein or MR mRNA levels are not involved in the switch from anti-
inflammatory effects by MPA or DEX to pro-inflammatory effects (Fig. 3.17). However, the results do not 
exclude the possibility that different steroid receptors could be involved in this process via non-genomic 
actions of SRs on downstream gene expression. 
While the mechanism of the switch from anti-inflammatory to pro-inflammatory responses was not 
determined in this study, similar observations have been reported in the literature. Glucocorticoids are 
widely used as immunosuppressive drugs, (Tsitoura & Rothman, 2004; Africander et al., 2011). However, 
after prolonged treatment, glucocorticoids, in some patients, no longer inhibit cellular proliferation and 
cytokine production at the site of inflammation (Tsitoura & Rothman, 2004; Goleva et al., 2002). Tsitoura 
and Rothman (2004) found that prolonged glucocorticoid treatment (72 hours) lead to glucocorticoid 
resistance in CD4+ T cells, and that this mechanism was dependent on IL2 levels and the enhancement of 
MEK/ERK signalling. The authors found that primary T cells incubated with DEX and IL2 showed a 
proliferation pattern similar to that of control T cells, compared to DEX treatment alone, which significantly 
reduced proliferation (Tsitoura & Rothman, 2004). This finding is contrary to the results reported in this 
study, where, DEX reduction of cellular viability was observed in the presence of IL2 (Fig 3.11 and 3.17). It 
could be that the concentration of IL2 necessary to mediate this complete reversal in the DEX response 
was higher than used in the present study. Pandolfi et al. (2013) found that an IL2 dose of 50 - 80 U/ml 
rescued different T cell populations from DEX induced apoptosis (Pandolfi et al., 2013). However, the 
concentration of IL2 used in this study (30 U/ml) did not reduce the DEX induced effect on cell viability. In 
addition, Tsitoura and Rothman (2004) found that this increase in DEX insensitivity was mediated via the 
activation of the transcription factor, NF-AT and activation of the MEK/ERK signalling pathway (Tsitoura & 
Rothman, 2004). The authors found that DEX alone did not stimulate ERK or JNK activation via 
phosphorylation. However in the presence of IL2, DEX increased phosphorylated ERK and JNK levels 
shortly after activation (Tsitoura & Rothman, 2004). Thus it could be that over time, DEX and MPA 
treatment in the presence of IL2, could promote the stimulation of the NF-AT pathway resulting in the 
production of inflammatory cytokines such as IL6, as suggested by the results in the time course study (Fig. 
3.16) and infection studies (Fig. 3.12 and 3.14). In some donor samples, as observed in the infection 
experiments in this study, IL6 mRNA repression was maintained by DEX and MPA in the absence and 
presence of HIV-1 (Fig. 3.13), suggesting that the presence of IL2 alone, may not be the only factor that 
contributes to a loss of IL6 mRNA expression levels over time. It has also been observed that DEX 
treatment could promote the development of T regulatory (T reg) cells in PBMCs in the presence of IL2 
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(Chen et al., 2006). T reg cells are defined as suppressor cells and play a crucial role in maintenance of 
peripheral tolerance and prevent a number of immune-mediated diseases (Murphy et al., 2012), The 
authors found that co-stimulation with DEX and IL2 amplified the capacity of IL2 to expand T-reg cells and 
CD4+FoxP3+ cells and concluded that IL2 can rescue T reg cells from DEX-dependent cell death, and that 
DEX promotes the expansion of T reg cells (Chen et al., 2006). Thus it could be that the results observed in 
Figures 3.12, 3.14 and 3.16 are due to an increase in T reg cells.  
The results suggest that DEX and MPA repression of IL6, IL8 and RANTES in activated PBMCs is present 
after 4 days, where after the repressive effects are lost. It was observed in this study that regulation of SRs 
did not contribute to this loss of repression. However the activity of SRs as assessed by phosphorylation 
was not measured in this study. Further, DEX and MPA significantly decreased cell viability over the time 
course, and suggests that apoptosis could have important implications in this loss of regulation, by targeting 
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The effects of progestogens on gene regulation and HIV-1 replication have not been fully elucidated in 
any cervical ex vivo model to date. The primary ex vivo cervical explant model is a useful and relevant 
model in which to assay the effects of these progestogens on differential gene expression and HIV-1 
replication, as it is a model of the local female genital mucosal immune environment.  
To date, it has been established that the lower female genital tract is an important site for initial 
infection, with several studies finding key HIV-1 target cells present within the ectocervix, endocervix 
and vagina (Pudney et al., 2005; Greenhead et al., 2000; Collins et al., 2000), and that these cell types 
are permissible to and important in initial infection events of the HIV-1 viral cycle (Greenhead et al., 
2000; Hladik et al., 2007; Maher et al., 2005). Further, it has been established that the menstrual cycle 
may affect the distribution of these cell types within the different compartments of the FGT (reviewed 
in Wira et al., 2005; Wira et al., 2010) and that explants obtained from women in the secretory phase (or 
luteal phase) were more permissible to HIV-1 infection and had higher viral loads (p24 levels) than 
explants obtained from women in the proliferative phase (follicular phase) (Saba et al., 2013), 
suggesting a role for high progesterone (P4) levels in increasing HIV-1 infectivity. 
Research on the effects of progestogens on HIV-1 infection, immune function and gene expression 
has been performed in primary epithelial cells (Ferreira et al., 2014), vaginal mononuclear cells 
(Huijbregts et al., 2013) or in observational studies utilising biopsy samples, purified cell types or 
cervicovaginal secretions (CVL) (Hughes et al., 2008; Chandra et al., 2013; Huijbregts et al., 2014; Michel 
et al., 2015; Michel et al., 2013; Guthrie et al., 2015). Taken together, the data suggest, that MPA 
regulates the expression levels of key immune response genes (Huijbregts et al., 2013; Huijbregts et al., 
2014; Michel et al., 2013; Guthrie et al., 2015), changes cell type distributions within the epithelium 
(Chandra et al., 2013), alters cell mediated immune functions in select cell types (Hughes et al., 2008; 
Huijbregts et al., 2014; Michel et al., 2015), increases HIV-1 transcytosis through the primary epithelium 
(Ferreira, Dizzell, et al., 2014), decreases vaginal epithelial thickness (Michel et al., 2013) and increases 
CCR5 and CXCR4 expression on key target cells (Huijbregts et al., 2014; Goode et al., 2014), all of 
which may lead to an increased susceptibility to HIV-1 infection.  
Only a few studies have reported on the effects of progestogens other than MPA. Huijbregts et al. 
(2013) found that NET and LNG had no significant effects on cytokine gene expression, or cell 
function in VMMCs, CD4+ and CD8+ cells (Huijbregts et al., 2013). Michel et al. (2013) found that 
NuvaRing (containing the progestin etonorgestrel and ethinyl estradiol) users have suppressed human 
β-defensin 2 and 3 levels in CVL samples (Michel et al., 2013). Michel et al. (2015) found that the use 
of the NuvaRing was associated with a reduction IFN-ɑ and TNF-ɑ expression in pDCs, as well as a 
reduction in CD207+ Langerhan cells in the vaginal epithelium (Michel et al., 2015).  
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The effects of MPA, NET and LNG on gene expression and HIV-1 replication in primary models have 
not been established, nor have the effects of the menstrual cycle on steroid receptor expression levels 
in this model been elucidated.  
Therefore the aims of this study were to: 
1.) Determine the steroid receptor profile in primary cervical explants at different phases of the 
menstrual cycle. 
Cervical samples were obtained from premenopausal women undergoing hysterectomies for benign 
reasons, with P4, E2, follicular stimulating hormone (FSH) and luteinising hormone (LH) serum 
concentration levels obtained for each patient. Using the serum concentrations of these hormones, women 
were grouped into either the follicular or luteal phase of the menstrual cycle. Protein was isolated from the 
cervical samples from women in both groups, and PR, ER, AR and GR protein expression levels were 
evaluated using western blots.  
2.) Determine whether the progestogens and glucocorticoids differentially modulate select immune 
gene expression and steroid receptor levels in different cervical compartments. 
Ectocervical explants were incubated with 100 nM CORT, DEX, MPA, P4, NET or LNG for 48 hours and 
RNA was isolated. RNA samples were converted to cDNA and the expression levels of IL6, IL8 and GILZ 
mRNA was determined using qPCR. Steroid receptor mRNA levels were determined via real time qPCR. 
ER, MR, AR, GR and PR levels were assessed. Protein was harvested from one patient and GR and PRAB 
expression levels were assessed via western blots. Endocervical samples were processed in the same 
manner. However due to the small sample sizes of this tissue the effects of only 100 nM DEX, MPA and 
NET were investigated, as well as differential regulation of IL6, IL8 and GILZ mRNA levels. 
3.) Determine if the repressive effects exerted by MPA on IL6, IL8 and GILZ mRNA expression are 
dose dependent in ectocervical explants. 
Ectocervical explants were treated with increasing concentrations of MPA (1 nM - 1 µM) for 48 hours. Gene 
expression was determined using real time qPCR. Dose response curves were analysed and potencies 
(EC50) were determined. 
4) Determine the effects of progestogens on HIV-1 replication and gene expression in primary 
ectocervical explants. 
Ectocervical tissue samples were incubated for 48 hours with either 100 nM MPA or NET, before being 
infected with either X-tropic  (HIVpNL4.3) or R-tropic (HIVBaL_Renilla) HIV-1 IMCs for 2 hours. Explants were 
extensively washed and replaced with media with 100 nM MPA or NET. HIV-1 infection was determined by 
harvesting the supernatant from the explants at days 0, 3, 5, 7 and 10 post infection and assessing p24 
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expression levels via a p24 ELISA. Tissue was harvested at the end of the time course for RNA isolation 







Primary ectocervical explants express all the steroid receptors and their expression levels 
are dependent on the menstrual cycle of the women 
 
It has been suggested that the sex hormones E2 and P4 regulate the steroid receptor levels present in 
the female genital tract (Camacho-Arroyo et al., 1996; Tibbetts et al., 1998). Thus it was of interest to 
determine the effects of the menstrual cycle on the expression levels of the PR, AR, ER, GR and MR. 
Women in this study had their P4, E2, LH and FSH serum concentrations determined by ELISA at the 
National Health Laboratory Services (NHLS, South Africa), that allowed for the determination of the 
menstrual phase cycle for each donor (See Appendix C for donor information). The concentrations of 
each hormone from a donor were matched to the most likely phase of the menstrual cycle by 
comparing the concentrations of the hormones from the donor to the known ranges of each hormone 
within each phase of the menstrual cycle. The range of concentrations of each hormone at each phase 
of the menstrual cycle was supplied by the NHLS, South Africa. 
Donors were sorted into follicular and luteal phases, and their cervical explant tissue was harvested 
for protein isolation whereafter the different steroid receptor levels were determined by western 
blotting. Protein isolation was optimised for this study. However protein yields were still variable 
(appendix E, Table E.2). For this experiment, 20 μg of protein was loaded per sample according to the 
Bradford assay of protein determination. However upon inspection of the GAPDH levels (Fig. 4.1. D), it was 
obvious that the Bradford method of protein determination was not accurate. Despite this inaccuracy, 
protein quantitation by densometric analysis reduced this error by normalising the intensity of the protein 
band of interest (IDV) to the intensity of its corresponding GAPDH protein band. After normalisation, distinct 
protein expression patterns emerged. 
Twenty-four donors were used in this study, with 12 donors identified in the luteal phase (high P4 and 
low E2) and 12 donors identified in the follicular phase (low P4 and high E2). Upon densometric 
analysis of the western blots (as seen in Fig. 4.1. D), the total average PR levels were found to be 
higher in the follicular phase compared to the luteal phase. When separating total PR levels into its 
isoforms, it was observed that women in the follicular phase, had, on average, elevated levels of PRB 
(Fig. 4.1 A) and significantly higher levels of PRA compared to the luteal phase (Fig. 4.1 B). While 
there was more PRB in the follicular phase, there was also more PRA, suggesting that there may be 
more active PRB in the luteal phase, however this comparison is yet to be performed or validated. 
ERɑ levels were also regulated, with significantly higher average levels of the ERɑ protein present in 
the follicular phase than the luteal phase (Fig. 4.1 C). GR and AR protein levels were hard to detect in 
these samples, and may be due to the low abundance of the GR and AR compared to the ERɑ and the 
PR isoforms. Additionally, it could also be due to the inaccuracy of the Bradford assay in protein 
quantitation that resulted in less protein per sample added to each well of the SDS-PAGE gel that 
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could affect the detection of the GR and AR via western blotting. As such, it may be that a more 
accurate method of protein determination is needed to ensure equal loading. Additionally, it could also 
be that higher concentrations of total protein are needed for the visualisation and subsequent 
quantitation of the GR and AR (Fig. 4.1 D).  
The representative western (Fig. 4.1 D) shows the variation in the steroid receptor levels within a 
donor (each lane) as well as between donors (across lanes). However, this variation may not be as a 
result of donor variation but could be from the isolation method used. It could be that the isolation 
method from the Qiagen® AllPrep isolation kit, which uses a heavy metal (Zn2+) precipitation step 
could preferentially precipitate charged proteins. It could also be that some proteins have undergone 
proteolysis within the sample. Additionally, it could also be that the GR and AR are more labile than 
the ER and PR, and are thus more difficult to detect. Due to cross-reactivity of the MR antibodies used 




Figure 4.1: Endogenous SR profiles in ectocervix are differentially modulated during the 
menstrual cycle. Primary ectocervical explants were homogenised in 800 µl Buffer RLT (Qiagen, 
Netherlands) and processed for protein isolation. Protein concentration was determined using the Bradford 
assay, where 20 µg total protein was loaded onto an 8% SDS-PAGE gel and electrophoresed for 1 hr and 30 
min at 120 V. The gel was subsequently electroblotted onto a nitrocellulose membrane, and probed for the 
steroid receptors with the appropriate primary antibodies. The nitrocellulose membranes were incubated for 1 
minute in ECL-chemiluminescent substrate and visualised using audio-radiography. Relative PR B (A), PR A 
(B), ER (C) levels were determined using densomitry analysis software (AlphaEC™) with each sample 
normalised to its’ corresponding GAPDH levels. (D) A representative blot showing 12 donors (6 in the follicular 
and 6 in the luteal phase) with differing steroid receptor expression levels and GAPDH. COS-1 positive controls 
for each steroid receptor was electrophoresed with each sample set to confirm steroid receptor detection in the 
ectocervical samples and is donated as + in the representative western blot. 
Progestogens differentially regulate mRNA and protein expression levels of key 
immunomodulatory genes in ectocervical and endocervical explants 
Having established in PBMCs that MPA, unlike P4 and NET, repressed mRNA levels of 
immunomodulatory genes at 48 hours (Fig. 3.1), the mRNA expression of IL6, IL8 and GILZ after 48 
hours incubation was assessed in two different compartments of the lower female genital tract, the 
ectocervix and endocervix. Before these experiments could be performed, RNA isolation and tissue 
conditions needed to be optimised. Many RNA isolation techniques were tested. However 
homogenisation with the Qiagen TissueRuptor® in combination with the RNA isolation solution, 
TriReagent®, consistently produced good quality and high quantity total RNA in comparison to the 
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other methods (appendix E, Fig. E.2.1 and Table E.2). Furthermore, it was also established that fresh 
tissue should be used for all incubation experiments. It was found during optimisation studies, that 
freeze/thawing of the tissue greatly decreased the tissue viability compared the fresh tissue 
counterpart (data not shown). 
In the ectocervical tissue explants, CORT, DEX, MPA and P4 significantly decreased IL6 mRNA levels 
(Fig. 4.2 A), while only CORT, DEX and MPA significantly repressed IL8 mRNA levels (Fig. 4.2 C) 
compared to the vehicle control. NET and LNG had no significant effect on IL6 mRNA levels and P4, 
NET and LNG had no significant effect on IL8 mRNA levels (Fig. 4.2 A and C). GILZ mRNA 
expression in the ectocervical explants was significantly increased by DEX and MPA treatment, and 
slightly elevated with CORT, while P4, NET and LNG had no effect on gene expression (Fig. 4.2 E). 
RANTES mRNA expression was not readily detected in the explants, with C(t) values only detectable 
after 40 cycles in some donor samples (data not shown), thus RANTES levels were not assessed.  
The endocervix samples were smaller than the ectocervical samples, as such limited incubations 
could be performed per experiment. In the endocervical tissue, DEX and NET had no effect on IL6 or 
IL8 mRNA levels compared to the vehicle control after 48 hours (Fig. 4.2 B and D), while MPA 
appeared to reduce IL6 and IL8 mRNA levels. Both DEX and MPA significantly increased GILZ mRNA 
levels in the endocervix, while NET had no effect compared to the vehicle control (Fig. 4.2 F). The 
data suggest that there could be compartment specific effects of these ligands on gene expression, 
with more pronounced effects by MPA in the ectocervix than the endocervix. Cytokine expression 
levels were determined via Luminex, however due to the unreliability of the standard curve, accurate 







Figure 4.2: IL6, IL8 and GILZ expression in ectocervical and endocervical explant tissues are 
differentially modulated by glucocorticoids and progestogens.  Ectocervical (A, C and E) or 
endocervical explant tissue (B, D and F) samples were stimulated with 100 nM cortisol (CORT), DEX, MPA, P4, 
NET or LNG or with vehicle i.e. 0.1% (v/v) ethanol (EtOH), for 48 hours after which RNA was isolated, cDNA 
was synthesised and relative IL6, IL8, RANTES and GILZ mRNA levels determined by real time qPCR, 
normalised to GAPDH. Relative fold change in expression was determined by setting vehicle control to 1. In the 
ectocervix relative mRNA expression levels of (A) IL6, (C) IL8 and (E) GILZ were determined with all the 
ligands. Due to the small amount of tissue in the endocervix relative expression levels of (B) IL6, (D) IL8 and (F) 
GILZ were determined for 100 nM DEX, MPA and NET treated samples. (A-F) shows histograms of pooled 
results from four donors (Prog 0010, 0011, 0024 and Prot 0001) with vehicle set to one, plotted as mean +/- 
SEM. A one-way ANOVA with either a Dunnet’s post hoc test (A and C) or student’s t-test (B and F) was 
performed. Statistical significance is denoted by *, ** or **** to indicate P< 0.05, P< 0.01 or P< 0.0001, 
respectively.   
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MPA dose dependently affects immunomodulatory mRNA levels in ectocervical explants 
Ectocervical explants were treated with increasing concentrations of MPA in order to determine dose-
dependent effects of MPA on relative IL6, IL8 and GILZ mRNA expression. Dose response curves give 
useful information on the efficacy (maximal response) and potency (EC50 or half maximal response) of 
the ligand on a particular gene (Africander et al., 2011; Hapgood et al., 2013). This information gives 
insight into the concentrations necessary to exert a transcriptional response. There was both inter- 
and intra-individual variation on the dose response curves, with some samples exhibiting pro-
inflammatory effects by MPA on the target genes at the lower concentrations (Fig. 4.3).  
The dose response analysis on IL6 mRNA expression levels indicated that MPA repressed IL6 mRNA 
expression between 100 nM and 1 µM, with a calculated EC50 of ~70 nM (Fig. 4.3 A). MPA repression 
on IL8 mRNA expression appeared to be more sensitive, with mRNA expression levels reduced 
between 10 - 100 nM, with a calculated EC50 of ~18 nM (Fig. 4.3 B). GILZ mRNA expression levels 
increased with increasing concentrations of MPA, although the error was high in this data set (Fig. 4.3 
C). The non-linear regression curve fit indicated that the EC50 for transactivation by MPA on GILZ 
mRNA expression was ~7.5 nM. The data suggest that MPA may exhibit dose and gene selective 
sensitivities on gene expression (Fig. 4.3). The dose response experiments in primary ectocervical 
explants showed high inter-individual variation in the responses measured from the samples of the 
different donors, resulting in the large error found in this experiment. Thus, dose responses should be 




Figure 4.3: MPA appears to regulate IL6, IL8 and GILZ mRNA expression in a dose dependent 
manner in ectocervical explant tissues. (A-C) Ectocervical explants were treated in triplicate with 0.1% 
(v/v) ethanol (EtOH or ctrl), or increasing concentrations of MPA (1 nM, 10 nM, 100 nM and 1 µM) for 48 hours 
after which RNA was isolated, cDNA was synthesised and relative IL6 (A), IL8 (B) and GILZ (C) mRNA levels 
determined by qPCR, normalised to GAPDH. Dose response curves show pooled results from three donors 
(Prog 0026, 0027 and Prog 0028) with vehicle set to 100%, plotted as mean +/- SEM. A (log) agonist vs. 
response - variable slope (four parameters) non-linear regression analysis with a HillSlope set at 1, was 
performed on the data set, with vehicle treatment set as 100%. (A) IL6 dose response for MPA, (B) IL8 dose 
response (C) GILZ dose response. 
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Progestogens and glucocorticoids do not alter the gene expression profiles of the different 
steroid receptors in primary ectocervical explants after 48 hours incubation 
Primary ectocervical explants were assessed for mRNA expression of the AR, ERα, GRα, MR and 
PRAB as well as the protein expression of GRα, PR A and PR B. Ectocervical explants had detectable 
mRNA expression levels of all the SRs (Fig. 4.4). Additionally, GRα and PR protein levels were 
assessed. However isolation of total protein from the TriReagent® fraction was only successful in one 
donor (Fig. 4.5). 
The SRs did not appear to be differentially regulated by the different ligands at an mRNA expression 
level after 48 hours (Fig. 4.4). This also appears to be the case at the protein expression level for the 
GR and PR (Fig. 4.5). However the results of the protein levels must be cautiously interpreted since 
they are only from one donor. AR mRNA levels appeared to be highly expressed. However detection 
of the AR protein via western blotting was not successful in this experiment. AR mRNA levels 
appeared to be slightly elevated by all treatments except LNG, which was similar to the vehicle control 
(Fig. 4.4 A). ERɑ levels (Fig. 4.4 B) were all similar to the vehicle control in the different treatment 
groups. Interestingly, MR mRNA appeared to be expressed at a low level in all the treatment groups 
(Fig. 4.4 F). Thus, the quantitation of the MR by qPCR should be cautiously interpreted due to the low 
expression levels observed (Fig. 4.4 C and 4.4 F). GRɑ mRNA expression levels appeared to be 
increased in the P4 treated group after 48 hours post treatment, while results for the other treatment 
groups were similar to the vehicle control (Fig. 4.4 D). PRAB expression also appeared to be slightly 
elevated in all groups compared to the vehicle (EtOH) control, except in the P4 group which had 






Figure 4.4: Progestins do not appear to modulate SRs mRNA levels in primary ectocervical 
explants. Primary ectocervical explants were incubated with vehicle i.e. 0.1 % (v/v) ethanol (EtOH), or treated 
with 100 nM cortisol (CORT), DEX, MPA, P4, NET or LNG for 48 hours after which explants were homogenised 
in 800 µl TriReagent® (Sigma). RNA was isolated and 250 ng was used for cDNA synthesis. Relative (A) AR, 
(B) ERɑ, (C) MR, (D) GRɑ or (E) PR AB mRNA levels were determined by qPCR and normalised to relative 
GAPDH, with vehicle treatment set to 1. Five times sample application buffer (Fermantas) was added to each 
qPCR reaction and 10 µl of the samples were loaded onto a 1% Agarose-1 X TAE gel and electrophoresed for 1 
hour at 60 V. Agarose gels were visualised under 256 nM UV light in a Syngene, G:Box (Vacutec, England) and 
images acquired using GeneSnap from synGene, version 7.08 (SynGene, England). A representative gel is 
shown for each SR and GAPDH control (F). Histograms represent pooled data from three donors (Prot 0001, Prog 




In order to compare the mRNA expression levels of the SRs with protein levels, western blotting was 
performed. As previously mentioned, these results are representative of one donor. Total protein 
isolated from the phenol layer of the TriReagent® fraction was only successful in one donor, while the 
protein isolated from the other donors appeared to be degraded upon western blotting analysis (data 
not shown). From this donor, it appeared that PR A was more abundant that PR B in this sample set 
across treatment (Fig. 4.5 D). PR A (Fig. 4.5 B) and B (Fig. 4.5 A) protein expression levels appeared 
to be elevated in MPA and P4 treated samples, while NET treatment appeared to have lower levels 
than the vehicle control. CORT appeared to elevate PR A expression levels only (Fig. 4.5 B), while 
DEX and LNG appeared to have no effect on PR protein expression (Fig. 4.5 A and B). Similarly it 
appeared that GRɑ levels were slightly elevated in P4 treated samples (Fig. 4.5 C), while the other 
ligands had no effect on relative protein expression levels. Interestingly, DEX turnover of the GR, was 
only observed in 1 of the 3 replicates (Fig. 4.5 D). More repeats need to be performed to elucidate the 
regulation of the SRs in response to the different ligands. Taken together, it appears that SR levels 
are not modulated in response to glucocorticoid or progestogen treatment after 48 hours. 
 
Figure 4.5: Progestins do not appear to modulate GR and PR protein levels from one donor. 
Primary ectocervical explants were incubated with vehicle i.e. 0.1% (v/v) ethanol (EtOH), or treated with 100 nM 
cortisol (CORT), DEX, MPA, P4, NET or LNG for 48 hours after which explants were homogenised in 800 µl 
TriReagent® (Sigma-Aldrich, South Africa). Protein samples, isolated from the phenol fraction, were 
electrophoresed on an 8% SDS-PAGE gel before being electroblotted onto a nitrocellulose membrane and probed for 
GR⍺, PR A B and GAPDH. Nitrocellulose blots were incubated for 1 minute in ECL-chemiluminescent substrate before 
being visualised by audio-radiography. (A-C) Represent the average PR B (A), PR A (B) or GR (C) expression 
normalised to GAPDH, determined by densometric analysis (AlphaEC™, Alpha Innotech, version 3.1.2) with a 
representative blot of one of the three replicate samples for each treatment group (D). Due to the isolation method, GR 
and PR protein bands appear to migrate slightly differently, possibly due to different amounts of salt and phenol 
contamination in each sample, and not indicative of the different isoforms of these proteins. Histograms represent 
pooled data from one donor (Prog 0024) with treatments performed in triplicate, plotted at mean ± SD.  
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Progestogens do not significantly modulate IL6 and IL8 mRNA levels after prolonged 
exposure in the absence and presence of HIV-1 
It was observed in PBMCs that MPA no longer repressed IL6 mRNA levels after 9 days in the 
presence and absence of HIV-1, and that the expression of IL6 mRNA levels by MPA in these 
samples, correlated with an increase in HIV-1 infection levels in PBMCs. It was thus of interest to 
determine whether similar effects were observed in the primary genital mucosa using primary 
ectocervical explants. However, due to the high biological variability between donors and within donor 
treatments, no correlations could be made in this study. Furthermore, it was challenging to isolate 
good quality RNA from primary cervical explants after long term treatment (see appendix E, Fig. E.2.1 
B). As such, the results should be cautiously interpreted due to both the methodological limitations 
and donor variability observed in this study. 
After 12 days incubation with 100 nM MPA or NET, gene expression from 4 donors was analysed. The 
data suggest that in the presence of HIV-1BaL_Renilla at 10 days post infection, 100 nM MPA appeared to 
elevate relative IL6 and IL8 mRNA levels compared to the vehicle control; however this was not 
significant (Fig. 4.6 A and B). Additionally, 100 nM NET treatment had no effect on IL6 or IL8 mRNA 
levels. GILZ mRNA expression appeared to increase with MPA treatment, while NET had no effect 
(Fig. 4.6 C). These experiments need to be confirmed with additional repeats, in the absence of HIV-1, 
so that the effects of the progestogens on gene expression after long term incubations can be 
determined in primary ectocervical explants. 
 
Figure 4.6: MPA and NET do not significantly modulate IL6 and IL8 mRNA expression, while 
MPA appears to transactivate GILZ mRNA expression in ectocervical explants after 12 days in 
the presence of HIV-1BaL_Renilla. Ectocervical tissue was treated for 48 hours with vehicle i.e. 0.1% (v/v) 
ethanol (EtOH), 100 nM MPA, or NET after which 500 IU/ml HIV-1BaL_Renilla was added for 2 hours. Explants 
were washed 4 X with 1 X PBS, and media was replaced. The explants were cultured for a further 10 days, in 
the presence of ligands. Tissue was harvested in TriReagent® at 10 days post infection, where RNA was isolated 
and cDNA synthesised for use in subsequent real time qPCR. Relative IL6 (A), IL8 (B) and GILZ (C) mRNA 
expression levels were normalised to GAPDH. Relative fold change expression levels were determined by setting the 
vehicle control to 1. A - C are histograms representing pooled results from four donors, with each treatment 
performed in triplicate (Prog 0025, Prog 0028, Prot 0003 and Prog 0042), plotted as mean ± SEM.  
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Primary ectocervical explants were infected with the X4 tropic IMC, HIV-1pNL4.3, and gene expression 
was assessed after 12 days. In this experiment, mRNA levels were assessed in the presence and 
absence of HIV-1. 
The data from 4 donors after 12 days incubation with ligand indicated that in the absence of HIV-
1pNL4.3 infection, MPA appeared to reduce the mRNA levels of IL6, but had no effect on IL8 mRNA 
levels compared to the vehicle control (Fig. 4.7 A and B). In the presence of HIV-1, MPA appeared to 
have no effect on IL6 and IL8 mRNA levels compared to the vehicle control (Fig. 4.7 A and B). NET 
treatment in the absence of HIV-1 infection, appeared to have no effect on IL6 and IL8 mRNA 
expression levels. However, it appeared in the presence of HIV-1 that NET treatment elevated IL6 and 
IL8 mRNA levels (Fig. 4.7 A and B). MPA treatment after 12 days in primary ectocervical explants 
appeared to elevate GILZ mRNA expression levels compared to the vehicle control in both the 
absence and presence of HIV-1, however this was not significant (Fig. 4.7 C). NET had no effect on 
GILZ mRNA expression in any of the treatment conditions (Fig. 4.7 C). 
Taken together, the data suggest that after 12 days in the presence of HIV-1, 100 nM MPA does not 
repress IL6 and IL8 mRNA levels (Fig. 4.6 A, B and 4.7 A, B), unlike the repressive effects observed 
after 48 hours. Similarly, 100 nM MPA appears to have no effect on IL6 and IL8 mRNA levels in the 
presence of HIV-1, 10 days post infection (Fig. 4.6 A, B and 4.7 A, B). While it appears that 100 nM 
MPA is able to transactivate GILZ mRNA expression this increase in expression is not significant (Fig. 
4.6 C and 4.7 C). Additionally, it appears that virus tropism has no effect on MPA and NET driven 
gene expression (Fig. 4.6 and 4.7).  
 
Figure 4.7: MPA and NET do not affect IL6 and IL8 mRNA expression, while MPA appears to 
transactivate GILZ mRNA expression in ectocervical explants after 12 days in the absence and 
presence of HIV-1pNL4.3. Ectocervical tissue was treated for 48 hours with vehicle i.e. 0.1% (v/v) ethanol 
(EtOH), 100 nM MPA, or NET after which 500 IU/ml HIV-1pNL4.3 was added for 2 hours. Explants were washed 4 
X with 1 X PBS, and media was replaced. The explants were cultured for a further 10 days, in the presence of 
ligands. Tissue was harvested in TriReagent® at 10 days post infection, where RNA was isolated and cDNA 
synthesised for use in subsequent real time qPCR. Relative IL6 (A), IL8 (B) and GILZ (C) mRNA expression levels 
were normalised to GAPDH. Relative fold change in expression was determined by setting vehicle control (EtOH) in 
each group to 1. A - C are histograms representing pooled results from four donors (Prog 0035, Prog 0037, Prog 




MPA treatment exhibits variable effects on HIV-1 replication, while NET treatment appears 
to cause consistently reduced HIV-1 replication in tissue from most donors 
Some observational studies as well as the current meta-analyses suggest that MPA increases HIV-1 
acquisition in women (Polis et al., 2014; Ralph et al., 2015; Morrison et al., 2015). The lower female 
genital tract is a key site of initial HIV-1 transmission (Haynes & Shattock, 2008; Jespers et al., 2010), 
having a multitude of target cells present (Greenhead et al., 2000; Haynes & Shattock, 2008; Hladik & 
Hope, 2009). As such it was next sought to assess the direct effects of MPA and NET on HIV-1 
replication in primary ectocervical explants, consisting of the upper epithelial layer as well as the 
underlying stroma. The advantage of using primary explants to assess the effects of the different 
progestins on HIV-1 viral replication is that this eliminates most of the confounding behavioural issues 
inherent in observational studies. Additionally these experiments allow one to determine the direct 
effect of a progestogen on cervical tissue as apposed to the indirect effects observed in in vivo 
studies. 
Optimisation of the infection method for these experimental conditions was extensive. In the initial pilot 
experiments, tissue explants were infected individually. However due to the low titre of viral stocks 
produced in this study, the amount needed to obtain measurable productive infection was more than 
the volume of the 96 well. Therefore before proceeding with the experiments in this section, a better 
infection strategy was needed. A method from Arakelyan et al. (2013) was adapted for this study 
(Arakelyan et al., 2013). After 48 hours incubation with the different ligands, explants in triplicate 
treatments were removed and placed into a well of a 24 well plate, whereafter samples were infected 
for 2 hours with an appropriate IMC. After infection, samples were washed and placed back into the 
same 96 well plate. It was found that infecting each triplicate group in one well greatly reduced the 
error between the replicates when measuring p24 levels (appendix E, Fig. E.2.2 B). Further, the 
infection trend between the two methods (infecting individually versus infecting in triplicate) was 
similar (appendix E, Fig E.2.2 A and E.2.2 B) suggesting that the infection method did not change the 
outcome in infection. This method was subsequently used as the infection method for the results 
presented in this chapter.  
In addition to the infection method, it was important to establish that the tissue explants were 
productively infected. One pilot experiment showed that the R5 HIV-1 entry inhibitor, Maraviroc, 
appeared to reduce HIV-1BaL_Renilla replication levels over time compared to the vehicle control 
(appendix E, Fig.E.2.4). However no such studies were performed with HIV-1pNL4.3. In order to assess 
productive infection levels accumulative plot curves for the vehicle control conditions in each 
experiment was assessed for a linear trend. That is, if the infection levels in the control group 
increased over time, a linear trend should establish that the increase was significant and had a 
positive slope. If the increase was not significant, and or the slope of the trend was negative, then the 
experiment was excluded from all subsequent analyses (see appendix E, Fig E.2.3 for examples). 
 
125 
Furthermore, in two of the experiments where explants were infected with HIV-1pNL4.3, samples were 
taken immediately after infection (plotted as day 0 post infection). Here, it was shown that HIV-1 
replication levels at days 3, 5, 7 and 10 post infection are greater than at day 0 post infection (Fig. 4.9 
G and H). Taken together, these controls show that the tissue explants were productively infected in 
this current study. 
Ectocervical explants were incubated with either 100 nM MPA or NET for 48 hours, before being 
infected for 2 hours with HIV-1 (X-tropic HIV-1pNL4.3 or R-tropic HIV-1BaL_Renilla IMCs). Explants were 
cultured for a further 12 days in the presence of the ligand, with supernatants collected at various time 
points. It was evident in this experiment that there was significant inter-individual variation in the 
response to progestin treatment on HIV-1 replication and gene expression. When analysing the 
individual plots of the relative infection (p24) levels (Fig. 4.8 and Fig. 4.9) for each HIV-1 virus type 
(HIV-1BaL_Renilla or HIV-1pNL4.3) it appeared that there were two types of responses to MPA treatment; 
those that appeared to have increased HIV-1 viral replication, and those that had no effect to 
decreased HIV-1 viral replication.  
For the HIV-1BaL_Renilla results, samples from donors Prot 0003 (Fig. 4. 8 A), Prog 0044 (Fig. 4. 8 B) and 
0043 (Fig. 4. 8 C) appeared to have elevated HIV-1 replication levels in the MPA treated group 
compared to the vehicle control over time. Samples from donors Prog 0042 (Fig. 4. 8 D), 0025 (Fig. 4. 
8 E) and 0049 (Fig. 4. 8 F) appeared to have similar or lower levels of HIV-1 replication in the MPA 
treated group compared to the vehicle control over time. At an individual level, NET treatment 
appeared to increase viral replication in one donor sample, less than MPA (Prot 0003, Fig. 4.8 A), and 
appeared to increase viral replication at day 10 post infection more than MPA in another donor sample 
(Prog 0043, Fig. 4.8 C). In samples from donors Prog 0044, 0042, 0025 and 0049 (Fig. 4.8 B, D, E 
and F respectively), NET treatment resulted in lower or similar effects to the vehicle control at all time 
points. 	
It appeared that phase of menstrual cycle did not contribute to the outcome of HIV-1 replication in 
MPA or NET treated samples. Five out of six donors were in the follicular phase, with 2 of these 
samples showing an increase in infection with MPA (Prot 0003 and Prog 0045), one showing a 
decrease in HIV-1 replication with MPA (Prog 0025), and two samples showing no difference in HIV-1 
replication in the MPA treated samples compared to the vehicle control (Prog 0042 and Prog 0049). 
Donor Prog 0043 showed an increase in HIV-1 replication in the MPA treated samples and the donor 
was in the early ovulatory phase. 
In this experimental subset, the average donor age was 45.8 years old (95% CI; 43.1 - 48.6), the 
average LH levels were 10.6 IU/L (95% CI; 1.0 - 20.1), FSH levels were 9.5 IU/L (95% CI; 5.1 - 14.0), E2 





Fig. 4.8: Individual data plots showing ectocervical explants infected with HIV-1BaL_Renilla over 
time, suggest that MPA and NET result in varied responses within and between donor samples. 
Ectocervical tissue from each donor was incubated in triplicate with vehicle i.e. 0.1% (v/v) ethanol (EtOH), or 
stimulated with 100 nM MPA, or NET for 48 hours after which 500 IU/ml HIV-1BaL_Renilla was added for 2 hours. 
Explants were cultured for a further 10 days, in the presence of ligands, and infection was measured by p24 
ELISA (Innogenetics, Belgium). (A-F) shows the relative infection levels of each donor at time points 3, 5 (only 4 
donors were sampled at this time), 7 and 10 days post infection with HIV-1BaL_Renilla with Day 3 EtOH set to 
100% infection. A - F are pooled XY graphs of one donor representing relative infection plotted as mean +/- SD. 
See appendix C for individual donor information regarding hormone levels.	
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For the HIV-1pNL4.3 infection data set, samples from donors Prog 0035 (Fig. 4.9 A), 0037 (Fig. 4.9 B), 
0042 (Fig. 4.9 E), 0049 (Fig. 4.9 F) and 0050 (Fig. 4.9 G), appeared to have increased HIV-1 
replication in the MPA treated group compared to the vehicle control. Samples from Prog 0039 (Fig. 
4.9 C), 0040 (Fig. 4.9 D) and 0051 (Fig. 4.9 H) exhibited similar or lower levels of HIV-1 replication in 
the MPA treated group compared to the vehicle control. NET treatment appeared to increase HIV-1 
replication compared to the vehicle control, but less than MPA, in one donor sample (Prog 0050, Fig. 
4.9 G), while NET treatment of Prog 0035, 0037, 0039, 0042, 0049, and 0051 samples, resulted in no 
or lower levels of HIV-1 viral replication compared to the vehicle control.  
As observed in the HIV-1BaL_Renilla infected donor group, phase of menstrual cycle did not appear to 
affect the outcomes in HIV-1pNL4.3 replication in the MPA treated samples. Of the 5 donor explants that 
showed an increase in HIV-1 replication, 3 were in the follicular phase (Prog 0042, Prog 0049 and 
Prog 0050), one was in the luteal phase (Prog 0035) and one donor explant was perimenopausal 
(Prog 0037). In donor explants that results showed a decrease or no effect in HIV-1 replication with 
MPA, two donors were in the luteal phase (Prog 003 and Prog 0051) and one was in the follicular 
phase (Prog 0040).  
Interestingly, the effects by MPA and NET on HIV-1pNL4.3 viral replication appeared to be more 
pronounced compared to the effects by the progestins on HIV-1BaL_Renilla viral replication. That is, the 
differences between MPA and NET were greater in the samples infected with HIV-1pNL4.3 compared to 
the differences between the samples in the HIV-1BaL_Renilla infected group. At day 10 post infection, the 
average fold change difference of infection in the MPA group compared to the vehicle control was 1.1, 
while NET treatment was 0.78. In comparison, the mean relative fold change difference of infection at 
day 10 post infection with HIV-1BaL_Renilla in the MPA treated group was 0.99 compared to the vehicle 
control, while the mean relative infection level in the NET treated group was 0.93.  
It was apparent in the HIV-1BaL_Renilla and HIV-1pNL4.3 data sets the effects on viral replication by MPA 
and NET were prone to large intra-individual variation as evidenced by the large standard deviation at 
each time point within each patient (Fig. 4.8 and Fig 4.9). 
In this experimental subset, the average donor age was 44.4 years old (95% CI; 41.1 - 47.7), the 
average LH levels were 8.3 IU/L (95% CI; -1.3 - 17.8), FSH levels were 12.3 IU/L (95% CI; -5.2 - 29.7), E2 





Fig. 4.9: Individual data plots showing ectocervical explants infected with HIV-1PNL4.3 over time, 
suggest that MPA results in more varied responses compared to NET treatment between 
donors. Ectocervical tissue from each donor was treated in triplicate for 48 hours with vehicle i.e. 0.1% (v/v) 
ethanol (EtOH), 100 nM MPA, or NET after which 500 IU/ml HIV-1PNL4.3 was added for 2 hours. Explants were 
cultured for a further 10 days, in the presence of ligands, and infection was measured by p24 ELISA 
(Innogenetics, Belgium). (A-H) shows the relative infection levels of each donor at time points 0 (only 2 donors 
were sampled at this time) 3, 5 (only 4 donors were sampled at this time), 7 and 10 days post infection with 
HIV-1PNL4.3 with Day 3 EtOH set to 100% infection. A-H are pooled XY graphs of one donor representing relative 




MPA increased HIV-1 replication in the majority of explant samples, while NET causes 
consistently reduced viral replication levels in explant samples 
The individual infection data from the different donor samples strongly suggested that MPA may have 
different effects on HIV-1 replication. As such, the donor explant data were grouped as described above 
into groups where MPA appeared to increase viral replication or into groups where MPA appeared to have 
no or reduced effects on relative HIV-1 viral replication levels. 
In the HIV-1BaL_Renilla group where the results suggested an increase in viral replication (Fig 4.10 A, 
purple line), MPA treatment resulted in significantly higher levels of HIV-1 replication compared to the 
vehicle control and NET treatment at all the time points assayed (Appendix B, Table B3; n= 3, Day 3 
pi, p<0.001; Day 7 pi, p<0.001 and day 10 pi, p<0.05). NET treatment (Fig. 4.10 A, orange line) 
showed significantly lower levels of HIV-1 replication compared to MPA treatment at all the time points 
assayed and at days 7 and 10 post infection to the vehicle control (Appendix B, Table B3). 
Additionally, time, treatment and the interaction thereof, were significant factors in the analysis 
(Appendix B, Table B3). In the HIV-1BaL_Renilla group where MPA treatment resulted in similar or 
decreased levels of relative p24 levels, MPA treatment showed significantly lower levels of HIV-1 viral 
replication compared to the vehicle control at day 10 post infection (Fig. 4.10 B and Appendix B Table 
B4, n = 3, p<0.05). Interestingly, in this grouping, vehicle, MPA and NET treatment were similar at 
most time points, with only time contributing significantly to the analysis (Appendix B, Table B4).  
HIV-1pNL4.3 data indicated that in the donor samples that appeared to show an increase in HIV-1 viral 
replication (Fig. 4.10 C, purple line, n = 5), MPA treatment showed significantly higher levels of HIV-1 
viral replication compared to the vehicle control (Appendix B, Table B5; Day 3: p < 0.05, Day 7 and 10 
pi: p < 0.0001) and the NET treated group at all of the time points assayed (Appendix B, Table B5; 
Day 3: p < 0.05, Day 7 and 10: p < 0.0001). In addition, time, treatment and time X treatment 
interaction were all significant factors in the analysis (See appendix B, Table B5). NET treatment (Fig. 
4.10 C, orange line) resulted in significantly lower HIV-1 replication than the vehicle control (Day 7: p< 
0.001 and Day 10 pi: p<0.0001) and MPA treatment (Appendix B, Table B5; Day 3 and 7 pi: p < 0.001, 
and 10 pi: p < 0.0001). When grouping the samples that appeared to show similar or decreased levels 
in HIV-1 viral replication (Fig. 4.10 D, n = 3), MPA treatment (Fig. 4.10 D, purple line) resulted in 
significantly lower levels of HIV-1 replication compared to the vehicle control group at day 10 post 
infection (p<0.05, appendix B, Table B6). In addition, time, treatment and time X treatment interaction 
were all significant factors (See appendix B, Table B6). Unfortunately, the NET group only had 2 
replicates, and as a consequence the statistical analysis could not be performed on this data set.   
When comparing the relative infection levels in the group that showed an increase in HIV-1 viral 
replication (Fig. 4.10 A and C) to the group that showed a decrease in viral replication with MPA 
(Fig.4.10 B and D), MPA treatment resulted in higher relative levels of p24, compared to the group 
where MPA treatment decreased viral replication (Fig. 4.10 A and C compared to B and D 
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respectively). In the HIV-1BaL_Renilla group, it appeared that the relative levels were about 2 fold higher, 
with the MPA relative p24 levels at day 10 post infection at a mean of 300% relative infection in the 
groups showing an increase (Fig. 4.10 A) versus the 160% relative infection in the group that showed 
a decrease in viral replication at day 10 post infection (Fig 4.10 B). Similar trends were observed 
between the vehicle control groups (Fig 4.10 A and B). However, NET relative infection levels between 
the groups appeared to be similar (Fig. 4.10 A and B).  
As observed in the HIV-1BaL_Renilla group, similar differences in viral replication levels were observed 
between the HIV-1pNL4.3 groups (Fig. 4.10 C and D). In the group that showed an increase in HIV-1 
replication with MPA (Fig. 4. 10 C), the mean relative infection level at day 10 post infection was 
230%. In the group that showed a decrease in HIV-1 replication in the MPA treated group (Fig. 4.10 
D), a mean infection level of 150% was observed at day 10 post infection. The data suggests that 






Figure 4.10: Treatment with MPA either significantly increases or significantly decreases HIV-1 
viral replication in primary ectocervical tissue infected with either HIV-1PNL4.3 or HIV-1BaL_Renilla. 
Ectocervical tissue was incubated with vehicle i.e. 0.1% (v/v) ethanol (EtOH), or stimulated with 100 nM MPA, or 
NET for 48 hours after which 500 IU/ml HIV-1PNL4.3 or HIV-1BaL_Renillawas added for 2 hours. Explants were 
cultured for a further 10 days, in the presence of ligands, where infection was measured by p24 ELISA 
(Innogenetics, Belgium). (A-B) shows the relative infection levels of three donors at time points 3, 7 and 10 days 
post infection with HIV-1BaL_Renilla. (C) Shows the relative infection levels of five donors at time points 3, 7 and 10 
days post infection with HIV-1PNL4.3 with Day 3 EtOH set to 100% infection. (D) Shows the relative infection 
levels of three donors at time points 3, 7 and 10 days post infection with HIV-1PNL4.3. A repeated measures two 
way ANOVA was performed on these data sets (see Appendix B, Tables B3 - B6 for statistical outcomes). A - D 





When pooling all the data, MPA showed no significant effect on HIV-1 replication, while 
NET treatment resulted in significantly reduced HIV-1 replication levels in primary 
ectocervical explants  
The grouping analysis suggested that while MPA treatment had differential effects on HIV-1 
replication, NET treatment appeared to result in consistently reduced HIV-1 replication. The data from 
the HIV-1PNL4.3 or HIV-1BaL_Renilla were pooled to determine the overall effect of these progestogens on 
HIV-1 replication for all the explant experiments showing productive infection. 
When ectocervical explants were infected with HIV-1BaL_Renilla, MPA treated explants showed similar 
effects on HIV-1 replication compared to the vehicle control (EtOH) (Fig. 4.11 A). However, results of 
NET treatment appeared to be different to both MPA and the vehicle control (Fig. 4.11 A).  
In order to analyse in more detail and determine the statistical significance of the effects of MPA and 
NET on HIV-1 replication over time in the ectocervical explants, a repeated measure two-way ANOVA 
was used. Only matched time points could be utilised in this analysis. As such only relative p24 levels 
from days 3, 7 and 10 post infection were analysed (See Appendix B). The statistical analysis for the 
HIV-1BaL_Renilla data set showed that the NET treated group had significantly lower relative infection 
levels (p < 0.05) compared to the MPA treated group at day 7 post infection (Fig. 4.11 B, and 
Appendix B Table B1). In addition, the repeated measure two-way ANOVA analysis revealed that time 
was a significant factor, while treatment was not (see Appendix B, Table B1). At day 10 post infection, 
the vehicle control (EtOH) had a mean relative infection level of 241.2% (95% confidence interval (CI) 
184 - 298.4). The MPA treated group had a mean of 239.1 (95% CI 175.5 - 302.7) and the NET 
treated group had a mean relative infection level of 221.9% (95% CI 177.8 - 266.1). The confidence 







Figure 4.11: NET treatment significantly reduces HIV-1BaL_Renilla replication, while MPA does not 
in pooled data from all primary ectocervical explants. Ectocervical tissue was treated in triplicate for 
48 hours with vehicle i.e. 0.1% (v/v) ethanol (EtOH), 100 nM MPA, or NET after which 500 IU/ml HIV-1BaL_Renilla 
was added for 2 hours. Explants were cultured for a further 10 days, in the presence of ligands, and infection 
was measured by p24 ELISA (Innogenetics, Belgium). (A) Shows the relative infection levels of six donors at 
days 3, 5, 7 and 10 post infection with HIV-1BaL_Renilla with Day 3 vehicle control (EtOH) set to 100% infection. (B) 
Shows the data set used for statistical analysis, with matched data sets for six donors at time points 3, 7 and 10 
days post infection with HIV-1BaL_Renilla with Day 3 vehicle control set to (EtOH) 100% infection. A repeated 
measure two way ANOVA was performed (see appendix B, Table B1, for statistical outcomes). A and B are 
pooled XY graph of six donors representing relative infection plotted as mean ± SEM. 
 
Ectocervical explants were infected with an X-tropic HIV-1 infectious molecular clone, HIV-1pNL4.3, and 
HIV-1 p24 levels were measured. The data suggest that MPA treated samples infected with HIV-1pNL4.3 
(Fig. 4.12 A) had similar viral replication levels compared to the vehicle control at all the time points 
assayed (Fig. 4.12 A). Although the results from the MPA and the vehicle control groups were similar, 
the MPA treated group had slightly higher mean values at the later time points (days 5, 7, and 10 post 
infection). In contrast, relative infection levels in the NET treated group were lower than the MPA and 
vehicle control groups (Fig. 4.12 A). Interestingly, when p24 levels were assessed directly after 
infection (taken as day 0 post infection) for two donors, results suggest that the predominant amount 
of p24 expression occurs between 0 - 5 days post infection. This is evident when comparing the slope 
of the curve at day 0 – 5 and the slope from day 5 – 10 days post infection (Fig. 4.12. A).  
For the HIV-1PNL4.3 data set, it was evident that at days 3, 7 and 10 post infection, the NET treated 
group relative p24 levels were lower than the MPA and vehicle treated groups (Fig. 4.12 A and B). 
This was confirmed in the repeated measure two-way ANOVA (Fig. 4.12 B), where NET treatment was 
found to result in significantly lower HIV-1 replication levels compared to MPA treatment and the 
vehicle control at all the time points assayed (Day 3: p < 0.05, day 7 and 10: p < 0.0001; Appendix B, 
Table B2). In addition the two way ANOVA analysis suggested that both time and time X treatment 
interaction were significant factors in this analysis (see appendix B, Table B2), with treatment having a 
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modest but not significant contribution (p = 0.0564) to the analysis. The mean relative infection levels 
at day 10 post infection for each group was, 214.4% (95% CI 189-4 - 239.4) for the vehicle control 
group (EtOH), 214.9% (95% CI 176.8 - 253) for MPA and 166.02% (95% CI 123.4 - 209.1) for NET. 
Once again, the confidence intervals suggest that the variation within each treatment group is high.  
Taken together the data suggest that while the effects of MPA on the majority of samples may be 
masked when grouping the results from all the donors (Fig. 4.11 B and 4.12 B), the effect of NET on 
HIV-1 replication is consistently and significantly lower compared to the MPA treated and the vehicle 






Figure 4.12: NET treatment has significantly reduced levels of HIV-1PNL4.3 replication compared 
to the vehicle control while MPA appears to have no effect on HIV-1PNL4.3 replication in pooled 
results from all infected primary ectocervical explants. Ectocervical tissue was incubated in triplicate 
for 48 hours with vehicle i.e. 0.1% (v/v) ethanol (EtOH), or treated with either 100 nM MPA, or NET after which 
500 IU/ml HIV-1PNL4.3 was added for 2 hours. Explants were cultured for a further 10 days, in the presence of 
ligands, and replication was measured by p24 ELISA (Innogenetics, Belgium) at various time points. (A) Shows 
the relative infection levels of eight donors at time points 0 (only 2 donors were sampled at this time) 3, 5 (only 
4 donors were sampled at this time), 7 and 10 days post infection with HIV-1PNL4.3 with Day 3 vehicle control 
(EtOH) set to 100% infection. (B) Shows the matched relative infection levels of seven donors at time points 3, 7 
and 10 days post infection with HIV-1PNL4.3 with Day 3 vehicle control (EtOH) set to 100% infection, used for the 
statistical analysis. A repeated measure two way ANOVA was performed on both data sets (see appendix B for 
statistical outcomes). A and B are pooled XY graph of eight (A) or seven (B) donors representing relative 





The female genital tract (FGT) is a major site for heterosexual infection and transmission in women. As 
such, the effects of different progestogens on immune gene expression and their effects on HIV-1 
replication are important to establish in light of the recent observational and meta-analysis studies which 
suggest that MPA increases HIV-1 susceptibility in women (Noguchi et al., 2014; Noguchi et al., 2015; 
Ralph et al., 2015; Morrison et al., 2015). Furthermore, recent studies have observed that women on DMPA 
have a distinct immunosuppressive cytokine profile in their CVL (Ngcapu et al., 2015), as well as distinct 
cytokine profiles that are associated with an increased risk in HIV-1 infection (Morrison et al., 2014). 
However, these studies have not assessed the direct effects of different progestogens on immune gene 
expression or HIV-1 replication. This study utilised primary cervical explants from pre-menopausal women 
to assess the direct effects by the different progestogens on cervical tissue.  
Primary cervical explants are useful models of the FGT to address the direct effects of progestogens in the 
genital mucosa (Hladik et al., 2007; Hladik & Hope, 2009; Merbah et al., 2011; Anderson et al., 2010; 
Hapgood, 2013). They are multicellular models consisting of epithelial cells, stromal cells, T cells, dendritic 
cells, Langerhan cells and macrophages (Hladik & Hope, 2009; Miller & Shattock, 2003; Pudney et al., 
2005). However the relative distribution of these immune cells is dynamic within the ectocervix and 
endocervix (Anderson et al., 2010; Pudney et al., 2005; Merbah et al., 2011), posing challenges in 
biological reproducibility within a donor and between donors. Despite these challenges, this study found 
significant effects on gene expression in explant tissue from 5 donors upon short term incubation with the 
different progestogens. While the effects on infection were varied, when pooling for different types of 
responders, significant differences were observed within and between treatment types. 
The menstrual cycle differentially affects steroid receptor levels in primary cervical 
explants 
It was of interest to determine whether there are differences in the steroid receptor levels during the 
different phases of the menstrual cycle. As previously mentioned, progestogens are able to bind to 
and have differential activity towards steroid receptors other than the PR (Africander et al., 2011; 
Stanczyk et al., 2013; Hapgood et al., 2004). Further to this, it has been reported that changes in the 
steroid receptor concentration could change the apparent affinity (IC50) and the potency (EC50) of the 
ligand for the receptor (Hapgood et al., 2013). Thus it was hypothesised in this study, that the 
differential effects of P4 and E2 on the immune response could be mediated through changes in SR 
expression. In this study, pre-menopausal women that were undergoing hysterectomies for benign 
reasons were recruited. During consent, P4, E2, LH and FSH levels were obtained to accurately cycle 
women (see Appendix C). Select patients were chosen in the different phases of the menstrual cycle 
(follicular or luteal) and total protein was isolated from ectocervical tissue for downstream analysis by 
western blot. The data from this study suggest that the ERɑ and the PR isoforms, PRA and PRB, are 
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differentially expressed, with significantly lower expression levels of these receptors found in the luteal 
phase during the menstrual cycle compared to the follicular phase (Fig. 4.1). While the results in this 
study are preliminary, they support the results observed in Snijders et al. (1992), where the authors 
observed maximal PR and ER expression by immunohistochemistry in the glandular epithelial and 
stromal cells of the endometrium in the proliferative or follicular phase of the menstrual cycle (Snijders 
et al., 1992). Tibbets et al. (1998) observed that E2 stimulation in the mice uterus had compartmental 
effects on ERɑ expression increasing levels in the luminal epithelial cell layers, while decreasing in 
the stromal and glandular epithelial cells. E2 stimulation also increased PR levels in the stroma and 
myometrium. The authors found that P4 stimulation, negatively regulated PR levels in all the sites of 
the mice reproductive tract tested (Tibbetts et al., 1998). Similarly it has been observed that E2 
increases PR mRNA expression levels, while P4 decreases PR levels in the cerebral cortex of 
ovarectomised rabbits (Camacho-Arroyo et al., 1996), and that there are estrogen response elements in 
the promoter regions of the PR (Kastner et al., 1990). It has also been observed in a breast cancer cell 
line, that PRB is able to repress ERɑ mRNA transcriptional levels via binding to a 1/2 PRE site in the 
promoter region of the ERɑ gene (De Amicis et al., 2009). Lastly, it has been observed in a vaginal 
epithelial tissue model, that E2 increased PRB expression levels (Ayehunie et al., 2015). Interestingly, 
these authors used ectocervical explants as controls, and observed that ERɑ expression within the 
ectocervix was predominantly expressed in the epithelial cells, while PRB expression was 
predominantly in the basal stromal layer (Ayehunie et al., 2015). These studies corroborate the data 
observed in this present study, whereby there are higher ERɑ, PRA and PRB levels in the follicular 
phase, where E2 is high and P4 low, compared to the luteal phase, where E2 is low and P4 is high. It 
may be that when E2 levels are elevated in the follicular phase, ERɑ, PRA and PRB levels increase 
through an increase in ER-driven transcription of the ER and PR genes in the epithelial and stromal 
cells of the ectocervix. While PR and ERɑ are easily and detectably expressed in the primary 
ectocervical explants in this study, the expression levels of GRɑ and AR are low (Fig. 4.1). As such, 
GRɑ and AR expression levels could not be accurately determined (Fig. 4.1). This is the first study to 
report GR and AR protein expression in primary human ectocervical tissue. Further, this study 
suggests that MPA, NET and LNG may be able to induce transcriptional responses through their 
partial agonism towards the GR (MPA only) or the AR in the ectocervix. While the detection of AR and 
GR was not possible in all donor explants, either due to biological variation or methodological 




Progestogens differentially modulate immune gene expression and cause distinct 
expression profiles in the ectocervix and the endocervix 
Having investigated the expression levels of steroid receptors, the difference in gene expression of 
selected immune function genes by the different progestogens compared to glucocorticoids was 
investigated after 48 hours incubation. Additionally, the effects of the progestins on gene expression in 
different cervical compartments, as well as changes in steroid receptor profiles, were assessed.  
When investigating the effects of progestogens on gene expression in primary cervical explants, it was 
evident that compartment specific regulation occurs between the ectocervix and the endocervix (Fig. 
4.2). In the ectocervical explants 100 nM CORT, DEX, MPA and P4 treatment significantly decreased 
IL6 mRNA expression. NET and LNG also appeared to slightly reduce IL6 mRNA expression levels, 
although this was not significant. CORT, DEX and MPA significantly repressed relative IL8 mRNA 
expression levels compared to the vehicle control, while P4, NET and LNG had no effect after 48 
hours. These results suggest that there could be different sensitivities towards different genes by the 
different ligands in the ectocervix. Additionally only MPA and DEX significantly increased GILZ mRNA 
levels (Fig. 4.2), suggesting that in the ectocervix, MPA, like DEX, exerts glucocorticoid effects most 
likely via the GR. Thus it could be that in the ectocervix, 100 nM MPA has a greater effect on IL6 and 
IL8 mRNA expression than NET, P4 and LNG through differential steroid receptor usage, as well as 
the recruitment of different co-repressors to the promoter elements of the genes, to elicit different 
responses. DEX and MPA were able to significantly transactivate GILZ mRNA expression after 48 
hours in the ectocervix. P4, NET and LNG had no effect on GILZ mRNA expression (Fig. 4.2). 
Interestingly, CORT (the natural glucocorticoid ligand) also had no effect on GILZ mRNA expression in 
the ectocervix, showing that DEX and MPA are more efficacious than CORT on GILZ mRNA 
transactivation in the ectocervix. Hadley et al. (2011) reported similar effects with CORT, DEX and 
MPA on GILZ transactivation in an airway epithelial cell line (A529), and found that these ligands had 
differential effects on GR translocation and recruitment to the promoter regions of the GILZ gene 
(Hadley et al., 2011). Thus it could be that DEX, more so than MPA, more so than CORT, increases 
nuclear translocation and subsequent GR recruitment to the promoter element of the GILZ gene, 
increasing transcription in ectocervical explants.  
When assessing the mRNA expression levels in the endocervix after 48 hours incubation with the 
different ligands, it was interesting to observe that MPA appeared to exhibit less repressive effects on 
IL6 and IL8 mRNA expression levels compared to the ectocervix, and that DEX treatment did not 
repress IL6 or IL8 mRNA expression (Fig. 4.2). DEX and MPA significantly increased GILZ mRNA 
levels suggesting that the transactivation mechanism of action by DEX and MPA is more effective in 
the endocervix compared to the transrepression mechanism of action, or that the factors necessary for 
transactivation via the GR are present in the endocervix, while factors necessary for transrepression 
may be limiting in the endocervix. Govender et al. (2014) observed in an endocervical cell line that DEX 
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and MPA significantly repressed IL6, IL8 and RANTES mRNA expression levels, and that this was via a GR 
dependent mechanism, while NET-A had no effect on mRNA levels for these genes (Govender et al., 
2014). While the data from this study did not report significant repressive effects by MPA on IL6 and IL8 
mRNA levels, the results from Govender et al. (2014) suggest that repressive effects may occur in the 
epithelial cells of the endocervix. Additionally, Verhoog et al. (2011) found that in End1/E6E7 cells activated 
with TNF-ɑ, IL6 mRNA expression levels were significantly reduced by DEX treatment, and that this 
repression was via the GR (Verhoog et al., 2011). However, of interest is that DEX at the same 
concentration as MPA had no effect on transrepression in the endocervix, supporting the idea that factors 
necessary for GR dependent gene repression may be limiting in the endocervix, compared to the 
ectocervix. The lack of repression by DEX, and the reduced repression by MPA (no significant effect) on 
IL6 and IL8 mRNA levels in the endocervical explants compared to the ectocervical explants also suggests 
that there could be cell type differences present in the endocervix compared to the ectocervix, as well the 
differential expression levels of steroid receptors in these cell types, which may govern the level of 
responses observed.  
In a study comparing the effects of P4, MPA and NET on mRNA levels in different cell types, 
Africander et al. (2011) found in ectocervical and vaginal cell lines that 1 μM P4 increased TNF-α induced 
IL6 mRNA expression levels, while 1 μM MPA and NET had no effect in both cell lines after 24 hours 
(Africander, et al., 2011). The authors also found that TNF-α induced IL8 mRNA expression was 
significantly upregulated by P4 and MPA, but not NET-A in ectocervical cells, while the ligands had no 
effect on IL8 mRNA expression in vaginal cells (Africander et al., 2011). While the results from the latter 
study appear contrary to the current findings, the ectocervical explant experiments are in the context of a 
multicellular environment with different cell types such as epithelial cells, dendritic cells, stromal cells, T 
cells, and macrophages within each explant tissue (Pudney et al., 2005; Greenhead et al., 2000), which 
most likely contribute to the total effect of mRNA gene expression observed (Fig. 4.2). The concentrations 
of ligands used in this current study were also lower than those reported by Africander et al. (2011) and 
mRNA levels were assayed at a longer time point in this study. In addition, the results in Fig.4.2 are from 
experiment in the absence of immune activation, while Africander et al. (2011) performed experiments in 
the presence of TNF-ɑ (Louw-du Toit et al., 2014a; Africander et al., 2011). Collectively, these results 
highlight that the progestogens may exert differential effects in individual cell types, suggesting that this 
may be due, in part, to the differential expression levels of steroid receptors.  
Few studies have used primary cell systems to assess the changes in gene expression by different 
progestins. In one such study, Huijbregts et al. (2013) found in vaginal mucosal mononuclear cells 
(VMMCs) that IL6 protein expression levels were reduced, while IL8 protein levels were unaffected by MPA 
treatment. Interestingly, P4 significantly increased IL8 protein expression at 100 nM after 24 hours 
treatment (Huijbregts et al., 2013). These results agree with some of the mRNA expression data observed 
in this study, whereby MPA but not P4, decreased IL6 mRNA expression in both ectocervical (significantly) 
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and endocervical explants (Fig. 4.2) and suggest that MPA directly represses several proinflammatory 
responses after 24 – 48 hours in different cell types in the female genital tract. However the results from the 
current study suggest that the significant repression of IL8 mRNA expression by MPA after 48 hours in the 
ectocervical explants may not be via the mononuclear cells. Additionally the results suggest that length of 
incubation with MPA may be important in determining the outcome of repression on IL8 mRNA levels. 
Results from the PBMC short time course (Fig. 3.1) in this study also showed repression with MPA on IL8 
mRNA levels after 48 hours, but not at 24 hours. Moreover, this data suggest that variation in the 
repressive effects of MPA on key immune gene may due to the relative levels of the different cell types 
present within the tissue sample. In a recent transcriptome analysis on endometrium and cervical 
transformation zone tissue obtained from women on DMPA and LNG for at least 6 months (IUD), Goldfien 
et al. (2015) observed that DMPA and LNG differentially regulated gene expression. Interestingly, the 
authors found that both LNG and DMPA had greater transcriptional effects in the endometrium, with little 
expression changes observed in the cervical transformation zone (Goldfien et al., 2015). The authors 
propose that the progestins alter the immune milieu in the upper female genital tract, that changes the 
recruitment of target cells, and key signalling pathway responses that may increase the risk in sexually 
transmitted diseases, including HIV-1 (Goldfien et al., 2015). LNG in this current study, had weak to no 
effects on IL6, IL8 and GILZ mRNA expression (Fig 4.2), while MPA had significant effects on the mRNA 
expression levels of these genes in ectocervical explants. Goldfien et al. 2015) reported in their global 
analysis, that there were greater effects on gene expression in the ectocervix than the endocervix which is 
in agreement with the results of this current study whereby greater effects on gene expression were 
observed in the ectocervix compared to the endocervix.  
When comparing the gene expression results of ectocervical and endocervical explant results to the 
results obtained in PBMCs after 48 hours using the same concentration of ligands, it is interesting to 
observe that the results in the ectocervical explants are more similar to the results observed in PBMCs 
than to the endocervical explant results. This could be due to differential cell type distributions, and 
the different relative expression levels of SRs, particularly the presence of the GR, in mediating the 
DEX and MPA repression on IL6 and IL8 mRNA levels after 48 hours. Furthermore, the current study 
shows that ectocervical explants express the PR, unlike PBMCs, suggesting that NET, P4 and LNG 
may have more pronounced effects in the local mucosa compared to the systemic system through 
exerting more prominent progestational effects via the PR. What is not known is the SR expression 
levels in endocervical explants, which would provide further insight into the site specific regulation of 
IL6, IL8 and GILZ mRNA levels in different immune environments. However the data suggest that the 
repressive effects by DEX, CORT and MPA in the ectocervical explants are most likely via the GR, 
similar to what was observed in PBMCs. 
Taken together, the data from this study suggest that progestogens and glucocorticoids have 
differential effects on gene expression in different mucosal compartments. The data suggest that 
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differential cell type distribution, and consequently steroid receptor and co-factor expression may 
determine the effects on gene expression by the different progestogens and glucocorticoids. 
Furthermore the results of this study suggest that the effects of MPA on gene expression after 48 
hours in the ectocervical explants are most likely mediated via the GR. 
Progestogens do not appear to regulate SR expression after 48 hours in the ectocervix 
The results from the current study suggest that there is compartment specific gene regulation within the 
different sites in the FGT. Further this suggests that the different progestogens, at the same concentration 
within the same tissue environment, have differential effects on gene expression. These differences could 
be due to the differential expression levels of the steroid receptors that may be regulated by the different 
ligands. The effects of these progestogens and glucocorticoids on steroid receptor expression levels in 
ectocervical explants were investigated in order to elucidate some of the mechanisms underpinning the 
gene regulation observed. Due to sample constraints, mRNA levels in the endocervical explants could not 
be determined. Consequently, the differences in the relative steroid receptor levels in the endocervix 
compared to the ectocervical explants could not be established.  
The results suggest that the progestogens do not significantly alter mRNA levels of the AR, ERɑ, GRɑ, MR 
or PR after 48 hours (Fig. 4.4). Additionally, the data from one donor sample indicated that DEX increases 
turnover of the GR, while no other ligand had any effect on GR expression levels. It also appeared that PRA 
protein levels were greater than PRB protein levels in this donor sample. However, there was little 
difference in the protein expression patterns of these isoforms upon ligand treatment (Fig. 4.5). Only NET 
treatment appeared to affect the protein expression levels of PRB and PRA (Fig. 4.5). As previously 
mentioned, P4 is known to negatively regulated PRB expression in myometrial cells (Camacho-Arroyo et 
al., 1996; Tibbetts et al., 1998), as such it was thought that the treatment with the progestogens may also 
decrease the PR expression levels in primary cervical explants. More repeats are needed to elucidate the 
regulation of the SRs by different progestogens. Surprisingly P4, MPA and LNG did not exert strong effects 
on PR mRNA or protein expression, after 48 hours. However, it could be that effects may be observed at 
longer time points with these progestogens on SR regulation. While the expression of the PR is important, it 
is the expression of the different isoforms that may contribute to the differential effects of the different 
progestogens on gene expression. Mesiano et al. (2002) found that when comparing the ratios of PRA to 
PRB and gene expression in myometrium, obtained from labouring and non-labouring women, P4 
responsiveness in the myometrium was, in part, controlled by the relative ratio of PRA to PRB (Mesiano et 
al., 2002). Tan et al. (2012) found that the relative ratio of PRA to PRB correlated with the transcriptional 
effects in a myometrial cell line. The authors found that increasing levels of PRA compared to PRB resulted 
in a change from anti-inflammatory actions via PRB to pro-inflammatory responses via PRA through 
inhibiting PRB, in response to P4 (Tan et al., 2012). While it was not possible to discriminate between PRA 
and PRB mRNA levels in the current study (Fig. 4.4), the protein results from one donor sample suggested 
that the PRA to PRB ratios may be different upon MPA, P4, NET and LNG treatment in primary ectocervical 
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explants (Fig. 4.5). Thus, it could be that the different ratios of PRA to PRB could also contribute towards 
the transcriptional responses observed in this study by the different progestogens.  
Regulation of steroid receptor mRNA and protein levels is not the only mechanism by which these ligands 
may affect SR mediated responses. It may be that these ligands activate the SRs differentially via 
phosphorylation. For example, Avenant et al. (2010) found that 100 nM MPA but not NET resulted in GR 
phosphorylation after 24 hours, and positively correlated with transactivation and transrepression potential 
on promoter-reporter constructs (Avenant et al., 2010). Thus it could be that ligand selectivity for 
phosphorylation of SRs could play a deterministic role on the outcome of the response. Indeed, Chen et al. 
(2008) found that the extent of phosphorylation of the GR at the different serine residues was concentration 
dependent and resulted in differential effects on mRNA expression levels on GR-driven genes (Chen et al., 
2008). Thus it could be that the ligands differentially modulate SR phosphorylation in a concentration 
dependent manner that mediates their differential effects on gene expression in ectocervical explants.  
Taken together the results from this study suggest that these ligands have no effect on SR mRNA or protein 
expression levels, although more repeats are needed to elucidate this issue. While not investigated in this 
study, it could be that these ligands may affect SR activation through post-transcriptional or post-
translational effects that may modulate their transcriptional responses, either by changing relative ratios of 
PRA to PRB or GR phosphorylation (Avenant et al., 2010; Tan et al., 2012; Chen et al., 2008; Mesiano et 
al., 2002). 
The effects of MPA on gene expression in the ectocervix are dose dependent 
In order to fully understand the effects of concentration of the progestogens on mRNA gene expression, 
dose response analyses were performed. This is vitally important, as the concentration of MPA within 
different tissue environments is not known. Circulating serum concentrations have been elucidated in 
several studies, and have indicated that between individuals, MPA serum concentrations vary 
substantially (Shelton & Halpern, 2014; Halpern et al., 2014). Studies have shown that MPA 
concentrations peak a few days after subcutaneous injection ranging from 2.5 - 65 nM (Ortiz et al., 
1977; Mishell, 1996; Hiroi et al., 1975; Mathrubutham & Fotherby, 1981), before plateauing to ~ 2.5 nM 
for the remainder of the prescribed course (Africander et al., 2011; Mishell, 1996). As such using a 
range of concentrations is important to reflect the possible concentrations of MPA in the ectocervix. 
Due to the limited availability of tissue in this study, a dose response was performed with only MPA in 
primary ectocervical explants.  
This is the first study to report a dose response analysis in primary ectocervical explants with MPA 
treatment. The data suggested that repression by MPA was more potent on IL8 mRNA gene expression 
than IL6 mRNA gene expression. That is, a low concentration of MPA may significantly decrease IL8 
mRNA levels while have no effect on IL6 mRNA levels at the same concentration. A potency (EC50) of ~ 18 
nM was calculated for IL8 compared to an EC50 of ~70 nM for IL6 gene expression (Fig. 4.3). 
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Interestingly, it is apparent that at the lower concentrations of MPA gene expression was more 
variable with some samples showing an apparent increase in IL6 mRNA expression at 1 and 10 nM 
concentrations, with variation of IL8 mRNA expression at 1 nM MPA only. In addition, MPA was able 
to transactivate GILZ mRNA expression at low concentrations, with an EC50 of ~ 7.5 nM (Fig. 4.3). 
This data also highlights the gene specific effects of MPA, with some pro-inflammatory genes being 
more sensitive to MPA treatment than others. Due to the limited availability of tissue for this study, 
only four concentrations were used in order to determine the EC50, as such the potencies determined for 
this study should be cautiously interpreted. Irvin and Herold (2015) observed in vaginal Vk2/E6E7 cell 
line, that MPA (70 – 388 µM) dose dependently increased the mRNA and protein expression levels 
select immune modulators (Irvin & Herold, 2015). While these data are contrary to the data obtained in 
the current study that shows increased concentrations of MPA lead to an increase in repressive 
effects, the Irvin and Herold (2015) study used concentrations of MPA well above the range reported 
in this study. Further, the authors assessed transcription at 5 days post treatment (Irvin & Herold, 2015) 
compared to this study that assessed transcriptional effects at 2 days post treatment (Fig. 4.3). 
However, their data together with those reported in this study suggest that time and concentration of 
ligands used may greatly affect the outcome of gene expression. The results in this current study are 
near peak serum MPA concentrations in women, and thus may be more indicative of what is most 
likely to occur in vivo.  Huijbregts et al. (2013) found that at increasing doses of MPA (10, 100 nM and 
1 µM) increased the repression on IL6 protein levels in primary vaginal mononuclear cells (Huijbregts 
et al., 2013). While the authors did not perform a dose response analysis, it appeared in their study 
that the EC50 for MPA on IL6 protein expression is most likely between 10 – 100 nM, similar to what was 
observed in this study in primary ectocervical explants. Their data, together with the data in this study, 
suggest that in the lower FGT, the effects of MPA on IL6 mRNA levels occur at peak serum concentrations. 
Dose response analyses performed by Govender et al. (2014) in an endocervical cell line observed 
potencies (EC50) of ~21 nM for IL6 mRNA and ~ 4 nM for IL8 mRNA expression by MPA after 24 hours 
incubation (Govender et al., 2014). While Govender et al. (2014) reported more potent EC50s for MPA on 
IL6 and IL8 repression, MPA was more potent on IL8 than IL6 mRNA levels, as found in this current study. 
The differences in the potency values reported in this study compared to those reported by Govender et al. 
(2014) could be due to the different models used. In this current study, a multicellular ectocervical explant 
system was used compared to an endocervical cell line used by Govender et al. (2014). Additionally, it has 
been reported by Govender et al., (2014) that the endocervical End1/E6E7cell line, only expresses the GR, 
while primary ectocervical explants express the AR, ER, GR and PR at an mRNA and protein level (Fig. 
4.1, 4.4 and 4.5). Interestingly, transactivation of GILZ by MPA in the endocervical cell line had a 
potency of ~24 nM (Govender et al., 2014), compared to ~7.5 nM observed in this study, suggesting a 
stronger transactivation potential in primary ectocervical explants. 
Taken together, the data suggest that MPA at concentrations similar to and below peak serum 
concentration (100 nM) has distinct gene specific effects after 48 hours. The data suggests that 
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concentration of MPA is important in determining the range and extent of the effects on gene expression. At 
peak serum concentrations, MPA may exert significantly repressive effects on IL6 and IL8 gene expression 
and increase GILZ mRNA expression, while at lower concentrations, MPA may exert significant repressive 
effects on IL8 but not IL6 mRNA expression, while maintaining the increase in GILZ mRNA expression. The 
EC50 observed in this study for IL6, IL8 and GILZ are similar to what was reported by Govender et al. 
(2014). Additionally the profile of MPA on IL6 and IL8 are similar profile to that observed by Huijbregts et al. 
(2013). 
The immunosuppressive effects on pro-inflammatory genes of MPA are reduced or lost 
after long term exposure in the absence and presence of HIV-1 
It was observed in the PBMC results that MPA no longer repressed IL6 mRNA levels in the majority of 
donors over a longer time course in the absence and presence of HIV-1. It was therefore of interest to 
determine the effects on gene expression by MPA and NET in primary cervical explants over a longer 
time course. However, RNA isolated from donors after long term incubation with different ligands was 
of poor quality (appendix E, Fig E.2.1 B). As such the RNA data obtained after 12 days in this study 
had large variability. In comparison, short term incubation with the ligands in ectocervical explants 
produced good quality RNA and the data obtained had significant differences between the treatment 
groups (Fig. 4.2 and appendix E, Fig E.2.1 A). Therefore, the data obtained after 12 days are 
preliminary and should be interpreted cautiously.  
Data from the HIV-1BaL_Renilla group showed that after 10 days post infection, MPA did not repress IL6 
or IL8 mRNA expression levels in the presence of HIV-1BaL_Renilla, where in some cases it appeared to 
be pro-inflammatory. MPA treatment appeared to increase GILZ mRNA expression at day 10 post 
infection relative to the vehicle control (Fig. 4.6). NET had no effect on gene expression in this group 
(Fig. 4.6). In the HIV-1pNL4.3 group, gene expression in the absence and presence of HIV-1 was 
determined. In this data subset, MPA treatment appeared to lose its repressive effects on IL6 and IL8 
mRNA levels in the absence and presence of HIV-1 (Fig. 4.7). Interestingly, MPA induction of GILZ 
mRNA levels was varied in the presence of HIV-1 and was not significant (Fig. 4.7), unlike that 
observed at a shorter time point (Fig. 4.2). Additionally NET had no effect on gene expression in the 
absence of HIV-1, however, it appeared in some donors that in the presence of HIV-1, IL6 mRNA 
expression increased (although this was not a significant trend) (Fig. 4.7).  
Taken together, the data suggests that MPA does not decrease IL6 or IL8 mRNA levels in the 
presence of HIV-1 after 12 days. In some cases NET had apparent pro-inflammatory effects on IL6 
mRNA in both the absence and presence of HIV-1pNL4.3 after 10 days. Interestingly, this was not 
observed in HIV-1BaL_Renilla. There could be differential effects on gene expression by MPA and NET 
that may be in part regulated by the type of virus. Further, while not significant, it appeared that MPA 
increased GILZ mRNA transcription in the absence and presence of HIV-1. Due to the high variability 
in gene expression in this study, statistical analysis did not reveal any significant effects. 
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MPA significantly increases HIV-1 replication is a subset of donor explants, while NET 
significantly and consistently decreases HIV-1 replication in primary ectocervical explants 
Having established that there are differential effects on gene expression by the different progestogens, the 
next step was to focus on the direct effects of MPA and NET, the two most common injectable 
contraceptives in South Africa (Tomasicchio et al., 2013; United Nations, Department of Economic and 
Social Affairs, Population Division, 2011) on HIV-1 replication in primary cervical explants. This study is the 
first to report on the direct differential effects of MPA and NET on HIV-1 replication in primary cervical 
explants. While observational studies have provided useful evidence on the effects of these 
progestogens in vivo, these studies have unavoidable confounders; such as the reporting of 
contraceptive type, adherence and switching of contraceptive type, sexual behaviour and condom 
usage (Ralph et al., 2015; Morrison et al., 2015; Polis et al., 2014) which affects the outcome of the 
results. Furthermore, the individual observational studies vary in sampling times, population groups 
and types of progestogens tested (Polis et al., 2014). Thus ex vivo methodologies are useful in 
determining the direct effects of these progestogens on HIV-1 replication as they eliminate most of the 
behavioural confounders present in the observational studies. 
The HIV-1 replication studies were performed on ectocervical explants. While it has been reported that 
the endocervix and the transformation zone may be the most receptive to HIV-1 infection (Pudney et 
al., 2005; Haynes & Shattock, 2008), Carias et al. (2013) reported using ex vivo tissue models and 
rhesus macaque infection models, that HIV-1 is able to efficiently traverse the squamous epithelial 
barrier through passive percolation, into areas where target cells like T cells or dendritic cells may be 
found and productively infected (Carias et al., 2013). Using an X-tropic (HIV-1pNL4.3) or an R tropic (HIV-
1BaL-Renilla) HIV-1, explants were infected 2 days post treatment with either MPA or NET, where 
supernatant was collected on days 3, 7 and 10 post infection.   
When assessing the effects of MPA and NET on HIV-1 replication in explants from different donors 
(Fig. 4.8 and 4.9), it was apparent that in some samples MPA increased HIV-1 viral replication (R5 
and X4), while in other cases it appeared that MPA had no effect or decreased HIV-1 replication 
compared to the vehicle control. In the group infected with HIV-1BaL_Renilla 3 out of 6 donor samples 
showed an increase in HIV-1 replication in the MPA treated group. Interestingly, the effect on viral 
replication by MPA in this group was modest. However at day 7 post infection, results for MPA were 
significantly different compared to the vehicle control. NET treatment had no effect to lower levels of 
viral replication (Fig. 4.10 A), and had significantly lower levels of HIV-1BaL_Renilla replication compared 
to MPA and the vehicle control at days 3, 7 and 10 post infection (Fig. 4.10 A). In the HIV-1pNL4.3 
group, 5 out of 8 donor samples had significantly increased viral replication in the MPA treated group 
at all the time points compared to both the vehicle control and NET (Fig 4.10 C). The grouping 
suggests that the differential effects of MPA on HIV-1 viral replication is donor specific, occurring in 8 
out of the 14 infection experiments in this study. Interestingly, in two instances, the same donor 
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explant was infected with both HIV-1pNL4.3 and HIV-1BaL_Renilla. While MPA increased HIV-1pNL4.3 
replication it had no effect on HIV-1BaL_Renilla replication in the same donor sample. While this was only 
observed in a small subset of donors, this result suggests that there may be HIV-1 subtype specific 
effects. In contrast, NET treatment had consistent effects on HIV-1 viral replication, having no effect or 
lower levels of viral replication throughout the time course in most of the donor samples (Fig. 4.8, 4.9 
and 4. 10 A, B and C). The differences in results for MPA could be due to distinct biological 
differences within a population, such as the relative levels of HIV-1 target cell types present, the state 
of activation of the cells as well as the relative co-receptor (CCR5 and CXCR4) expression levels on 
HIV-1 target cells. Additionally, it has been observed in one study that not all explant samples are 
productively infected (Saba et al., 2013), and that this could be due, in part, to the phase of the 
menstrual cycle. In this study, four donor tissues were not productively infected. Saba et al. (2013) 
found that tissue in the luteal phase of the menstrual cycle (low E2, high P4), was more permissible to 
HIV-1 infection than tissue obtained from the follicular phase (High E2, low P4) (Saba et al., 2013). 
Most donor samples that were productively infected in this study were in the follicular phase (appendix 
C). However all 4 donor samples not productively infected, were from donors with low P4 levels. Two 
of the four donors were in the follicular phase, one donor was in the ovulatory phase and the other 
donor was perimenopausal (Appendix C, donors Prog 0041, 0043, 0045 and 0052). Thus, while phase 
of menstrual cycle did not play a significant role in the differences in viral replication between the 
different treatment groups observed in this study, it may contribute towards the donor sample 
becoming productively infected. In addition to the phase of menstrual cycle, meta-analyses performed 
on some of the observational studies assessing the effects of progestogens on HIV-1 risk in women, 
found that inflammation and women being in high risk areas may be factors that could also contribute 
to the increased risk of HIV-1 susceptibility in DMPA users (Heffron et al., 2011; Ralph et al., 2015; 
Morrison et al., 2015). Women recruited in this current study were not on contraception, were HPV and 
HIV-1 negative, and most women were HSV-2 negative (only 2 women were HSV-2 positive by serum 
ELISA in this cohort, see Appendix C). In these experiments, non-activated tissue was used to 
determine the differential effects of MPA and NET on HIV-1 replication. Thus the differences observed 
between donor samples are unlikely to be due to activation by the infections tested for in this study, 
but rather are most likely reflective of other differences within a population. These could include 
infections with other STIs not measured in this study and/or Bacterial vaginosis and/or other genetic or 
environmental differences. 
This is the first study to use an X4 and an R5 tropic IMC to assess the effects of MPA on HIV-1 
replication in primary cervical explants. Interestingly, the differences between MPA and NET on HIV-1 
replication levels were more pronounced in the donors infected with HIV-1pNL4.3 (Fig. 4.10 C and D). 
This could be due to tissue specific differences within the tissue that may favour X4 replication over 
R5 replication with MPA treatment. These tissue specific differences could include the immune 
activation state of the donor, the cell types present, co-receptor expression levels as well as different 
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levels of steroid receptors present within the tissue of each donor. Interestingly, some studies have 
observed that in primary tissue explant models, R5 viruses may have higher replication levels 
compared to X4 viruses. However there were no differences in replication competency for the pooled 
data from all the explant samples between the X4 and R5 viruses in this study (Fig. 4.8, 4.9 and 4.10). 
Le Tortorec et al. (2008) found that an X4 tropic strain of HIV-1 was less efficient in productively 
infecting and replicating in prostate explants compared to an R5 tropic strain of HIV-1 (Le Tortorec et 
al., 2008). Additionally, Schmitt et al. (2006) observed in mice thymic explants that X4 and R5 viruses 
were able to productively infect the tissue. However there were cell type differences in infection, with 
X4 strains restricted to certain cell types more so than an R5 strain (Schmitt et al., 2006). These two 
studies suggest that there may be differences in HIV-1 subtype replication in tissue explant samples, 
with R5 viruses showing higher viral infection levels than X4 viruses (Le Tortorec et al., 2008; Schmitt et 
al., 2006). The data from this current study appear to be contradictory to the findings from Le Tortorec 
et al. (2008) and Schmitt et al. (2006). However, several studies have reported that both CCR5 and 
CXCR4 are expressed on select immune cells in the ectocervix (Patterson et al., 2002; Trifonova et al., 
2014; Chandra et al., 2013; Pudney et al., 2005), suggesting that both X4 and R5 HIV-1 viruses can 
infect cells within the ectocervix. Taken together, the data from this current study suggests that while 
there are no differences in replication competency, there may be virus subtype specific effects. 
However this preliminary observation needs to be validated, as the differences were observed in a 
small subset of donor explants within this study. As such the differences in HIV-1 subtype replication 
differences may be due to biological and or technical error. Importantly, this was not observed in 
cervical explants with NET treatment. In fact, NET treated explants infected with either HIV-1pNL4.3 or 
HIV-1BaL_Renilla, had significantly lower levels in viral replication compared to those treated with MPA 
and the vehicle control (Fig. 4.10). 
When pooling the results of the tissue from the different types of responders per virus type, the results 
suggested that MPA treatment did not have an effect on HIV-1 replication in primary ectocervical 
explants compared to the vehicle control (Fig. 4.11 and Fig. 4.12). However, NET treatment resulted in 
significantly lower levels of viral replication at 3, 7 and 10 days post infection in both HIV-1 groups 
relative to the vehicle control and MPA (Fig. 4.11 and Fig. 4.12, appendix B). This is the first study to 
report such differences between MPA and NET on HIV-1 replication using R5 and X4 HIV-1 IMCs in 
primary ectocervical explants.  
Interestingly, primary ectocervical explants were used to eliminate the behavioural confounders 
present in observational studies. However, large variations in HIV-1 replication were still observed. 
While these results in this study are direct measurements on HIV-1 replication and not on 
observational HIV-1 risk or acquisition in women, it is interesting to observe that the explant 
methodology is still prone to large variations. The data from this current study suggest that it may not 
only be behavioural confounders that contribute to the variations in results observed in the 
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observational studies, but also inherent biological variations within a population. In a recent 
observational study by Noguchi et al. (2015) the authors directly compared the effects of MPA versus 
NET usage on HIV-1 acquisition. The authors found that MPA users had a higher risk of HIV-1 
acquisition than NET users (Noguchi et al., 2015). The results from the current study showed that NET 
had lower viral replication levels than MPA in primary ectocervical explants. Taken together, 
observational studies as well as this present study suggests that NET has a lower HIV-1 risk profile 
than MPA due to direct effects of progestogens in the FGT.  
Taken together the infection data indicates that there is donor variability in MPA-driven effects on HIV-
1 replication in ex vivo explants, and that there is a significant increase in HIV-1 replication in 8 out of 
14 of the explants treated with MPA compared to the vehicle control. Interestingly, NET treatment 
appears to cause significantly lower HIV-1 replication levels compared to the vehicle control in this 
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Recent research into the effects of hormonal contraceptives on HIV-1 acquisition in women suggests that 
the injectable contraceptive, MPA, increases HIV-1 risk, while NET and oral contraceptives do not 
(Morrison et al., 2015; Ralph et al., 2015; Noguchi et al., 2015). Thus identifying the differential actions of 
these progestogens may provide insight into why different progestogens have differential effects on HIV-1 
susceptibility. This study is the first step to understanding some of the complex mechanisms contributing to 
the differential direct effects of progestogens on gene expression and HIV-1 replication in ex vivo models. A 
table below summarises the main findings of this study (Table 5.1). 
MPA unlike P4, NET and LNG differentially modulates gene expression in PBMCs and 
primary ectocervical explants 
The results from this study highlight the striking contrast between MPA and the other progestogens, 
and its differential effects on gene expression over time. This study shows that MPA, unlike the 
endogenous ligand P4, and other progestogens NET and LNG, differentially modulates expression of select 
immune genes at concentrations similar to peak serum ranges of MPA users after 48 hours in ectocervical 
explants and PBMCs.  
This study found that in PBMCS, MPA, at near peak serum contraceptive concentrations, significantly 
modulated IL6, IL8, RANTES and GILZ mRNA expression levels, while P4 and NET did not (see Table 5.1). 
Select Luminex and MSD® ELISAs were performed on PBMC supernatants in this study. The results 
showed that MPA, like DEX, significantly decreased IL8, IL-1β and IL-1ra protein expression levels 
after 48 hours, while P4 and NET had no effect. Further, flow cytometry indicated that MPA, like DEX 
significantly decreased IL6 protein expression levels in CD14+ monocytes, and significantly increased 
GILZ protein expression levels in CD4+ T cells. The data from this study is consistent with the data in the 
literature that suggests that MPA has a general anti-inflammatory profile after short term incubations in 
PBMCs (Huijbregts et al., 2013; Huijbregts et al., 2014; Michel et al., 2013; Michel et al., 2015; Cherpes et 
al., 2008; Vicetti Miguel et al., 2012; Quispe Calla et al., 2015). Huijbregts et al. (2013) analysed the effects 
of MPA compared to P4 and NET in PBMCs and found that MPA, unlike P4, decreased IL6 and IL8 protein 
expression after 24 hours (Huijbregts et al., 2013), and that MPA, unlike P4 and NET, decreased IL6 and 
IL8 protein expression levels in CD2/CD3/CD28 activated mononuclear cells (Huijbregts et al., 2014). To 
date, the effects of MPA have been found by identifying changes in secreted protein expression levels in 
PBMCs (Huijbregts et al., 2013; Huijbregts et al., 2014; Michel et al., 2013; Michel et al., 2015; Cherpes et 
al., 2008; Vicetti Miguel et al., 2012; Quispe Calla et al., 2015). The results from this study are the first to 
report on the direct effects of MPA, P4, NET and LNG in parallel on mRNA levels in PBMCs. 
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Table 5.1: Summarised findings from this study
  IL6 IL8 RANTES GILZ Other genes HIV-1 replication 
Experiments PBMCs Explants PBMCs Explants PBMCs Explants PBMCs Explants PBMCs Explants PBMCs Explants 
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Several studies by others have also reported that MPA at peak serum concentrations significantly regulates 
several important cytokines and chemokines in PBMCs, that have key roles in modulating the immune 
response, including IFN-α, INF-γ and TNF-α (Vicetti Miguel et al., 2012; Cherpes et al., 2008; Quispe Calla 
et al., 2015; Huijbregts et al., 2013; Huijbregts et al., 2014), suggesting that MPA may affect the mounting 
of an immune response in vivo. However, the results from this study found no significant effects on INF-γ 
and TNF-α protein expression in PBMCs after 48 hours with MPA treatment. There are several factors that 
may contribute to the differences in gene expression by the different progestogens, such as; time, 
activation and cell type specific effects. Huijbregts et al. (2013) observed that INF-γ was significantly 
repressed after 24 hours with 100 nM MPA in PBMCs and that TNF-α was significantly repressed in select 
cell types or in activated PBMCs (Huijbregts et al., 2013). The effects of gene expression by MPA in 
Cherpes et al. (2008) and Quispe-Calla et al. (2015) were shown to occur in CD8+ memory T cells and in 
dendritic cells. Taken together, it could be that the results from this current study using non-activated 
PBMCs could be masking the repressive effects found in select cell types within the population for some 
genes. Interestingly, Huijbregts et al. (2013) found more significantly repressive effects on cytokine protein 
expression after 24 hours in activated PBMCs with 100 nM MPA compared to the results found in this study 
after 48 hours. It could be that length of incubation time is critical to the repressive effects of MPA on 
protein expression levels. It could also be that the secreted proteins in the supernatant used in the Luminex 
assay in the current study were degraded at the time of the assay. Nevertheless, it is evident from both 
the literature and the current study that the effects of MPA on cytokine and chemokine gene 
expression are generally anti-inflammatory after 1 to 2 days of exposure to MPA. 
This study also found similar anti-inflammatory effects with MPA in primary cervical explants after 48 
hours, as found for PBMCs (see Table 5.1). This is the first study to report on the direct effects of 
different progestogens on select immune genes in cervical tissue explants. In primary ectocervical 
explants, MPA, unlike NET and LNG, significantly decreased IL6 and IL8 mRNA levels and 
significantly increased GILZ mRNA levels. In endocervical explants, MPA had reduced anti-
inflammatory effects, but significantly increased GILZ mRNA levels after 48 hours. Multiple epithelial 
cell line studies have found that MPA, unlike NET, decreases pro-inflammatory gene expression after 24 
hours (Africander et al., 2011; Koubovec et al., 2004; Louw-du Toit, et al., 2014b; Govender et al., 2014), 
however there were some cell type specific effects found between cell lines (Africander et al., 2011). A 
study in the endocervical cell line, End1/E6E7 found that MPA, like DEX, decreased IL6, IL8 and 
RANTES mRNA levels (Govender et al., 2014). The results from this study found no significant effects 
on IL6 and IL8 mRNA levels with MPA treatment after 48 hours in the endocervical explants. These 
differences could be due to the differences in the models used. Govender et al. (2014) used an 
endocervical cell line, while the results from this study were from multicellular endocervical tissue 
explants. If the results from the endocervical cell line are indicative of what may occur in primary 
endocervical epithelial cells, then the results in the endocervical explants suggest that the responses 
from the epithelial cells may be masked. Consistent with this observation is that RANTES mRNA 
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levels in both endocervical and ectocervical explants were not readily detected in this study. However, 
RANTES mRNA was detectable and regulated by MPA treatment in both ectocervical and 
endocervical cell lines (Africander et al., 2011; Govender et al., 2014). 
The data from this current study suggest that there are distinct expression effects with progestogens 
in different immunological environments. In both primary ectocervical explants and PBMCs, MPA, 
unlike P4 and NET, differentially modulates key immune response genes. However, some differences 
were observed in the gene expression profiles between PBMCs and ectocervical explants after 48 
hours of exposure. While P4 treatment in PBMCs had no effect on gene expression at any of the 
concentrations used in this study, it was found to significantly reduce IL6 mRNA levels in primary 
ectocervical explants after 48 hours. Interestingly, the results from primary ectocervical explants were 
more similar to the results from PBMCs than to the results from endocervical explants.  
When comparing the cervical explant and PBMC data from this study to select clinical studies that 
measured changes in secreted protein levels in the CVL of women, some differences were observed. 
While IL6 and IL8 mRNA levels were significantly modulated after 48 hours after ex vivo MPA 
exposure in both PBMCs and ectocervical explants, recent clinical studies found no effect on these 
genes in the CVL of women on injectable contraceptives (Ngcapu et al., 2015; Morrison et al., 2014). 
In addition, Morrison et al. (2014) found that RANTES levels were increased in DMPA users, while 
Ngcapu et al. (2015) found no difference in RANTES expression levels. In contrast, this study found 
that RANTES mRNA expression was undetectable in endocervical and endocervical explants, while 
100 nM MPA significantly reduced RANTES mRNA levels in PBMCs after 48 hours ex vivo exposure. 
Importantly in the study by Ngcapu et al. (2015) the effects on gene expression were representative of 
both MPA and NET users, thus the effects of MPA on some genes may be masked due to the 
inclusion of NET users in the analysis. The differences in gene expression in the PBMCs and 
ectocervical explants compared to the CVL from women could also be due to the differences in the 
concentration and the length of exposure to MPA. Furthermore, the results from this study investigated 
the direct effects of MPA on target cells, while the results from the clinical studies are representative 
of indirect effects taken from a secretory sample of the entire lower female genital tract (FGT). As 
such it may be that the results found in the CVL of women may not accurately reflect the direct effects 
of MPA on some genes in distinct regions in the FGT. However, the results from these clinical studies 
are similar to the results observed in the endocervical experiments after 48 hours. This suggests that 
perhaps the endocervix may be more indicative of the general expression profile, which the CVL from 
women represents. Importantly, protein expression levels were not determined in this study, nor were 
the effects of MPA and NET on genes other than IL6, IL8 and GILZ investigated in cervical explants. 
More research to assess the direct effects of different concentrations of MPA and NET on protein 
expression levels of key immunomodulatory genes on distinct cell populations in the FGT would be 
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informative. Nevertheless this study provides evidence for the first time for direct effects with different 
progestogens on mRNA levels.  
Future areas of research should investigate why differential effects on gene expression are found in 
different immune environments. In particular, how DEX and MPA are able increase gene expression of 
key genes across systems (GILZ) but are only able to decrease mRNA levels of select genes (IL6 and 
IL8 mRNA levels) in some models. As mentioned previously, the differences in gene expression with 
the same ligand the same time point observed in different cellular models suggest that there may be 
differential co-factor availability, differences in GR activation as well as differences in the relative 
abundance of the GR and other steroid receptors in these different immune environments. Therefore 
future research should investigate the above issues, including identification of co-factors that are 
important in mediating these different responses. Additionally, it may be of use to determine the 
effects of MPA on factors important in mediating the viral response. Using a PCR array specific for the 
HIV host response (SABiosciences, Qiagen, Netherlands), one could analyse the global change on 
immune response genes by MPA in both PBMCs and primary cervical explants. In parallel, one could 
perform Luminex assays and determine the protein secretion levels of the different cytokines and 
chemokines. This may help to provide a better understanding in the gene expression effects of MPA 
on the immune response. 
The results from this study suggest that time of exposure to MPA may have profound effects on the 
immune response. Experiments in PBMCs showed that while MPA and DEX significantly repressed 
IL6, IL8 and RANTES mRNA expression after 2 to 3 days, this repression was lost after day 4. 
Further, results in ectocervical explants suggest that IL6 and IL8 mRNA levels are no longer repressed 
by MPA after 12 days incubation. Collectively, the data from this study strongly suggest that the 
effects of MPA may be time dependent in PBMCs and primary cervical explants, with anti-
inflammatory and immunosuppressive effects observed initially up to 2 days, followed by no effects or 
even pro-inflammatory effects after longer times of incubation. This is of particular importance as 
MPA, as an injectable contraceptive, is administered every three months. It has been shown that MPA 
concentrations change over time, with peak serum concentrations reached soon after injection 
(Mishell, 1996; Hiroi et al., 1975). For two months, MPA is at serum concentrations of around 2.6 nM 
(Mishell, 1996; Africander et al., 2011). The results from this study highlight that the length of incubation 
could have significant downstream effects on changes in gene expression.  
Therefore, it will be of further interest to investigate the differential and time dependent effects of MPA 
on gene regulation in both PBMCs and primary cervical explants. Additionally, the effects of low 
concentrations of MPA over a long time course should be investigated. Figure 5.1 is a model 
suggesting some of the mechanisms that may be involved in mediating the transcriptional effects of 
long and short term incubations with MPA in PBMCs. Some studies have reported pro-inflammatory 
effects of MPA at different times and concentrations (Louw-du Toit, et al., 2014a; Africander et al., 2011; 
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Morrison et al., 2014), while many others have reported potent anti-inflammatory effects of MPA on 
gene expression (Koubovec et al., 2004; Koubovec et al., 2005; Hapgood et al., 2004; Ronacher et al., 
2009; Avenant et al., 2010; Govender et al., 2014; Huijbregts et al., 2013; Huijbregts et al., 2014; Michel et 
al., 2015). This is the first study to suggest that there may be a switch from anti-inflammatory 
responses to pro-inflammatory responses with MPA treatment over time; however this finding must be 
confirmed. Several studies have observed the development of glucocorticoid resistance in different 
cellular systems over time (Tsitoura & Rothman, 2004; Cvoro et al., 2011; Van Bogaert et al., 2010; Cruz-
Topete & Cidlowski, 2015). The authors observed that glucocorticoid resistance correlated with an 
increase in T reg cells over time (Chen et al., 2006; Goleva et al., 2002; Tsitoura & Rothman, 2004) and 
an increase in NF-AT expression (Tsitoura & Rothman, 2004). It could be both an increase in T reg 
cells over time (Chen et al., 2006; Goleva et al., 2002; Tsitoura & Rothman, 2004), as well as a possible 
escape mechanism whereby NF-AT transcription factors are up-regulated in response to MPA over 
time, to exert pro-inflammatory responses, which are not repressed via the GR tethering mechanism 
(Tsitoura & Rothman, 2004; Camargo et al., 2009). Future research should include identifying whether 
there is a shift in cellular populations over time in PBMCs in response to MPA treatment using flow 
cytometry. These experiments would shed light into why both pro-inflammatory and anti-inflammatory 
effects are observed by MPA. Additionally, some reports suggest that there is also selective 
modulation by the GR to initiate some pro-inflammatory actions through crosstalk with other steroid 
receptors such as the ER (Beck et al., 2009; Bolt et al., 2013; Cvoro et al., 2011), or through the GR itself 
(reviewed in Cruz-Topete & Cidlowski, 2015). The effects of time and treatment are important in 
understanding the differential effects of MPA-induced gene expression in PBMCs. MPA, having both 
anti- and pro- inflammatory effects over time on gene expression may have important implications for 
HIV-1 susceptibility and disease progression. An increase in select cell types as well as a dynamic 
change in pro- and anti-inflammatory effects may create time dependent favourable environments for 





Figure 5.1: A proposed model for the differential effects of gene expression by MPA over time. The 
data from this study in PBMCs, suggests that at 48 hours stimulation (short term treatment), MPA via the GR, 
decreases IL6, IL8 and RANTES gene expression. This decrease in expression is most likely to occur through a 
tethering mechanism of the GR to NF𝛋B transcription factors (Van Bogaert et al., 2010; De Bosscher & Haegeman, 
2009; Mahita & Cidlowski, 2013; Govender et al., 2014). GILZ mRNA expression is increased upon stimulation with 
MPA, via direct binding of GR dimers to glucocorticoid response elements (GRE) in the promoter of the gene (Ayroldi 
& Riccardi, 2009; Berrebi, 2002; Di Marco et al., 2007; Smit et al., 2005). After prolonged MPA exposure, 
glucocorticoid resistance develops through an increase in T regulatory (T reg) cells and a shift from Th-1 to Th-2 cells 
(Chen et al., 2006; Goleva et al., 2002; Tsitoura & Rothman, 2004; Kaushic et al., 2003). In addition, there may be a 
shift in transcription factor use, through an increase in MEK/ERK signalling via an IL2 dependent pathway, that leads 
to an increase of NF-AT transcription factors (Tsitoura & Rothman, 2004; Kam et al., 1993; Cruz-Topete & Cidlowski, 
2015). NF-AT is able to bind to its cognate binding sites in target pro-inflammatory genes and increase expression, 
such as IL6, IL8 and RANTES (Tsitoura & Rothman, 2004). 
 
In injectable contraceptive users, the concentration of the progestogen changes over time. Shortly after 
injection, MPA and NET concentrations peak, where after, they decline and plateau (Mishell, 1996; 
Fotherby, 1981; Stanczyk et al., 2013; Africander et al., 2013). It was thus of interest to determine the effect 
of dose on gene expression. The results from this study found that in PBMCs, MPA had significant effects 
on immunomodulatory gene expression from 10 to 1000 nM, while P4, NET and in some cases LNG 
had no significant effect on gene expression at any of the concentrations after 48 hours (see Table 
5.1). Furthermore, the glucocorticoid DEX had the most pronounced effects on gene expression in 
PBMCs with significant effects found from 1 nM to 1000 nM. In ectocervical explants, dose response 
curves were performed with MPA only. Similar to PBMCs, MPA appeared to decrease IL8 mRNA, and 
increase GILZ mRNA expression at 10, 100 and 1000 nM. Interestingly it appeared that MPA had 
reduced effects on IL6 mRNA expression in the ectocervical explants, appearing to reduce expression 
at 100 and 1000 nM only. 
In the ectocervical dose experiments, potencies, which indicate the half maximal response of ligand 
(Hapgood et al., 2013), were calculated. The potency of MPA, for IL8 was ~ 18 nM, but ~ 70 nM for 
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IL6 in ectocervical explants. For the PBMC study, it appeared that the potency for both IL6 and IL8 in 
PBMCs is between 10 – 100 nM. Interestingly in PBMCs, GILZ potency appeared to be between 1 – 
10 nM, similar to the potency for GILZ in the ectocervical explants, which was ~ 7.5 nM. Thus it 
appears that MPA may be more potent for IL6 repression in PBMCs than in the ectocervical explants, 
suggesting that cellular environment may contribute towards the potency of the ligand. Further, the 
data suggest that there could be significant differences in the gene expression profiles soon after 
injection where MPA serum levels peak around 2.5 – 65 nM (Ortiz et al., 1977; Mishell, 1996; Hiroi et al., 
1975; Mathrubutham & Fotherby, 1981), compared to that for the remainder of the three month period, 
where MPA serum levels plateau to 2.6 nM (Mishell, 1996; Africander et al., 2011). These dramatic 
changes in serum concentrations may indicate that there could be a window period, whereby 
immunomodulatory effects of MPA are more pronounced. Taken together, at near peak serum 
concentrations of MPA, MPA has stronger immunomodulatory effects than at lower concentrations, 
while the potency is gene specific, with different genes showing a different dependency on MPA dose.  
When looking at the effects of dose by P4 and NET in PBMCs, the data from this study suggest that at 
high concentrations (100 – 1000 nM), these progestogens have no effect on gene expression. 
However, at lower concentrations (1 – 10 nM), these progestogens appeared to have slight (but non-
significant) pro-inflammatory responses. Interestingly, at 100 nM, P4 significantly reduced IL6 mRNA 
levels in the ectocervix. This suggests that while P4 has no significant effect in PBMCs at any of the 
concentrations used in this study, P4 may have immunomodulatory effects in the FGT. This result 
further highlights that at the same concentration, progestogens have differential effects in different 
systems. Therefore more research is needed on the effects of the different progestogens at different 
concentrations on gene expression in different primary systems. Additionally, the effects of LNG at 
lower concentrations are yet to be established, and as such future research should investigate the 
effects of low concentrations of LNG on gene expression in primary systems. 
Of particular importance, is that while serum concentrations, for injectable contraceptive users, are 
known, there is no information on the concentrations of MPA NET or LNG in the female genital tract 
(FGT). Further there is no information on whether the concentration of these progestogens varies 
between different tissue compartments in the FGT. Understanding whether there are tissue specific 
differences in concentrations of progestogens within the FGT, as well how this changes during 
different physiological states, may shed light into which areas are more permissible to changes with 
MPA. Furthermore, knowing the concentrations within the tissue will aid in interpreting ex vivo data 
and design of experiments. These studies need to be performed urgently so that more informed 
studies using primary tissue explants can be performed to better address the question of whether 
MPA increases the risk in HIV-1 acquisition. Additionally, more dose response experiments are needed 
to obtain more accurate curves to confirm the potencies obtained in this study. Further, dose response 
curves should be performed with other progestogens in primary cervical explants. 
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The effects of MPA on gene expression after 48 hours are most likely via the GR  
This study found that the immunomodulatory effects by MPA, like DEX, on IL6, IL8, RANTES and GILZ are 
mediated via the GR in PBMCs using antagonist and knockdown strategies. This data is in agreement with 
the literature that suggests MPA is a partial agonist for the GR (Koubovec et al., 2005; Ronacher et al., 
2009; Govender et al., 2014; Avenant et al., 2010). Further the results from this study suggest that the 
effects of MPA on IL6, IL8 and GILZ mRNA expression in the ectocervix and GILZ in the endocervix are 
most likely via the GR. While all the SRs are expressed in the ectocervix, MPA, like the glucocorticoids DEX 
and CORT, significantly decreased IL6 and IL8 mRNA levels, and increased expression of a GR-driven 
gene, GILZ. Interestingly, while DEX and MPA increased GILZ mRNA expression in endocervical explants, 
DEX and MPA did not significantly decrease IL6 or IL8 mRNA levels.  
While the relative abundance of SRs in the endocervical explants was not examined, the differential effects 
of MPA on different genes in the same system, suggest that there may be different activation effects of the 
GR and or differential levels of co-factor availability or recruitment in these different systems. Ronacher et 
al. (2009) observed in the COS-1 cell line, that there were ligand selective differences for transactivation 
and transrepression via the GR that were in part dependant on ligand selective interaction with different GR 
co-factors (Ronacher et al., 2009). Further Avenant et al. (2010) found that MPA, but not NET increased 
GR phosphorylation at key serine residues (S211 and S226) that correlated with an increase in both 
transactivation and transrepression on promoter-reporter constructs (Avenant et al., 2010). Additionally, 
Avenant et al. (2010) observed that phosphorylation of the GR, at any of the serine residues tested, was 
required for interaction with a key GR co-factor, GRIP-1 (Avenant et al., 2010). Thus it could be that the 
differences observed in the gene expression effects, could not only be due to the relative abundance of the 
different SRs, but in part due to the activation state of the GR and the availability of co-factors for optimal 
transcriptional activity. 
It is therefore important that the role of the GR in mediating the differential effects by MPA on gene 
expression is determined in primary ectocervical and endocervical explants. It may be difficult to 
perform siRNA knockdown strategies in whole tissue; as such it may be useful to use selective 
antagonists to determine GR involvement on differential gene expression within the different cell 
types. Additionally how MPA, P4, NET and LNG may differentially activate the GR through differential 
phosphorylation at key serine residue sites within the GR has not been established in PBMCs or in 
primary cervical explants. Furthermore, the relative abundance of important co-factors has not been 
established in these systems. Investigating the effects of phosphorylation and co-factor recruitment by 
MPA compared to P4, NET and LNG in these systems will provide important mechanistic insight into 
why there may be differential effects on gene expression in these cellular systems. 
Further it may be important to investigate the role of the GR in different cell types in PBMCs. Studies by 
Huijbregts et al. (2013) and Quispe-Calla et al. (2015) found that pDCs and CD8+ T cell cellular functions 
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are altered in response to MPA at serum concentrations. It would therefore be of interest to determine 
whether the GR is involved in mediating this process in pDCs and CD8+ cells, as it will give further weight 
to the mechanism of action of MPA.  
This study found that GR levels did not change over time in PBMC samples treated with MPA. However, 
the differential activation states of the GR or the involvement of other transcription factors and co-factors 
were not investigated. It would thus be of interest to investigate the role of the GR as well as the role of 
other transcription factors like, NF-AT on MPA dependent gene expression in PBMCs over time. Using both 
real time qPCR, knockdown, antagonist and chromatin co-immunoprecipitation (ChIP) assays, one will be 
able to elucidate the change in transcription factor use over time, as well as the role of NF-AT in mediating 
the pro-inflammatory responses observed at a later time point. 
The role of steroid receptors in mediating the effects of progestogens in the systemic and 
local immune environments  
This study found that PBMCs had detectable protein expression levels of the GR, with detectable 
mRNA expression levels of the GR, MR and ERɑ. Primary ectocervical explants contained detectable 
protein expression levels of the AR, ERɑ, GRɑ, PRA and PRB, and mRNA expression levels of all the 
steroid receptors listed as well as MR. The differential levels of the steroid receptors within these 
different cellular systems may help to explain the differences on the effects of gene expression in this 
study. It was also observed that the expression levels of the PR isoforms and ERɑ were significantly 
different in the luteal phase compared to the follicular phase in primary ectocervical explants. 
However, what is not known are the relative expression levels of SRs in the endocervix, and if these 
SRs are differentially expressed at the different phases of the menstrual cycle. Furthermore it must 
also be established whether AR, MR and GR protein levels are regulated by the menstrual cycle in 
ectocervical explants.  
Of importance is that the role of steroid receptors in mediating these differential effects has not been 
elucidated. Several cell line studies have shown that the GR is important in mediating transcriptional 
effects in response to MPA treatment (Govender et al., 2014; Louw-du Toit et al., 2014a; Ronacher et al., 
2009; Koubovec et al., 2004), while others have found that the AR may be involved in some of the 
MPA-driven effects (Africander et al., 2011; Africander et al., 2014). The results from this study found 
that the GR was important in mediating the effects of MPA on IL6, IL8, RANTES and GILZ mRNA 
levels in PBMCs. However the role of the GR in mediating gene effects by MPA in primary cervical 
tissue has not been established. While it may be difficult to perform siRNA knockdown strategies in 
whole tissue, it may be useful to use different selective SR agonists and antagonists to determine 
which SRs may be important in gene modulation in response to progestin treatment. One could also 
digest the tissue and separate using filtering to isolate different cellular populations. Upon separation, 
one could treat with the different progestins and different antagonists (e.g. RU486: GR/PR, 
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hydroxyflutamine: AR) and using a combination of flow cytometry and real time qPCR, determine 
steroid receptor involvement on differential gene expression within the different cell types. 
Nevertheless, the findings that MPA acts more like the glucocorticoid DEX, than P4 or NET, in the 
measured responses, coupled with the known relative activity of the progestogens via the different 
SRs, strongly suggest that MPA is acting predominantly via the GR in the ectocervical explants, and 
not the PR or AR, which do not discriminate between MPA and NET. This is despite the presence of 
both the GR and PR in these tissues.  
The differential levels of steroid receptors expressed within the menstrual cycle may help to explain 
why there are differential outcomes in immune responses at the different phases. Interestingly, it has 
been proposed that there is a window of vulnerability to HIV-1 infection, 7 - 9 days post ovulation 
during the luteal phase (Wira & Fahey, 2008; Vishwanathan et al., 2011). It has been hypothesised by 
the Hapgood group that differential ratios and relative abundance of the steroid receptors in the 
ectocervix during the menstrual cycle, could contribute to the changes in susceptibility to HIV-1 
infection, through mediating effects via the different steroid receptors. It has been established that 
MPA is a partial agonist for the GR (Ronacher et al., 2009; Koubovec et al., 2005; Avenant et al., 2010). 
Since MPA induces changes that mimic the luteal phase of the menstrual cycle, it could be that the 
steroid receptor profile is similar and could contribute to the effects of MPA on HIV-1 susceptibility. 
Indeed, it has been shown that MPA more so than P4, increases HIV-1 and HSV-2 viral replication 
(Trunova et al., 2006; Kaushic et al., 2003) and suppresses cell mediated immunity (Kaushic et al., 2003; 
Gillgrass et al., 2003; Hughes et al., 2008; Michel et al., 2013; Huijbregts et al., 2013; Huijbregts et al., 
2014). It has also been established that E2 and P4 are able to alter the expression of immunoglobulins 
within the FGT, with P4 decreasing the expression of immunoglobulins, and depressing the maturation 
of B cells (Lü et al., 2003). It has also been observed in naturally cycling women, that during the luteal 
phase (high P4), IL6 protein levels increase in the cervical mucus (Franklin & Kutteh, 1999). It could be 
if GRɑ: PRA/PRB ratios are greater (that is more GR available) in the luteal phase, the effects on cell 
mediated immunity could be greater, through mediation via the GR by MPA, which mediates the 
inflammatory response (Beck et al., 2009; De Bosscher & Haegeman, 2009). The results from this study 
found no significant regulation of SR mRNA by the different progestogens after 48 hours in primary 
cervical explants. Additionally, the results from the long time course experiment suggested that mRNA 
levels of the MR and protein expression levels of the GR were not significantly modulated by MPA. 
However the relative ratios and the different activation states of these SRs were not investigated in 
this study. Therefore, further investigation into the role of the steroid receptors and their relative ratios 
and expression profiles at the different phases of the menstrual cycle as well as in response to 
progestogen treatment, on immune gene expression must be investigated in both PBMCs and primary 
cervical explants.  
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The effects of MPA on select pro-inflammatory gene expression and HIV-1 replication in 
PBMCs 
The direct effects of the different progestogens on HIV-1 replication were assessed in PBMCs. The 
results from this study found that both the progestogens and glucocorticoids used in this study had varied 
effects on HIV-1 replication after 7 days post infection. Half of the donor samples assayed showed 
increased levels of HIV-1 replication with DEX, CORT, P4 and LNG treatment. Seven out of ten donor 
samples treated with MPA had showed an increase in HIV-1 replication. Interestingly, NET was the only 
progestogen that had no effect on HIV-1 replication. When grouping the data from seven donor samples, 
only MPA significantly increased HIV-1 replication in these seven donor samples, while CORT, DEX, P4, 
NET and LNG had no significant effects. Interestingly, in the three donor samples in which MPA reduced 
HIV-1 replication, the effects of MPA were also significant. Taken together, the data suggests that MPA 
increased HIV-1 replication in the majority of PBMC samples, while opposite effects were observed in a 
minority of donor samples. While these results suggest that there may be different responses upon MPA 
treatment, further repeats must be performed to validate the observations reported in this study.  
Few studies have reported on the direct effects of progestogens on HIV-1 replication in PBMCs. In addition, 
of the studies that have reported on these effects, none have been performed under similar conditions. 
Huijbregts et al. (2013) found that in CD8+ depleted PBMCs or purified CD4+ T cells that had been 
differentially activated for 24 hours after 5 days, treatment with 1 μM DEX and MPA significantly increased 
HIV-1BaL replication after 7 days post infection in all conditions except in CD4+ T cells activated with PHA 
(Huijbregts et al., 2013). Sampah et al. (2015) recently observed in un-stimulated CD8+ T cells, that MPA at 
concentrations similar to serum contraceptive concentrations, increased HIV-1 replication. Furthermore, the 
authors established that this increase in HIV-1 replication required the presence of CD14+ monocytes 
(Sampah et al., 2015). The results from the current study showed that MPA increased replication in the 
majority of PBMC donor samples. While it appears that the activation state of the different cells, as well as 
the different cell types may have important roles in HIV-1 replication, the data from the literature together 
with the data from this current study strongly suggest that MPA increases HIV-1 replication in the majority 
of PBMCs at near contraceptive serum concentrations. No other studies to date, have investigated the 
effects of P4, NET and LNG, in parallel, on HIV-1 replication in PBMCs. Thus the results from this study 
provide important insights into the direct effects of these progestogens on HIV-1 replication. Interestingly, 
the variable effects of P4 and LNG on HIV-1 replication, unlike the results for NET, suggest that these 
progestogens behave differently, despite their similar steroid receptor selectivity profiles (Africander et al., 
2011; Stanczyk et al., 2013), further supporting the hypothesis that not all progestogens are the same 
(Hapgood et al., 2004). 
Gene expression was also investigated in parallel with HIV-1 replication. The results from this study 
showed that in the MPA treated samples, HIV-1 replication correlated with IL6 mRNA levels. DEX had 
a similar mechanism of action to MPA on HIV-1 replication and IL6 mRNA expression, suggesting that 
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this mechanisms for both may be modulated, at least in part, by the GR. Interestingly the data from 
this study showed that after prolonged treatment (9 days), IL6 mRNA repression by MPA is lost. 
Future studies in the absence and presence of an IL6 neutralising antibody are needed to confirm the 
role of IL6 in modulating the effects of MPA on HIV-1 replication in PBMCs. Furthermore it will be of 
interest to determine the cell types involved in this mechanism. The model below (Figure 5.2), 
describes the possible mechanisms whereby MPA may modulate HIV-1 replication. In some donors, 
long term treatment may result in the activation and recruitment of NF-AT, which drives IL6 
transcription. This may result in an increase in IL6 levels. Furthermore, long term treatment may shift 
the population of T cells present, to that of T reg cells, that are thought to be GC resistant (Tsitoura & 
Rothman, 2004). This may increase the expression of IL6, further increasing HIV-1 replication. In 
addition, MPA may dampen the CD8+ and pDC cell mediated immune response, potentially increasing 
the pool of replicating HIV-1 in CD4+ T cells (Huijbregts et al., 2014; Michel et al., 2015). It may also be 
important to determine the role of apoptosis in this system, and to determine which cell types are 
programmed for cell death. It may be that there is a shift to promote viral replication by increasing 
apoptosis in a different cell type. Using flow cytometry as in Tomasicchio et al. (2013), one could 
determine which cell types are programmed for cell death, as well as the effects on cytokine 
expression (Tomasicchio et al., 2013). These results would provide insight into the possible role of MPA 
on HIV-1 disease progression in women.  
However a small subset of donors (3 out 10) maintained low mRNA levels of IL6 mRNA at day 9 with 
MPA, which correlated with low HIV-1 replication levels, compared to the vehicle control. It appeared 
that in some cases, MPA sensitivity was maintained throughout the time course, and HIV-1 viral 
replication was reduced. In this case, it may be that there is no increase in MEK/ERK signalling, that 
drives the activation of NF-AT transcription factors. As such, the GR, thought to bind as a monomer to 
NFκB (Van Bogaert et al., 2010; De Bosscher & Haegeman, 2009), may maintain its repressive function 
on gene expression, resulting in low levels of IL6 and subsequently low viral replication. These 
findings need to be confirmed by performing more repeats in PBMCs and identifying more donors, 
which maintain MPA responsiveness to IL6 gene repression. In addition, it may be informative to 
determine the mechanism in this population and identify possible targets for decreasing HIV-1 
replication. Using flow cytometry, one could perform these experiments to identify cell type usage and 
population shift over time with treatment with MPA, looking specifically for a shift towards T reg cells 
(CD4+FoxP3+, CD4+CD25+ and CD4+IL10+) (Tsitoura & Rothman, 2004; Pandolfi et al., 2013; Chen et 
al., 2006; Nelson, 2004). In addition, to investigate transcription factor involvement ChIP assays could 
be performed and recruitment of NF-AT to the promoter region of IL6 could be determined, similar to 
experiments performed by Louw-du Toit et al. (2014a), Govender et al. (2014), Verhoog et al. (2011) and 
Hadley et al. (2011).  
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In the infection experiments, PBMCs were activated with PHA, and maintained in 30 U/ml IL2 for the 
duration of the study. IL2 is an important cytokine that is a key mediator in T cell maintenance and 
proliferation (Murphy et al., 2012; Kam et al., 1993). It has been found in several studies, that IL2 may lift 
the GR dependent apoptotic effects by DEX in PBMCs (Kam et al., 1993; Camargo et al., 2009; Vazquez-
Tello et al., 2012). Additionally one study found that IL2 in combination with IL4 decreased GRα expression, 
that contributed to the diminished effects of DEX on cellular proliferation and apoptosis in PBMCs 
(Vazquez-Tello et al., 2012). Therefore, the effects of IL2 on MPA and DEX mediated gene 
transcription, via the GR, need to be determined. However, these effects were not observed in this study, 
as DEX significantly decreased cellular viability in PBMCs after 9 days in the presence of IL2. Since DEX 
and MPA significantly repressed IL6, IL8 and RANTES gene expression in the longer time course 
experiments (Fig. 3. 16), at days 2 and 3, it may be that the effects of IL2 in this system are time and 
or concentration dependent. Therefore, experiments using different amounts of IL2 with constant MPA 
and DEX concentrations in PBMCs should be performed, and changes in gene expression and 
apoptosis should be measured. The results of the experiments will give insight into the role of IL2 in 
changing the DEX and MPA effects on gene expression via the GR. Additionally the experiments 
should be performed in the absence of IL2 so that the effects of DEX and MPA can be compared to 





Figure 5.2: A proposed mechanism for the differential outcomes of HIV-1 replication in 
response to MPA treatment over a prolonged time course. (A) It could be that after prolonged MPA 
exposure, that glucocorticoid resistance develops through an increase in T reg cells and a shift from Th-1 to Th-
2 cells (Chen et al., 2006; Goleva et al., 2002; Tsitoura & Rothman, 2004; Kaushic et al., 2003) that leads to a shift 
in transcription factor usage, such as NF-AT (Tsitoura & Rothman, 2004; Kam et al., 1993; Cruz-Topete & 
Cidlowski, 2015). This change in transcription factor use could lead to an increase in IL6 mRNA levels (Tsitoura & 
Rothman, 2004). When IL6 levels are pro-inflammatory, HIV-1 replication in target cells could increase (Birx et 
al., 1990; Rollenhagen & Asin, 2011). (B) In some cases, prolonged treatment does not result in a loss of GC 
sensitivity, suggesting that the IL2 dependent MEK/ERK signalling pathway is not always activated. Here, MPA, 
via the GR, is still able to decrease IL6, IL8 and RANTES gene expression while maintaining GILZ 
transactivation. When, IL6 mRNA expression levels are low, HIV-1 replication in target cells is reduced in 
PBMCS compared to basal.   
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MPA increases HIV-1 replication in the majority of donors, while NET has no or reduced 
effects on HIV-1 viral replication in cervical explants  
Due to tissue sample constraints in obtaining primary cervical explants, only the effects of MPA and NET on 
HIV-1 replication were investigated. This is the first study to assess the direct effects of these progestogens 
in a cervical tissue model. In this study, MPA increased HIV-1 replication in the majority of ectocervical 
explants. However, the effect of MPA on HIV-1 replication was lost when pooling results from all 
donors. This may be due to the high inter-individual variation observed between the treatment groups, 
potentially masking or confounding the results. Indeed, it was observed that 5 out of 8 donor samples 
infected with HIV-1pNL4.3 and 3 out of 6 donor samples infected with HIV-1BaL_Renilla, had increased HIV-
1 replication profiles in the MPA treated samples, and that these were significantly different to the 
vehicle control when grouped together. Interestingly, the results from this study found that NET, unlike 
MPA, significantly reduced HIV-1 replication pooled data from all donor samples.  
It could be that, in some cases, MPA increases HIV-1 infection by increasing the expression of CCR5 
and CXCR4 on target cells (Chandra et al., 2013; Huijbregts et al., 2013; Sciaranghella et al., 2015; 
Goode et al., 2014), and/or by increasing cellular activation (Chandra et al., 2013; Huijbregts et al., 
2013). In contrast, NET treatment has been found by others to have no significant immunomodulatory 
effects on DC and T cell function (Huijbregts et al., 2014; Huijbregts et al., 2013), and as such may not 
increase HIV-1 susceptibility in the FGT. Thus, it could be that the differences between MPA and NET 
may be due to their differential effects on target cell recruitment or activation. As such it could be that 
NET is a more acceptable contraceptive choice due to its limited effect on cell recruitment or 
activation, however this must be confirmed. Future research should therefore establish the effects of 
the progestogens on cell type activation, relative abundance of different cell types and relative co-
receptor expression levels in the absence and presence of HIV-1 infection. These experiments may be 
difficult to perform, considering the effects of tissue digestion on receptor expression that may prevent 
adequate analysis using flow cytometry. It could be that select markers like CCR5, HLA-DR and CD4 
be used in immunohistochemistry to determine the effects of the different progestogens on the relative 
expression levels of these markers. Furthermore, the effects of P4 and LNG on HIV-1 replication are 
not known, and should be assessed in the future. 
Determination of the reasons underlying the differential inter-donor effects of MPA on HIV-1 replication 
in primary ectocervical explants was beyond the scope of this project. As such future research into the 
differential effects of MPA on HIV-1 replication in different donors should be elucidated. Some authors 
have proposed that young women are more susceptible to HIV-1 infection (Abdool Karim et al., 2010; 
Morrison et al., 2010; Morrison et al., 2012), and that this could be due to the state of inflammation and 
composition of the FGT (Roberts et al., 2012; Masson et al., 2014; Shrier et al., 2003). This may be why 
only modest effects on HIV-1 replication were observed in this current study, due to the greater age of 
the pre-menopausal women consented in this study (see Appendix C). However, the effect of age on 
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HIV-1 susceptibility or HIV-1 replication in women has not been directly proven. The differential effects 
between different donor samples by MPA on HIV-1 replication could also be due to the dynamic 
distribution of immune cells within the ectocervix. Some donors may have had a greater number of 
HIV-1 target cells and or greater relative expression levels of HIV-1 co-receptors compared to other 
donors. It could also be that the phase of menstrual cycle may also have an important role in the 
differences in HIV-1 replication between donors. A study by Saba et al. (2013) which found that 
explants from women in the luteal phase of the menstrual cycle were more permissible to HIV-1 
infection (Saba et al., 2013). However, results from this current study suggests that the stage of the 
menstrual cycle does not affect the outcome of HIV-1 replication in samples treated with either MPA or 
NET, but may contribute to the likelihood of the sample becoming productively infected. It may 
therefore be of use to increase donor numbers, including more donors from different stages of the 
menstrual cycles and different ages, to further explore the effects of these inherent biological 
differences. It may be unrealistic to perform immunohistochemistry or flow cytometry on each donor 
sample to elucidate cell types and numbers per donor in these types of experiments. Grouping the 
samples according to phase of cycle, age or into groups of responses is the most appropriate way in 
which to measure the differential effect of MPA on HIV-1 replication as this study has done. 
The effects of progestogens in PBMCs versus ectocervical explants on HIV-1 replication 
Interestingly, the results from both PBMCs and primary cervical explants suggest that MPA increases 
HIV-1 replication in the majority of donor samples, while NET has no effect or reduced effects on HIV-
1 replication. The results strongly suggest that MPA directly affects HIV-1 replication in both the 
systemic and in the local mucosa immune environments. The effects on HIV-1BaL-Renilla replication by 
MPA were more pronounced in PBMCs compared to the effects in primary cervical explants. These 
differences could be due to the cell type differences between these two multicellular systems. PBMCs 
used in the HIV-1 replication experiments were activated and most likely contain a greater relative 
amount of HIV-1 target cells compared to ectocervical tissue. However the differences in cell types, 
and the relative abundance of HIV-1 target cells between these two systems have yet to be fully 
elucidated. A recent study by Joag et al. (2014) found that viral entry was about three fold higher in 
cervical CD4+ T cells compared to their matched blood CD4+ T cell counter parts (Joag et al., 2014). In 
addition, the authors found that there may be shared host factors that influence viral entry in both 
CD4+ T cell populations (Joag et al., 2014). It may be of interest to isolate these cell types from 
matched PBMC and tissue sample donors and assess the effects of the different progestogens on 
HIV-1 replication. This may help to identify if there are host determinants that contribute to an increase 
in HIV-1 replication. Furthermore, this study found that there were differences in steroid receptor 
expression levels between PBMCs and primary cervical explants. It could be that the relative 
abundance of the different SRs could also play a role in the outcome in HIV-1 replication in PBMCs 
and primary ectocervical explants. Despite these differences, the results from this study show that 
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treatment with MPA increases HIV-1 replication in the majority of donors in both PBMCs and ectocervical 
explants. Further, the results show that after short term treatment, MPA significantly represses key pro-
inflammatory genes, while after long term incubation, repression of these genes is lost in both PBMCs and 
ectocervical explants. Taken together the results suggest that MPA may exert similar effects on similar cell 
types (like T cells and dendritic cells) found in both PBMCs and ectocervical explants that may lead to an 
increase in HIV-1 replication via a common mechanism.  
The role of the SRs in HIV-1 replication in PBMCs and primary ectocervical explants  
While the results found that MPA increased HIV-1 replication in the majority of PBMC and cervical explant 
samples, the study did not directly investigate the role of the GR in mediating these differential effects in 
these different cellular systems. However the results from this study indirectly suggest that the GR may 
have an important role in modulating the effects of MPA on HIV-1 replication. In PBMCs, MPA, like DEX, 
increased HIV-1 replication that correlated with increased IL6 mRNA levels. Further, results from this study 
found that PBMCs expressed detectable levels of GR protein and ER, MR and GR mRNA levels. Thus the 
results suggest that the changes in both HIV-1 replication and gene expression most likely involve the GR, 
since progestogens exert their responses via SRs. Similarly, MPA increased HIV-1 replication in the 
majority of explant samples. While the ectocervical explants detectably express AR, ER, PR and GR protein 
levels and all the SRs at an mRNA level, the data in the explants suggest that MPA may act predominantly 
via the GR. In addition, the results from this study found that PR and ER levels were significantly different in 
the different phases of the menstrual cycle. Saba et al. (2013) found that explants in the luteal phase were 
more permissible to HIV-1 infection and had higher viral titres compared to samples in the follicular phase 
(Saba et al., 2013). Taken together, the data suggests that SRs, particularly, the GR could have an 
important role in HIV-1 infection and replication in PBMCs and cervical explants. Therefore, the next step is 
to elucidate the role of the GR in HIV-1 replication in PBMCs and explants. Using the selective antagonist 
RU486, one could determine the role of the GR in mediating this response. The role of the GR may be 
difficult to elucidate in primary ectocervical explants, due to the presence of both the PR and the GR within 
this system. Therefore it may be necessary to separate and purify the different cell types using different cell 
sorting and tissue digestion techniques. Single cell types may be more permissible to mechanistic research 
questions, and allow one to elucidate the role of the GR on HIV-1 replication in select cell types. 
Furthermore, the use of specific agonists and antagonists for the different steroid receptors may help to 
identify which SRs are important in modulating the effects of HIV-1 replication with the different 
progestogens. 
The relationship between inflammation and HIV-1  
A direct causal link between inflammation and HIV-1 replication was not investigated in the current 
study. However the results from this study have shown that the effects of MPA on select pro-
inflammatory genes change over time. Furthermore, the results in PBMCs show that the effects of 
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gene expression by the different progestogens in the presence of HIV-1 after 9 days were similar to 
the effects of the progestogens in the absence of HIV-1. This result strongly suggests that HIV-1 
infection does not significantly contribute to the effects on pro-inflammatory cytokine expression by the 
different progestogens. However, the results do suggest that changes in expression of 
immunomodulatory genes a short time after exposure to relatively high MPA concentrations, such as 
shortly after injection, may contribute to an increase in HIV-1 replication in PBMCs. Furthermore, the 
results suggest that in MPA treated PBMCs, IL6 mRNA levels may contribute to HIV-1 replication after 
9 days post infection. The effects of MPA and NET on HIV-1 replication and gene expression in 
ectocervical explants were not fully elucidated, but the data suggest that MPA does not significantly 
increase IL6 mRNA expression, after 12 days, as seen in the PBMCs. 
 
 Whether the state of inflammation in the female genital tract is important in directly determining the 
susceptibility to HIV-1 infection remains to be determined (Wira et al., 2010; Wira et al., 2014; Wira et 
al., 2015; Shattock et al., 2008; Miller & Shattock, 2003). Few studies have assessed the link between 
pro-inflammation and HIV-1 susceptibility. Clinical studies have used correlation analysis to suggest 
links, but it should be noted that these do not prove a causal relationship. Morrison et al. (2014) found 
that an increase in RANTES, and a decrease SLPI correlated with HIV-1 seroconversion in women 
(Morrison et al., 2014). Masson et al. (2014) found that women with identified sexually transmitted 
infections (STIs) had high concentrations of pro-inflammatory cytokines in the CVL compared to the 
CVL of women with no infections (Masson et al., 2014). Some evidence for causal relationships has 
been obtained in ex vivo studies, and suggests that exogenous IL8 (Lane et al., 2001) and TNF-ɑ (de 
Jong et al., 2008) may increase HIV-1 replication in primary cells. It has also been observed in latently 
infected monocytes and T cell lines, that TNF-ɑ can stimulate HIV-1 replication (Griffin et al., 1989; 
Griffin et al., 1991; Lane et al., 1999). However there are some contrary reports with regards to a link 
between inflammation and HIV-1 susceptibility, from both clinical and ex vivo data. One study found 
that lower levels of IL6 and IL10 were associated with an increased risk in HIV-1 infection (Lehman et 
al., 2014). Another study found that IL8 added exogenously before infection with HIV-1 in ectocervical 
tissue explants, decreased initial HIV-1 reverse transcription and viral integration (Rollenhagen & Asin, 
2010). In addition, Lane et al. (1999) found that TNF-ɑ dose dependently decreased HIV-1 replication 
in freshly isolated peripheral blood monocytes, through a mechanism involving the increase in 
RANTES expression (Lane et al., 1999). Taken together the different studies indicate that the pro-
inflammatory molecules may increase or decrease HIV-1 replication, and suggest that the role of 
these pro-inflammatory molecules on HIV-1 susceptibility and infection may be complex and time-
dependent. The results from this study did not show any significant changes in IL6 and IL8 mRNA 
levels with MPA or NET treatment in the presence of HIV-1 after 12 days. However, it could be that 
IL6 and IL8 mRNA levels have a role in HIV-1 susceptibility and initial infection. MPA, unlike NET, 
significantly repressed IL6 and IL8 mRNA levels after 48 hours in ectocervical explants. It could be 
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that select repression of key immunomodulatory genes by MPA after short term exposure could lead 
to an increase in HIV-1 susceptibility by dampening the initial immune response (Huijbregts et al., 
2014; Quispe-Calla et al., 2015). However the role of IL6 and IL8 on HIV-1 susceptibility are yet to be 
fully elucidated. 
In order to understand the role of inflammation on HIV-1 replication in the FGT, one could perform add 
back experiments. Here supernatants collected from explant samples treated with the different 
progestogens would be harvested at select time points. Thereafter, the supernatants could be added 
to an infected indicator cell line and changes in HIV-1 replication could be monitored. In parallel, a 
Luminex assay could be performed to determine the changes in pro-inflammatory gene expression. 
This experiment would elucidate whether the different progestogens differentially affect pro-
inflammatory gene expression that may favour HIV-1 replication. In addition, this experiment could be 
repeated to assess the effects on initial HIV-1 infection, whereby the supernatant from the explants 
could be added to an uninfected indicator cell line. After incubation with the supernatant, the indicator 
cells lines could be infected with HIV-1, and changes in HIV-1 replication could be monitored. This 
experiment would elucidate whether the different progestogens differentially affect select pro-
inflammatory gene expression that may differentially affect HIV-1 target cells to increase initial HIV-1 
infection. Furthermore, the role of progestogens in the presence of the endogenous glucocorticoid, 
cortisol should be investigated. The effect of endogenous cortisol on the responses observed on gene 
expression and HIV-1 infection by the different progestins also remains to be investigated.  
 
Future research should also investigate the role of individual cell types, as it could also be that 
inflammation selectively activates and recruits target cells to different and localised regions in the local 
female genital tract to increase the susceptibility to infection (de Jong et al., 2008). In a recent review 
by Shey et al. (2015), the authors suggest that dendritic cells play an important role in facilitating or 
preventing HIV-1 infection by driving inflammation in the genital tract (Shey et al., 2015).Thus using 
DCs isolated from primary ectocervical tissue (Rodriguez-Garcia et al., 2013; Wira et al., 2014; Wira et 
al., 2015; Rodriguez-Garcia et al., 2013), one could stimulate with MPA before infecting with HIV-1 and 
subsequently co-culture the pDCs with PBMCs or an indicator T cell line and measure the differences 
in HIV-1 replication (Buffa et al., 2009). It has also been shown that Langerhan cells, a type of DC, are 
important in early infection in the FGT (Kawamura et al., 2000; Kawamura et al., 2004; Matsuzawa et al., 
2014; Blauvelt et al., 2001; Sugaya et al., 2004), and the effects of progestogens on this cell type should 
be explored. Furthermore, recent reports suggest that MPA increases transcytosis in primary epithelial 
cells (Ferreira et al., 2014). However, more research must be performed into comparing these effects 
with other progestins and the natural ligand P4 at concentrations that mimic serum concentrations. 
Recently, Ayehunie et al. (2015) developed a vaginal epithelial tissue model (EpiVaginal) that is 
responsive to E2 and P4 treatment, and expresses PR-B, which is under E2 control. Microarray 
analysis showed that this model expresses genes involved in the immune response, epithelial 
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differentiation and wound healing (Ayehunie et al., 2015). Thus it could be useful to perform select 
experiments in this model to determine the effects of MPA, P4, NET and LNG on epithelial thickness 
and gene regulation.  
While it has been proposed that inflammation may play a critical role in the susceptibility to disease in 
the FGT (Masson et al., 2015; Masson et al., 2014), the cytokine profiles from plasma did not show any 
significant differences or associations with STIs (Masson et al., 2014; Masson et al., 2015). Thus, how 
inflammation in the systemic system may relate to or indicate an increased susceptibility in STIs 
remains unknown. In a recent study by Sciaranghella et al. (2015), the authors found that women on 
DMPA or using an LNG intrauterine device had increased expression levels of CCR5 in CD4+ T cells 
in their PBMCs compared to women on no hormonal contraception and oral contraceptives. 
Interestingly, LNG had greater effects on T cell expression and CCR5 expression levels in this study 
(Sciaranghella et al., 2015). Thus the effects of MPA on CCR5 and CXCR4 expression and cellular 
activation, through an increase in HLA-DR and CD68+ receptors (Camargo et al., 2009), are important 
to elucidate. Using flow cytometry, one will be able to determine how MPA at serum contraceptive 
concentrations, changes the activation state of PBMCs. Interestingly, a recent study found that MPA 
increased HIV-1 infection in non-activated PBMCs, and that this increase required CD14+ monocytes 
(Sampah et al., 2015), suggesting that the state of activation is not the only mechanism by which MPA 
increases HIV-1 replication. The results from the current study found that MPA increased HIV-1 
replication increase correlated with IL6 mRNA levels in PBMCs. Further, the results in this study found 
that IL6 was predominantly expressed in CD14+ monocytes after 48 hours. Thus it could be that MPA, 
after prolonged exposure, increases IL6 mRNA levels in CD14+ monocytes that could contribute to an 
increase in HIV-1 replication in other HIV-1 target cells. Therefore future research should focus on the 
changes in IL6 mRNA or protein levels in CD14+ monocytes after prolonged exposure to MPA and 
determine whether these changes affect HIV-1 replication in HIV-1 target cells.  
Taken together, the data reported in this study as well as others suggest that pro-inflammation is not the 
only mechanism whereby susceptibility to HIV-1 infection is increased, nor does it appear to be a reliable 
predictor. Rather, it appears to be a more dynamic interplay between which cytokines or chemokines are 
regulated and the recruitment of target cells to the target sites in response to MPA treatment. It also 
appears to be driven in a compartmental, time, and concentration dependent manner. What is not known is 
the effect of DMPA on early HIV-1 infection events, and whether long term treatment with DMPA could lead 
to a pro-inflammatory state in the FGT. This area should be focused upon in future experiments, as it is 
pivotal in the understanding of how contraceptives may increase HIV-1 acquisition in women. The infection 
experiments were performed on activated PBMCs in this current study. It may therefore be of interest to 
perform the infection experiments in the absence and presence of activation in matched donors so that the 
effects of MPA on HIV-1 replication in activated and non-activated PBMCs can be determined. It may be 
that while pro-inflammation in the FGT is an indicator of disease susceptibility and disease progression; it 
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may not be a good indicator of disease susceptibility and or disease progression in the systemic immune 
system.  
Cervical explants are useful models but have limitations 
The use of ex vivo cervical explants has provided researchers with key insights into which cell are target 
cells of HIV-1 infection in the FGT (Hladik et al., 2007; Greenhead et al., 2000). Furthermore, cervical 
explants have been used to assess the effects of HIV-1 inhibitory compounds on HIV-1 replication (Fletcher 
et al., 2006; Fletcher et al., 2008 Dodou et al., 2014; Harman et al., 2012). However the methodology has 
some important limitations. 
The results from this study found significant differences in gene expression with different 
progestogens after 48 hours in four explant donor samples, with triplicate replicates. Additionally, HIV-
1 replication studies found significantly different effects in HIV-1 replication after 10 days post 
infection in 5 – 8 donor samples, each in triplicate. These results show that even with relatively few 
donors, statistically significant differences of p < 0.05 to p < 0.0001 can be measured. However, the 
large inter- and intra- donor variability in the results with ectocervical explants suggests that for some 
experiments where the effects are different for different donors or responses are small, the n-value 
would need to be substantially increased in order to measure statistically significant differences. One 
way to decrease the experimental error in these experiments would be to improve the uniformity of the 
explant tissues pieces used in replicates. In this study, a punch was used in order to obtain similar 
pieces of tissue for each replicate treatment. However, the depth of the tissue varied; as such more 
stroma may have been present in one sample compared to another from the same donor. Since 
distribution of immune cells is dynamic (Chandra et al., 2013; Pudney et al., 2005; Wira et al., 2015), it 
could be that the depth of the tissue could be a contributing factor to why high intra-individual variation 
was observed in the HIV-1 replication experiments. This problem could be improved by increasing the 
replicate number or by more uniform and time consuming cutting of the tissue pieces or weighing. 
Both of these strategies, however, have other disadvantages such as increased and variable time of 
preparation and hence potentially increased loss of tissue integrity and loss of reproducibility. 
Although weighing each sample to account for tissue size may lead to lower variability, it may not be 
feasible to weigh each sample, especially if sample sizes are large.  
Inter-donor variability may be as the result of several variables. These include the differences in age, 
menstrual phase, contraceptive use, medication use, the presence of infections and or the presence of 
unique microflora (Anderson et al., 2010). Only women who were pre-menopausal and undergoing a 
hysterectomy for benign reasons were consented for this study. Additionally, hormone levels, HSV, 
HIV-1 and HPV status were determined for each donor. While these controls greatly contributed to the 
study and to the analysis thereof, not all differences could be accounted or controlled for. The age of 
the donor is also particularly important in HIV-1 studies. Some observational studies have observed 
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that young women on MPA may be more susceptible to HIV-1 infection (Leclerc et al., 2008; Morrison 
et al., 2010; Morrison et al., 2012). However, the likelihood of a young woman undergoing a 
hysterectomy is low, and thus the use of tissue explants may be restricted to donors from older 
women. The donors in this study were not on contraception at the time of surgery. Thus observing the 
differences in gene expression or HIV-1 replication in explants from women on contraception was not 
possible. It may be that the only way to observe differences in MPA versus NET in young women, is to 
enrol young women in a study, place them on different contraceptive arms and acquire biopsy, CVL 
and blood samples, similar to what several studies have done (Huijbregts et al., 2013; Huijbregts et 
al., 2014; Michel et al., 2015). However, the ethical considerations, cohort management and the costs 
involved in acquiring these samples may be prohibitive in some environments. While it may be that 
cervical explants are from older donors, it is a useful approach in which to analyse the direct effects of 
multiple progestogens on gene expression and HIV-1 replication, given that a relatively large amount 
of tissue is obtained, compared to biopsies. Further categorising the explants received could be a 
useful approach to reduce variability. Immunohistochemistry or immunofluorescence techniques could 
be used to determine basal levels of select cell types (CD4+ T cells, Langerhan cells, macrophages) 
or steroid receptor profiles of a donor that may be useful as a means to group and characterise 
responses. Furthermore, one could expand the profile of the donor by acquiring information on 
inflammation state and drug use, which may greatly help to group donors into response types. 
Another of the challenges and limitations of explant studies is establishing conditions and obtaining 
productive infection. For the HIV-1 replication studies, it would be important to include controls such 
as an HIV-1 viral replication or entry inhibitor (such as Lamivudine or Maraviroc) to confirm productive 
viral infection, similar to the methods used by Saba et al. (2013). A pilot study was performed in the 
current study with the R5 HIV-1 viral entry inhibitor, Maraviroc. The inhibitor was added 15 minutes 
prior to infection at a final concentration of 5 μg/ml. The data indicated, that while HIV-1 viral replication 
decreased over time, initial viral replication levels at day 3 post infection were the same as the control 
(appendix E, Fig. E.2.4). This may be due to too short a pre-exposure time to Maraviroc or too low a 
concentration of inhibitor. Further experiments are needed to determine the optimal conditions for these 
experiments, so that these compounds may be used as appropriate controls.  
A limit of explant methodology is achieving a true polarised tissue environment in which to study HIV-1 
transmission. Polarisation of the tissue involves orientating the tissue epithelial side up on a transwell 
system and providing structure such that HIV-1 entry is limited to the epithelial surface of the explant 
(Anderson et al., 2010; Merbah et al. 2011; Dezzutti et al., 2012). However, due to the rate of tissue 
deterioration and subsequent changes in cellular permeability (Anderson et al., 2010), these methods 
have been used with limited success. Additionally, recruitment of target cells from nearby vessels or 
tissue sites are absent in an isolated tissue explant. Due to these limitations associated with 
transmission methodology, transmission was not investigated in this study. While polarisation may be 
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difficult to achieve, another consideration for these infection experiments is the use of a non-polarised 
transwell system or collagen raft to better mimic the tissue environment. Several studies have used 
non-polarised transwell system to identify targets cells in early viral infection (Hladik et al., 2007; 
Dezzutti & Hladik, 2012) and viral penetration of the cervical epithelium (Dezzutti et al., 2001; Carias et 
al., 2013). In addition, it has been observed, that the tissue structure is maintained better using the raft 
system (reviewed in Merbah et al., 2011). Thus, it could be of benefit to repeat these experiments in a 
transwell system or on a collagen raft (Merbah et al., 2011), that may better mimic the primary 
environment.  
Another important consideration in explant methodology is the viability of the tissue over time. It was 
found that tissue viability did not significantly vary over time (see Appendix A.6.1 B). However, when 
looking at the MTT viability of each donor over time, there were distinct differences in viability over 
time between donors (Appendix A.6.1 A). In some donors, viability dramatically decreased, while in 
others there was no change or a slight increase in viability. These differences could be due to the 
different tissue sizes used for each assay that could contribute to these differential effects in viability. 
Another caveat in the viability assay used in this study, is that it gives a measure of total cellular 
viability, which may mask changes in viability of individual cell types. This is one of the first studies to 
report on tissue viability at the start and end of an infection experiment. While the results of this study 
found that that there was no difference in viability over time, it is an important factor to monitor. In 
addition, only fresh tissue was used in all experiments. Initial pilot experiments found that frozen 
tissue had an ~80% reduction in viability compared to its fresh tissue counterpart. Interestingly, RNA 
quality was greatly reduced in explant samples after 12 days incubation. It could be that while viability 
of the tissue may not greatly affect HIV-1 replication, it could contribute to the quality of the RNA 
isolated. Given the high susceptibility of RNA to degradation, it may be that measuring secreted 
cytokines and chemokines in the supernatants is the only feasible method for determination of gene 
expression after 12 days. 
Taken together, explants are a useful model in which to study the direct effects of progestogens in 
tissue of the female genital tract. However, donor variability, sample acquisition, culture set up, length 
of incubation time, tissue uniformity and viability are important factors to consider in the experimental 
design and in the subsequent outcomes of the experiment. 
NET may be a better choice of injectable contraceptive for women in high risk areas 
Importantly, this study suggests that NET does not result in an increase in HIV-1 replication. While 
MPA significantly increased HIV-1 replication in most donor samples, it may be that the finding that 
NET is better than MPA is more important. In this study NET had little to no impact on immune gene 
expression and in both PBMCs and primary ectocervical explants as well as no to reduced levels of 
HIV-1 replication in PBMCs and primary ectocervical explants. It could be that NET is able to convert 
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to estrogen, and that this may offer protective effects (Kuhnz et al., 1997). It has been suggested that 
the effects of MPA on immune function and epithelial integrity could be due to the fact that MPA 
induces hypoestrodial levels in women (Borgdorff et al., 2015; Morrison et al., 2015; van de Wijgert et al., 
2013). With a reduction in estrogen levels, barrier function and proliferation in the local genital mucosa 
are reduced more so than women in the luteal phase. Thus, the difference between MPA and NET 
could be due to the different levels of E2 in vivo. It will thus be of interest if E2 levels could be 
assessed in the ex vivo explant experiments to confirm if there is an increase in E2 levels in the NET 
treated samples over time, and will further support what has been suggested in the literature. 
Additionally, most observational studies that have reported on NET use, have reported no significant 
effects on HIV-1 susceptibility, with only one study finding significance (reviewed in Polis et al., 2014; 
Morrison et al., 2015), while recent meta-analyses have suggested that MPA may increase HIV-1 
acquisition (Ralph et al., 2015; Morrison et al., 2015). In a recent study reporting on the effects of MPA 
on transmission and acquisition, the authors observed that MPA did not increase transmission or 
acquisition (Wall et al., 2014b; Wall et al., 2014a; Wall et al., 2015). Wall et al. (2015) suggest that good 
counselling and condom use in this cohort may have contributed to the low rates observed in the 
study, but also encourage increasing the contraceptive method mix used in high risk areas (Wall et al., 
2015). Additionally, in an observational analysis comparing the effects of MPA and NET usage on HIV-
1 risk in women, Nouguchi et al. (2015) observed that women on DMPA compared to women on NET 
had an increased risk of HIV-1, with an aHR of 4.76 (95% CI 2.15 – 10.52) (Noguchi et al., 2015).   
The issue of contraceptive use in high risk areas has reached a critical point. Comment pieces by 
Hapgood (2013) and Colvin and Harrison (2015), suggest that the debate over the need for a trial may 
be unnecessary and inhibitory (Hapgood, 2013; Colvin & Harrison, 2015). Further Colvin and Harrison 
(2015) suggest that a more holistic approach where both biological, clinical and basic scientific 
research are all needed to address the use of DMPA, so that the most informed decision can be made 
(Colvin & Harrison, 2015). As such the findings reported in this study and others, together with 
observational data, suggest that MPA should be reconsidered as a choice of contraception in the 
contraceptive method mix in high risk areas. However, there are more ethical considerations that need 
to be taken into account if policy makers are to make these decisions. Haddad et al. (2015) recently 
reviewed these considerations in accordance with the Baum framework for ethical considerations, and 
stated that policymakers need to determine the benefit of removing MPA from the useable pool 
contraceptives versus the harm that may follow in the reduction of effective and available 
contraceptives especially in areas where contraceptive use is already limited (Haddad et al., 2015). 
Indeed, Ralph et al. (2015) stated in their meta-analysis that removing MPA without a suitable 
replacement (Ralph et al., 2015) will not be beneficial. The authors also state that contraceptive use 
should be re-evaluated in the context of graphical location and site-specific need (Ralph et al., 2015).  
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A recent review article by Halpern et al. (2015) sought to address the current limitation on longer 
acting progestins in the contraceptive method mix, by highlighting potential new candidates using new 
delivery technologies for development. However the authors highlighted that these new technologies 
and formulations must take into consideration the limitations of the current long acting progestins 
(Halpern et al., 2015), so that contraceptives with the lowest risk profile are taken forward in 
development. It has also been found that MPA administered at a lower dose subcutaneously (104 mg) 
had better efficacy compared to MPA administered at a higher dose intramuscularly (150 mg), while 
maintaining lower MPA serum concentrations in women (Shelton & Halpern, 2014). This may not be an 
adequate option however, as the peak serum concentrations are still similar to that of the 
intramuscularly delivered DMPA (Shelton & Halpern, 2014). Additionally, several studies have shown 
that pre-exposure prophylactic (PrEP) treatment in conjunction with MPA does not diminish the 
efficacy of PrEP, nor MPA efficacy (Heffron et al., 2014). However, PrEP is not yet available to women 
in these areas, and as such other alternatives are needed in the interim, nor has a lower dose 
formulation of MPA been approved for contraceptive use. Lastly, while a trial has been approved 
assessing the differences between DMPA, LNG (intrauterine device) and the copper T (Rees, 2014), 
this may take a few years before results are forthcoming (Ralph et al., 2015; Westhoff & Winikoff, 2014), 
further supporting the need for basic research on this topic to help inform contraceptive choice in the 
interim. 
Concluding remarks 
This study, together with recent findings in the literature, suggest that MPA use changes the 
immunomodulatory landscape at both the systemic and local immune environment, increasing HIV-1 
susceptibility and potentially disease progression. Further, this study suggests that MPA increases 
HIV-1 viral replication in PBMCs, which positively correlated with an increase in IL6 mRNA expression 
levels, while MPA increases or decreases HIV-1 replication in primary cervical explants via an 
unknown mechanism. LNG, used in oral contraceptives and intrauterine devices, had no effect on 
gene expression or HIV-1 replication in PBMCs at high concentrations, however studies in explant 
systems are yet to be performed. However of importance, is that NET has little to no effect on immune 
gene expression, does not result in an increase HIV-1 viral replication in PBMCs, and appears to have 
the least variable effects in primary cervical explants, significantly reducing viral replication. Comment 
pieces by Hapgood (2013) and Jones and van de Wijgert (2015) suggest that women in high risk 
areas be encouraged to use NET-EN over MPA, due to the lower reported risk profile of NET on HIV-1 
susceptibility compared to MPA, as well as their similar efficacy in pregnancy rates (Jones & van de 
Wijgert, 2015; Hapgood, 2013). While several commentaries caution against removing MPA from the 
contraceptive pool (Jain, 2013; Jain, 2012; Haddad et al., 2015; Ralph et al., 2015; Morrison et al., 2015), 
NET, rather than MPA, may be a preferable choice of injectable contraceptive in regions of high HIV-1 
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A.1. Luminex PBMC Data 
 
Figure A.1.1 shows the supplementary Luminex data to accompany those results presented in Chapter 3 
(Fig. 3.5), which showed strong dose dependent repressive effects for DEX treatment more so than MPA 
treatment on IL-1ra, VEGF, IL7, IL12 (p70) and TNFα relative protein levels. Figure A.1.1 shows that DEX, 
unlike MPA, has significant effects on IL-10 (Fig. A.1.1 B), IL2 (Fig. A.1.1 C), IFN-γ (Fig. A.1.1 D), Eotaxin 
(Fig. A.1.1 E), GM-SCF (Fig. A.1.1 F), IL4 (Fig. A.1.1 G) and FGF basic (Fig. A.1.1 H) protein levels 
compared to the vehicle control. While both DEX and MPA significantly reduce IL-1β protein expression 
levels compared to the control (Fig. A.1.1 A). Furthermore, the results show that P4 and NET have no effect 





Figure A.1.1: DEX more so than MPA, dose-dependently regulates select cytokine and chemokine 
basal protein expression levels in primary PBMCs. PBMCs were stimulated with increasing amounts of DEX, 
MPA, P4, NET-A or vehicle (0,1% EtOH) for 48 hrs. Supernatants were harvested and processed for differential 
protein expression using the Bio-Rad 27-plex Human cytokine and chemokine panel (Bio-Rad, Germany) on a Bio-
plex 200 (Bio-Rad, Germany). Relative protein expression levels of IL-1β (A), IL-10 (B), IL-2 (C), IFN-ɣ (D), Eotaxin 
(E), GM-CSF (F), IL4 (G) and FGF Basic (H) levels were normalised to vehicle control (EtOH) set to 1. Histograms 
represent pooled data from four independent experiments from female donors plotted as mean ± SEM.  Statistical 
significance was determined by one-way ANOVA with a post hoc Dunnett’s test or unpaired student t-tests comparing 
each sample to the vehicle control (EtOH) with *, **, *** denoting p<0.05, p<0.01 and p<0.001 respectively. 
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A.2. Gating Strategies for flow cytometry  
 
Figure A.2.1 and A.2.2 show the gating strategies and the scatter plots for IL6 and GILZ protein expression 
used in the flow cytometry data reported in Fig. 3.6. 
 
 
Figure A.2.1: Gating strategy for IL6 detection in CD14+ monocytes. Cells were treated with 100 nM DEX, 
1 µM MPA, 1 µM P4, 10 µM NET-A, 10 µM NET, 10 µM LNG or vehicle control (EtOH) for 48 hrs. Cells were stained 
with anti-CD4, anti-CD14 and 7-AAD, followed by intracellular detection of IL6. Above is the gating strategy and 
representative zebra plots of the vehicle control (EtOH) and the ligands listed above. Data was acquired on a FACS 






Figure A.2.2: Gating strategy for GILZ detection in CD4+ T-cells. Cells were treated with 100 nM DEX, 1 
µM MPA, 1 µM P4, 10 µM NET-A, 10 µM NET, 10 µM LNG or vehicle control (EtOH) for 48 hrs. Cells were stained 
with anti-CD4, anti-CD14 and 7-AAD, followed by intracellular detection of GILZ. Above is the gating strategy and 
representative zebra plots of the vehicle control (EtOH) and the ligands listed above. Data was acquired on a FACS 




A.3. HIV-1 replication and relative IL6 mRNA expression levels in DEX treated 
PBMCs 
 
It was found in chapter 3 that MPA increased HIV-1 replication in PBMCs from most donors, and that this 
increase correlated with an increase in IL6 mRNA levels in those samples. To further support that these 
effects observed in the MPA treated samples were glucocorticoid-like, more so than for the other 
progestogens, IL6 mRNA levels were matched with their HIV-1 replication data in each treatment group. A 
Pearsons r correlation was performed for each of these treatment groups. For samples treated with CORT, 
P4, NET and LNG HIV-1 replication levels did not correlate with IL6 mRNA levels in their respective 
treatment groups. However, DEX, positively correlated with relative infection levels in the DEX treated 
samples, with a significance of p=0.0381 (Fig. A.3.1 A). In addition, the data indicate that the relative 
infection levels were higher in the high IL6 mRNA expression group than in the low IL6 mRNA expression 




Figure A.3.1: Higher DEX infection levels positively correlate with higher IL6 mRNA infection levels. 
PHA activated PBMCs were treated as described in the legend of Fig. 3.11. (A) Relative DEX infection levels, 
normalised to vehicle treatment (EtOH), were plotted against matching relative IL6 mRNA expression levels, 
normalised to vehicle treatment (EtOH). Relative IL6 mRNA transcript levels were determined by comparing C(t) 
values to a standard curve derived from a serial dilution of pooled cDNA (from the experimental repeats) with a known 
concentration. An XY scatter plot represents 10 individuals with mean infection levels on the Y-axis and IL6 relative 
mRNA expression on the X-axis. A Pearsons r correlation analysis (comparing r for X vs. Every Y data set) was 
performed with a two-tailed post-test t-test analysis. (B) DEX infection levels were grouped according to low IL6 mRNA 
expression levels or high IL6 mRNA expression levels. The histogram is representative of 4 -5 biological repeats per 
bar plotted as mean ± SEM. Statistical significance was determined by an unpaired student t-tests comparing the two 





A.4. Gene expression data separated according to high and low relative HIV-1 
infection levels in MPA treated PBMCs  
 
In chapter 3, it was found that the results for PBMCs treated with MPA and infected with HIV-1 could be 
grouped into two groups. In some samples, HIV-1 replication was significantly higher with MPA treatment 
as compared to the control group (Fig. 3.11). Additionally, it was found that HIV-1 replication in this MPA 
treated group significantly correlated with higher IL6 mRNA levels compared to the control group (Fig 3.14). 
As such, the mRNA expression levels were separated. Figure A.4.1 shows the effects of the different 
ligands on IL6 mRNA levels again (as seen in chapter 3) as well as IL8, RANTES and GILZ mRNA 
expression levels in this group. The results show that while IL6 mRNA levels are significantly upregulated 
with CORT and MPA in the presence of HIV-1 (Fig. A.4.1 A), IL8 and RANTES levels are not (Fig. A.4.1 B 
and C). Transactivation of GILZ by CORT, DEX and MPA is maintained in the absence and presence of 
HIV-1 (Fig. A.4.1 D). Furthermore, P4, NET and LNG had no effect on the relative expression levels of 







Figure A.4.1: Gene expression in donor samples where MPA increased HIV-1 infection in primary 
PBMCs. PHA activated PBMCs were pre-treated with 0.01% (v/v) 100 nM Cortisol (CORT), DEX, MPA, P4, NET or 
LNG, with a vehicle control (EtOH), for 48 hours. Pre-treated PBMCs were infected with 10 IU/ml HIV-1BaL-Renilla IMC for 
2 hours and media with the respective ligands was replaced every second day. PBMCs were harvested at 7 days post 
infection in TriReagent® and subsequently processed for RNA. 250 ng RNA was reversed transcribed to cDNA 
(Roche Applied Science, South Africa), where it was used in subsequent real time qPCR as template to determine the 
differential expression levels. Relative mRNA expression levels of IL 6 (A), IL 8 (B), RANTES (C) and GIL Z (D) were 
normalised to GAPDH mRNA expression levels. Relative fold change in mRNA levels was determined by setting the 
vehicle treatment (EtOH) to 1. Histograms represent pooled data from seven independent experiments from female 
donors plotted as mean ± SEM. Statistical significance was determined by a non-parametric Wilcoxon Rank Test 
comparing each sample to the vehicle control (EtOH) set to 1, with * and ** denoting p<0.05, and p<0.01 respectively. 
 
 
Additionally, the results in chapter 3 found that in the MPA treated samples where HIV-1 replication was 
low, IL6 mRNA levels were reduced or lower compared to the control group (Fig 3.15). Figure A.4.2 shows 
the changes in gene expression with the different ligands in the presence and absence of HIV-1 infection 
for this group. Fig A.4.2 shows the results for IL6 mRNA levels again (as seen in Fig 3.15), as well as the 
results for IL8, RANTES and GILZ mRNA levels. The data indicates that IL6 mRNA levels decreased with 
CORT, DEX, and similar to basal for MPA in the presence of HIV-1 (Fig. A.4.2 A). Similarly, IL8 mRNA 
levels appear to be reduced with CORT and DEX in the presence of HIV-1, while MPA like P4, NET and 
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LNG has no effect on IL8 mRNA gene expression in the presence of HIV-1. RANTES mRNA levels were 
not regulated in the presence or absence by CORT, DEX, P4, NET or LNG. However, MPA in the presence 
of HIV-1 significantly increased RANTES mRNA levels (Fig. 4.2 C). Transactivation of GILZ by CORT, DEX 






Figure A.4.2: Gene expression in donors samples where MPA decreased HIV-1 infection in primary 
PBMCs. PHA activated PBMCs were pre-treated with 0.01% (v/v) 100 nM Cortisol (CORT), DEX, MPA, P4, NET or 
LNG, with a vehicle control (EtOH), for 48 hours. Pre-treated PBMCs were infected with 10 IU/ml HIV-1BaL-Renilla IMC for 
2 hours and media with the respective ligands was replaced every second day. PBMCs were harvested at 7 days post 
infection in TriReagent® and subsequently processed for RNA. 250 ng RNA was reversed transcribed to cDNA 
(Roche Applied Science, South Africa), where it was used in subsequent real time qPCR as template to determine the 
differential expression levels. Relative mRNA expression levels of IL 6 (A), IL 8 (B), RANTES (C) and GIL Z (D) were 
normalised to GAPDH mRNA expression levels. Relative fold change in mRNA levels was determined by setting the 
vehicle treatment (EtOH) to 1. Histograms represent pooled data from three independent experiments from female 
donors plotted as mean ± SEM. Statistical significance was determined by a non-parametric Wilcoxon Rank Test 









A.5. Basal Expression levels of IL6, IL8, RANTES and GILZ in the presence of HIV-1 
or over time 
 
In Chapter 3, gene expression was determined by normalising each treatment group to the vehicle control 
(EtOH) set to 1. While these data are useful in presenting the effects of the different progestogens on gene 
expression, it does not give an indication on the changes in basal transcription levels in the presence of 
HIV-1BaL_Renilla or indicate if basal mRNA expression levels change over time. As such the following gene 
expression data from Figures 3.12 and 3.16 were reanalysed and re-plotted so that changes in basal 
transcription levels in the control groups could be determined. For Figure 3.12 gene expression was plotted 
relative to the vehicle control in the uninfected group, so that changes in basal transcription in the presence 
of HIV-1BaL_Renilla could be evaluated. Similarly in Figure 3.16, data was analysed such that gene expression 
was relative to the day 2 EtOH control so that changes in basal transcription levels over time could be 
evaluated.  
 
In Figure A.5.1, it is evident that basal mRNA levels of IL6 (A), IL8 (B), RANTES (C) or GILZ (D) in the 




























Figure A.5.1: Gene expression in donors samples where MPA decreased HIV-1 infection in primary 
PBMCs. PHA activated PBMCs were pre-treated with 0.01% (v/v) 100 nM Cortisol (CORT), DEX, MPA, P4, NET or 
LNG, with a vehicle control (EtOH), for 48 hours. Pre-treated PBMCs were infected with 10 IU/ml HIV-1BaL-Renilla IMC for 
2 hours and media with the respective ligands was replaced every second day. PBMCs were harvested at 7 days post 
infection in TriReagent® and subsequently processed for RNA. 250 ng RNA was reversed transcribed to cDNA 
(Roche Applied Science, South Africa), where it was used in subsequent real time qPCR as template to determine the 
differential expression levels. Relative mRNA expression levels of IL 6 (A), IL 8 (B), RANTES (C) and GIL Z (D) were 
normalised to GAPDH mRNA expression levels. Relative fold change in mRNA levels was determined by setting the 
vehicle treatment (EtOH) in the uninfected group to 1. Histograms represent pooled data from three independent 
experiments from female donors plotted as mean ± SEM. Statistical significance was determined by a non-parametric 
Wilcoxon Rank Test comparing each sample to the vehicle control (EtOH) set to 1, with ** and *** denoting p<0.01, 
and p<0.001 respectively. 
 
In Figure A.5.2, it is evident that IL6 mRNA expression levels decrease over time (Fig A.5.2 A). Similarly IL8 
mRNA expression levels decrease substantially over the time course (Fig. A.5.2 B), while RANTES basal 
mRNA expression levels (EtOH) moderately decrease over time (Fig. A.5.2 C). Interestingly, it appears that 
basal GILZ mRNA expression levels do not change over time (Fig. A.5.2 D).  
 
Furthermore the data suggests that while basal IL6 and IL8 mRNA levels decrease over time, DEX and 
MPA treated expression levels do not decrease in expression levels to the same extent as the basal 


































Figure 3.16: DEX and MPA-mediated repressive effects on select genes is lost over time, while 
transactivation effects are maintained. PHA activated PBMCs were pre-treated with 100 nM DEX, MPA or 
0.1% (v/v) vehicle control (EtOH) for 7 days with half media exchange at day 3 and 6. Samples were harvested every 
day from day 2 to day 7 for RNA isolation. 250 ng RNA was reverse transcribed to cDNA and used as template in 
subsequent real time qPCR. Relative mRNA expression levels of IL6 (A) and IL8 (B) were normalised to GAPDH 
mRNA expression levels. Relative fold change in expression was determined by setting vehicle treatment (EtOH) at 
day 2 to 1. Histograms represent pooled data from four independent experiments from four female donors plotted as 
mean ± SEM. Statistical significance was determined by one-way ANOVA with a Dunnett’s post-test or unpaired 
student t-tests comparing each sample to the vehicle control (EtOH) with *, **, *** and **** denoting p<0.05, p<0.01, 
p<0.001 and p<0.0001 respectively  
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A.6. MTT Viability Assay in Explants 
 
In chapter 4, primary cervical tissue was obtained from women who had undergone hysterectomies for 
benign reasons. For each sample, an MTT viability assay was performed to determine the viability of the 
tissue upon arrival. Additionally, for the infection experiments in which incubation times were longer than 2 
days, MTT viability assays were also performed at the end of the experiment (Fig A.5.1). This was done to 
compare the viability of the sample at the start of the experiment to the viability at end of the experiment. 
The cervical tissue obtained from the pathologist varied greatly in size. Thus for some of the infection 
experiments, an MTT assay was not performed at the end of the experiment (Prog 0049 and Prog 0051), 
as there was no available piece of tissue (Fig A.6.1 A). When pooling the MTT data, there was no 
difference between the viability of the donor tissue at the start of the experiment compared to the viability of 
the donor tissue at the end of the experiment (Fig. A.6.1 B). Interestingly, in two donors (Prog 0028 and 
Prot 0003) viability was greater at the end as compared to the start of the experiment. This could be due to 
the fact that the MTT viability assay is performed on a different piece of explant tissue at the start and at the 
end of the experiment. Since sample sizes varied in this study, it could be that larger explant pieces 
produced higher levels of the purple formazan that could contribute to the variability of the viability 




Figure A.6.1: Viability of tissue used in the infection studies. Where possible, MTT assays were performed 
at the start (solid bar) and at the end (checked bar) of the experiment. 5 mg/ml MTT in phenol red free RPMI was 
added at a final concentration of 10% of the culture volume. Tissues were incubated for 2 hours at 37℃. The tissue 
was subsequently removed and measured on a scale, and placed in 200 µl 0.1N HCl in isopropanol overnight at -
20℃. 100 µl of the sample was measured at 520 nM, with a background measure at 620 nM in a spectrophotometer 
(Thermo Scientific). MTT values were measured and divided by the weight of the tissue. (A) For each donor, MTT 
values at the end of the experiment were normalised to the MTT value obtained at the start of the experiment. (B) 
shows the average MTT values obtained at the start and end of the pooled infection experiments. 
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Repeated measure two way ANOVA analysis for ectocervical 
explant HIV-1 infection time course analysis 
 
Introduction ........................................................................................................................................... 212 
Table B1: Pooled repeats (n = 6) of ectocervical explants infected with HIV-1BaL_Renilla .................. 212 
Table B2: Pooled repeats (n = 7) of ectocervical explants infected with HIV-1pNL4.3 .............................. 213 
Table B3: Pooled repeats (n = 3) of ectocervical explants where MPA treated samples had increased 
infection levels compared to the vehicle control for samples infected with HIV-1BaL_Renilla ....................... 213 
Table B4: Pooled repeats (n = 3) of ectocervical explants where MPA treated samples had decreased 
infection levels compared to the vehicle control for samples infected with HIV-1BaL_Renilla ....................... 214 
Table B5: Pooled repeats (n = 5) of ectocervical explants where MPA treated samples had increased 
infection levels compared to the vehicle control for samples infected with HIV-1pNL4.3 ............................ 214 
Table B6: Pooled repeats (n = 3) of ectocervical explants where MPA treated samples had decreased 








In order to statistically analyse the effects of MPA and NET on HIV-1 infectivity in explants compared to 
the vehicle treatment, a repeated measures two way ANOVA was performed. In these analyses, only 
matched samples with matched time points can be used. As such data from days 3, 7 and 10 post 
infection were used in the analysis for all treatment groups. Results from the analysis of ectocervical 
explants infected with either HIV-1BaL_Renilla or HIV-1pNL4.3 were either pooled to represent the entire data 
set, or grouped together for those donor samples that indicated an increase in infection, or a decrease in 
infection, with MPA treatment compared to the vehicle control. Statistical significance of difference for 
time, treatment or an interaction was determined using two way ANOVA, with a Tukey’s multiple 
comparison test to determine the statistical significance between treatment groups at the selected time 
points. 
 


















Table B3: Pooled repeats (n = 3) of ectocervical explants where MPA treated samples had 






Table B4: Pooled repeats (n = 3) of ectocervical explants where MPA treated samples had 
decreased infection levels compared to the vehicle control for samples infected with HIV-1BaL_Renilla 
 
 
Table B5: Pooled repeats (n = 5) of ectocervical explants where MPA treated samples had 






Table B6: Pooled repeats (n = 3) of ectocervical explants where MPA treated samples had 




*For this grouping, only two out of the three experiment groups included treatment with NET, as such for this analysis 
























How long since 
contraception? 
Type of experiments 
performed on tissue 
Prog 
0001  _  _  _  _ 45 3 3.2 274.6 9 Luteal  No N/A N/A SR western 
Prog 
0002  _  _  +  _ 43 8.6 11.9 367.6 1.4 Follicular No N/A Never Taken SR Western 
Prog 
0005  _  _  +  + 43 5.9 2.8 504.5 30.3 Luteal  No N/A N/A SR western 
Prog 
0006  _  _  +  + 37 4.0 4.3 318.4 9.1 Follicular No N/A N/A SR western 
Prog 
0007  _  _  +  _ 41 6.2 3.5 929.2 1.6 Follicular No N/A N/A SR Western 
Prog 
0008  _  _  +  _ 42 2.3 3.7 280.6 11.1 Follicular No N/A N/A SR western 
Prog 
0010  _  _  +  _ 45 34.3  34.8 18.4 0.7 Perimenopausal No N/A Unknown 
Progestins + 
Glucocorticoids 48 hr 
Prog 
0011  _  _  +  _ 49 7.9  6.0 1325 1.6 Ovulatory No N/A Unknown 
Progestins + 
Glucocorticoids 48 hr, SR 
western 
Prog 
0012  _  _  +  + 50 1.7 3.7 306.8 43.1 Luteal No N/A Unknown SR western 
Prog 
0013  _  _  +  + 45 1.5 4.3 237.6 8.6 Luteal No N/A Unknown SR western 
Prog 
0015  _  _  +  + 48 24.7  33.9  197.7 0.9  Perimenopausal No N/A Unknown 
Progestins + 
Glucocorticoids 48 hr 
Prog 
0021  _  _  +  _ 47 8.8 14.0 194.1 0.8 Follicular No N/A Unknown SR western 
Prog 
0023  _  _  +  _ 37 13.3 4.3 2110 2.0 Follicular No N/A Unknown SR western 
Prog0024  _  _  +  + 45 1.8  1.9  1016 52.9 Luteal  No N/A Unknown 
Progestins + 
Glucocorticoids 48 hr, SR 
western 
Prog0025  _  _  +  + 47 12.6 17.5 152.7  0.5  Follicular No Depo 
Discontinued 1 
year prior to 
surgery 
100 nM progestins + BaL 
infection; SR western 
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Patient 















How long since 
contraception? 
Type of experiments 
performed on tissue 
Prog0026  _  _  +  _ 35 7.4  5.7 197.4 0.7 Follicular No N/A N/A 
MPA dose response, 100 
nM progestins fo 
endocervix; SR western 
Prog 0027  _  _  +  _ 36 2.4 2.8  341.7 7.3 Luteal  No N/A N/A 
MPA dose response, 100 
nM progestins fo 
endocervix, SR western 
Prog 0028  _  _  +  _ 45 5.4 4 1169 0.2 Follicular No N/A N/A 
MPA dose response, 100 
nM progestins of 
endocervix, SR western 
Prog 0032  _  _  +  _ 45 0.1 0.1 18.4 0.4 Perimenopausal No N/A N/A 100 nM progestins of endocervix 
Prog 0034    +  _ 41 4.1 2.6 343.1 18.8 Luteal No Sterilisation N/A SR western 
Prog 0035  _  _  +  _ 50 4.1 2.6  343.1 18.8 Luteal  No Sterilisation N/A 100 nM progestins + Infection with pNL4.3 
Prog 0037  _  _  +  _ 46 35.7 63.8  39.3 0.5 Perimenopausal No N/A N/A 100 nM progestins + Infection with pNL4.3 
Prog 0039  _  _  +  _ 49 3.8 2.8  408.6 12 Luteal  No Sterilisation N/A 
100 nM progestins + 
Infection with pNL4.3, SR 
western 
Prog 0040  _  _  +  _ 43 3.1 7.2 125.9  0.3 Follicular No N/A N/A 100 nM progestins + Infection with pNL4.3 
Prog 0041  _  _  +  _ 52 78.3 70.2  36.8 0.2 Perimenopausal No N/A N/A 100 nM progestins + Infection with pNL4.3 
Prog 0042  _  _  +  + 44 10.4 6.1 230.4  1.6 Follicular Yes DepoProvera 
Discontinued 1 
month prior to 
suergery 
100 nM progestins + 
Infection with pNL4.3 and 
Bal 
Prog 0043  _  _  +  _ 43 27.5 9.8 2501.0 0.9 Ovulatory No N/A N/A 
100 nM progestins + 
Infection with pNL4.3 and 
Bal, SR western 
Prog 0044  _  _  +  _ 48 6.3 6.1 537.1 0.3 Follicular No N/A N/A 
100 nM progestins + 
Infection with pNL4.3 and 
Bal 
Prog 0045  _  _  +  + 50 4.9  9.1  113.6 1.4  Follicular No N/A N/A 
100 nM progestins + 
Infection with pNL4.3 and 
Bal 






































How long since 
contraception? 
Type of experiments 
performed on tissue 
Prog 0049  _  _  +  _ 44 3 5.9  84.2 0.5  Follicular No N/A N/A 
100 nM progestins + 
Infection with pNL4.3 and 
Bal 
Prog 0050  _  _  _  _ 38 5.6 6.3  476.3  0.9  Follicular No N/A N/A 
100 nM progestins + 
Infection with pNL4.3; SR 
western 
Prog 0051  _  _  +  + 41 0.6 3.3 212.4  0.5 Luteal  No N/A N/A 100 nM progestins + Infection with pNL4.3 
Prog 0052  _  _  +  _ 40 8.9 8.8 141.8  0.9 Follicular No N/A N/A 100 nM progestins + BaL infection 
PROT 
0001  _  _  +  + 43 0,6 1,9 370,5 32,1 Luteal  No Sterilisation N/A 
Progestins + 
Glucocorticoids 48 hr 
PROT 
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D 1: Growth Media for E. coli 
Luria Broth (LB): 
 
1% (w/v)  tryptone (Merck, South Africa) 
0.5% (w/v)   yeast extract (Merck, South Africa) 
1% (w/v)  NaCl (Merck, South Africa) 
 
Containing 100 μg/ml ampicillin or 100 μg/ml ampicillin and 100 µg/ml carbenicillin for IMC propagation 
 
For LB-agar plates add 1.5% agar (Merck, South Africa) 
 
D 2: DNA gel electrophoresis 
 
50 X TAE buffer for gel electrophoresis: 
 
2.0 M   TRIS (Sigma-Aldrich, South Africa) 
0.05 M  EDTA (Merck, South Africa) 
 
pH 8.2 - 8.4 (at 25°C) 
 
Use glacial acetic acid  (Merck, South Africa) to pH buffer.  
Autoclave. 
 
Prepare 1 X TAE from stock with dH2O. 
 
1 X TAE gel with agarose: 
 
For 100 ml gel: 
 
Dissolve appropriate amount of agarose (SeaChem) into 100 ml 1 X TAE and bring to the boil 
 
For plasmid DNA:     0.5% agarose 
For PCR product visualisation:  1.5% agarose 
 
Once cooled, add 1 µl of 10 mg/ml EtBr per 100 ml 1 X TAE - agarose 
 
Mix well and pour into gel casting set. 
 




1 ml  diethyl pyrocarbonate (DEPC; Sigma-Aldrich) 
in 1 L  dH2O (1:1000 dilution) 




10X Morpholinopropanesulfonic acid (MOPS) buffer: 
 
0.2 M   MOPS (Sigma-Aldrich) 
0.05 M  sodium acetate (Merck) 
0.01M   EDTA, pH 8.0 (Merck) 
 
Adjust pH to 7.0 with 10 M NaOH 
 
Denaturing formaldehyde gel mix (1% 100 ml): 
 
Dissolve 1 g agarose (SeaChem) in 70 ml DEPC-treated H2O and bring to boil.  
Add 10 ml 10X MOPS buffer and 20 ml formaldehyde (Merck, South Africa) in fume hood.  
Mix well and pour. 
 
RNA sample loading buffer: 
 
1.8 ml  DEPC H2O  
0.8 ml   Bromophenol blue solution (saturated) (Merck, South Africa) 
1 ml   glycerol (Merck, South Africa) 
1.5 ml   10x MOPS 
2.6 ml   formaldehyde (Merck, South Africa) 
7.3 ml   formamide (Merck, South Africa) 
 
Add 2.5 μl 10 mg/ml ethidium bromide (Sigma-Aldrich, South Africa) per 1 ml RNA sample loading buffer 
just before use. 
 
RNA electrophoresis buffer (500 ml): 
 
50 ml   1x MOPS 
14 ml   formaldehyde 
436 ml  DEPC-treated water 
 
D 4: Western blot analysis 
 
1 X TAPS lysis buffer: 
 
0.1 M   TAPS, pH 9.5 (1 M stock in water, pH to 9.5 at 25°C, filter sterilise) 
1 mM    PMSF (0.1 M stock in isopropanol) 
5 µg/ml   Leupeptin  (5 mg/ml stock in H2O) 
2 µg/ml  Aproptinin (2 mg/ml stock in H2O) 
1 X   completeMini protease inhibitor tablet (1 tablet/ 10 ml buffer; Roche Applied Science, South 
Africa) 
 
Vortex, until dissolved and store at 4°C. 




5X SDS sample buffer: 
 
100 mM  TRIS-HCl, pH 6.8 
5% (w/v)  SDS (Sigma-Aldrich, South Africa) 
20% (v/v)  glycerol 
2% (v/v)  β-mercaptoethanol (Merck, South Africa) 
0.1% (w/v)  bromophenol blue 
 
1X Running buffer: 
 
25 mM  TRIS-HCl, pH 6.8 
250 mM  glycine 




25 mM  TRIS-HCl, pH 6.8 
200 mM  glycine (Merck, South Africa) 
10% (v/v)  methanol (Merck, South Africa) 
 
1 X TRIS buffered saline (TBS): 
 
50 mM  TRIS-HCl, pH 6.8 




50 mM  TRIS-HCl, pH 6.8 
150 mM  NaCl 




100 mM  β-mercaptoethanol 
2% (w/v)  SDS 
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E.1: Infection optimisation experiments in PBMCS 
 
In chapter 3 it was necessary to establish optimal infection conditions in PBMCs. The first optimisation step 
was to determine whether the use of IL2 was necessary for the infection experiments. In Fig. E.1.1 it was 
evident that IL2 was needed to detect p24 levels in PBMCs over time. In samples infected without IL2, p24 
values in the virus control (VC) and EtOH HIV samples were low and similar to the mock infected conditions 
(cells only: CO and EtOH). In contrast, PBMCs infected in the presence of IL2 had much higher detectable 




Figure E.1.1 Higher p24 expression levels were detected via p24 ELISA in PBMCs incubated with 30 
U/ml IL2. PBMCs were activated with PHA for one day and subsequently cultured in the presence or absence of 30 
U/ml IL2 for the duration of the experiment. PBMCs (± IL2, with +IL2 conditions indicated with a bracket in the Fig) 
were either left untreated [cells only (CO)], or incubated with the vehicle control (EtOH) for 48 hours. Thereafter, 
PBMCs were either infected with 10 IU/ml HIV-1BaL_Renilla or mock infected with a media control for 2 hours. PBMCs 
that were untreated and subsequently infected with HIV-1BaL_Renilla are shown as the virus control (VC). PBMCs 
stimulated under control conditions (EtOH) and subsequently infected with HIV-1BaL_Renilla are denoted as “EtOH HIV”. 
PBMCs infected with the mock control (media), remained labeled as either “CO” or “EtOH”. After infection, PBMCs 
were washed 4 times with 1 X PBS and media with the respective ligands was added. Media was replaced every 
second day. PBMCs were harvested at days 5 and 7 days post infection and p24 expression levels were measured by 
p24 ELISA. Histograms show pooled results of three independent experiments, with three donors and plotted as mean 




Given the prohibitively high cost of purchasing of highly sensitive p24 ELISAs; the use of HIV-1BaL-Renilla IMC 
which allows one to detect HIV-1 replication levels via luminescence, was investigated. In addition PBMC 
viability over time was investigated to determine the time point with minimal loss of viability but sufficient 
time for HIV-1 replication to be detected. In Figure E.1.2 A, it was evident that cell viability did not change 
over time, and that 0.01% EtOH had no effect compared to no treatment (CO), in the absence of HIV-1 
infection. In addtion in samples infected with HIV-1, EtOH HIV samples were similar to the virus control 
samples (VC). Furthermore, PBMC viability was the similar in all conditions. Interestingly, when comparing 
the results for the p24 ELISA to those from the renilla assay, it was observed that the p24 assay results had 
higher background levels in the uninfected group compared to the uninfected renilla group (Fig. E.1.2 B and 
C). Furthermore, in the renilla assay, an increase in luminescence was observed over time (Fig. E.1.2 C) in 
the infected group, compared to the p24 ELISA assay (Fig.E.1.2 B). These differences could be due to the 
fact that the luminescence is measured from the cells, whereas the p24 ELISA measures secreted p24 
levels in the supernatant, which may be more variable. Therefore for the infection experiments in PBMCs, 





Figure E.1.2: Cell viability did not greatly change between days 5 and 7 post infection in PBMCs. 
Moreover, relative infection levels detected via luminscence were less variable than p24 levels 
measured by p24 ELISA in PBMCs. PHA activated PBMCs were either pre-treated with 0.01% (v/v) EtOH or left 
untreated (CO) for 48 hours. Pre-treated PBMCs were either infected with 10 IU/ml HIV-1BaL_Renilla IMC (VC and EtOH) 
or a mock control for 2 hours (CO and EtOH), washed 4 times with 1 X PBS and media with the respective ligands 
was added. Media was replaced every second day. PBMCs were harvested at days 5 and 7 post infection and MTT 
viability, p24 expression levels and luciferase activity were measured. (A) MTT activity was detected with a multiplate 
reader (Thermo Scientific) using a MTT cell viability kit (Sigma-Aldrich, South Africa). Values were normalised to 
vehicle which was set to 1. (B) PBMCs were harvested at days 5 and 7 days post infection and p24 expression levels 
were measured by p24 ELISA or (C) Renilla luciferase was measured with the Promega Renilla-Glo™ kit using a 
luminometer (Modulus Microplate, Glomax, Promega). P24 values and renilla values from B and C were normalised 
against their corresponding MTT values, and normalised to the virus control (VC) at day 5 post infection set to 100%. 
Histograms (A-C) show pooled results of three independent experiments, with three donors and plotted as mean ± 
SEM. CO: cells only, VC: virus control. 
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E.2: RNA isolation and infection optimisation experiments in primary cervical 
explants 
 
It was important to establish RNA isolation conditions in primary cervical explants for the work undertaken 
in chapter 4. Initially RNA isolation kits were used to optimise RNA isolation conditions from explant 
samples after 48 hours of culture. Several RNA isolation kits, namely the Qiagen AllPrep Mini Kit 
RNA/DNA/Protein, Qiagen RNeasy Nano Kit, The Bioline RNA Mini Kit and the Machery Nagel XS-RNA 
isolation kit. As a comparison, TriReagent® was used. OD readings (including 260/280 and 260/230 ratios) 
and RNA formaldehyde gels were used to assess the quantity and quality of the total RNA isolated by these 
different methods. Surprisingly, TriReagent® was the best RNA isolation method used as judged by both 
yield and integrity.  
Interestingly, no kit produced sufficient RNA yields for subsequent downstream applications (see Table 
E.2). RNA yields as determined from the OD/ml measurements were low, and were insufficient for analysis 
on an RNA formaldehyde gel (less that 150 ng). Interestingly, TriReagent® produced the best yields of 
RNA (Table E.2) and quality. When assessing the quality of the TriReagent® isolated RNA from explant 
tissue after 48 hours of culture on an RNA formaldehyde gel, the 28S and 18S ribosomal bands were 
relatively sharp. Additionally there was minimal smearing on the gel (Fig. E.2.1 A), suggesting that the 
quality of the RNA was acceptable. Furthermore 260/280 ratios were between 1.8 – 2.0 and 260/230 ratios 
were between 1.4 – 1.8, suggesting that there was some protein, phenol and/or salt contaiminants using 
this isolation method. 
Similarly protein isolation was optimised (Table E.2). The Qiagen AllPrep Kit produced the highest quantity 
of protein as assessed by western blotting. Additionally protein isolation using the Qiagen AllPrep kit was 
the most consistent out of all the other methods tested. This method was used in Fig 4.1 in chapter 4. 
Some of the protein isolation methods included the resuspension of the protein pellet in a sample 
application buffer, as such these samples could not be quantitated using the Bradford assay. 
It is also known that one can isolate protein from the phenol fraction left in the TriReagent® RNA isolation 
method. This method was used and the results can be seen in chapter 4, Fig 4.5. However, this method 
was inconsistent in both quality and quantity of protein. Some samples had no protein precipitate. In 
addtion, some samples appeared degraded on the SDS-PAGE gel.  
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Table E.2: Quantity and yield of RNA and protein using different commercially available kits or reagents. 
 
Kit RNA Isolation Protein Isolation 
Qiagen AllPrep Kit Poor                                     (3 - 50 ng yield in 25 μl) 
Best                                
(200 - 300 μg yield) 
Machery Nagel TriPrep Kit Poor (0 – 10 ng yield in 20 μl)  Good 
Machery Nagel XS RNA isolation  Poor                                    (0 - 20 ng yield in 20 μl) N/A 
TriReagent® (Sigma-Aldrich) Best                                     (400 - 2000 ng yield in 10 μl) Good 
Bioline RNA Mini Kit Worst                                    (no RNA eluted) N/A 
 
When isolating RNA, using the TriReagent® method, from samples that had been incubated for 14 days, 
RNA quality was greatly reduced as assessed using RNA formaldehyde gels. As seen in Fig E.2.1, RNA 
from samples that had been incubated for 48 hours with different ligands produced good quality RNA (Fig. 
E.2.1 A), while RNA isolated from samples after 12 days incubation with ligands did not (Fig. E.2.1 B). RNA 
in this sample set appeared degraded, with 28S and 18S ribosomal bands indistinct. Additionally samples 
in Fig. E.2.1 B had high levels of smearing, indicating the low quality of the RNA isolated. 
 
 
Figure E.2.1: RNA isolation from primary ectocervical explants using TriReagent® produces 
the best possible quality RNA from samples after 48 hours, while RNA quality is significantly 
reduced after 12 day incubation with ligands. (A) 250 ng RNA obtained from ectocervical explants after 
48 hours incubation with 0.1% EtOH and (B) 250 ng RNA obtained from ectocervical explants after 12 days 
incubation with 0.1% EtOH was electrophoresed for 30 minutes at 65 V on a A 1% agarose RNA formaldehyde 
gel. Gels were visualised on a Agarose gels were visualised under 256 nM UV light in a Syngene, G:Box 
(Vacutec, England) and images acquired using GeneSnap from synGene, version 7.08 (SynGene, England). (A) 
Lanes 1,2 and 3 are individual explant samples from the same donor treated with EtOH for 2 days. (B) Lanes 





One of the challenges experienced in this project was the optimisation of the infection experiments with 
primary cervical explants. In order to acquire the data for chapter 4, it was necessary to establish the 
conditions. The technique was learned at Imperial College, UK in 2011, and subsequently set up in South 
Africa. Due to the lower titre virus produced for the duration of this project, infecting each tissue explant 
individually was not feasible. As such, conditions were adapted from Arkeylan et al (2013) so that a 
triplicate treatment group was infected in one 24 well for 2 hours. Figure E.2.2 A and B shows the results 
using two donors, with three explant samples used per condition. In each experiment, triplicate groups were 
either mock infected (NV control), infected individually, or infected in a group of three in a 24 well plate (as 
described in chapter 2) with HIV-1BaL-Renilla. Virus replication levels were assessed by measuring p24 HIV-1 
protein levels in the supernatant. The results from these pilot experiements suggest that the group infection 
method results in higher levels of p24 levels produced (Fig. E.2.2 A and B). In addition, the data from one 
donor indicated that infecting the samples in a group appeared to reduce the error within a group (Fig. E.2.2 
B). Furthermore, the infection levels were similar between the two methods, suggesting that infecting in a 
group did not change the trend in the infection levels over time as compared to infecting individually. Thus 




Figure E.2.2: Primary cervical explants were infected using different methods. (A) and (B) 
Ectocervical explants in triplicate, were either infected individually or placed in a well of a 24-well plate and 
infected with 500 IU/ml HIV-1BaL_Renilla for 2 hours. Additionally a no virus control (NV) was included. Explants 
were cultured for a further 7 days and infection was measured by p24 ELISA (Innogenetics, Belgium). The 
histograms are representative of absolute p24 values (pg/ml). Histograms show pooled results of one independent 






Since a virus inhibitor control was not included in every experiment, it was important to establish whether 
productive infection occured. As such, it was thought that a good indication of productive infection would be 
if the infection levels of the vehicle control increased significantly over time. Supernatants were harvested 
at days 3, 5, 7 and 10 post infection from the explant samples. Thereafter, p24 levels were measured using 
a p24 ELISA. In order to assess the effects of MPA and NET on HIV-1 replication, p24 expression levels 
were made relative to the vehicle control (EtOH), with the EtOH values set to 100% relative infection at day 
3 post infection. The relative expression values of the vehicle control were then analysed using a one-way 
ANOVA with a linear post-test, to determine if HIV-1 replication under the control conditions increased over 
time. Fig. E.2.3 shows the results from one such experiment. In Fig. E.2.3 A, Prog 0043 was infected with 
HIV-1pNL4.3 IMC and the relative infection levels were subsequently assessed using the post-test analysis. It 
was observed in this experiment that the infection levels did not significantly increase over time, with a p 
value = 0.3067. As such this experiment was excluded from all subsequent analyses. In Fig E.2.3 B, Prog 
0043 was infected with HIV-1BaL_Renilla IMC. In this sample, the linear trend post-test indicated that the 
values significantly increased over time (p = 0.0011), as such this experiment was included in all analyses. 
 
Figure E.2.3: Productive infection in primary cervical explants was determined using a one-
way ANOVA with a post-test for a linear trend. Ectocervical explants were processed as described in Fig 
4.8 and 4.9. The relative infection levels of the vehicle control were assessed for a linear trend as a correlator of 
productive infection. (A) The relative infection levels in the vehicle control of donor, Prog 0043, infected with HIV-
1pNL4.3 IMC did not increase over time. The table below decribes the slope, R squared value and p value of the curve. 
(B) The relative infection levels in the vehicle control of donor, Prog 0043, infected with HIV-1BaL_Renilla IMC increases 
over time, and that this increase is significant. The table below the graph decribes the slope, R squared value and p 
value of the curve. The XY plots are representative of the mean +/- SD of triplicates from one donor. A one-way 
ANOVA with a post-test for a linear trend was performed in Prism 6 for Mac OS X (GraphPad Software, version 6). 
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One pilot experiment using the R5 HIV-1 entry inhibitor, Maraviroc (MVC), observed that HIV-1 replication 
decreased over time in the MVC treated tissue explant compared to the vehicle control (EtOH) (Fig. E.2.4). 
However pre-incubation time with 5 µg/ml MVC did not reduce initial virus infection levels compared to the 
control (Fig E.2.4, day 3). It could be that a longer pre-incubation time or a higher concentration of MVC are 
needed. The data from this pilot experiment suggests that the increase in HIV-1BaL_Renilla replication in the 
vehicle control (EtOH) is productive (Fig. 2.4) compared to MVC in which HIV-1 levels decrease over time.   
 
Figure E.2.4: Pilot study with MVC to determine productive infection in primary cervical 
explants. Ectocervical explants were processed as described in Fig 4.8. The XY plots are representative of the 
mean +/- SD of triplicates in the vehicle control (EtOH) or the mean of one sample in the MVC treated group from one 
donor.  
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Abstract
Clinical studies suggest that the injectable contraceptive medroxyprogesterone acetate (MPA) increases susceptibility to
infections such as HIV-1, unlike the injectable contraceptive norethisterone enanthate (NET-EN). We investigated the
differential effects, molecular mechanism of action and steroid receptor involvement in gene expression by MPA as
compared to NET and progesterone (P4) in the End1/E6E7 cell line model for the endocervical epithelium, a key point of
entry for pathogens in the female genital mucosa. MPA, unlike NET-acetate (NET-A) and P4, increases mRNA expression of
the anti-inflammatory GILZ and IkBa genes. Similarly, MPA unlike NET-A, decreases mRNA expression of the pro-
inflammatory IL-6, IL-8 and RANTES genes, and IL-6 and IL-8 protein levels. The predominant steroid receptor expressed in
the End1/E6E7 and primary endocervical epithelial cells is the glucocorticoid receptor (GR), and GR knockdown experiments
show that the anti-inflammatory effects of MPA are mediated by the GR. Chromatin-immunoprecipitation results suggest
that MPA, unlike NET-A and P4, represses pro-inflammatory cytokine gene expression in cervical epithelial cells via a
mechanism involving recruitment of the GR to cytokine gene promoters, like the GR agonist dexamethasone. This is at least
in part consistent with direct effects on transcription, without a requirement for new protein synthesis. Dose response
analysis shows that MPA has a potency of ,24 nM for transactivation of the anti-inflammatory GILZ gene and ,4–20 nM
for repression of the pro-inflammatory genes, suggesting that these effects are likely to be relevant at injectable
contraceptive doses of MPA. These findings suggest that in the context of the genital mucosa, these GR-mediated
glucocorticoid-like effects of MPA in cervical epithelial cells are likely to play a critical role in discriminating between the
effects on inflammation caused by different progestins and P4 and hence susceptibility to genital infections, given the
predominant expression of the GR in primary endocervical epithelial cells.
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Introduction
A central issue in women’s health in developing countries is
choice of contraceptive with minimal effects on susceptibility to
infectious diseases, in particular to human immunodeficiency virus
(HIV)-1 acquisition via the female reproductive tract (FRT).
Epithelial cells lining the FRT are the first line of defence against
pathogens and serve not only as a physical barrier but also express
a wide variety of immune mediators aiding in both innate and
adaptive immunity [1–3]. Interleukin (IL)-6, IL-8 and regulated-
upon-activation-normal-T-cell-expressed-and-secreted (RANTES)
are expressed in both primary and immortalised vaginal and
cervical epithelial cells [4–6]. In particular, the simple columnar
epithelial cells of the endocervix constitutively express IL-6, IL-8,
and RANTES genes [5], with the endocervical cells being more
active in cytokine secretion than the ectocervical cells [7,8].
Pathogens such as herpes simplex virus (HSV), human papillo-
mavirus (HPV), and HIV have been shown to infect epithelial cells
of the FRT and the process is affected by treatment with hormones
such as progesterone (P4) [9,10].
Several reports suggest that endogenous steroid hormone levels
and synthetic progestins used in contraception, influence suscep-
tibility and disease predisposition to many genital tract infections
(reviewed in [2,11]). Treatment of animals and humans with P4 or
synthetic progestins has been reported to increase susceptibility to
viral and bacterial infections [12–16]. Consistent with these
findings, the progestin medroxyprogesterone acetate (MPA) is used
as an immuno-compromising agent to induce viral infectivity in
mice [17]. Furthermore, a prospective cohort study reported that
injectable contraceptive users are more susceptible to both
chlamydia and gonococcal infections than oral contraceptive users
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[15]. MPA, administered for contraception as Depo-MPA
(DMPA) or Depo-Provera, is a 150 mg three-monthly intramus-
cular injection used by millions of women worldwide, particularly
in Sub-Saharan Africa with high HIV-1 incidence and prevalence
[18,19]. Norethisterone enanthate (NET-EN) is a 200 mg two-
monthly injectable with less widespread use than MPA, although
its usage is high in some regions of South Africa [20]. In most
studies the adjusted hazard ratio for HIV-1 acquisition by DMPA,
or injectable contraceptives users where the majority of women are
on MPA, is higher than that associated with no contraception or
oral contraception [18,21–30]. While only a few studies have
investigated the risks associated with the use of injectable NET-EN
on HIV-1 acquisition, none have shown a significant association
with HIV-1 acquisition [18,27,30]. In addition, increases in both
HIV-1 and HSV shedding have been reported with MPA [31,32],
as well as the presence of more viral variants and higher viral loads
in DMPA users infected with HIV than non-users [33]. The
mechanisms whereby endogenous P4 and synthetic progestins
affect pathogen entry and transmission in the FRT are not well
understood, but may involve modulation of the immune response
both at the systemic level and at the genital mucosa. Understand-
ing the relative effects of MPA vs NET on genital mucosal immune
function is extremely important for choice of contraception,
especially for developing countries where injectable contraception
usage is high. For example, at the Kwazulu-Natal site in South
Africa for the CAPRISA microbicide trial, about 80% of the
women investigated were on injectable progestin-only (DMPA or
NET-EN), as compared to 15% on oral contraceptives [34]. HIV
prevalence among young women in the general population in
southern Africa is highest (about 25%) in the 20–24 age group and
the ratio of the prevalence of HIV infection among women relative
to men shows that these women are approximately 3.3 times more
likely to be infected with HIV than young men in this region [35].
Clinical research on the effects of contraceptives on HIV-1
acquisition, transmission and disease progression has been
hampered by a lack of understanding of the molecular mecha-
nisms of action of the progestin components of contraceptives and
a lack of appreciation of the differences between progestins, which
cannot be considered to act as a single class of compounds
regarding their side-effect profiles [36–38]. Although MPA and
NET elicit similar progestational effects to P4 [39,40], differences
in biological effects mediated via steroid receptors other than the
progesterone receptor (PR) could be expected [36–38], and have
been demonstrated for the GR [41]. Synthetic progestins were
designed to mimic the actions of the natural ligand P4 but with
better bioavailability [38]. Both NET-EN and NET-A are
metabolised to the active molecule NET, as well as other
metabolites, unlike MPA, which is itself the active compound
[42]. Progestins were also designed to be potent, high affinity PR
agonists. However, many progestins bind to other members of the
steroid receptor family, including the GR, the androgen receptor
(AR) and mineralocorticoid receptor (MR) [43], thereby exhibiting
off-target effects via these receptors [37,38]. It has been shown that
MPA has a higher relative binding affinity compared to NET-A
and P4 for the human GR (relative binding affinity % of 79.1, 0.88
and 5.57 for MPA, NET-A and P4, respectively) [41] and unlike
NET-A and P4, acts as a potent partial to full GR agonist for both
transactivation and transrepression [41,44]. The GR, a ligand
activated steroid receptor, has potent anti-inflammatory and
immunosuppressive activity [45]. Consistent with this idea, we
have previously shown that MPA, at doses in the range found in
serum of contraceptive users, represses expression of mRNA and
protein levels of the pro-inflammatory cytokine IL-6 and the
chemokine IL-8, in mouse fibroblast cells, most likely via the GR
[46]. Similarly, Bamberger et al. showed that MPA represses IL-2,
IL-1, and IL-6 protein expression in normal human lymphocytes,
most likely via the GR [47]. Thus it is possible that MPA used as
contraceptive modulates immune function and inflammation, and
hence responses to pathogens, by changes in cytokine gene
expression, particularly in the genital mucosa. A key question that
remains to be investigated is what the effect is of different synthetic
progestins as compared to P4 on cytokine gene expression and
immune function in the FRT. These are likely to vary since we
have previously shown that MPA, compared to NET-A and P4,
elicit very different effects on IL-8 promoter expression in
HEK293 cells, mediated via the GR [41], as well as exhibit
differential effects in several steps of the GR pathway [44]. In
support of an immunosuppressive role of MPA in increasing HIV-
1 pathogenesis, MPA was recently shown to have immunosup-
pressive effects on key regulators of cellular and humoral immunity
and increased HIV-1 replication in activated peripheral blood
mononuclear cells (PBMCs) ex vivo [48,49]. The Hel laboratory
also showed that women using DMPA displayed lower levels of
IFNa in plasma and genital secretions compared to controls with
no hormonal contraception, consistent with an immunosuppres-
sive effect of DMPA in vivo [48,49]. A possible mechanism for
differential effects of progestins and P4 on HIV-1 acquisition may
include differential effects on inflammation in the FRT. However
the direct effects of MPA, as compared to NET and P4, on
expression of inflammatory markers in endocervical cells, the
prime site for HIV-1 acquisition, have not been previously
investigated. Using a human immortalised endocervical (End1/
E6E7) epithelial cell line [50] as a model for the mucosal surface of
the endocervix, as well as the HeLa cervical cell line, the present
study aimed to determine the relative effects, molecular mecha-
nisms and steroid receptor involvement of MPA, P4 and NET-A
in expression of key inflammatory response genes.
Materials and Methods
Antibodies and Compounds
The following primary antibodies were obtained from Santa
Cruz Biotechnology Inc., USA; GR(H-300): sc-8992, PR(C-20)
(which detects PRA and B isoforms): sc-539, AR(441): sc-7305,
GAPDH(0411): sc-47724, MR(MCR, H300): sc-11412, ERa(MC-
20): sc-542. The flotillin-1 (610820) antibody was purchased from
BD Transduction Laboratories (USA). The following secondary
antibodies were obtained from Santa Cruz Biotechnology Inc.,
USA; anti-mouse: sc-2005, anti-goat: sc-2350 (used as IgG for the
ChIP assay) and anti-rabbit: sc-2313. The ligands dexamethasone
(DEX), MPA, P4, NET-A, NET, aldosterone (ALD) and
mibolerone (MIB) were obtained from Sigma-Aldrich (South
Africa). Human tumour necrosis factor a (TNFa) was obtained
from Celtic Diagnostics (South Africa). Protease inhibitor cocktail
tablets (EDTA-free) (cat #04693159001) were obtained from
Roche (South Africa). Cycloheximide (CHX) was purchased from
Sigma-Aldrich (South Africa).
Cell Culture
Human epithelial cervical cancer cells (HeLa) purchased from
America Type Culture Collection (ATCC, USA) were cultured in
75 cm2 flasks (Greiner Bio-one International, Austria) in Dulbec-
co’s modified Eagle’s medium (DMEM) (Sigma-Aldrich, South
Africa) supplemented with 10% (v/v) foetal bovine serum (High-
veld Biological, South Africa) 100 IU/mL penicillin and 100 mg/
mL streptomycin (Gibco, Invitrogen, UK). End1/E6E7 (human
endocervical cells immortalized with human papillomavirus E6/
E7 [54] were obtained from Dr Fichorova, OB/GYN Depart-
Differential Repression of Inflammation by Progestins
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ment, Brigham & Women’s Hospital, Boston, USA. The End1/
E6E7 cells were cultured in 75 cm2 flasks (Greiner Bio-one
International, Austria) in keratinocyte serum-free medium (ker-
sfm; Sigma-Aldrich, South Africa) supplemented with keratinocyte
growth supplement, 100 U/ml penicillin and 100 mg/ml strepto-
mycin (Gibco, Invitrogen, UK). All cells were maintained at 37uC
in a 5% CO2 incubator. Cells were passaged with 0.25% trypsin/
0.1% EDTA in PBS (Highveld Biological, South Africa).
Trypsinization was terminated with neutralization medium
[DMEM (Sigma-Aldrich, South Africa), 10% (v/v) calf serum
(Highveld Biological, South Africa), 100 U/ml penicillin and
100 mg/ml streptomycin (Gibco, Invitrogen, UK)]. The cell lines
were regularly tested for mycoplasma infection by means of
Hoechst staining [55], and only mycoplasma-negative cells were
used in experiments.
Plasmids
pcDNA3 (empty vector) plasmid was obtained from Invitrogen,
while the pcDNA3-hGR (GR) plasmid was a gift from Prof. D.W.
Ray (Centre for Molecular Medicine, School of Clinical and
Laboratory Sciences, University of Manchester, UK [56]. pMT-
PR-B (PR) was obtained from Prof. S. Okret (Karolinska Institute,
Sweden) [51]. pRS-hMR (MR) expression plasmid was obtained
from Prof. R.M. Evans (University of California, USA) [52]. pSV-
hAR (AR) was a kind gift from Prof.F. Classens (Catholic
University of Leuven, Belgium) [53]. pSG5-hER (ER) was
obtained from Prof.F. Gannon (EMBL, Germany) [54].
RNA Isolation and Quantitative Real Time PCR (qRT-PCR)
Total RNA was isolated from cells using Tri-reagent (Sigma-
Aldrich, South Africa) according to the manufacturer’s instruc-
tions, and RNA (500 ng) was reverse transcribed using the
Transcriptor First Strand cDNA synthesis kit (Roche Applied
Science, South Africa) according to the manufacturer’s instruc-
tions. RT-PCR was performed using the Rotor-gene, RG-3000A
(Corbett Research, South Africa) according to the manufacturer’s
instructions using the Sensi-Mix SYBR Green I system (Celtic
Diagnostics, South Africa). The specific primer sets used were as
follows; for GILZ (cat #QT00091035, Qiagen, South Africa), for
IkBa, 59-ACTCGTTCCTGCACTTGGCC-39 (forward primer)
and 59-TGCTCACAGGCAAGGTGTAG-39 (reverse primer), for
IL-6, 59-TCTCCACAAGCGCCTTCG-39 (forward primer) and
59-CTCAGGGCTGAGATGCCG-39 (reverse primer), for IL-8,
59-TGCCAAGGAGTGCTAAAG-39 (forward primer) and 59-
CTCCACAACCCTCTGCAC-39 (reverse primer), for RANTES
59-TACCATGAAGGTCTCCGC-39 (forward primer) and 59-
GACAAAGACGACTGCTGG-39 (reverse primer), for GAPDH
59-TGAACGGGAAGCTCACTGG-39 (forward primer) and 59-
CCACCACCCTGTTGCTGTA-39 (reverse primer). Relative
transcript levels were calculated with the method described by
Pfafflet al 2001 and were normalized to relative GAPDH transcript
levels [55].
Western Blotting
For the steroid receptor controls, COS-1 cells were seeded into
12-well plates (Greiner bio-one, Cellstar, Austria) at a density of
256104 cells/well. The next day the cells were transfected with
1 mg/well of empty vector, GR, AR or PR and 2 mg/well of MR
or ER using FuGENE 6 (Roche Diagnostics, South Africa). After
24 hrs, the cells were washed once with PBS and lysed with 50 ml
2X SDS sample buffer (5 X SDS sample buffer: 100 mM TRIS-
HCL pH 6.8, 5% (w/v) SDS, 20% (v/v) glycerol, 2% b-
mercaptoethanol and 0.1% (w/v) bromophenol-blue) and boiled
for 10 min at 100uC. In addition, lysates were prepared from
End1/E6E7 and HeLa cells seeded into 12-well plates at a density
of 356104 cells/well and 156104 cells/well, respectively. Equiv-
alent amounts of protein were loaded on either a 6% or 8% SDS-
PAGE before being transferred onto a Hybond-ECL nitrocellulose
membrane (Amersham, South Africa) using the Mini Protean III
blotting system (Bio-Rad, South Africa). Blots were probed for
anti-GR (1:4000), anti-PR (1:1000), anti-AR (1:1000), anti-ER
(1:500), anti-MR (1:1000), anti-GAPDH (1:20 000) at 4uC
overnight. Blots were washed 3 times with TBS containing 0.1%
Tween for 5 mins each and subsequently incubated with
horseradish peroxidise (HRP)-conjugated goat anti-rabbit
(1:10000) or goat anti-mouse (1:5000) secondary at room
temperature for 1 hr. Protein detection was performed using
ECL substrate (Thermo Scientific, South Africa) with visualization
on X-ray hyperfilm (Amersham, South Africa). Bands on the X-
ray film were quantified using AlphaEaseFC software version 3.1.2
(Alpha Innotech Corporation).
GR Knockdown by Small Interference RNA (siRNA)
GR knockdown was performed as previously described [56], but
briefly End1/E6E7 cells were seeded in 12-well plates at a density
of 356104 cells/well and incubated for 24 hrs. Thereafter, the
cells were transfected with 10 nM validated GR HS_NR3C1_5
(cat #SI02654757) (Qiagen, South Africa) siRNA directed against
the human GR or validated non-silencing scrambled sequence
control (NSC) siRNA (cat#1027310) (Qiagen, South Africa) using
HiPerfect transfection reagent (Qiagen, South Africa) as per the
manufacturer’s instructions. Cells were incubated for 48 hrs before
being treated for 24 hrs with 100 nM test compounds. RNA was
then harvested and mRNA levels were analysed by qRT-PCR, as
described above. To verify the protein knockdown, cells were
transfected in parallel and analysed by Western blotting as
described above.
Luminex
Supernatants were collected from the siRNA experiments prior
to cell harvest. Thereafter, cytokine protein levels were measured
using a luminex assay kit according to the manufacturer’s protocol
(Bio-rad, South Africa).
Chromatin Immunoprecipitation (ChIP) Assay
ChIP was performed as described in Verhoog et al 2011 with
modifications [56]. HeLa cells were plated at 36106 cells per dish
in 15 cm dishes and grown for 24 hrs in full DMEM, before
changing to phenol red-free DMEM (Sigma-Aldrich, South
Africa) for an additional 24 hrs. Thereafter, the cells were
incubated with serum-free, phenol-free DMEM for 2 hrs, before
treatment with 100 nM DEX, MPA, P4 and NET-A for 1 hr.
Cells were crosslinked for 10 min at 37uC with1% formaldehyde
and the reaction was stopped with 0.1 mM glycine for 5 min,
shaking at room temperature. Cells were scraped in PBS, pelleted
by centrifugation and resuspended in 500 ml nuclear lysis buffer
(1% SDS, 50 mMTRIS-HCL, pH 8.0, 10 mM EDTA, 1x
protease inhibitor cocktail), before sonication. For immunopre-
cipitation, 100 mg DNA was pre-cleared with protein A/G agarose
beads (sc-2003, Santa Cruz Biotechnology, USA) for 1 hr, rotating
at 4uC, before incubating with 2 mg anti-GR (H300) (Santa Cruz
Biotechnology, USA) or 2 mg anti-goat (Santa Cruz Biotechnol-
ogy, USA), as IgG control, overnight on a rotator at 4uC. The
following day, the complex was precipitated with protein A/G
agarose beads for 6 hrs at 4uC, before being washed sequentially
with 1 ml each of wash buffer I, II and III [57], followed by three
washes with 1 ml TE buffer [10 mMTris pH 8, 0.1 mM EDTA].
Proteins were eluted from the beads by addition of 300 ml elution
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buffer (1% SDS, 100 nM NaHCO3), before the addition of
300 nM NaCl and incubation at 65uC overnight to reverse
crosslinks. The following day 15 nM EDTA, 125 nM TRIS-HCL
pH 6.5 and 20 mg proteinase K (Roche, South Africa) were added
and samples were then incubated at 45uC for 1 hr. DNA was
purified using PCR cleanup columns (Qiagen, South Africa). Real
time qRT-PCR was performed on a Corbett Rotorgene, using the
Sensimix (Quantace, South Africa), which measures SYBR Green
fluorescence. ChIP primers used: for IL-6 59-TCTACAA-
CAGCCGCTCACAG-39 (forward primer) and 59- AGCGTTC-
CAGTTAATTTGTATTTGT-39 (reverse primer), for IL-8 59-
GGGCCATCAGTTGCAAAT-39 (forward primer) and 59-
TTCCTTCCGGTG GTTTCTTC-39 (reverse primer).
Primary Cervical Epithelial Cells
Primary cervical epithelial cells (VEN-100) were bought from
Mat Tek Corporation (USA). Delivery time was 5 days. Upon
arrival, the cells were incubated overnight in VEN-100-MM
medium (Mat Tek Corporation, USA) at 37uC in a 5% CO2
incubator. The following day cell viability was determined using
the Thiazolyl Blue Tetrazolium Bromide (MTT) cell determina-
tion kit (cat #CGD1, Sigma-Aldrich, South Africa) according to
the manufacturer’s instructions [58]. At this time, some cells were
washed with PBS and either lysed with a N-[Tris(hydroxymethyl)-
methyl]-3-aminopropanesulfonic acid (TAPS) buffer (0.1 M
TAPS, pH 9.5) on ice (to perform Western blotting as above) or
with TRIzolH (for RNA isolation, cDNA synthesis and qRT-PCR
as described above). Having established the viability of the cells,
the majority of the VEN-100s were incubated in VEN-100-ASY-
HCF hydrocortisone free assay medium (Mat Tek Corporation,
USA) and 100 nM test compound for 48 hours, before performing
an additional MTT assay.
Results
MPA, but not NET-A, Acts like a Full to Partial GR Agonist
for Upregulation of anti-Inflammatory and
Downregulation of Pro-inflammatory mRNAs
We investigated the effects of the synthetic progestins on the
expression of GR regulated inflammatory genes in the End1/
E6E7 endocervical epithelial cell line as well as the HeLa cervical
epithelial cell line. These cell lines were chosen as the model
systems for this study due to the ability to perform mechanistic
studies using current methodology. Furthermore, the End1/E6E7
cell line displays similar morphological and immunocytochemical
properties to those of primary endocervical epithelial cells [50].
The genes investigated were chosen based on their established
mechanism of regulation via the GR, and their constitutive
expression in endocervical epithelial cells [7]. GILZ and IkBa are
anti-inflammatory genes that are upregulated by glucocorticoids
(GCs) such as DEX, while IL-6, IL-8 and RANTES are pro-
inflammatory genes that are downregulated by DEX [59,60]. The
GILZ and IkBa genes contain multiple glucocorticoid response
elements (GREs) and are commonly referred to as GR
transactivation genes [61,62]. The IL-6 and IL-8 gene promoters
have binding sites for transcription factors that include activator
protein-1 (AP-1) and nuclear factor kB (NFkB) [63], and these
genes are transrepressed by the liganded GR via tethering
mechanisms [64]. Cells were treated with P4, MPA and NET-A,
as well as the GR agonist DEX for 24 hrs. Thereafter, cytokine
gene mRNA was measured by real time qRT-PCR. As expected
the GR synthetic agonist DEX upregulated both GILZ and IkBa
mRNA in both the cell lines (Figure 1). In addition, MPA
upregulated GILZ and IkBa mRNA in both End1/E6E7 and
HeLa cell lines (Figure 1). P4 and NET-A have no effect on the
expression of GILZ or IkBa mRNA in either of the cell lines
(Figure 1). Figure 2 A and B show that DEX and MPA, unlike
NET-A and P4, repress both IL-6 and IL-8 mRNA levels,
respectively, in the End1/E6E7 cell line. Interestingly, RANTES
mRNA levels are repressed by DEX, MPA and P4 (Figure 2 C).
The regulation of IL-6 mRNA levels by the ligands in the HeLa
cells (Figure 2 D) is similar to the End1/E6E7 cells (Figure 2 A),
where both DEX and MPA repress IL-6 mRNA levels.
Furthermore, it appears that NET-A upregulates IL-6 mRNA
levels in the HeLa cells (Figure 2 D). Similar to the End1/E6E7
cell line, DEX appears to repress IL-8 mRNA levels in the HeLa
cells (Figure 2 E). However, unlike the End1/E6E7 cell line, at the
24 hr time point MPA does not appear to effect IL-8 mRNA
expression in the HeLa cells (Figure 2 E). Interestingly though, at a
4 hr time point both DEX and MPA repress IL-8 gene expression
in the HeLa cell line (Figure 2 H). It appears that NET-A and P4
upregulate IL8 mRNA levels in the HeLa cells (Figure 2 E). In
contrast to the End1/E6E7 cells, the DEX, MPA and P4
repression of RANTES mRNA levels does not occur in the HeLa
cells (Figure 2 F), although this could be due to low basal levels of
RANTES in HeLa cells (as indicated by real time qRT-PCR Ct
values, data not shown). Interestingly, it appears that NET-A
upregulates RANTES mRNA levels (Figure 2 F). Taken together,
these results show that MPA acts like the GR agonist DEX in
upregulating GILZ and IkBa anti-inflammatory gene and
generally downregulating IL-6, IL-8 and RANTES pro-inflam-
matory gene mRNA levels, unlike P4 and NET-A, with some
exceptions. The results also suggest cell-specific, gene-specific and
temporal differences in the regulation of some of the genes in
response to the ligands, such as undetectable repression of IL-8
and RANTES mRNA by MPA in HeLa cells at 24 hrs, but similar
repression of IL-8 in HeLa cells at 4 hrs compared to IL-8 in
End1/E6E7 cells at 24 hrs. In addition, some experiments show
repression by P4 of RANTES in the End1/E6E7 cells at 24 hrs,
unlike in HeLa cells. Furthermore, it appears that regulation of
mRNA levels by the ligands may be time dependent (Figure2).
The experiments in Figure 1 and 2 were performed in the absence
of induction of the cytokine/chemokine genes with a pro-
inflammatory ligand, since these genes are constitutively expressed
in cervical epithelial cells. Experiments performed in the presence
of TNFa, to mimic infection, showed a similar % repression of the
pro-inflammatory genes with DEX and MPA, unlike P4 and NET
(Figure S1). All further experiments were performed in the absence
of TNFa.
MPA Regulation of Inflammatory Gene mRNA Levels is
dose- and Time-dependent
Having shown that MPA acts like a GR agonist in regulating
mRNA levels of inflammatory genes, it was next determined if this
regulation is dose- and/or time-dependent. End1/E6E7 cells were
treated with increasing concentrations of the ligands for 4 hr and
24 hrs, respectively, followed by qRT-PCR analysis. Figure 3 A
and B show that both DEX and MPA increase GILZ mRNA
levels in a dose-dependent manner, whileP4 and NET-A appear to
have no effect on GILZ gene expression at any of the
concentrations or time points. It also appears that the maximal
response for MPA and DEX regulation of GILZ mRNA levels
does not change between 4 and 24 hours. DEX and MPA, unlike
P4 and NET-A, repress IL-6 mRNA levels in a dose-dependent
mannerat both 4 hrs and 24 hrs (Figure 3 C and D). However,
MPA appears to show a greater maximal repression of IL-6
mRNA levels at 24 hrs than at 4 hrs, acting like a partial agonist at
4 hrs, but a full agonist at 24 hrs. Interestingly, it appears that
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1 mM NET-A may upregulate IL-6 mRNA at 24 hrs. Figure 3 E
and F show that IL-8 mRNA levels are also dose-dependently
repressed by DEX and MPA at both 4 hrs and 24 hrs, with the
MPA dose-dependent repression of IL-8 being more robust at
24 hrs. In addition, P4 and NET-A appear to be upregulating IL-8
at 4 hrs only. No repression of RANTES mRNA is apparent at
4 hrs (Figure 3 G). However, at 24 hrs RANTES mRNA levels are
repressed by DEX and MPA in a dose-dependent manner, while
NET-A and P4 appear to show some partial agonist activity (10–
20%) for repression at high concentrations (Figure 3 H). MPA
appears to have a potency (EC50) of,24 nM for transactivation of
GILZ and a potency of ,21, 4 and 5 nM for repression of IL-6,
IL-8 and RANTES mRNA, respectively at 24 hrs.
The GR is the Predominant Steroid Receptor Protein
Detected in Cervical Cell Lines and Primary Cervical
Epithelial Cells
Given the differential steroid receptor selectivity of MPA, NET
and P4, we next investigated whether the GR, AR, PR, MR or
ERa are expressed in these cell lines, with a view to determination
of steroid receptor involvement in the differential gene expression
responses. Cell lysates were prepared and the steroid receptor
mRNA and protein levels were detected by qRT- PCR and
Western blotting, respectively. The Western blot and PCR screen
show that the End1/E6E7 cells express only endogenous GR
mRNA and protein, respectively (Figure 4 A and B). According to
the PCR screen (Figure 4 A), HeLa cells express endogenous GR,
AR and MR mRNA. However the Western blot (Figure 4 B)
Figure 1. MPA, but not NET-A or P4, acts like a partial GR agonist for upregulation of anti-inflammatory mRNAs. (A and B) End1/E6E7
cells were treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL). (C and D) HeLa cells were treated for 24 hrs with 100 nM
DEX, 1 mM MPA, 10 mM P4, 10 mM NET-A or vehicle (ethanol) (CTRL). Thereafter the cells were harvested; total RNA was isolated and reverse-
transcribed. Relative GILZ and IkBa gene expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression. In addition,
relative gene expression was normalized to basal activity (CTRL) in order to obtain relative fold expression. Graphs represent pooled results of at least
three independent experiments and are plotted as mean6SEM. Statistical analysis was carried out using GraphPad Prism software (version 5) using a
one-way ANOVA with Dunnett post-test. Statistical significance is denoted by *, ** or *** to indicate P,0.05, P,0.001 or P,0.0001, respectively.
doi:10.1371/journal.pone.0096497.g001
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reveals that in HeLa cells only endogenous GR protein is
detectable. Although it appears that the HeLa and End1/E6E7
cells express MR protein (Figure 4 B), this is a non-specific band
that also appears in the negative control. Since the End1/E6E7
cells do not express detectable MR mRNA it is highly unlikely that
the cells express MR protein. However, it is possible that the HeLa
cells do express low levels of the AR and MR that are beyond the
detection level of the Western blots. It was therefore determined if
the repression of cytokine genes in this cell line could be mediated
via the AR and MR. HeLa cells were treated with the GR, AR
and MR specific agonists (DEX, mibolerone and aldosterone,
respectively) and cytokine gene expression was measured by qRT-
PCR. IL-6 and IL-8 gene expression was measured since it was
established above that RANTES is not regulated by the ligands of
interest in the HeLa cells. Figure 4 C shows that only DEX
represses IL-6 gene expression, while it appears that aldosterone,
and possibly and mibolerone, upregulate IL-6 mRNA expression.
In addition, it appears that DEX represses IL-8, while aldosterone,
and possibly mibolerone, upregulate IL-8 gene expression (Figure 4
D). These results indicate that DEX- and MPA-mediated
repression of the cytokine genes in HeLa cells is likely to occur
via the GR. Additionally, since only GR mRNA and protein were
Figure 2. MPA, but not NET-A, acts like a full/partial GR agonist for repression of pro-inflammatory mRNAs. (A–C) End1/E6E7 cells
were treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL). (D–H) HeLa cells were treated for 24 hrs (D–F) or 4 hrs (G–H)
with 100 nM DEX, 1 mM MPA, 10 mM P4, 10 mM NET-A or vehicle (ethanol) (CTRL). Thereafter the cells were harvested, total RNA was isolated and
reverse-transcribed. Relative IL-6, IL-8 and RANTES gene expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression.
In addition, relative gene expression was normalized to basal activity (CTRL) in order to obtain relative fold expression. Graphs represent pooled
results of at least three independent experiments and are plotted as mean 6 SEM. Statistical analysis was carried out using GraphPad Prism software
(version 5) using a one-way ANOVA with Dunnett post-test. Statistical significance is denoted by *, ** or *** to indicate P,0.05, P,0.001 or P,0.0001,
respectively.
doi:10.1371/journal.pone.0096497.g002
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detected in the End1/E6E7 cells, these results indicate that in both
the cell lines, the DEX and MPA regulation of expression of the
inflammatory genes is most likely mediated via the GR.
Whether the steroid receptor expression profile in the cervical
epithelial cell lines mimics that of primary cervical epithelial cells is
unknown. We investigated the steroid receptor content in
commercially available primary endocervical cells (VEN-100;
bio-engineered multilayer of primary cells) by PCR and Western
blot. While we could detect GR, MR, AR and ERa mRNA
(Figure5 A), the only steroid receptor protein we detected in the
primary cells was the GR (Figure 5 B). No PR mRNA or protein
was detected in the cell lines or primary cells, despite positive
controls showing that PR expression can be detected by these
methods. Thus despite the finding that some MR, AR or ERa
mRNA was detected in some of the cells lines or primary cells, the
only steroid receptor protein detected in any of the models was the
GR, suggesting that the GR is the predominant steroid receptor
mediating responses to MPA in both the cervical epithelial cell
lines and primary endocervical cells.
Regulation of Inflammatory Gene mRNA Levels by DEX
and MPA is Mediated by the GR and is Mimicked at the
Protein Level for IL-6 and IL-8
In order to provide direct proof that the GR is involved in the
regulation of the inflammatory genes in response to the synthetic
progestin MPA, GR knockdown experiments were performed in
the End1/E6E7 cell line. Reduction of GR protein in these cells
was verified by Western blotting (Figure 6 A and 6B). As expected
DEX and MPA upregulated GILZ mRNA, while P4, NET-A and
NET did not (Figure 6 C). Notably, NET was included in this
experiment as a control to exclude the possibility that the acetate
form (NET-A) would regulate the genes differently. However, it is
shown that NET-A acts similarly to NET. Both the DEX- and
MPA-induced upregulation of GILZ mRNA is diminished when
GR is knocked down. Figure 6 D shows that DEX upregulates
IkBa mRNA levels and this induction is repressed when GR is
knocked down. Here the MPA induction of IkBa is not significant,
possibly due to the blunting of the response in the NSC
knockdown conditions, and therefore a loss of induction is not
apparent with the knockdown. Western blotting revealed that,
unlike for the mRNA levels, DEX, MPA and NET-A all
significantly increased total IkBa protein levels (Figure S2).
Protein levels could not be determined for GILZ due to the
unavailability of a suitable antibody. As expected DEX and MPA
repress IL-6 mRNA levels (Figure 7 A), which is lifted when the
GR is knocked down. In addition, DEX-mediated repression is
also evident on IL-6 protein levels (Figure 7 B). Consistent with the
mRNA data, MPA appears to repressIL-6 protein levels and the
repression is lifted in the knockdown. Interestingly P4 also appears
to repress IL-6 protein levels, although significance could not be
established. Similarly, a significant difference is observed for both
DEX and MPA responses upon GR knockdown for IL-8 mRNA
levels (Figure 7 C). Figure 7 D shows that DEX and MPA also
appear to repress IL-8 protein levels, while GR knockdown
appears to lift this repression. RANTES mRNA levels are shown
in Figure 7 E to be repressed by both DEX and MPA, but not by
P4 or NET-A, in a GR-dependent manner. We were unable to
detect secreted RANTES protein, possibly due to its instability in
the medium (data not shown). Gene expression studies could not
be performed with the primary cells since they did not maintain
cell viability for the long periods of time required for the
assessment (Figure S3). Taken together, these results show that
DEX- and MPA-mediated regulation of the inflammatory gene
mRNA levels is mediated via the GR in the endocervical cell line.
This GR dependence is mimicked at the protein level for DEX
and appears to also be mimicked at the protein level for MPA, for
IL-6 and IL-8.
We have previously shown in COS-1 cells that the most potent
GR ligands result in the most rapid GR degradation, with a good
correlation shown between ligand-selective GR half-life and
transactivation and transrepression efficacy [65]. Consistent with
these results, we show that in the End1/E6E7 cells, MPA results in
GR turnover typical for a relatively potent GR partial agonist,
unlike NET-A and P4 (Figure S4).
Inhibition of Protein Synthesis Supports a Mechanism of
Direct Regulation by the GR of the Inflammatory Genes
In order to investigate whether the GR is directly or indirectly
involved in the regulation of these genes, cycloheximide (CHX;
de novo protein synthesis inhibitor) experiments were performed in
the End1/E6E7 cells to determine whether the GR-mediated
regulation of the mRNA levels requires new protein synthesis [66].
Figure 8 A shows that the addition of CHX only partially dampens
the DEX while ablating the MPA induction of GILZ mRNA.
However, the effects of all the ligands on IkBa mRNA levels were
unchanged by CHX (Figure 8 B). These results suggest that
upregulation of GILZ mRNA levels is only partially dependent on
transactivation by the GR and it is also in part dependent on
synthesis of another protein. IkBa mRNA upregulation, however,
appears independent of new protein synthesis, suggesting that the
mechanism predominantly involves direct transactivation by the
GR of the IkBa gene. Figure 8 C shows that DEX, but not MPA-
mediated repression of RANTES is partially lifted by treatment
with CHX, suggesting a mechanism at least partially involving
transrepression of these promoters by the GR. In contrast, both
DEX- and MPA-mediated repression of IL-6 are independent of
new protein synthesis, as they are not affected by CHX treatment
(Figure 8 D). A similar trend is observed for DEX on the IL8
promoter (Figure 8 E), although for this gene the results for MPA
were inconclusive. To confirm that the CHX inhibited de novo
protein synthesis, End1/E6E7 cells were pre-treated with CHX
and then treated with DEX (in the presence of CHX) for 24 hrs,
thereafter cell lysates were prepared and Western blotting was
performed. lkBa protein levels were used as a positive control to
show that the concentration of CHX used was sufficient to prevent
new protein synthesis (Figure 8 F and G). In summary, we
demonstrate that under conditions where CHX is shown to inhibit
new protein synthesis, all the anti-inflammatory and pro-inflam-
Figure 3. MPA-mediated regulation of inflammatory gene mRNA levels is dose- and time-dependent. End1/E6E7 cells were treated with
increasing amounts (1 nM, 10 nM, 100 nM and 1 mM) of DEX, MPA, P4 or NET-A, or vehicle (ethanol) (CTRL) for 4 and 24 hrs, respectively. Thereafter,
the cells were harvested, total RNA was isolated and reverse-transcribed. Relative (A, B) GILZ, (C, D) IL-6, (E, F) IL-8 and (G, H) RANTES gene
expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative GILZ gene expression was
normalized to 1 mM DEX set to 100% in order to obtain % partial agonist activity. Relative IL-6, IL-8 and RANTES expression was normalized to basal
activity (CTRL) set to 100 in order to obtain % repression. For IL-6 and RANTES mRNA, statistically significant repression with MPA relative to control
was found at 10 nM, 100 nM and 1 mM. The 1 mM data point for P4 on IL-8 4 hrs (E) is 231% and is not displayed due to the y-axis scale. Graphs
represent pooled results of at least three independent experiments and are plotted as mean 6 SEM.
doi:10.1371/journal.pone.0096497.g003
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Figure 4. End1/E6E7 and HeLa cells only express detectable GR protein. (A and B) (A) HeLa and End1/E6E7 cells were harvested, total RNA
was isolated and reverse-transcribed. Steroid receptor (SR) gene expression was measured by real time qRT-PCR. SR expression vectors (pcDNA3-hGR,
pMT-PR-B, pSV-hAR, pRS-hMR and pSG5-hER) served as positive controls (+CTRL) for the GR, PR-B, MR and ER, respectively. COS-1 cells transiently
transfected with pcDNA3 (empty vector) served as negative control (2CTRL). (B) Whole cell lysates were prepared from the HeLa and End1/E6E7 cell
lines. Equal volumes of lysate were analysed by Western blotting with antibodies against specific SRs and GAPDH as loading control. (C and D) SR
agonist screen indicates that in the cervical cells the GR, but not the MR or AR repress IL-6 and IL-8 in the presence of receptor-
specific agonist. HeLa cells were treated with 100 nM DEX, 100 nM mibolerone (MIB), 10 nM aldosterone (ALD) or vehicle (ethanol) (CTRL) for 4 hrs.
Total RNA was isolated and reverse-transcribed. Relative (C) IL-6 and (D) IL-8 gene expression was measured by real-time qRT-PCR and normalised to
GAPDH mRNA expression. In addition, relative gene expressions were normalized to basal activity (CTRL) in order to obtain fold expression. The
primers and antibody used to investigate PR levels are capable of detecting both PR-A and PR-B isoforms, however the positive protein control
shown is specific for PR-B isoform only. Graphs represent pooled results of at least three independent experiments and are plotted as mean 6 SEM.
Statistical analysis was carried out using GraphPad Prism software (version 5) using a one-way ANOVA with Dunnett post-test. Statistical significance
is denoted by * to indicate P,0.001.
doi:10.1371/journal.pone.0096497.g004
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matory genes investigated are at least in part regulated by direct
effects of DEX without a requirement for new protein synthesis,
and where this could be established, similar trends are observed for
MPA.
DEX and MPA Result in Recruitment of the GR to the
Promoters of the IL-6 and IL-8 Genes
In order to further investigate the mechanism of transcriptional
regulation of these cytokine genes via the GR, ChIP assays were
performed in HeLa cells. Attempts to perform ChIP assays in the
End1/E6E7 cells were unsuccessful. This may be due to high
background and low sensitivity for ChIP signals in these cells.
Figure 9 A shows that stimulation with DEX, but not MPA results
in the recruitment of the GR to the GILZ promoter. Furthermore,
both DEX and MPA stimulation resulted in significant recruit-
ment of the GR to the IL-6 and IL-8 promoters (Figure 9 B and
C). The inability to observe GR recruitment to the GILZ
promoter with MPA may be because some of the effects of
MPA on GILZ are not direct, as suggested by the CHX
experiments. However, since we have previously shown in A549
cells that the GR is recruited to the GRE region of the GILZ
promoter by both DEX and MPA [67], it is more likely that a
small amount of GR is recruited by MPA, but this is below the
limits of detection of the ChIP assay in these cells. In summary
these results strongly support a model whereby both DEX and
MPA suppress inflammation in the cervical epithelial cells by
activating and thereby recruiting the GR to promoters of these
genes and consequently inducing transcription of the anti-
inflammatory gene GILZ, while repressing transcription of the
pro-inflammatory genes IL-6 and IL-8.
Discussion
We show for the first time that the synthetic progestins MPA
and NET-A, used in contraception and hormone replacement
therapy, exert differential effects on expression of mRNA levels of
key pro-inflammatory and anti-inflammatory genes constitutively
expressed in an endocervical epithelial cell line, as compared to
P4. MPA, unlike NET-A and P4, increases mRNA expression of
the anti-inflammatory genes GILZ and IkBa, in both the cervical
epithelial cells lines. Interestingly, this differential regulation of
IkBa mRNA is not mimicked by IkBa protein levels, suggesting
that GR-mediated increase in IkBa protein levels does not play a
major role in regulation of IL-6, IL-8 and RANTES genes in these
cells, consistent with reports for some cells but not others [68–72].
Figure 5. Only GR protein is detected in primary cervical epithelial cells (VEN-100). (A) Upon arrival the VEN-100 cells were rested
overnight before being washed once with PBS and harvested with TRIzolH. Total RNA was isolated and 500 ng RNA was reverse-transcribed. Steroid
receptor gene expression was measured by qRT-PCR with receptor-specific primers, followed by gel electrophoresis to confirm the PCR products. (B)
VEN-100 cells were rested overnight before harvesting in 2X SDS sample buffer. COS-1 cells were transiently transfected with 1 mg/well pcDNA3
(empty vector) which served as negative control (2CTRL) or with 1 mg/well steroid receptor expression vectors (GR, PR-B, AR, MR and ERa) which
served as positive controls (+CTRL). Twenty fourhrs later, the COS-1 cells were washed once and lysed with 2X SDS sample buffer. Equal volumes of
cell lysate (VEN-100 and COS-1 ctrls) were analysed by Western blotting with antibodies specific for the GR and Flotillin-1 (loading control),
respectively.
doi:10.1371/journal.pone.0096497.g005
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MPA unlike NET-A, decreases expression of the pro-inflamma-
tory IL-6, IL-8 and RANTES genes in the endocervical epithelial
cell line, as well as IL-6 and IL-8 in the HeLa cell line. These
effects are mimicked at the protein levels for IL-6 and IL-8 in the
epithelial cell line. Thus MPA, unlike NET-A and P4, shows an
anti-inflammatory profile in both cell lines, for most genes
investigated. Furthermore, we show for the first time that the
predominant steroid receptor protein detected in the endocervical
epithelial cell line and in primary endocervical epithelial cells is the
GR, with no detectable PR mRNA or protein. Consistent with this
finding, we also demonstrate by a combination of GR knockdown
and ChIPs, that MPA, unlike NET-A, represses pro-inflammatory
cytokine gene expression in cervical epithelial cells via a
mechanism involving recruitment of the GR to cytokine gene
promoters. These results are consistent with a direct effect of the
GR without a requirement for new protein synthesis, as shown by
cycloheximide experiments. Our findings that DEX recruits GR to
the IL-6 and IL-8 promoter regions are consistent with previous
reports [56,73], while we show here for the first time, that
stimulation with MPA recruits GR to the IL-6 and IL-8 promoter
regions, thereby repressing expression of these genes. These results
are consistent with our hypothesis and our previously published
data that MPA, unlike NET-A or P4, acts like a partial to full GR
agonist with a relatively high affinity for the GR on endogenous
genes in other cells and via synthetic reporter genes [36,41,44,74].
The findings of the present study suggest that in the context of the
genital mucosa, these GR-mediated effects of MPA in cervical
epithelial cells are likely to play a critical role in discriminating
Figure 6. MPA- and DEX-mediated upregulation of anti-inflammatory mRNAs is mediated via the GR. End1/E6E7 cells were transfected
with 10 nM GR or NSC siRNA (A–D) and then treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A, NET or vehicle (ethanol) (CTRL). For verification of
GR knockdown a representative blot is shown in (A). (B) Western blots of at least three independent experiments were quantified to determine the
relative GR protein expression and is plotted as mean 6 SEM. Total RNA was isolated and reverse-transcribed. Relative (C) GILZ and (D) IkBa gene
expression was measured by real-time qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative gene expressions were normalized
to basal activity (CTRL) in order to obtain relative fold expression. Graphs in (C) and (D) represent pooled results of at least three independent
experiments and are plotted as mean 6 SEM. Statistical analysis was carried out using GraphPad Prism software (version 5) using a one-way ANOVA
with either a Dunnett post-test, followed by a student’s t-test to compare specific conditions to each other. Statistical significance is denoted by * or
*** to indicate P,0.05 or P,0.0001, respectively.
doi:10.1371/journal.pone.0096497.g006
Differential Repression of Inflammation by Progestins
PLOS ONE | www.plosone.org 11 May 2014 | Volume 9 | Issue 5 | e96497
between the effects on inflammation caused by different progestins
and progesterone and hence susceptibility to genital infections,
given the predominant expression of the GR and lack or PR
protein expression in these cells. The GR knockdown results
furthermore suggest that changes in GR expression levels are likely
to significantly modulate the inflammatory response in the
endocervix, with reduced GR levels even possibly resulting in
some pro-inflammatory effects by both MPA, NET-A and P4.
Our findings that MPA has anti-inflammatory gene expression
effects in the endocervical cells are consistent with previous reports
that show MPA suppresses pro-inflammatory immune markers in
primary mouse uterine and cervical tissue and in primary human
vaginal mucosal mononuclear cells [49,75]. Given the different
steroid receptor selectivities of MPA, NET and P4 [36–38], it is
likely, however, that the steroid receptor profile of different
compartments of the female genital tract will determine the
outcome of inflammatory gene expression effects of these ligands.
In the current paper we show that both primary endocervical cells
and the endocervical cell line express predominantly the GR. In
contrast, we have previously shown that the Ect1/E6E7
Figure 7. MPA- and DEX-mediated repression of pro-inflammatory cytokine gene mRNA is mediated via the GR. End1/E6E7 cells were
transfected with 10 nM GR or NSC siRNA (A–F) and then treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL). Total RNA
was isolated and reverse-transcribed. Relative (A) IL-6 (C) IL-8 and (E) RANTES gene expression was measured by real-time qRT-PCR and normalised to
GAPDH mRNA expression. In addition, relative gene expressions were normalized to basal activity (CTRL) in order to obtain fold expression. The
corresponding cytokine protein levels for (B) IL-6 and (D) IL-8 were determined by Luminex of supernatants collected prior to cell harvest. Graphs
represent pooled results of at least three independent experiments and are plotted as mean 6 SEM. Statistical analysis was carried out using
GraphPad Prism software (version 5) using a one-way ANOVA with a Dunnett post-test followed by a student’s t-test to compare specific conditions
to each other. Statistical significance is denoted by * or ** to indicate P,0.05 or P,0.001, respectively.
doi:10.1371/journal.pone.0096497.g007
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ectocervical epithelial and Vk2/E6E7 vaginal epithelial cell lines
appear to express a greater variety of steroid receptors, including
the PR, GR, AR and ERa [76]. This is consistent with the report
that the ectocervix is covered by a mucosal layer that is
histologically similar to the vagina but different to the endocervix
[77]. Our previous results show that IL-6, IL-8 and RANTES
mRNA levels are regulated differently in the ectocervical and
vaginal cell lines compared to the endocervical cell line, consistent
with their different steroid receptor profiles. MPA and NET have
no effect on IL-6 mRNA levels in both the ectocervical and vaginal
cell lines, while MPA is pro-inflammatory for IL-8 in the
ectocervical cell line, in contrast to the anti-inflammatory results
we observed for MPA in the endocervical cell line. P4 appears to
be pro-inflammatory at 1 mM concentrations for most of the pro-
inflammatory genes in the ectocervical and vaginal cell lines, an
effect which we also observe for some genes at 1 mM P4 for IL-6,
but not IL-8 or RANTES. Interestingly MPA represses RANTES
in both the ectocervical and endocervical cell lines, with no
significant effect in vaginal cells. However, in the ectocervical cells,
this effect is mediated predominantly via the AR, while in the
endocervical cells, we show that it is mediated via the GR.
Interestingly, we have recently found that MPA, unlike P4 and
NET, shows a very similar pattern and potency of repression of
pro-inflammatory genes in human PBMCs to that observed in the
current study in the endocervical cell line, with a similar
predominantly GR steroid receptor profile [78]. Collectively, our
results support the hypothesis that MPA, when acting predomi-
nantly via the GR, is likely to exert anti-inflammatory effects on
gene expression via classical transrepression mechanisms, unlike
NET and P4, but when the steroid receptor profile is changed, the
responses are likely to vary. Furthermore the results collectively
suggest that different compartments of the genital tract are likely to
exhibit different inflammatory responses to MPA vs NET vs P4,
with their associated different effects on susceptibility to genital
infections. Our lack of detection of PR expression in the
endocervical primary cells or cell lines raises the question as to
what is the role of the PR in mediating responses to progestins and
progesterone in the endocervix. It is possible that other cells
besides epithelial cells in the cervix express functional PR, as is
suggested from one report [79], while others report the expression
of both the GR and ERa [80].
Whether the observed effects of MPA, NET and P4 are relevant
to the physiological doses of these ligands in vivo is a critical
question, which we investigated here by dose response analysis
[81] to determine potencies (EC50s) and efficacies (maximal
response). The MPA serum concentrations of DMPA-users are
reported to be in the range 2.5 to 65 nM a few days after injection
and to plateau at about 2.6 nM for about three months thereafter
[38,48,82], while serum concentrations for injectable NET-EN, in
the range of 1.5–59 nM have been reported [83]. The concen-
tration of endogenous P4 in serum of premenopausal women is
low during the follicular phase (0.65 nM) but rises to about 80 nM
during the luteal phase, and to about 600 nM during pregnancy
[37]. We show that MPA at 10 nM significantly represses both IL-
6 and RANTES at 24 hrs (Figure 3 C and H). Furthermore our
dose response analysis show that MPA has a potency of ,24 nM
for transactivation of the anti-inflammatory GILZ gene and a
potency of ,4–20 nM for repression of the pro-inflammatory IL-
6, IL-8 and RANTES genes. This suggests that these immuno-
suppressive effects are likely to be relevant at physiological doses of
MPA used in injectable contraception, particularly shortly after
injection, while any possible effects of NET-EN injectable
Figure 8. The GR at least in part directly regulates mRNA levels of the inflammatory genes. End1/E6E7 cells were pretreated with 1 mg/ml
cycloheximide (CHX) then treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL), in the absence or presence of CHX. Total
RNA was isolated and reverse-transcribed. Relative (A) GILZ (B) IkBa, (C) RANTES, (D) IL-6 and (E) IL-8 gene expressions was measured by real-time
qRT-PCR and normalised to GAPDH mRNA expression. In addition, relative gene expressions were normalized to basal activity (CTRL) in order to
obtain relative fold expression. Graphs represent pooled results of at least three independent experiments and are plotted as mean 6 SEM. To verify
that the CHX inhibited de novo protein synthesis, End1/E6E7 cells were pretreated with CHX then treated with 100 nM DEX or vehicle (ethanol) (CTRL)
for 24 hrs. (F) Cells were harvested and equal volumes of lysate were analysed by Western blotting with an antibody specific for IkBa and a GAPDH
specific antibody as loading control. (G) Western blots of four independent experiments were quantified to determine the relative GR protein
expression. Statistical analysis was carried out using GraphPad Prism software (version 5) using a one-way ANOVA with a Dunnett post-test followed
by a student’s t-test to compare specific conditions to each other. Statistical significance is denoted by *, ** or *** to indicate P,0.05, P,0.001 or P,
0.0001, respectively.
doi:10.1371/journal.pone.0096497.g008
Figure 9. DEX and MPA recruit GR to the IL-6 and IL-8 cytokine gene promoters. HeLa cells were serum starved for 2 hrs and then treated
for 1 hr with 100 nM DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL). ChIP was carried out using an anti-GR antibody to immunoprecipitate
endogenous GR and an anti-IgG antibody as a negative control. Real-time qRT-PCR was performed on input and immunoprecipitated DNA with
primers specific for endogenous (A) GILZ, (B) IL-6 and (C) IL-8 promoters. GR recruitment was measured relative to input. Graphs represent pooled
results of at least three independent experiments and are plotted as mean 6 SEM. Statistical analysis was carried out using GraphPad Prism software
(version 5) using a one-way ANOVA with Dunnett post-test. Statistical significance is denoted by * or *** to indicate P,0.05 or P,0.0001, respectively.
doi:10.1371/journal.pone.0096497.g009
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contraceptive on inflammation via the GR are likely to be
negligible, even shortly after injection. Since P4 at concentrations
up to 100 nM shows very little effect on expression of the genes
investigated, P4 at doses other than during pregnancy, are unlikely
to exert major effects on inflammation or immune function in
endocervical epithelial cells. However, about 20% repression of
IL-6 is observed by P4 at 4 hrs at 10–100 nM, suggesting that in
the presence of a predominant GR, P4 could exert some anti-
inflammatory effects. At pregnancy concentrations, P4 may exert
some pro-inflammatory effects on some genes, as suggested by our
dose response analysis showing this trend for some genes at 1 mM.
It should, however, be noted that the concentrations of MPA,
NET and P4 in cervical tissue may not be the same as that found
in the serum of contraceptive users.
The physiological significance of changes in expression of pro-
inflammatory mediators like IL-6, IL-8 and RANTES in genital
epithelial cells is difficult to predict. Increased pro-inflammatory
mediators could increase recruitment of dendritic cells (DCs) or
Langerhans cells (LCs) as well as CD4+ T cells and monocytes/
macrophages, thus potentially increasing HIV-1 acquisition by
increasing the number of target cells. Thus progestins like MPA,
unlike NET-A, that exert anti-inflammatory gene expression
effects in the female genital tract may decrease HIV-1 acquisition
by decreasing the number of target cells. However, decreased pro-
inflammatory mediators could also inhibit immune function, such
as B-cell maturation, T-cell activation and differentiation, IgA
production, neutrophil/monocyte/macrophage/dendritic cell ac-
tivity, reducing the host’s ability to mount a defence against a
pathogen [84]. Additionally, RANTES is a ligand for the CCR5
receptor, which has the ability to block HIV-1 entry [85]. Thus a
decrease in RANTES expression by endocervical epithelial cells,
as we show for MPA but not NET, with a potency of 5 nM, could
increase HIV-1 infection of CD4+ T cellsin vivo. Interestingly,
MPA shows the greatest efficacy for RANTES mRNA repression,
acting like a full GR agonist. Whether or not DMPA usage
increases or decreases the expression of inflammatory mediators in
the female genital tract in vivo is unclear and requires further
investigation. Several studies suggest that a pro-inflammatory
environment is associated with an increase in HIV-1 acquisition
[86–88]. Furthermore, DMPA-usage was recently reported to be
associated with increased HIV-1 acquisition and increased levels of
RANTES [88]. However, in this study it was not possible to
discriminate between elevated RANTES levels being a cause of
infection or a consequence of exposure to HIV-1 prior to
seroconversion. Additionally, since 76% of the DMPA users in
this study were positive for an STI, it may be that elevated
RANTES was a consequence of STI infection, despite attempts to
correct for that confounding variable. In contrast to the latter
study, the study by Huijbregts et al. found that DMPA-usage is
associated with immunosuppressive effects in the cervical mucosa
[49]. Furthermore, we have recently shown that MPA, unlike
NET or P4, increases apoptosis of T-cells, which is potentiated
after HIV-1 infection [74], potentially decreasing the ability of T-
cells to mount an anti-viral defence. Currently available clinical
data from women on DMPA, taken together with animal data plus
our and other biochemical ex vivo data, certainly suggest that
immunosuppressive properties of long term MPA contraceptive
usage may be a significant factor contributing towards increasing
HIV-1 acquisition, transmission and possibly disease progression.
Importantly, our results show that MPA effects on genital mucosal
immune function and susceptibility to infections are likely to be
very different to those of NET and P4, when mediated via the GR,
and that choice and concentration of progestin in contraception
are likely to be critical factors.
Supporting Information
Figure S1 Only DEX andMPA represses basal as well as
TNF-induced cytokine mRNA expression. End1/E6E7 cells
were treated for 24 hrs with 100 nM DEX, MPA, P4, NET-A or
vehicle (ethanol) (CTRL), in the absence or presence of 20 ng/ml
TNFa. Thereafter the cells were harvested, total RNA was isolated
and reverse-transcribed. Relative (A) IL-6, (B) IL-8 and (C)
RANTES mRNA expression was measured by real-time qRT-
PCR and normalised to GAPDH mRNA expression. In addition,
relative gene expression was normalized to basal activity (CTRL)
in order to obtain relative fold expression. Graph represents
pooled results of at least three independent experiments and are
plotted as mean 6 SEM. Statistical analysis was carried out using
GraphPad Prism software (version 5) using a one-way ANOVA
with Dunnett post-test, followed by a student’s t-test to compare
specific conditions to each other. Statistical significance is denoted
by * or ** to indicate P,0.05 or P,0.001, respectively.
(TIF)
Figure S2 DEX, MPA and NET-A induce total IkBa
protein. End1/E6E7 cells were treated for 24 hrs with 100 nM
DEX, MPA, P4, NET-A or vehicle (ethanol) (CTRL). Thereafter,
cells were harvested and equal volumes of lysate were analysed by
(A)Western blotting with an antibody specific for total IkBa and a
GAPDH specific antibody as loading control. (B) Western blots of
five independent experiments were quantified to determine the
relative GR protein expression. Statistical analysis was carried out
using GraphPad Prism software (version 5) using a one-way
ANOVA with a Dunnett post-test followed by a student’s t-test to
compare specific conditions to each other. Statistical significance is
denoted by *, ** or *** to indicate P,0.05, P,0.001 or P,0.0001,
respectively.
(TIF)
Figure S3 Cell Viability of VEN-100. VEN-100 cells were
either incubated for 24 hrs (day 1, treatment day) or 72 hrs (day 3,
end of treatment day), followed by, analysis for cell viability (MTT
assay). Absorbance readings were measured at 570 nm. Cell
culture media served as the control (CTRL). CTRL for each day
was set to 1 to obtain relative fold cell viability. The graph
represents results of at least three independent experiments,
plotted mean +/2 SEM. Statistical analysis was carried out using
GraphPad Prism software (version 5) using a one-way ANOVA
with a Dunnett post-test followed by a student’s t-test to compare
specific conditions to each other. Statistical significance is denoted
by ** or *** to indicate P,0.001 or P,0.0001, respectively.
(TIF)
Figure S4 Ligand-selective GR protein turnover. End1/
E6E7 cells were treated with increasing amounts (1 nM, 10 nM,
100 nM and 1 mM) of DEX, MPA, P4 or NET-A, or vehicle
(ethanol) (CTRL) for 24 hrs. Thereafter, the cells were harvested
and equal volumes of lysate were analysed by Western blotting
with antibodies specific for GR and GAPDH as loading control.
(TIF)
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a  b  s  t  r  a  c  t
Progestogens  are  widely  used  in contraception  and  in  hormone  therapy.  Biochemical  and  molecular  bio-
logical  evidence  suggests  that  progestogens  differ  widely  in  their  affinities  and  transcriptional  effects
via  different  steroid  receptors,  and hence  cannot  be  considered  as a  single  class  of compounds.  Consis-
tent  with  these  observations,  recent  clinical  evidence  suggests  that, despite  their  similar  progestogenic
actions,  these  differences  underlie  different  side-effect  profiles  for  cardiovascular  disease  and  susceptibil-
ity  to  infectious  diseases.  However,  choice  of progestogen  for maximal  benefit  and  minimal  side-effects  is
hampered  by  insufficient  comparative  clinical  and  molecular  studies  to understand  their  relative  mech-
anisms  of  action,  as well  as their relative  potencies  for different  assays  and  clinical  effects.  This  review
evaluates  the  usage,  meaning  and  significance  of the  terms  affinity,  potency  and  efficacy  in  different
models  systems,  with  a view  to  improved  understanding  of  their  physiological  and  pharmacological
significance.
This  article  is  part  of a Special  Issue  entitled  ‘Menopause’.
© 2013 Published by Elsevier Ltd.
Contents
1. Introduction  . .  . . . .  . .  .  . . .  .  . . .  .  . . .  .  . .  .  . . .  . . . . . . .  .  . . . .  . . . .  . . . .  . . . . . . . . . .  . .  .  .  . .  .  . . .  . . .  . . . . . .  . . . . . . .  . . . . . . .  .  . . . . . . .  .  . . .  .  . . .  .  . . . . .  . . .  . .  . . . . . . . . . .  . .  .  . . .  . .  .  .  . 00
2. Receptor  binding  and  affinity  .  . . .  .  . . . .  . . .  . . . . . . . . . . . .  . . .  .  . . .  . . . . . .  .  . . . . .  . .  . . . . . . .  .  . . . . .  . . .  . . . .  .  . . . . .  . .  .  .  . . . . . .  . . . . . . .  .  . .  .  . . . . . .  .  .  .  .  .  .  .  . . . . .  . . . . .  . .  .  . . 00
3. Potency,  efficacy  and  biocharacter .  .  .  . . .  . . .  . . . .  . . .  .  .  . .  .  . . .  . . . . . . .  .  . . .  .  . .  . . .  . . .  . . . .  . . . . . . .  . . .  . . . .  .  . . . . . .  . . . . .  . .  .  . . . .  . . .  .  .  . . .  . . . . . . .  .  . . .  . .  . . .  .  . . . . . .  . .  . 00
4. Conclusions  . . .  . . . .  . . .  . . .  .  . . .  . . . .  .  . . .  .  . . . . . .  . . . . . . . . . . . .  .  . . . . . .  . . . . .  . . .  .  . . .  . . . . . . . . .  .  . . .  . . . . . .  .  . . .  . . . .  . . .  . .  .  . . . .  . . .  . . .  .  . . . .  .  .  .  . .  .  .  . . . . . .  . . . .  . . . .  .  .  . . .  . 00
Acknowledgement . .  .  . . .  . . . .  .  . . .  .  . . . .  . . . . . . . . . .  . . . . . . . .  .  . . .  . . . . . . .  . . . . .  . .  . . . . .  . .  .  . . . . .  .  . . . . . .  . . .  . . . . .  . . .  . . . . .  . .  . . .  . . . . . . . .  . . . . .  .  .  .  .  .  .  . . . .  . . . . .  .  . . .  .  .  . 00
References . . .  . . .  .  .  . . .  . . . . . . . . . . . .  . . .  .  . . .  .  . . .  . . .  .  .  . .  . . .  .  . . . .  . . .  . . . .  .  . .  .  . . .  . . .  .  . . .  . . . .  .  . . . . . . .  . . .  . . . . .  . . . . . . .  .  . . . . . .  . . .  . . . . . . .  .  . . .  .  . . . . .  . .  . .  . .  .  .  .  .  .  . .  . . 00
1. Introduction
Progestogens are compounds that exhibit progestational activ-
ity, and include both endogenous progesterone (Prog) and synthetic
progestogens designed to mimic  its actions. A wide variety of syn-
thetic progestogens is available and their common progestogenic
Abbreviations: SR, steroid receptor; PR, progesterone receptor; GR, gluco-
corticoid  receptor; MR,  mineralocorticoid receptor; AR, androgen receptor; ER,
estrogen receptor; GREs, glucocorticoid response elements; NFB, nuclear factor
kappa B; AP-1, activator protein-1; RBA, relative binding affinity; Prog, pro-
gesterone;  MPA, medroxyprogesterone acetate; NOMAC, nomegestrol acetate;
R5020,  promegestone; TMG, trimegestone; NET, norethisterone/norethindrone;
NET, Anorethisterone/norethindrone acetate; DRSP, drospirenone; DHT, dihy-
drotestosterone; IC50, inhibitor concentration for 50% inhibition.
∗ Corresponding author. Tel.: +27 21 650 5977; fax: +27 21 6897573.
E-mail  address: Janet.Hapgood@uct.ac.za (J.P. Hapgood).
effects are exploited for many therapeutic applications in female
reproductive medicine, including their use in contraception and
for menopausal therapy. However, these synthetic progestogens
also exhibit a range of biological effects that differ not only from
each other, but also from that of Prog [1–3]. Choice of progesto-
gen for maximal benefit and minimal side-effects is hampered by
a limited understanding of their relative mechanisms of action due
to insufficient comparative clinical and molecular studies.
Multiple factors such as route of delivery, metabolism and bind-
ing to and regulation of serum proteins affect the bioavailability
of the active form of progestogens at target cells [2–6]. Progesto-
gens mediate their intracellular effects by modulating transcription
of target genes in specific cells via binding not only to the pro-
gesterone receptor (PR), but also with varying affinities to other
steroid receptors (SRs) such as the glucocorticoid, mineralocorti-
coid and androgen receptors (GR, MR  and AR, respectively) [2,3,7,8].
0960-0760/$ – see front matter ©  2013 Published by Elsevier Ltd.
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It is generally assumed that their progestational effects are medi-
ated via the PR in female reproductive tissue while the plethora of
side-effects occur via the GR, AR and MR.
SRs are ligand-activated transcription factors that function by
similar genomic mechanisms, but differ in their target genes and
tissues [9]. Once the inactive receptor is activated by hormone bind-
ing, the hormone receptor–complex translocates to the nucleus
where it binds to specific DNA sequences in the promoter regions of
target genes to activate (transactivation) gene expression. In con-
trast, the expression of specific target genes can also be repressed
(transrepression) via protein–protein interactions between the
receptor and other transcription factors such as nuclear factor-
kappa B (NFB) and activator protein-1 (AP-1) [10].
A  number of assays have been developed to elucidate the
intracellular mechanisms of action of progestogens via specific
receptors. Binding assays are used to determine the affinity of pro-
gestogens for a specific receptor in a number of different model
systems, including animal or human tissue or cell lines, as well as
in vitro systems. In contrast, most of the data on the subsequent
relative biological responses via different SRs following binding,
including the potency, efficacy, and biocharacter of the progesto-
gens, have been obtained from animal experiments [2,3].
The  aim of this review is to evaluate ‘potencies’ determined
by different assays and in different model systems, as well as the
meaning and significance of the term ‘potency’, as applied to pro-
gestogens in the current literature.
2. Receptor binding and affinity
The affinity of a progestogen for binding to the PR and other
SRs is a major determinant of the potency of its biological response
since it affects receptor fractional occupancy and hence the per-
centage maximal response in a dose response curve. However it
should be noted that receptor affinity may  not reflect biological
activity, which is also affected by the particular conformation of
the receptor–ligand complex induced by ligand binding. This is
well illustrated by the fact that an antagonist can have a higher
affinity for a receptor than an agonist, but exhibits a very differ-
ent biological response due to the induction of a different receptor
conformation as compared to the agonist. Consistent with their dif-
ferent structures, reported affinities of different progestogens for
SRs other than the PR vary widely. However, affinities reported for a
particular progestogen for a specific SR also vary greatly, most likely
due to different methods and sources of biological material used
to determine affinity. Table 1 shows a range of relative affinities
reported in the literature for progestogens binding to SRs, where
the same reference agonist is used for a particular SR, while Supple-
mentary Table 1 shows relative affinities reported using different
reference agonists, as well as details of methods and model systems
used.
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.jsbmb.
2013.08.001.
Most  reported binding data are obtained by performing heterol-
ogous competition binding experiments and expressing the results
as relative binding affinity (RBA). The constructed binding curves
should theoretically be sigmoidal in shape with a Hill slope value of
one, for a single ligand binding to one site on a receptor molecule,
without cooperative binding. The Hill slope (steep part of the curve)
indicates whether cooperative binding occurs, with a slope of one
indicating no cooperative binding, while of slope of less or greater
than one indicates negative or positive cooperativity, respectively.
The IC50, the concentration of unlabeled progestogen (inhibitor or
competitor) that corresponds to 50% inhibition of the total spe-
cific binding of the radiolabeled reference agonist, can then be
determined.  Many apparent discrepancies in RBAs reported in the
literature are due to the use of different reference ligands (set as
100% RBA). These include promegestone (R5020) versus Prog for
the PR, which differ in their RBAs by about five fold, and mibolerone
or methyltrienolone (R118) versus testosterone or dihydrotestos-
terone (DHT) (Supplementary Table 1), where the synthetic
agonist have about 100-fold greater RBA than the natural ligands
[2,3]. Thus, these apparent RBA differences are not necessarily
real differences. RBAs can be directly compared by recalculat-
ing values relative to a common ligand, if the information is
available.
Another potential source of variable affinities is inherent in
the method of RBA determination. While several reports sim-
ply use relative IC50 values as RBAs [11–15], these are only an
approximate measure of relative affinity since IC50 varies due to
experimental and biological parameters, such as the concentra-
tion of radiolabeled steroid and the concentration of the receptor
being investigated. Fig. 1A illustrates how the IC50 changes in a
competition binding assay as a function of receptor concentration.
Interestingly, if the Hill slope is not fixed during plotting, it also
increases as receptor concentration increases, suggesting that cau-
tion should be exerted when interpreting changes in Hill slope in
competitive binding studies when receptor concentration is much
greater than the true Kd. A more accurate measure of affinity of pro-
gestogens for a SR that circumvents these problems can be obtained
by saturation binding to obtain an equilibrium dissociation con-
stant (Kd). These Kd values are likely to be more accurate than RBAs
determined by competitive binding, provided that the Kd is greater
than the total receptor concentration in the assay and that other
sources of technical and samples source error are not present. How-
ever, only a few reports use saturation binding to measure RBAs of
progestogens. For example, Kd values of 10.9 nM and 4.42 nM for
the PR have been determined for drospirenone (DRSP), and R5020,
respectively [27], while a Kd value of 1.7 nM was  determined for
medroxyprogesterone acetate (MPA) for the AR [17]. Sometimes
RBAs are calculated from Kd values. For example, Kd values were
determined for NOMAC and Org2058 for the PR by saturation bind-
ing in rat uterus (Kd = 5 nM and 0.6 nM,  respectively) and human
T47D breast cancer cells (Kd = 4 nM and 3 nM,  respectively). RBAs
were then calculated relative to Prog set with a RBA of 100%, such
that NOMAC and Org2058 displayed RBAs of 67% and 692%, respec-
tively for the PR in rat uterus, and 192% and 212%, respectively
for the PR in human T47D cells (Table 1 and Supplementary Table
1). The differences in the Kd values for Org2058 and the RBAs for
both ligands relative to Prog most likely reflect different off-target
and/or metabolism and/or species effects in the two systems.As
an alternative to saturation binding, homologous or heterologous
competition binding displacement assays can be used to determine
accurate Kd or Ki values using the Cheng–Prussof equation (Sup-
plementary Table 1), provided the concentration of radiolabeled
ligand is less than the IC50 [19,20]. The Ki is the equilibrium disso-
ciation constant of the unlabeled competitor or inhibitor, and is a
true constant that does not vary with receptor concentration in the
assay, provided certain experimental restrictions are adhered to.
Using this method, similar Ki values were obtained by two groups
for Prog and MPA  binding to the GR (Ki: 95.2 nM and 215 nM and Ki:
3.7 nM and 10.8 nM,  respectively) [21,22]. RBAs for the GR can also
be calculated from Ki values (e.g. relative to dexamethasone set at
100%, RBAs for Prog: 0.84%, and 2%, RBAs for MPA: 21.6% and 39%)
(Table 1 and Supplementary Table 1). However, when comparing Ki
values and RBAs calculated from Ki values obtained from different
groups, large discrepancies are still often found. For example, for
binding to the AR, a two-fold difference in the RBA of MPA  has been
reported, while a five- to nine-fold difference in the Ki values has
been reported (151%, Ki = 19.4 nM [23]; 75%, Kd = 1.7–3.6 nM [24],
RBAs relative to DHT set at 100%), (Table 1 and Supplementary
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Table  1
Relative binding affinities (RBAs) and biological activities of progesterone and synthetic progestins via steroid receptors.
Progestogen PR AR GR MR
RBA % Progestogenic RBA % Agonistic Anti-androgenic RBA % Glucocorticoid RBA % Anti-mineralocorticoid
Progesterone-derived
Progesterone 100 + n/d ± (+) 0.84–35 ± 9–1000 +
Chlormadinone acetate 91–212 + n/d + − 8 + 0 −
Cyproterone acetate 46 + 13–21 + − 6 + 8 −
Medroxyprogesterone
acetate
65–298  ++ 36 ± − 21.6–79 + 0.1–160 −
Nestorone  186 + 0.2 − − 38 − n/d n/d
Nomegestrol acetate 67–303 + 12–31 − + 6 − 0 −
Promegestone 111–236 ++ n/d − − 5 + 53 −
Trimegestone 588 ++ 2.4 − ± 9–13 − 42–120 ±
Testosterone-derived
Dienogest  N/D + n/d − + 1 − 0 −
Gestodene  864 + 71 ± − 27–38 ± 11–290 ±
Levonorgestrel 96–323 ++ 58 + − 1–7.5 − 17–75 ±
Norethin-
drone/Norethisterone




27–43  ++ n/d + − 0.88–1.6 − 0.07 −
Spironolactone-derived
Drospirenone 19 ++ n/d − + 3–6 − 100–500 +
The reference radiolabelled ligands and ligands used for 100% RBA were as follows: PR, progesterone (Prog); AR, testosterone; GR, dexamethasone (Dex); MR, aldosterone
(Ald). For RBAs determined relative to other reference ligands and details about the assays and how RBAs were calculated see Supplementary Table 1. Biological activities
determined in animals (mostly rats and rabbits) using a range of assays are taken from Ref. [2]. Progestational activity: measured by the endometrial transformation (McPhail
Index), and/or pregnancy maintenance, and/or ovulation inhibition tests. Androgenic activity: increase in weight of ventral prostate and levator ani of immature castrated
male rats. Anti-androgenic activity: weight of seminal vesicles and prostate of castrated rats and/or feminization-inducing activity in male rats. Glucocorticoid activity:
production of glycogen and tyrosine transaminase in rat liver. Anti-mineralocorticoid activity: sodium and potassium excretion from ovariectomized rats fed with low
sodium diet. Key to hormonal activities: −, not effective; (+), weakly effective; +, effective; ++, strongly effective; ±, literature inconsistent. n/d: not determined.
Table 1). Possible reasons for these discrepancies may  be failure
to establish equilibrium and/or using a concentration of radiola-
beled ligand greater than the IC50. Very different RBAs are likely to
be obtained when using Ki values obtained by the Cheng–Prussof
method compared to simply using IC50 values. For example the
values obtained by Africander et al., for MPA  for the MR  (aldos-
terone = 100%) (0.08%; Ki = 197 nM)  and NET-A (0.07%; Ki = 229 nM)
are 40-fold different to previously reported values of 3.1% and 2.7%,
respectively (Table 1 and Supplementary Table 1) [23,25].
Another major source of variability in binding data is biolog-
ical sample variability. Different samples may  exhibit different
degrees of off-target binding of the progestogen to non-target SRs
and/or other proteins such as steroidogenic enzymes, to which
progestogens bind with variable affinity. Off-target binding would
effectively lower the apparent RBA, right-shift the binding curve
and increase the IC50, independent of the method used to deter-
mine binding, as illustrated in the simulated binding curve (Fig. 1B).
Off-target binding could also be a source of non-parallel binding
curves with Hill slopes greater than one with increasing concentra-
tions of off-target receptor relative to target receptor, as illustrated
in Fig. 1B. For example, remarkable differences in the RBAs of Prog
(1000% vs. 100%), DRSP (500% vs. 100% or 230%) and gestodene (97%
vs. 290%), all relative to aldosterone set to 100% (Table 1 and Sup-
plementary Table 1), were observed when comparing recombinant
human MR  in vitro binding, relative to rat tissue models, respec-
tively [25–27], most likely due to off-target and/or metabolism
effects in the tissues.The presence of metabolizing enzymes could
also potentially right-shift binding curves and lower the IC50 val-
ues without a change in Hill slope (assuming the metabolites do
not bind the target receptor), as illustrated in the simulated bind-
ing curves (Fig. 1C). Other sources of variability are the species
from which tissue is obtained, as well as the variations in age
and pre-treatment of the animal or human donors. For example,
when comparing rabbit versus rat uterine cytosols, different RBAs
were observed for the PR with MPA  (112% vs. 9.4%) (R5020 = 100%),
NOMAC (135% vs. 72%) (Prog = 100%) and trimegestone (TMG) (84%
vs. 152%) (R5020 = 100%), respectively, (Table 1 and Supplementary
Table 1) [15,18]. Some of the above differences are likely to be
due to species differences. However, species, age, or pre-treatment
differences may  also be confounded by differences in relative con-
centrations of off-target receptors and/or metabolizing enzymes.
As  mentioned, a failure to reach equilibrium by the reference
and competing ligand is another common cause of variabil-
ity in reported binding data [20]. The few cases where this is
investigated suggest that very different times are required for dif-
ferent progestogens and different concentrations thereof, to reach
equilibrium. For example, for 0.2 nM [3H]-aldosterone or [3H]-
mibolerone binding to the overexpressed hMR  or hAR in the COS-1
cell line, this was determined as 16 h [23], while for 1.25 nM [3H]-
dexamethasone binding to the GR endogenously expressed in the
A549 cells it was three hours [22]. Others showed that 20 nM Prog
reaches a saturation plateau faster than either 20 nM R5020 or
RU486 [16]. Higher RBAs have been reported for binding of several
progestogens to the PR in rabbit uterine tissue after incubation for
24 h, in comparison to 2 h [18]. Similarly, differences in the RBAs
of several progestogens for the cytosolic AR of the rat prostate
have been reported for different incubation times [18]. When plot-
ting binding curves, most software programs give the option to fix
or not to fix the Hill slopes for binding curves. Fixing the slope
could mask the presence of competing off-target effects or of high
receptor concentrations (as illustrated in Fig. 1A and B) or even the
presence of cooperative target SR binding effects, leading to inac-
curate determination of affinities. There are indeed some reports
in the literature of cooperative binding of steroids to the GR and
estrogen receptor (ER) [28,29], suggesting this may  be one reason
for non-parallel binding curves. Other sources of error in satura-
tion binding data could be the use of Scatchard plots rather than
non-linear regression in determination of binding parameters. This
method has been used extensively to determine Kd values for pro-
gestogens binding to the PR [14,16,21,27] (Supplementary Table 1
[63,64]). The Scatchard plot, which entails a linearization of binding
data, suffers from the same shortcoming as linear enzyme-kinetic
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Fig. 1. Apparent affinity (IC50) increases with target receptor or competing recep-
tor concentrations and with increased metabolism of competing progestogen.
Simulated  competition binding curves showing IC50 values and Hill slopes for a
progestogen binding to a target SR (A) in the presence of the indicated increasing
concentrations  of the target receptor, or (B) in the presence of 1 nM target recep-
tor  and the indicated increasing concentrations of competing receptor, or (C) with
increasing extents of progestogen metabolism in the presence of 1 nM target recep-
tor (met). The labeled reference agonist was assumed to bind to the target receptor
but  not to the competing receptor. The competing ligand was  assumed to bind to
both receptors; the true Kd for the competing receptor was  20 nM.  For C it was
assumed  that the down-stream metabolites do not bind to the receptor. Simula-
tion  parameters: reference agonist concentration, 10 nM;  Kd of reference agonist
for  target receptor, 4 nM;  Kd of competing ligand for target receptor, 11 nM; Kd of
competing ligand for competing receptor, 20 nM.  Hill slopes (h) and IC50-values are
annotated on the graph and were calculated by fitting the simulated data to the
competition binding equation: y = top/(1 + 10(x−log IC50)h).
treatments such as the Lineweaver–Burk plot: an uneven error dis-
tribution results in data points at low ligand concentrations being
given undue weight.
Despite  the sources of error discussed above, several trends
have emerged and much valuable data are available regarding
binding affinities of progestogens for different steroid receptors.
All the progestogens bind to the PR with a high affinity, typi-
cally in the nanomolar range. For example the synthetic agonist
R5020 was  found to bind to the PR expressed in human or calf
uterine cytosol with Kd values of 4.42 nM and 5.6 nM,  respec-
tively [16,27]. In contrast, progestogens do not bind to the ER, as
expected, due to the low homology between the ER ligand binding
domain and the PR, although there are reports that some progesto-
gen metabolites do bind the ER [2]. Consistent with the structural
similarities between some progestogens and testosterone, several
progestogens bind with relatively high affinity to the AR (Table 1),
although the reported affinities vary greatly, most likely due to
many of the factors described above. For example, some of the
older generation progestogens such as MPA, norethisterone (NET)
and levonorgestrel bind the AR with high affinity relative to metri-
bolone [27], DHT [11,30] and testosterone [18,25]. However other
researchers report that Prog, MPA, norethisterone-actetate (NET-
A), cyproterone acetate and DHT all have similar and relatively
high affinities for the AR [17,23,24] (Table 1). In contrast, DRSP,
dienogest and TMG  exhibit low RBAs [1,6,25,31], while nestorone
does not bind to the AR [12,32]. It is not surprising that several pro-
gestogens structurally similar to Prog, bind to the MR, given the
high affinity of Prog for the MR  (Ki for Prog 1.69 nM [23]). Indeed,
TMG [25,33] and DRSP (Table 1) [26,27,31], the latter derived from
the MR  antagonist spironolactone, both bind the MR  with high
affinity. These progestogens were specifically developed for their
anti-mineralocorticoid properties for contraceptive usage [34] and
for their predicted beneficial effects on blood pressure and cardio-
vascular function [26,35,36]. In contrast, many progestogens such
as chlormadinone acetate, dienogest and NOMAC exhibit unde-
tectable binding to the MR  [1,37], while MPA  (Ki = 197 nM) and
NET-A (Ki = 229 nM)  bind weakly to the MR  [2,23]. Unlike for the
PR, AR and MR,  few progestogens bind to the GR with affinities
in the significant pharmacological range. Of note, MPA  has a high
affinity in the nanomolar range for the GR (Table 1) [22,25,37,38],
with a Ki value of 10.8 ± 1.1 nM [22], significantly higher than the
endogenous glucocorticoid cortisol in humans [38]. Interestingly
gestodene also binds the GR with a relatively high affinity, while
progestogens such as NET, levonorgstrel, dienogest, TMG  and DRSP,
like Prog, bind the GR with low relative affinity [1,6,22,25,26,38,39].
3. Potency, efficacy and biocharacter
Potency, efficacy and biocharacter define the concentrations
of progestogens required to cause or inhibit particular biologi-
cal or physiological effects, the upper and lower limits of those
responses, as well as how these change over a range of con-
centrations or doses [40]. These parameters are thus important
for hormonal therapy. The current literature indicates that these
parameters are substantially different in cell, tissue, animal, and
clinical assays, both between progestogens and for the same
progestogen.Pharmacologically, potency is defined as the concen-
tration of ligand that induces half the maximal response, or EC50,
while the efficacy refers to the maximal effect a ligand can elicit
under defined experimental conditions. Efficacy also gives a mea-
sure of biocharacter of progestogens, which can vary from full
agonist to partial agonist to different types of antagonism, depend-
ing on the extent to which a ligand can inhibit the response to
a particular concentration of agonist (Fig. 2A and B) [2]. Potency,
efficacy and biocharacter can only be accurately determined by
performing dose response analysis and constructing a dose
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Fig. 2. Potency and efficacy are determined by dose response analysis which also
reveals biocharacter of progestogens as compared to reference agonist. Schematic
illustration  of dose–response curves indicating (A) a typical curve for a full agonist
(sigmoidal-shaped  curve with Hill slope of 1) showing potency (EC50 value) and
efficacy  (maximal response), as well as for a partial antagonist and a full antagonist.
(B)  illustrates other possible biocharacters for progestogens, i.e. full agonist, partial
agonist, inverse agonist and neutral antagonist.
response curve (Fig. 2A) [2]. It is important to note that these
parameters are not constant but are particular for a specific effect
or response under defined conditions. In most clinical and ani-
mal assays, potency, efficacy and biocharacter are not evaluated by
these pharmacological criteria. Evidence to date from ex vivo assays
suggests that all progestogens act as full agonist for transcription
via the PR, while their transcriptional activities via other steroid
receptors vary from no activity, to partial agonist, full agonist, and
varying levels of antagonism, in a cell- and promoter-specific man-
ner. Although best described for G-protein coupled receptors [41],
inverse agonists have also been identified for the PR [42], but have
to our knowledge not been reported for progestogens. Biocharacter
can vary depending on context. For example, decreasing SR concen-
trations can convert some progestogen agonists to antagonists [4].
In addition, whether a ligand is an agonist or antagonist can depend
on cell type, such as the case for asoprisnil, the selective PR mod-
ulator [43]. These modulators have been suggested as therapeutic
agents for the treatment of gynecological disorders. Some progesto-
gens may  display mixed agonist-antagonist activity, as has been
reported for androgenic activity by cyproterone acetate [44]. How-
ever, the selective receptor-mediated effects of most progestogens
remain to be investigated. Most of the progestogen biocharacter
data have been defined in animal bioassays (Table 1) and are usually
not  fully explored by dose response analysis. They do not neces-
sarily reflect activity or biocharacter via a particular SR, or that
obtained in other assays in either the same or different species. The
large number of inconsistencies reported for biocharacter (Table 1)
most likely reflects species- and/or tissue-specific differences as
well as difference in methodology.
Dose  response analysis (Fig. 2) can be performed on cells in
culture, in tissue, in animals or even in patients. Many different
responses can be measured, including mRNA levels, reporter gene
activity, gene product (e.g. enzyme) activity or even physiolog-
ical functions such as inhibition of ovulation. As in the case of
steroid ligand binding curves, dose response curves ex vivo gen-
erally follow a sigmoidal shape with a Hill slope value of 1 (Fig. 2).
Dose response curves with the same Hill slope are considered to be
parallel, while those that differ are non-parallel. In the absence of
dose response analysis, relative responses obtained by single doses
of progestogens will vary depending on which part of the dose
response curve is represented for each progestogen. For example,
if the dose for all progestogens is already at the maximal response,
then the progestogens could be incorrectly reported to have the
same ‘potency’. Furthermore, if the data from incomplete curves
represents different parts of the curve, or off-target competing
receptors are present, plots will be non-parallel. Taken together,
this will result in misleading estimates of relative potency, efficacy
and biocharacter.
Determination of relative potency (EC50) by dose response
assays in vitro is subject to the same sources of variability as
determination of affinity, since the EC50 and Hill slope of the dose
response curve are highly dependent on the binding of ligand to a
competing receptor that may  be present, and on metabolism of the
ligand. This is illustrated in Fig. 3A and B (compare with Fig. 1B and
C). All the determinants of potency are not fully understood, since a
response involves several steps downstream of progestogen bind-
ing to receptor. However, factors such as relative concentrations
of cofactors [45] and SRs [4] have been shown to shift (EC50) val-
ues. For example, dose response curves for transrepression have
been shown experimentally to left-shift with increasing concen-
trations of target receptor, with accompanying increases in Hill
slope, most likely due to effects downstream of ligand binding
to the receptor (Fig. 3C).Few studies have investigated relative
potency and efficacy of different progestogens via particular SRs
by dose response analysis in ex vivo models. For transactivation,
it has been shown that Prog, MPA, dienogest, and norethisterone
are all agonists for the expressed PR on a synthetic GRE promoter
in COS-1 cells, but that their potencies and efficacies differ [37].
We have shown that unlike NET-A, MPA  and Prog have GR ago-
nist activity, while MPA  and NET-A have AR agonist activity, and
Prog has anti-AR activity via expressed receptors on synthetic GRE
promoters in COS-1 cells [22,23,39]. Using a similar approach, dose
response studies with expressed receptors on another GRE pro-
moter reported that Prog and DRSP displayed no anti-AR activity,
weak MR  agonist and considerable anti-MR activity in CV-1 cells
[2]. Several studies have shown that transactivation efficacy for
progestogens appear to be highly promoter - and cell-specific. For
example, MPA  was  found to only minimally transactivate (partial
agonist) a synthetic GRE-reporter gene via overexpressed human
GR in the Jurkat T-lymphocyte cell line [46], while displaying potent
transactivation activity (full agonist) on another synthetic GRE-
reporter gene via endogenous mouse GR in L929sA cells [47]. For
transrepression, cell line studies have shown that MPA  exhibits
potent GR-mediated transrepression on synthetic and endogenous
AP-1 or NFB-containing promoters [47,48]. In contrast, NET-A is
a weak partial agonist for transrepression [22]. Using expressed
receptors in COS-1 cells, we  have shown that Prog and NET-A,
but not MPA, have partial MR  agonist activity for transrepres-
sion on an AP-1 promoter-reporter, while MPA  and NET-A, unlike
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Fig. 3. Apparent potency (EC50) increases with competing receptor concentrations,
with  increased progestogen metabolism and with target receptor concentrations. (A
and B) Simulated dose–response curves indicating potencies (EC50) and Hill slopes
for  a progestogen via a target steroid receptor (A) in the presence of the indicated
increasing concentrations of competing receptor, or (B) in the presence of increasing
extents of progestogen metabolism to inactive compounds. Simulation parameters
were  as in Fig. 1B and C, respectively, except that labeled reference agonist was
not involved. The response was assumed to be proportional to the concentration
of  reference agonist–receptor complex. The competing receptor was assumed not
to contribute to the response. Hill slopes and EC50 values were obtained by fit-
ting the simulated data to the dose–response equation: y = top/(1 + 10(log EC50−x)h). (C)
Experimental  data showing dose–response curves with increasing target receptor
concentrations.  Agonist (Dex)-mediated repression of PMA-induced NFB activ-
ity in COS-7 cells transfected with an NFB-luciferase reporter gene and varying
amounts  of a GR expression vector was plotted. Fig. 3C was  reprinted from Inter-
national Immunopharmacology,  vol. 3, Q. Zhao, J. Pang, M.F. Favata, J.M. Trzaskos,
“Receptor density dictates the behavior of a subset of steroid ligands in glucocor-
ticoid  receptor-mediated transrepression”, pp. 1803–1817, Fig. 2B, © (2003), with
permission from Elsevier.
Prog, display similar AR agonist activity for transrepression on a
NFB promoter-reporter construct [23]. Although very little work
has been done comparing relative potencies and efficacies of pro-
gestogens for transactivation or transrepression on endogenous
genes, we  have shown that saturating concentrations of MPA,
NET-A and Prog exhibit promoter- and cell-specific regulation of
endogenous cytokine genes in human cervical and vaginal epithe-
lial cell lines [49]. Other studies have reported different ‘efficacies’
of some progestogens for expression of the low density lipopro-
tein receptor protein in a placental cell line, using a single and
possibly non-saturating concentration of progestogens [50], while
others reported differential effects of progestogens on expression
of thrombospondin-1 mRNA in Ishikawa cells, using three concen-
trations of progestogens [51]. Some of these studies illustrate the
difficulties in obtaining accurate potency, efficacy and biocharacter
data from cell culture studies without the use of full dose response
curves. We have shown by dose response analysis that MPA, as
compared to other progestogens, exhibits very different potencies,
efficacies and biocharacter for expression of endogenous genes in
cells where the GR is the predominantly expressed SR, as assessed
by receptor knock down strategies or the use of receptor-selective
antagonists (unpublished data). More of such investigations are
required, including investigating tissue/cell- and promoter-specific
biological activities and the involvement of particular SRs and their
isoforms.
In clinical and animal studies, the term ‘potency’ has been widely
used to describe many different progestogen actions, including
RBAs, relative responses to fixed constant doses in animal or clinical
assays, or a dose required to obtain a particular defined response,
which may not be maximal [3,52]. Some studies have included
dose response analysis [53], but often only three doses are arbi-
trarily chosen and full curves are not generated [54,55]. Most
assays describing the ‘potency’ of progestogens are based on the
progestational effects of these ligands on uterine glandular prolifer-
ation, pregnancy maintenance, glycogen deposition in endometrial
glands, delay-of menses, or inhibition of ovulation [3,5] using ani-
mal  models [37,53,54] or healthy female volunteers [55–57]. An
early study involving administration of three different doses of pro-
gestogens to women reported that the ‘potency’ of norgestrel was
lower in a glycogen deposition assay than in the delay of menses
test [55]. When assessing the significance of this result, it should be
noted that the “potencies” determined were not obtained from full
dose response curves and the plots were non-parallel. Another pos-
sible reason for differences in relative ‘potencies’ between different
assays is the inclusion of estrogen together with the progestogen
in some assays, such as in the delay of menses assay [58], but not
others, since estrogen could affect the response by, for example,
changing receptor levels.
A  rat study by Lundeen and co-workers showed that TMG
was more ‘potent’ than MPA  when assessing complement compo-
nent C3 expression in epithelial cells of the uterus, less ‘potent’
than MPA  in the proliferation of endometrial stromal cells,
and ‘equipotent’ in inhibiting ovulation [54]. In these assays,
once again the plots generated did not reach a maximal level
and were not parallel. Differences were also observed when
comparing the ‘potencies’ of progestogens in a bioassay measur-
ing endometrial transformation in rabbits (‘potency’ rank order
MPA ≥ dydrogesterone > NET) to that of an ex vivo assay measur-
ing their transactivation potential via the human PR (‘potency’
rank order MPA  ≥ NET > dydrogesterone) [37]. Although the bioas-
say dose response curves did not reach a maximal level, indicating
that the ED50 values obtained by this assay may  be inaccurate, the
change in rank order may  also be due to difference in metabolism
between the animal study compared to the in vitro cell line study.
Interestingly, the rank order for ‘potency’ of the same progesto-
gens in a clinical assay measuring endometrial protection, by dose
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response analysis, indicated that NET > MPA  > dydrogesterone [59],
possibly reflecting species-specific intracellular responses. A com-
parison between the rank order for potencies of progestogens in
the above bioassays with their RBAs for the PR (Table 1), illustrates
that generally the two do not correlate. There could be many rea-
sons for this, including differences in the levels of competing SRs
in the different target tissues/cells.
Not  all of the biological activities exhibited by progestogens
(Table 1) are mediated via binding to SRs. For example, the anti-
estrogenic action of progestogens in the endometrium is due to the
progestogen-bound PR suppressing ER gene expression, and con-
sequently the ability of the cell to respond to estrogen. In addition,
progestogen-bound PR activates the 17-hydroxysteroid dehydro-
genase type 2 enzyme which converts active estradiol to inactive
estrone, as well as activating the estrone-sulfotransferase which
causes the conjugation of estrone [5]. All the synthetic progestins
in Table 1 display anti-estrogenic activity via this mechanism in ani-
mal  models [5]. Similarly, Prog displays anti-androgenic effects, not
via binding to the AR, but by inhibition of 5-reductase activity, and
hence decreasing the conversion of testosterone to the more active
androgen, DHT. It is thus plausible that synthetic progestogens
elicit similar effects. Indeed, the synthetic progestogen, dienogest,
that has low relative binding affinity for the AR and potent anti-
androgenic activity [2], has been shown to inhibit 5-reductase
activity [60]. The relative contribution of these non-receptor off-
target effects will vary depending on the relative concentrations of
the off-target proteins in different model systems.
4. Conclusions
Potency, efficacy and biocharacter are useful clinical parame-
ters since they define the concentrations of progestogens required
to cause or inhibit particular biological or physiological effects,
the extent of that response, as well as how the response changes
over a range of concentrations or doses, and are thus important to
understand for hormonal therapy. Receptor affinity alone does not
determine potency and appears unrelated to biocharacter. How-
ever, the affinity of a progestogen for a SR is a major contributor to
potency, since together with concentrations of progestogen, com-
peting endogenous hormone and receptor, affinity determines the
fractional occupancy of the receptor, which in turn affects the
percentage of maximal response. The current literature indicates
that affinity, potency, efficacy and biocharacter are substantially
different between progestogens and for the same progestogen in
cell, tissue, animal, and clinical assays. Since potency, efficacy and
biocharacter are operational definitions which always have to be
defined for a particular model system and response, it is not sur-
prising that these values will exhibit species-, tissue-, cell- and
assay-specific differences for a particular progestogen. However
equilibrium dissociation constants should theoretically not vary
within a species.
Reported binding data in the literature are highly variable, most
likely due to multiple factors, including methodological differences,
and differential affinities of progestogens for binding to the MR,  AR
and GR, which exhibit varying relative concentrations in different
assay systems. The different binding affinities of progestogens for
different SRs are likely to be a major determinant of differential
actions of progestogens in a tissue- and cell-specific manner and be
highly relevant to side-effects of progestogens. For example, since
MPA  has a relatively high affinity for the ubiquitously expressed
GR [2] and is widely used in hormonal therapy and contracep-
tion, this raises important questions about glucocorticoid-like
side-effects of MPA  on cardiovascular effects, breast cancer,
immune function, bone density and susceptibility to infectious dis-
eases [2,3,8,35,37,52,56,59,61,62].  It is thus essential that accurate
affinities  of progestogens are determined for different SRs, in order
to better assess their potential differential side-effect profiles and
aid in new drug design. When designing binding experiments,
potential confounding factors such as metabolism, off-target bind-
ing to other receptors, methodology and analysis thereof, need to
be carefully considered, since they can lead to shifts in the IC50
values, Hill slopes and hence inaccurate RBAs and Kd values.
Taken  together, it is clear that the task of contextualizing the
‘potencies’ determined for different progestogens in different assay
systems is challenging as each assay tells a different story. Clin-
ically it would be useful to know the potencies, efficacies and
biocharacters of different progestogens for specific biological and
physiological responses. This would enable better prediction of the
minimum dose required for a maximal response, as well as the dose
range likely to result in the most varied intra and inter-individual
responses (steep part of the dose response curve), along with
likely side-effect profiles. Many factors would result in expected
differences in relative potencies, efficacies and biocharacter for
ex vivo, animal and clinical assays. These include route and time
of administration, co-administration of estrogen, species-specific
metabolism and physiology, affinities of progestogens for different
steroid receptors, the relative concentrations of off-target receptor
and non-receptor proteins, as well as promoter-specific transcrip-
tional effects of progestogens in different target tissues/cells. For
example, the fact that MPA  is more ‘potent’ than NET in a rabbit
model, does not imply that it will be more potent in an ex vivo
assay via the PR, or more ‘potent’ as a contraceptive in humans.
Indeed, the many varying factors mentioned above preclude pre-
cise comparisons of the relative ‘potencies’ determined by animal,
clinical, and ex vivo assays. However, it is likely that many of the
reported differences in ‘potencies’ for animal and clinical assays are
confounded by the methods used to determine potency. Since the
term ‘potency’ means different things to different people, results
comparing relative activities of progestogens need to be interpreted
in this context.
Clearly more clinical and molecular data is required to better
quantify the relative affinities, potencies, efficacies and biocharac-
ters of progestogens in different, animal and clinical models, toward
better understanding of their mechanisms of action, assessment
of their relative side-effects and improvement of choice and con-
centrations of progestogens in hormonal therapy. An awareness
of the pharmacological background and standardization of defini-
tions would also improve our understanding of the significance of
the current and future data.
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Whether hormonal contraceptives increase HIV-1 acquisition, transmis-
sion and disease progression are critical questions. Clinical research has
been hampered by a lack of understanding that different progestins used
in contraception exhibit differential off-target effects via steroid recep-
tors other than the progesterone receptor. Of particular, relevance is the
relative effects of medroxyprogesterone acetate (MPA) and norethister-
one enanthate (NET-EN), widely used as injectable contraceptives in
sub-Saharan Africa. While most high-quality clinical studies find no
increased risk for HIV-1 acquisition with oral contraception or injectable
NET-EN, most do find an increase with MPA, particularly in young
women. Furthermore, mounting evidence from animal, ex vivo and bio-
chemical studies are consistent with MPA acting to increase HIV-1
acquisition and pathogenesis, via mechanisms involving glucocorticoid-
like effects on gene expression, in particular genes involved in immune
function. We report that MPA, unlike NET and progesterone, represses
inflammatory genes in human PBMCs in a dose-dependent manner, via
the glucocorticoid receptor (GR), at concentrations within the physiolog-
ically relevant range. These and published results collectively suggest
that the differential GR activity of MPA versus NET may be a mecha-
nism whereby MPA, unlike NET or progesterone, differentially modu-
lates HIV-1 acquisition and pathogenesis in target cells where the GR is
the predominant steroid receptor expressed.
Introduction
Whether hormonal contraceptives increase HIV-1
acquisition is a critical and unresolved issue, in par-
ticular for young women in high risk areas, and is
the subject of intense worldwide research and
debate.1,2 Furthermore, whether hormonal contra-
ceptives increase HIV-1 transmission and disease
progression, as well as increase susceptibility to other
infectious diseases and STIs, are also critical health
issues. These issues are also mostly unresolved and
are topics of ongoing research. Clinical research in
these areas has been hampered by a lack of under-
standing of the molecular mechanisms of action of
the progestin components of contraceptives and by a
lack of appreciation of the differences between prog-
estins, which cannot be considered to act as a single
class of compounds regarding their side effect pro-
files.3–5 Although progestins are designed to act like
the natural ligand progesterone (P4) via the proges-
terone receptor (PR), they are likely to exert very
different side-effects due to their differential affinities
and activities via other members of the steroid
receptor family.3–5 Currently a wide range of proges-
tins is used in contraceptives, with several different
delivery methods and varying progestin doses. Until
recently, clinical studies investigating effects of con-
traceptives on HIV-1 have grouped together data
based on methods of delivery (injectable versus
oral), while ignoring both the type of progestin and
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dose used within those groups. More recently,
attempts have been made to investigate effects of
one progestin versus another, but usually the sample
size has been too small to establish significant differ-
ences, above other confounding variables. Neverthe-
less, a picture is emerging from clinical, animal,
ex vivo and biochemical studies that the injectable
contraceptive, medroxyprogesterone acetate (MPA),
is likely to increase HIV-1 acquisition in women and
transmission from women to men.
The injectable contraceptive
medroxyprogesterone acetate (MPA), unlike
norethisterone enanthate (NET-EN), appears to
increase HIV-1 acquisition
MPA, administered for contraception as Depo-MPA
(DMPA) or Depo-Provera, is a 150 mg 3-monthly
intramuscular injection that is used by millions of
women worldwide, particularly in sub-Saharan
Africa with high HIV-1 prevalence.1,6 Norethisterone
enanthate (NET-EN) is a 200 mg 2-monthly inject-
able that is used less than MPA globally, although
its usage is high in some regions of South Africa.7
Injectable contraceptive usage and HIV-1 prevalence
are particularly high in young women in some areas
of South Africa, such as at the KwaZulu-Natal site
for the CAPRISA microbicide trial. In this trial,
about 82% of the women investigated were on
injectable progestin-only contraceptives, as com-
pared to 15% on oral contraceptives.8 The majority
of high-quality studies, in which the most common
progestin used was levonorgestrel (LNG), showed no
significant increase in HIV-1 acquisition for oral con-
traceptive pills.9 Although only a few studies have
investigated the risks associated with the use of
injectable NET-EN on HIV-1 acquisition, none have
shown a significant association with HIV-1 acquisi-
tion.9 However, the majority of high-quality studies
do show an increased risk associated with only or
predominantly injectable DMPA usage.9–11 Many
clinical observational studies do not investigate risks
associated with subgroups of women, such as those
grouped by age or HSV-2 status, usually due to a
lack of sufficient study size for a particular subgroup.
However, of particular concern is the finding of an
adjusted hazard ratio (HR) for DMPA of 9.29 in
women aged 18–20.12 Although others have not
reported such age-related findings, they may not
have had sufficient young women with high HIV-1
exposure in their studies.13–16 Also of concern is the
finding of an HR of 4.5 for DMPA for HSV-2 nega-
tive women.12 However, establishing indisputable
evidence from such studies is extremely difficult
due to methodological challenges and multiple
confounding factors, such as the degree of exposure
to HIV-1, condom usage, HSV-2 exposure as well as
varying ages of women that have been enrolled in
these studies.9 Furthermore increases in both HIV-1
and HSV shedding have been reported in women
using contraception,17–19 as well as the presence of
more viral variants and higher viral loads in HIV-
1-infected DMPA users than non-users.20 These
findings are consistent with an increase in HIV-1
transmission found for injectable DMPA users.16
DMPA usage has also been associated with increased
acquisition of cervical chlamydial and gonococcal
infections.21 These STIs have also been linked to
increased HIV-1 acquisition. Consistent with the
clinical data, MPA increases susceptibility to vaginal
simian–human immunodeficiency virus (SHIV)
transmission and suppresses the antiviral cellular
immune response in SHIV-infected rhesus maca-
ques.22 No information is available regarding other
progestins and HIV-1 acquisition. Contraceptives
may also affect diseases progression. Most of the
clinical studies to date indicate no effect of hor-
monal contraception on disease progression. How-
ever, this may be due to several study limitations
such as insufficient power to discriminate between
progestin groups or methods of contraception deliv-
ery, analysis of only chronically infected patients,
and confounding variables such as antiretroviral
(ARV) usage and pregnancy. This suggests that
effects of specific progestins like MPA on disease
progression from the time of HIV-1 acquisition, can-
not as yet be excluded.23,24 Collectively, these find-
ings raise questions as to the choice of progestin,
dose and method of administration in determination
of susceptibility to and transmission of pathogens,
such as HIV-1, particularly in young women. Since
the current data from observational studies are not
considered persuasive enough to recommend using
methods of contraception other than DMPA,1,2 more
research is urgently required. The key question is
what information is needed and how feasible it is to
obtain. Some have argued that more large-scale ran-
domized trials are needed,25 but these may not be
ethical or conclusive. Another approach is to investi-
gate direct biological effects and mechanisms ex vivo
of different progestins at specific doses for different
target cells relevant to HIV-1 pathogenesis.
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The mechanism of action is likely to involve
differential effects on gene expression on immune
function genes by MPA versus NET, mediated via
the glucocorticoid receptor
Effects of progestins on HIV-1 acquisition and trans-
mission are proposed to occur via multiple mecha-
nisms, including changes in vaginal structure,
endometrial thinning, effects on genital flora, effects
of other sexually transmitted infections, as well as
changes in immune function.26 At the cellular level,
progestins and sex steroid hormones mediate their
effects via alterations in transcription of specific
genes via binding to and regulating the activity of
steroid receptors.4 Progestins differ widely in their
steroid receptor selectivity profiles.3–5 MPA, NET and
LNG all exhibit some binding to the androgen recep-
tor with undetectable anti-androgenic activity and
some androgenic activity. MPA and NET exhibit very
little antimineralocorticoid activity at contraceptive
doses,27 unlike some reports for LNG.4,27 However,
MPA binds to the GR with an affinity (Kd of
4–11 nM) similar to that of the endogenous gluco-
corticoid cortisol and acts as a full to partial agonist
for the GR, whereas P4 and NET bind to the GR
with about a 50- to 100-fold lower affinity and are
very weak partial GR agonists with much lower
potency and efficacy.4,5 In contrast, the fourth-
generation progestins are much more selective for
the PR. The GR is a well-established regulator of
immune function via regulation of transcription of a
wide variety of immune function genes. Glucocortic-
oids are potent immunosuppressive agents which
exert multiple complex actions on dendritic cells,
myeloid cells and B- and T-lymphocytes, including
effects on apoptosis and differentiation fate and inhi-
bition of cytokine release and cell migration.28–30
Consequently, glucocorticoids are widely used as
anti-inflammatory and immunosuppressive drugs.
The immunosuppressive actions of glucocorticoids
are largely due to their repression of transcription of
target genes such as cytokine and chemokine genes,
via inhibition of the transcription factors nuclear fac-
tor kappa B (NFjB) and activator protein 1 (AP-1).30
Glucocorticoids, like cortisol, bind to inactive GR in
the cytoplasm. Ligand-bound GR is subsequently
hyperphosphorylated and translocates into the
nucleus where it is able to modulate transcription.
Once in the nucleus, ligand-bound GR binds as a
dimer to glucocorticoid response elements (GREs)
resulting in positive transcriptional regulation, called
transactivation.28–30 Additionally, ligand-bound
monomeric GR is also known to negatively regulate
transcription by interfering either directly or indi-
rectly with other DNA-bound transcription factors,
like NFjB or AP-1.30 This mechanism, known as
transrepression, prevents NFjB- and AP-1-mediated
transcription.28–30 Given that MPA, unlike other
progestins, acts as a relatively potent full to partial
agonist for the GR, MPA is likely to exert much
more potent and efficacious effects on gene promot-
ers involved in immune function than P4 or NET via
the GR, as we have demonstrated in cell lines.31–33
We proposed in 2004 that due to the differential
activity of MPA versus NET via the GR, MPA is
likely to exert different effects on immune function
and hence modulate susceptibility to infections like
HIV-1.3 MPA has been reported to modulate tran-
scription of a number of genes via the GR, including
IL2 in normal human lymphocytes,34 and IL6 and
IL8 in a mouse fibroblast cell line.31 We have also
recently shown that MPA, unlike NET and P4,
exhibits differential regulation of apoptotic genes
and dose-dependently enhances HIV-1-mediated
apoptosis in primary human CD4+ T cells via a
GR-dependent mechanism,35 consistent with the ste-
roid receptor selectivity of these ligands. Further-
more, MPA, to a greater extent than P4, suppresses
ex vivo the production of key regulators of cellular
and humoral immunity involved in orchestrating
the immune response to invading pathogens such as
HIV-1, most likely via the GR.36 It remains to be
determined how different progestins affect expres-
sion of key genes involved in immune function in
primary cells relevant to HIV-1 pathogenesis.
We have addressed this question in peripheral
blood mononuclear cells (PBMCs), representing key
targets for HIV-1 infection and replication. We deter-
mined the effects of varying doses of MPA, NET and
P4, in comparison with dexamethasone (DEX), a
synthetic GR agonist, on expression of four-key
immunomodulatory genes namely, glucocorticoid-
interacting leucine zipper (GILZ), interleukin (IL) 6,
IL8 and regulation on activation normal T cell
expressed and secreted (RANTES). The GILZ gene is
GRE-regulated and encodes an anti-inflammatory
protein that inhibits the activation of pro-inflamma-
tory transcription factors.37 IL6 and IL8 genes, which
are upregulated by NFjB and AP-1, are pro-inflam-
matory cytokines expressed by a number of innate
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and adaptive immune function cells.38 RANTES
(CCL5), also upregulated by NFjB, is a chemokine
that is involved in the recruitment of mononuclear
cells to sites of chronic inflammation39 and interferes
with HIV-1 entry into target cells by competitive
binding to the CCR5 co-receptor.40 A decline in
RANTES protein expression is also associated with
an increase in HIV-1 disease progression.39 Freshly
isolated PBMCs were stimulated with varying con-
centrations of the different ligands for 48 hrs, fol-
lowed by RNA isolation, reverse transcription and
real-time quantitative PCR. The results show that
DEX and MPA, unlike NET and P4, repress IL6 and
IL8 pro-inflammatory gene mRNA levels while
increasing GILZ anti-inflammatory mRNA levels
(Fig. 1), while RANTES mRNA repression was only
detectable with DEX under these conditions (Fig. 1).
Concurrent with mRNA expression analysis, protein
expression analysis by flow cytometry indicated that
the progestins mediated differential regulation on
IL6 and GILZ protein levels (Fig. 1 E and F). MPA
and DEX significantly repressed IL6 protein expres-
sion after 48 hrs, while P4, NET-A, NET and LNG
did not affect basal expression in CD14+ monocytes
(Fig. 1e). DEX significantly increased GILZ protein
expression levels in CD4+ T cells, while MPA indi-
cated a moderate, but not significant, increase in
basal expression of GILZ after 48 hrs. P4, NET, NET-
A and LNG did not affect GILZ protein expression
levels (Fig. 1 e and f). Both NET and NET-A were
included in these experiments to show that the lack
of an effect with NET-A is not due to an inability to
be metabolized to NET in PBMCs. We did not detect
substantial GILZ expression in monocytes or IL6
expression in CD4+ T cells. These results showing
immunosuppressive effects of MPA on gene expres-
sion are consistent with our previous data,31–33 as
well as with results reported by others in Bacillus
Calmette–Guerin-stimulated PBMCs and murine
M. tuberculosis models,41,42 and those from the Hel
laboratory in activated T cells and in primary vaginal
mucosal mononuclear cells (VMMCs)36 and cyto-
brushes from patients on DMPA.36
To investigate the role of the GR in mediating the
responses, PBMCs were treated with DEX and MPA in
the absence and presence of RU486, a known GR
antagonist. In Fig. 2, IL6, IL8 and RANTES mRNA
repression by DEX and MPA was lifted in the presence
of RU486, while DEX and MPA induction of GILZ
mRNA was attenuated by RU486 (Fig. 2 a-d). Simi-
larly Huijbregts et al. found that RU486 treatment
together with MPA lifted the MPA-mediated repres-
sion of IFN-c protein expression in VMMCs and acti-
vated PBMCs, CD3+ and CD14+ cells.36 Although
RU486 can also antagonize the PR, we have recently
shown that PBMCs under our conditions express no
detectable PR mRNA or protein.35 Thus, our RU486
results support a role for the GR in mediating these
anti-inflammatory effects in PBMCs. Importantly we
show for the first time that the GR is likely to play a
key role in discriminating between immunosuppres-
sive responses by MPA versus NET and P4 in primary
human cells representing key targets for HIV-1 infec-
tion and replication. We have recently shown that
this discriminatory role of the GR is also observed in
the End1/E6E7 endocervical epithelial cell line, a
model for the endocervical mucosa and site of hetero-
sexual HIV-1 transmission (data not shown). Interest-
ingly in these cells, as well as in primary endocervical
epithelial cells, the GR is the predominant steroid
receptor expressed (data not shown).
The concentrations of progestins used are critical
and determine dose–response
Previous research on the biological effects of
progestins and P4 has been hampered by a lack of
understanding of the significance that doses have
in determination of physiologically relevant
responses.43 Unfortunately there is also a paucity of
information about serum concentrations of progestins
in contraception users, which show high interindivid-
ual variability, as well as concentrations in tissues at
target sites, which may not mimic serum concentra-
tions. We investigated whether the observed effects
of MPA, NET and P4 are relevant to the physiological
doses of these ligands4,5 by dose–response analysis to
determine potencies and efficacies.43 Endogenous P4
serum concentrations vary substantially during the
menstrual cycle in pre-menopausal women and are
low during the follicular phase (0.65 nM), rising to
about 80 nM during the luteal phase, with higher
concentrations of about 600 nM during pregnancy.4
MPA serum concentrations are reported to be in the
range 2.5 to 65 nM a few days after injection in
injectable users and to plateau at about 2.6 nM for
about 3 months, while serum concentrations of NET-
EN are reported to be in the range 1.5–59 nM.4,5 Our
dose–response analysis in these experiments suggests
that MPA is likely to exert anti-inflammatory immu-
nosuppressive effects via GILZ gene expression within
the range of concentrations found in the serum of
American Journal of Reproductive Immunology (2014)
4 ª 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
HAPGOOD ET AL.
injectable contraceptive users (1–100 nM), as well as
possibly on IL6 and IL8, particularly shortly after
injection. However, the immunosuppressive effects of
NET-EN on PBMCs via the GR are likely to be negligi-
ble, even shortly after injection, while P4 is unlikely
to exert immunosuppressive effects in PBMCs even
during pregnancy via these genes. Interestingly, we
have recently shown that the GR may also play a key
role in PBMCs in discriminating between apoptotic
effects by MPA, unlike NET and P4, at doses within
the contraceptive range, in the absence and presence
of HIV-1 infection.35 The physiological consequences
of immunosuppressive and apoptotic effects of MPA
on PBMCs could include a wide range of effects bene-
ficial to the virus. These could include compromising
the ability of the host to mount effective innate and
adaptive immune responses, as well as increasing
binding of HIV-1 to CCR5 co-receptors. Effects seen
with MPA in PBMCs may also occur in T cells and
monocytes in the genital mucosa.
Conclusions
While controversy continues, a trend is emerging
from multiple clinical studies that the injectable




Fig. 1 DEX and MPA, dose-dependently regulate IL6, IL8, RANTES and GILZ mRNA levels in primary human PBMCs and decrease IL6 protein
expression in CD14+ monocytes and increase GILZ expression in CD4+ T cells. (a-d) PBMCs were stimulated with increasing amounts of DEX, MPA,
P4, NET-A or vehicle (EtOH) for 48 hrs. Relative levels of IL6 (a), IL8 (b), RANTES (c) and GILZ (d) mRNA were normalized to GAPDH mRNA levels.
(e-f) PBMCs were treated with 100 nM DEX and MPA, 1 lM P4, 10 lM NET-A, NET, and LNG (GR saturation concentrations) or vehicle (ETOH) for
48 hrs. Thereafter, cells were stained with surface antibody markers (CD4+ and CD14+) followed by IL6 (e) or GILZ (f) intracellular antibody staining
for protein expression. Protein expression was measured using a Becton–Dickinson FACS Calibur flow cytometer and analysed using FlowJo
software (Version X, Treestar Inc., Ashland, Ore). Fold changes in protein expression are indicated, with vehicle (EtOH) set to 1. Histograms show
pooled results from three to five independent experiments with samples from female donors. Statistical significance was determined by one-way
ANOVA with Student’s t-test to control where, *P < 0.05, **P < 0.01 and ***P < 0.001.
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acquisition and transmission, in particular in young
women with high exposure to HIV-1, unlike other
progestin contraceptives, such as the injectable con-
traceptive NET-EN. Several modelling studies have
attempted to weigh up the competing risks between
contraception and HIV-1 acquisition versus with-
drawal of contraception and associated maternal
mortality and other factors associated with unwanted
pregnancies.44–46 Their results suggest that with HRs
<2, the risks of withdrawal from DMPA outweigh
potential benefits. However, it should be noted that
risk assessments have not, to our knowledge, been
published for HRs associated with only younger
women in high risk areas for HIV-1 infection, or for
changing to another method of contraception such as
NET-EN, which has similar pregnancy risks and
compliance factors to DMPA. This would seem highly
relevant, given that risks for young women in sub-
Saharan Africa carry a disproportionate percentage of
the worldwide HIV-1 burden and are the highest
users of DMPA. Although the findings showing
increased HIV-1 acquisition and transmission with
DMPA could be due to confounding behavioural fac-
tors, the finding that NET-EN does not increase HIV-
1 acquisition argues against this, since DMPA and
NET-EN users would be expected to display similar
behavioural factors such as condom usage. Further-
more, both animal and ex vivo biochemical studies,
using contraceptive concentrations of MPA, support
the possibility that MPA increases HIV-1 infection
and transmission.47 We show directly for the first
time that the GR is likely to play a key role in dis-
criminating between immunosuppressive responses
by MPA versus NET and P4 in primary human cells
representing key targets for HIV-1 infection and repli-
cation. Biochemical studies such as we report here
provide strong support for a mechanism whereby
MPA, unlike other progestins like NET-EN, is likely
to modulate gene expression and immune function,
at concentrations within the range of peak serum
MPA concentration in injectable users, acting via the
GR. The GR is ubiquitously expressed, unlike the PR.
More research is needed to investigate the concentra-
tions of different progestins in target tissues and to
assess their likely dose–response effects. Given its
central role in transcription regulation in all mamma-
lian cells, effects of MPA on gene expression via the
GR are likely to be the molecular basis for several dif-
ferential effects of MPA versus other progestins that
do not act via the GR. These could include effects on
HIV-1 replication, host cell apoptosis, expression lev-
els of several host cell receptors, cell cycle and prolif-
eration effects and epithelial cell barrier function.
Future research on the effects of different progestins
on modulation of HIV-1 pathogenesis, at doses within
the contraceptive range, in primary cell and tissue
models will undoubtedly provide necessary insight
into the question of choice of progestin and dose
effects. However, it remains to be seen whether con-
firmatory information from such studies will be
(a) (b)
(c) (d)
Fig. 2 DEX- and MPA-mediated regulation of
GILZ, IL6, IL8 and RANTES mRNA requires the
presence of the GR. (a-d) PBMCs were
stimulated with 100 nM DEX and MPA in the
presence and absence of 1 lM RU486 for
48 hrs. Relative levels of IL6 (a), IL8 (b),
RANTES (c) and (d) GILZ transcripts were
determined by qPCR and normalized to
GAPDH. Histograms show results from three
independent experiments. Statistical
significance was determined by one-way
ANOVA with Dunnet’s post-test or paired
student t-tests. P < 0.05 denoted as *,
P < 0.01 denoted as ** and P < 0.001
denoted as ***.
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enough to change health policy, in the absence of
clinical data, which may not be possible or feasible to
obtain.
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The Progestin-Only Contraceptive Medroxyprogesterone
Acetate, but Not Norethisterone Acetate, Enhances HIV-1
Vpr-Mediated Apoptosis in Human CD4+ T Cells through
the Glucocorticoid Receptor
Michele Tomasicchio, Chanel Avenant, Andrea Du Toit, Roslyn M. Ray, Janet P. Hapgood*
Department of Molecular and Cell Biology, University of Cape Town, Cape Town, Western Province, South Africa
Abstract
The glucocorticoid receptor (GR) regulates several physiological functions, including immune function and apoptosis. The
HIV-1 virus accessory protein, viral protein R (Vpr), can modulate the transcriptional response of the GR. Glucocorticoids
(GCs) and Vpr have been reported to induce apoptosis in various cells, including T-cells. We have previously shown that the
injectable contraceptive, medroxyprogesterone acetate (MPA) is a partial to full agonist for the GR, unlike norethisterone
acetate (NET-A). We investigated the functional cross talk between the GR and Vpr in inducing apoptosis in CD4+ T-cells, in
the absence and presence of GCs and these progestins, as well as progesterone. By using flow cytometry, we show that, in
contrast to NET-A and progesterone, the synthetic GR ligand dexamethasone (Dex), cortisol and MPA induce apoptosis in
primary CD4+ T-cells. Furthermore, the C-terminal part of the Vpr peptide, or HIV-1 pseudovirus, together with Dex or MPA
further increased the apoptotic phenotype, unlike NET-A and progesterone. By a combination of Western blotting, PCR and
the use of receptor- selective agonists, we provide evidence that the GR and the estrogen receptor are the only steroid
receptors expressed in peripheral blood mononuclear cells. These results, together with the findings that RU486, a GR
antagonist, prevents Dex-, MPA- and Vpr-mediated apoptosis, provide evidence for the first time that GR agonists or partial
agonists increase apoptosis in primary CD4+ T-cells via the GR. We show that apoptotic induction involves differential
expression of key apoptotic genes by both Vpr and GCs/MPA. This work suggests that contraceptive doses of MPA but not
NET-A or physiological doses of progesterone could potentially accelerate depletion of CD4+ T-cells in a GR-dependent
fashion in HIV-1 positive women, thereby contributing to immunodeficiency. The results imply that choice of progestin used
in contraception may be critical to susceptibility and progression of diseases such as HIV-1.
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Introduction
Globally women account for ,49% of HIV infections [1], with
greater prevalence among young women vulnerable to both
pregnancy and HIV-infection than in men [2]. In Sub-Saharan
Africa, 59% of all those infected are women [3]. There is
substantial evidence from clinical studies that hormonal contra-
ception increases HIV-1 acquisition and transmission in young
women and disease progression, although some of the findings are
controversial, and some studies report no significant effects [4–15].
Of particular interest are the relative effects of the two most
commonly used injectable contraceptives, MPA and norethister-
one enanthate (NET-EN), in HIV-1 infection and AIDS pro-
gression. MPA, administered for contraception as Depo-MPA
(DMPA) or Depo-Provera, is a 150 mg three-monthly intramus-
cular injection that is used by millions of women worldwide and is
widely used in Sub-Saharan Africa and other areas with high
HIV-1 prevalence [6,14–17]. NET-EN is a 200 mg two-monthly
injectable that is used less than MPA, although in countries like
South Africa, its usage varies and is high in some regions [8,17–
19]. Both contraceptives have been shown to be highly effective
and relatively safe regarding most risk factors investigated [20].
However, there is evidence that DMPA but not NET-EN
increases HIV infectivity [5,6,8,10,15,21,22]. Increases in both
HIV-1 and HSV shedding have been reported in women using
contraception [23–25], as well as the presence of more viral
variants and higher viral loads in HIV-1 infected DMPA users
than non-users [7], consistent with an increase in HIV-1
transmission found for DMPA users [5]. DMPA usage has also
been associated with increased acquisition of cervical chlamydial
and gonococcal infections [26]. In addition, while there is evidence
both for and against an increase in disease progression in the
absence of antiretroviral drugs (ARVs) for HIV-1 positive DMPA
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users [7,9,11–13], to our knowledge no information is available for
effects of NET-EN. Whether DMPA or NET-EN affect disease
progression in HIV-1 positive antiretroviral users remains to be
established, although one study suggests no significant change in
CD4+ counts for DMPA users with and without antiretroviral drug
usage [27]. Adjusted hazard ratios (HRs), (reflecting the fold
increased risk relative to no contraception), of between 1.5 and 4.5
fold have been recently reported for DMPA (author’s response in
Gray [4,5,8,10]), while one study reported an HR as high as 10.4
for DMPA [28]. However, establishing indisputable evidence from
such clinical observational studies is extremely difficult due to
multiple confounding factors such as the degree of exposure to
HIV-1, condom usage, HSV-2 exposure as well as varying ages of
women that have been enrolled in these studies [15]. Therefore,
a central question remains as to what extent and via which
mechanisms different synthetic progestins affect HIV-1 pathogen-
esis at contraceptive doses and at various target sites, a question
perhaps best answered by ex vivo studies.
At the cellular level, progestins mediate their effects via
alterations in transcription of specific genes in target cells by
binding to and regulating the activity of steroid receptors, which
are ligand-activated transcription factors [29,30]. Although
progestins are designed to act like the natural ligand progesterone
(P4) via the progesterone receptor (PR), they are likely to exert
very different off target side-effects due to their differential
affinities and activities via other members of the steroid receptor
family of receptors [29–31]. NET-EN is converted to norethister-
one (NET) in the body, while water soluble derivatives of NET-EN
such as NET or norethisterone acetate (NET-A are used orally for
hormone replacement therapy) [27,28]. We have shown that MPA
and NET-A have different affinities for and activities via the
glucocorticoid receptor (GR) [32–34]. MPA binds to the GR with
a relatively high affinity and acts as a full to partial agonist for the
GR, whereas NET-A and P4 bind to the GR with about 100-fold
lower affinity and have little or no activity via the GR. This
differential activity via the GR suggest that MPA and NET may
exert different effects on HIV-1 pathogenesis via the GR, in
particular different effects on immune function, since the GR
regulates transcription of a wide variety of genes involved in
inflammation, immunity, and apoptosis [35,36]. Several different
mechanisms could contribute to the observed effects of DMPA
usage on HIV-1 pathogenesis, including alterations in the
composition of mucosal microflora and thinning of the cervical/
vaginal epithelium. However, the high affinity of MPA for the GR
and the known effects of the GR on immune function suggest that
effects of DMPA on both systemic and local immunity via the GR
may be highly significant.
Although very few studies have investigated this hypothesis,
some do show that MPA affects immune function in vivo in animals
and humans. Two studies in mice provide evidence that MPA
suppresses immune function to increase susceptibility to infections
or reduce defense against disease in mice, at similar doses to those
of women using DMPA [37,38]. Studies in primates have shown
that DMPA reduces systemic immune responses in SIV-infected
macaques [39,40]. MPA used at high doses in cancer therapy is
known to cause significant systemic immunosuppression in
patients [41–44] and a decrease in T-cell numbers and pro-
liferation in breast cancer patients [41,44]. Furthermore, DMPA
as a contraceptive has been shown to compromise cell-mediated
immune status [45] and causes increased recruitment of in-
flammatory cells in cervical vaginal lavages in women [46]. A
recent ex vivo study in primary immune function and cervical cells
from patients showed that MPA, unlike P4, suppresses both innate
and adaptive immune mechanisms at concentrations within the
range of peak serum concentrations found in DMPA users [47,48].
Importantly, the findings from the group of Hel [47] showing
significant repression of IFNl in peripheral blood mononuclear
cells (PBMCs) and lavages from DMPA users but not non-
contraceptive users strongly supports the idea that DMPA
concentrations in vivo are sufficient for immunosuppression. In-
terestingly, P4 is also known to regulate both the innate and
adaptive immune response in the female reproductive tract, other
mucosal tissues as well as systemic immune function in humans.
However, the precise mechanisms and receptors involved in this
regulation are not well understood, but appear to be specific for
different target sites and cell types [6,49,50]. In contrast, very little
is known about the effects of NET-EN/NET/NET-A on immune
function in women.
HIV-1 infection is characterized by rapid and extensive CD4+
T-cell depletion and eventual immunodeficiency. HIV-1-induced
apoptosis appears to play an important role in depletion of CD4+
T-cells, decreasing immune responses to infection and facilitating
viral persistence and increased viral loads and transmission rates
[51]. Furthermore, the loss of CD4+ T-cells correlates with disease
progression and increases in opportunistic infections [52].
Although the exact mechanisms and role of apoptosis during
disease progression remain to be resolved, several HIV-1 proteins
have been implicated in inducing apoptosis in T-cells, including
the 96 amino acid HIV-1 accessory protein viral protein R (Vpr)
[53]. Besides apoptosis, Vpr has been implicated to play a part in
other cellular functions such as cell cycle arrest at G2/M phase
and transport of the pre-initiation complex [53]. Vpr is packaged
within the virus particle where it is thought to be involved in the
early stages of viral replication through transactivation of the HIV-
1 long terminal repeat (LTR) [53]. The clinical observations that
mutations in key Vpr residues are associated with normal capacity
to replicate but loss of cytotoxicity [54] and long-term non-
progressive HIV-1 infections [55], support an important cytotoxic
role for Vpr in HIV-1 infection. Such a cytotoxic role may be
exerted by both virus-associated as well as virus-free Vpr, since
functional Vpr protein has been purified from serum and
cerebrospinal fluid of infected patients [56–58]. Vpr in the plasma
of HIV-1 infected individuals is present at similar concentrations
as the p24 antigen and has the ability to self-penetrate cells
(transduction properties) and to elicit its effects, including
apoptosis, in non-infected bystander cells [56,59]. Mapping
experiments of the Vpr protein indicated that amino acids 1–52
are important for the transduction properties of Vpr, but not for
induction of apoptosis [60]. The C-terminus (amino acids 52–96)
of Vpr, in particular amino acids 71–82 (71-HFRIGCRHSRI-82),
have been shown to be indispensable for apoptotic function [61–
64]. Although Vpr can induce apoptosis via the extrinsic pathway
in neuronal and epithelial cells [65–68], it has been implicated to
act predominately through the intrinsic pathway in a number of
other cell lines and primary cells, including T-cells [69].
Reminiscent of the effects of Vpr on apoptosis, GCs, like
cortisol, (F) acting via the GR, are also potent inducers of apoptosis
in a number of different cells, including T-cells [35]. Several lines
of evidence suggest that Vpr regulates transcription of host and
viral genes via the GR [70]. The mechanism may involve an
interaction of Vpr with the GR to modulate GR transcriptional
activity, as Vpr has been reported to associate with the GR in vitro
and modulate transcription of both host and viral genes [71,72].
This interaction was reported to occur via a signature LXXLL
steroid receptor co-activator motif [73]. Consistent with a role for
the GR in mediating Vpr effects on apoptosis at the transcriptional
level, it has been shown that RU486, a GR antagonist, prevents
Vpr-mediated apoptosis in the Jurkat T-cell line [74].
The Contraceptive MPA Increases T-Cell Apoptosis
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Cross talk between Vpr and the GR raises the question as to
how different GR ligands such as MPA would affect GR- and Vpr-
mediated T-cell apoptosis. As both the GR and Vpr have been
implicated to play a role in apoptosis in a number of cell lines and
primary cells, we sought to investigate the possible cross talk
between the GR and Vpr in modulating apoptosis in the presence
of the progestins, MPA and NET-A, and P4 in PMBCs.
Materials and Methods
Ethics Statement
Anonymous buffy packs, otherwise normally discarded, were
obtained from the Western Province Blood Transfusion (WPBT)
services in Pinelands, Cape Town. Written informed consent was
obtained from donors by WPBT and records kept by WPBT. The
Ethics Committee of the University of Cape Town (N05/11/187)
approved the procedure (SFREC_ 04_2010).
Plasmids, Western Blotting and Antibodies
The plasmids used in this study were as follows: pcDNA3-hGR
(GR) plasmid was a gift from Prof. D.W. Ray (Centre for
Molecular Medicine, School of Clinical and Laboratory Sciences,
Faculty of Medical and Human Sciences, University of Manche-
ster, UK). pMT-PR-B (PR) was obtained from Prof. S. Okret
(Karolinka Institute, Sweden). pRS-hMR (MR) expression plasmid
was obtained from Prof. R.M. Evans (University of California,
USA). pSV-hAR (AR) was a kind gift from Frank Claessens
(Catholic University of Leuven, Belguim). pSG5-hER (ER) was
obtained from F. Gannon (EMBL, Germany). The positive
controls for each steroid receptor were generated in COS-1 cells
(ATCC). Briefly, COS-1 cells were seeded at a density of 16105
cells in a 12-well plate. After 24 hrs the cells were transfected with
1 mg of the steroid receptor expression vector using X-treme-
GENE 9 DNA Transfection Reagent (Roche Applied Sciences)
according to the manufacturer’s specifications. The next day
whole cell lysates were prepared using a N-[Tris(hydroxymethyl)-
methyl]-3-aminopropanesulfonic acid (TAPS) buffer (0.1 M
TAPS, pH 9.5) on ice as described by Ronacher et al [34]. PBMC
lysates were also prepared in TAPS buffer from approximately
46106 cells.
Western blotting was performed essentially as previously
described [75]. All antibodies were purchased from Santa Cruz
biotechnology (USA, California). Antibodies included anti-andro-
gen receptor (AR, C-441, sc-7305) anti-estrogen receptor (ER,
MC-20, sc-542), anti-GR (H-300, sc-8992), anti-mineralocorticoid
receptor (MR, C-19, sc-6861), anti-PR (C-20, sc-539) and anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, sc-47724).
Conventional PCR
Conventional PCR was performed using GoTaq DNA poly-
merase (Promega, USA, M3001) with the steroid receptor specific
primers (Table 1) according to the manufacturer’s specifications.
Initial denaturation was for 90 sec at 95uC, while final extension
was for 5 mins at 72uC. The cycling parameters for 35 cycles are
shown in Table 1.
PBMC Isolation, Cell Culture and Test Compounds
Buffy packs were obtained from healthy donors who were
negative for HIV, syphilis and hepatitis B and C. PBMCs were
isolated using Histopaque (H1077 Hybri-MaxTM; Sigma-Aldrich,
South Africa) density centrifugation with Leucosep tubes (Greiner
Bio-One, Germany) according to the manufacturer’s instructions
[76]. PBMCs were cultured in high glucose (4.5 g/ml) Roswell
Park Memorial Institute medium (RPMI) (Gibco, South Africa)
supplemented with 10% (v/v) charcoal-stripped fetal calf serum (c-s
FCS) (Highveld Biological, South Africa), 2 mM L-glutamine
(Sigma-Aldrich, South Africa), 0.1 mg/mL sodium pyruvate
(Sigma-Aldrich, South Africa), 100 IU/ml penicillin and
100 mg/ml streptomycin (Sigma-Aldrich, South Africa) at 37uC
in a water jacket incubator (90% humidity and 5% CO2). Note
that each figure shows the results of experiments using PBMCs
isolated from different donors. Dex ((11b,16a)-9-fluoro-11,17,21-
trihydroxy-16-methylpregna-1,4-diene-3,20-dione), MPA (Me-
droxyprogesterone 17-acetate), NET-A (19-Norethindrone ace-
tate), NET (19-Norethindrone), P4 (progesterone), R5020 (17,21-
dimethyl-19-norpregna-4,9-dien-3,20-dione), Mib (mibolerone),
E2 (estradiol), Ald (Aldosterone) and RU486 (Mifepristone) were
purchased from Sigma-Aldrich, South Africa.
Cell Treatment without Vpr Peptide and Flow
Cytrometric Detection of Apoptosis
Approximately 16106 PBMCs/ml RPMI were seeded into
a 5 mL Becton-Dickinson Falcon tube (352063). Cells were then
treated with either Dex, F, MPA, NET-A, P4 or vehicle control
(EtOH) at the concentrations indicated in the figure legends for
24 hrs at 37uC. After treatment, cells were surface stained and the
apoptotic phenotype detected using the annexin V PE apoptosis
detection kit I according to the manufacturer’s specifications
(Becton-Dickinson-Biosciences; 559763). The following antibodies
Table 1. Primers used for conventional PCR.





95uC (45 sec), 60uC (45 sec), 72uC (45 sec) 209
ER alpha F: 59- TCGACGCCAGGGTGGCAGAG
R: 59-TGGTGCACTGGTTGGTGGCTGG-39
95uC (45 sec), 60uC (45 sec), 72uC (45 sec) 218
GR F: 59-TGCTGTGTTTTGCTCCTGATCTG-39
R: 59-TGTCAGTTGATAAAACCGCTGCC-39
95uC (45 sec), 53uC (45 sec), 72uC (45 sec) 299
MR F: 59-GAGCAGTGGAAGGGCAACAC-39
R: 59-TGGCTGCTCCTCGTGAATCC-39
95uC (45 sec), 60uC (45 sec), 72uC (45 sec) 182
PR A and PR B F: 59-GTGCTCAAGGAGGGCCTGCCG-39
R: 59-TGTGCTGCCCTTCCATTGCCC-39
95uC (45 sec), 60uC (45 sec), 72uC (45 sec) 214
F = Forward; R = Reverse.
doi:10.1371/journal.pone.0062895.t001
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were used to discriminate between cellular populations in PBMCs:
1 mL anti-CD4 fluorescein isothiocyanate (FITC) (Becton-Dick-
inson, 555346), 2 mL anti-CD14 allophycocyanin (APC) (Becton-
Dickinson, 555399) and 1 mL anti-CD3 APC (Becton-Dickinson,
555342) in 50 mL PBS. Samples were acquired using a Becton-
Dickinson FACS Calibur flow cytometer and analysed using Flo Jo
software (Treestar, Inc, Ashland, Ore).
Cell Treatment with Vpr Peptide
The C-terminal Vpr peptide (including amino acids 52–96;
GNTWAGVEAIIRILQQLLFIHFRIGCRHSRIGVTRGR-
RARNGASRS) was a kind gift from Dr Jeffrey Kopp (NIDDK,
National Institutes of Health, Bethesda, USA). Freshly isolated
PBMCs were treated with 5 mM Vpr peptide as previously
described [61]. Briefly, approximately ten million PBMCs were re-
suspended in 1 mL of balanced isotonic glucose-HEPES buffer
(2.4% glucose, 13 mM HEPES, 68 mM NaCl, 1.3 mM KCl,
4 mM Na2HP04 and 0.7 mM KH2PO4, pH 7.2). One million
Table 2. Primers used for real time PCR.





95uC (10 sec), 55uC (10 sec), 72uC (10 sec) 307
Bcl-2 F: 59-TTGTGGCCTTCTTTGAGTTCGGTG-39
R: 59-GTACAGTTCCACAAAGGCATCCCA-39
95uC (10 sec), 60uC (10 sec), 72uC (10 sec) 167
Bim F:59-GAGTGTGACCGAGAAGGTAGACAATTGC-39
R: 59-CCTTCACCTCCGTGATTGCCTTC-39
95uC (10 sec), 55uC (10 sec), 72uC (10 sec) 125
F = Forward; R = Reverse.
doi:10.1371/journal.pone.0062895.t002
Figure 1. The progestin MPA, but not NET-A or P4, induces apoptosis in CD4+ T-cells. Cells were treated with or without 100 nM Dex,
100 nM F, 1 mM MPA, 10 mM NET-A, 1 mM P4 or vehicle control (EtOH) for 24 hrs. Cells were stained with anti-CD4, anti-CD14, annexin V and 7-AAD
using the Apoptosis Detection kit I (BD biosciences). (A) Gating strategy and representative zebra plots of untreated (EtOH), MPA or Dex treated
PBMCs. (B) The histogram shows pooled results from two independent experiments with samples from three donors. Data were acquired on a FACS
calibur system (BD Biosciences) and analyzed using Flo-Jo software (Tree Star Inc., San Carlos, CA, USA). Statistical significance was determined by
one-way ANOVA with Dunnett’s post-test, where *, **, and *** indicate p,0.05, 0.01 and 0.005 respectively. Error bars represent standard deviation.
doi:10.1371/journal.pone.0062895.g001
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cells (100 mL) were treated with 2.5 mg (5 mM) Vpr peptide for
30 min at 37uC. The cells were washed and then cultured in
RPMI. A bovine serum albumin (BSA) trypic digest was prepared
according to a protocol obtained from the Sanford-Burnham
Medical Research Institute (Lo Jolla California, USA [77]) and
served as a control peptide wherever Vpr peptide was not added.
Control peptide was added at a final equivalent concentration as
Vpr, in mass/volume i.e. 25 mg/mL. Cells were treated with the
test compounds as indicated in the figure legends for 24 hrs at
37uC and apoptosis was detected as indicated above. Note that we
found that incubation with this buffer resulted in an increase in
basal apoptosis of the CD4+ T-cell population from about 2.5% to
about 5% (data not shown), which masked apoptotic effects with
MPA alone.
HIV-1 Pseudovirus Generation and Infection
HIV-1 pseudovirus was generated as described by Jochmann
et al [78]. HEK293T cells (obtained from ATCC) were seeded at
a density of 86105 cells/well in a 6-well plate in high glucose (1 g/
ml) phenol red-containing Dulbecco’s Modified Eagles Medium
(DMEM) (Sigma-Aldrich) supplemented with 10% (v/v) fetal calf
serum (FCS) (Highveld Biological, South Africa), 0.1 mg/mL
sodium pyruvate (Sigma, South Africa), 100 IU/ml penicillin and
100 mg/ml streptomycin (Gibco Invitrogen) at 37uC in a water
jacket incubator (90% humidity and 5% CO2). The next day the
cells were washed with PBS and phenol red free DMEM
(supplemented as described above) was added to each well. Cells
were then transfected with 5 mg pSG3.1 (containing the HIV-1
genomic sequences with a mutated envelope (env) gene. (AIDS
Research and Reference Reagent Program; [79]) and pDU15A
(encoding the HIV-1 envelope) [80] using X-tremeGENE 9 DNA
Figure 2. Apoptosis induction by Dex and MPA is most likely mediated primarily through the GR. (A) PBMCs were treated with vehicle
(EtOH), 100 nM MPA, 10 nM Ald, 100 nM E2, 100 nM Mib, 100 nM R5020, 10 mM NET-A or 10 mM NET for 24 hrs at 37uC. Cells were surface stained
with ant-CD3 and anti-CD4 antibodies, and apoptosis was detected using flow cytometry as described in Figure 1. The histogram shows pooled
results from two independent experiments with samples from three donors. Statistical significance was determined by one-way ANOVA with
Dunnett’s post-test, where *** indicates p,0.001. (B) Western analysis of lysates prepared from approximately 46106 PBMCs. Whole cell lysates of
COS-1 cells overexpressing the relevant steroid receptor (+ve) or empty vector (2ve) served as the controls. GAPDH was used as a loading control.
Note that the upper strong band on the MR blot is a COS-1 cell-derived non-specific signal which is absent for PBMCs, while the MR signal is the faint
band just below the non-specific band which is only seen in the positive control. We were unable to obtain a more-specific anti-MR antibody. (C)
Conventional PCR of cDNA prepared from human PBMCs using primers specific for the relevant steroid receptor. The controls were prepared by PCR
amplification of the relative steroid receptor cDNA from plasmid DNA. GAPDH served as a control for mRNA levels. MW: molecular weight; NTC: no
template control. Error bars represent standard deviation.
doi:10.1371/journal.pone.0062895.g002
Figure 3. Dose-dependent apoptosis induction with Dex, MPA,
NET-A and P4 in CD4+ T-cells. PBMCs were treated with vehicle
(EtOH), Dex, MPA, NET-A or P4 at the concentrations indicated for
24 hrs at 37uC. Cells were stained and analysed as described for Figure 1.
The figure shows pooled results from two independent experiments
with samples from three donors. Error bars represent standard
deviation. Statistical trend analysis for each dose response was
performed by the Wilcox rank-sum test, as further extended by Cuzick
[85], and showed a significant trend only for Dex (p,0.001) and MPA
(p= 0.047).
doi:10.1371/journal.pone.0062895.g003
Figure 4. The GR is involved in Vpr-mediated apoptosis in CD4+
T-cells. PBMCs were treated with 1 mM RU486 in the absence or
presence of 5 mM Vpr peptide (amino acids 52–96) for 24 hrs. A tryptic
BSA digest served as a control (bars 1 and 2) wherever Vpr peptide was
not added and was added at an equivalent mass/volume of peptide.
Cells were obtained and stained as described in the methods. The
histogram shows pooled results from two independent experiments
with samples from three donors. Statistical significance was determined
by one-way ANOVA with Dunnett’s post-test or a paired t-test, where *,
**, and *** indicate p,0.05, 0.01 and 0.005 respectively. Error bars
represent standard deviation.
doi:10.1371/journal.pone.0062895.g004
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transfection reagent (Roche, South Africa) according to the
manufacturer’s specifications. Cells were incubated for 3 days at
37uC, the medium passed through a 0.22 mM filter and charcoal-
striped (cs) FCS (Highveld Biological, South Africa) was added to
a final concentration of 40%. The viral stocks were aliquotted and
stored at280uC until use. The titre of the pseudotyped viruses was
determined using the Reed Muench method and expressed as log
TCID50/ml [81]. Prior to infection, PBMCs were activated with
5 mg/ml phytohemagglutinin (PHA) (Sigma Aldrich, South Africa)
and 20 U/ml recombinant human interleukin-2 (rhIL-2) (Roche,-
South Africa) for 3 days as previously described [82]. For
pseudovirus infection, pseudovirus was added to obtain a multi-
plicity of infection (MOI) of 0.00005 and incubated for 3 days
before stimulation and flow cytometric detection of apoptosis. A
standard p24 assay (Aalto Bio Reagents Ltd, Dublin Ireland) was
used to confirm that the cells were infected.
RNA Isolation, cDNA Synthesis and Real Time PCR
Approximately twenty million PBMCs were treated with 5 mM
Vpr or control peptide in 1 mL of balanced isotonic glucose-
HEPES buffer as described previously. Cells were then treated in
the presence or absence of 100 nM Dex, MPA, NET-A or P4 for
24 hrs. The cells were harvested by centrifugation at 3506g and
RNA was extracted using Tri Reagent (Sigma-Aldrich, South
Africa) according to manufacturer’s instructions. RNA was reverse
transcribed with oligo-dT priming, using the Transcriptor High
Fidelity cDNA Synthesis Kit (Roche, South Africa), and an equal
volume of each cDNA synthesis reaction was used as template for
real time PCR, using the Sensimix dT Kit (Quantace, London).
Quantitative PCR was carried out using primers for Bim and Bcl-2
(Table 2). GAPDH was used as a housekeeping gene for
normalization (Table 2; [83]). Initial denaturation and final
extension was as for conventional PCR while the cycling
parameters for 40 cycles are shown in Table 2. Standard curves
were used to determine the efficiency of each primer set, and the
relative expression of the genes of interest in each sample was
calculated according to the Pfaffl mathematical model [84].
Statistical Analysis
All experiments were performed with PBMCs isolated from at
least 3 different donors and at least two independent experiments
were performed. All data was normalized to appropriate controls.
Data were analysed for statistical significance by One-way
ANOVA and appropriate post-tests as indicated in the figure
legends using GraphPad Prism software. *, **, and *** indicate
p,0.05, p,0.01 and p,0.005, respectively. For dose response
analysis, a non-parametric statistical trend test was performed
across the concentration range for each compound, using the
Wilcox rank-sum test, as further extended by Cuzick [85].
Results
An important question is whether doses of DMPA and NET-
EN used for injectable contraception, and physiological con-
centrations of endogenous P4, are sufficient to cause significant
effects on immune function via the GR in vivo. MPA concentra-
tions in the serum of DMPA users are reported to be in the
range of 4.5 to 65 nM a few days after injection of 150 mg and
then to average at about 2.6 nM for about three months
[48,86–89]. NET has been shown to reach a peak plasma
concentration of 50 nM a few days after intramuscular injection
of NET-EN, followed by an average concentration of about
13 nM for about four months [90–92]. The concentration of
endogenous P4 in the serum of premenopausal women varies
from 0.65 nM to about 80 nM between the follicular and luteal
phases, respectively, while reaching about 600 nM during
pregnancy [29]. MPA has a high relative binding affinity for
the GR (Ki of 10.8 nM), similar to that of F (10–20 nM) [93],
whereas NET-A and P4 have lower affinity for the GR (Ki of
270 and 215 nM respectively) [34,94,95]. In order to investigate
effects of P4 and progestins via the GR on apoptosis,
experiments were thus performed at single concentrations
required for near or full saturation of the GR (10–506Kd or
Ki), as well as by dose response analysis using doses spanning
the range of concentrations found in the serum of DMPA and
NET-EN users, or doses spanning physiologically relevant
concentrations for P4. Since NET-EN is not soluble in aqueous
solution, we used the water soluble derivatives NET-A or NET
[29].
GCs and the Progestin MPA, but not NET-A or P4, Induce
Apoptosis in CD4+ T-cells
GCs have been shown to induce apoptosis in several different
cell lines, including CD4+ T-cells [35]. The progestin MPA is
Figure 5. The GR is involved in GC- and Vpr-mediated
apoptosis in CD4+ T-cells. PBMCs were treated with 100 nM Dex
or 1 mM RU486 in the absence or presence of 5 mM Vpr peptide (amino
acids 52–96) for 24 hrs. A tryptic BSA digest added at an equivalent
mass/volume ratio of peptide, served as a control wherever Vpr peptide
was present. Cells were obtained and stained as described in the
methods. The histogram shows pooled results from two independent
experiments with samples from three donors. Statistical significance
was determined by one-way ANOVA with Dunnett’s post-test or a paired
t-test, where *, **, and *** indicate p,0.05, 0.01 and 0.005 respectively.
doi:10.1371/journal.pone.0062895.g005
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a partial to full GR agonist, unlike NET-A and P4 which have
weak to no GR activity [30–33]. We investigated the relative
capability of MPA and NET-A to induce apoptosis in CD4+ T-
cells and CD14+ monocytes, as compared to the endogenous GC
agonist F, the synthetic GR agonist Dex and P4. Briefly, PBMCs
were isolated and treated with 100 nM Dex, 100 nM MPA,
10 mM NET-A, 1 mM P4 or vehicle control (EtOH) for 24 hrs.
Cells were stained with anti-CD4 (T-cells), anti-CD14 (mono-
cytes), 7-aminoactinomycin D (7-AAD), annexin V and the data
were acquired using the Becton Dickinson FACS Calibur. 7-AAD
was included to discriminate between live and dead cells. CD4+ T-
cells and CD14+ monocytes were gated from the total PBMC
population as indicated and the apoptotic cells were detected with
the apoptosis marker annexin V (Figure 1A). As expected Dex and
F induced apoptosis in a statistically significant manner in CD4+
T-cells by about 2-fold and 1.6-fold, respectively, compared to
untreated cells (Figure 1B). Importantly, MPA also statistically
significantly induced apoptosis in these cells (1.5-fold), yet to
a lesser extent than Dex. By contrast, when cells were treated with
NET-A or P4 no increase in apoptosis compared to control, was
detected in CD4+ T-cells (Figure 1B). The apoptotic effect of Dex,
F and MPA was however not observed in CD14+ monocytes (data
not shown) and therefore the following experiments were carried
out in CD4+ T-cells.
MPA Acts Primarily via the GR to Induce Apoptosis in
CD4+ T-cells
Next we sought to provide evidence that the increase in
apoptosis observed with Dex and MPA was mediated via the GR
and did not involve other steroid receptors. Since MPA is a PR
agonist, and a partial agonist for the androgen receptor (AR) and
a partial to full agonist for the GR [29], the possibility that MPA
exerts its apoptotic effects via the PR or AR was investigated
indirectly by using receptor-selective agonists. In order to de-
termine whether other steroid receptors (apart from the GR) could
induce apoptosis, PBMCs were treated with agonists that are
selective for the AR (100 nM Mib), estrogen receptor (ER)
(100 nM E2), mineralocorticoid receptor (MR) (10 nM Ald) and
PR (100 nM R5020), as well as 100 nM Dex, 100 nM MPA,
10 mM NET-A or 10 mM NET for 24 hrs, and apoptosis was
detected using flow cytometry as described previously. The ligands
were used at saturating concentrations for each steroid receptor to
control for the differences in relative binding affinities of each
Figure 6. MPA but not NET-A or P4 increases Vpr-mediated apoptosis in a dose-dependent manner. (A) PBMCs were treated with or
without 5 mM Vpr peptide (amino acids 52–96) and increasing concentrations of MPA, NET-A or P4 for 24 hrs. The graph shows results pooled from
two independent experiments with samples from three donors. (B) PBMCs were treated with 100 nM MPA, 10 mM NET-A, 1 mM P4 or in combination
with 5 mM Vpr peptide (amino acids 52–96) for 24 hrs. Cells were stained and acquired by flow cytometry as described in the materials and methods.
A tryptic BSA digest served as a control wherever Vpr peptide was not added, as for results in figure 4. The histogram shows results pooled from two
independent experiments with samples from three different donors compared to those in figure A. donors. Statistical trend analysis for panel A was
performed by the Wilcox rank-sum test, as further extended by Cuzick [85], and showed a significant trend only for MPA plus Vpr (p = 0.012) and P4
minus Vpr (p = 0.012). Statistical significance in panel B was determined by one-way ANOVA with Dunnett’s post-test or a paired t-test, where *, **,
and *** indicate p,0.05, 0.01 and 0.005 respectively. Error bars represent standard deviation.
doi:10.1371/journal.pone.0062895.g006
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ligand for their respective receptors [33,34,94]. As found earlier,
Dex significantly induced apoptosis by about 2-fold and about 3-
fold in CD3+ and CD4+ T-cells, respectively (Figure 2A). MPA
significantly induced apoptosis by about 1.5-fold compared to
untreated control cells in the CD3+ T-cells and appeared to
increase apoptosis in CD4+ T-cells to a similar extent as observed
before (Figure 1B). In both CD3+ and CD4+ T-cells, the other
steroid receptor-selective agonists did not induce apoptosis in
a statistically significant manner (Figure 2A). Therefore, it is likely
that the effects of MPA on apoptosis are mediated via the GR in
T-cells. In support of these findings, PBMCs expressed GR protein
whereas AR, PR, MR or ER protein expression was not detected
by Western blot analysis (Figure 2B). The ER and MR mRNAs,
but not AR or PR mRNAs, were however detected by PCR,
indicating that ER and MR proteins may be expressed, but at
a level undetectable by Western blot analysis (Figure 2C).
Together with the results presented in Figure 2A, these data show
that if low levels of ER and MR protein are expressed, they have
no effect on apoptosis in CD3+ or CD4+ T-cells (Figure 2A).
Taken together, these results strongly support the finding that the
PR, AR, MR and ER do not induce apoptosis in these cells, and
that MPA acts primarily via the GR to induce apoptosis in
PBMCs. It is noteworthy that NET was included in this
experiment as a control to exclude the possibility that the acetate
form (NET-A) may be less active. However, similarly to NET-A,
NET does not result in apoptosis.
Dex and MPA but not NET-A or P4 Increase Apoptosis in
a Dose-dependent Manner
Having established that both MPA and Dex induce apoptosis in
CD4+ T-cells, we next sought to determine whether this pro-
apoptotic effect was dose-dependent. Statistically significant trends
[85] were observed for Dex (p,0.001) and MPA (p= 0.047), but
not for P4 or NET-A, showing increased apoptosis with increasing
concentrations of ligand, in the absence of Vpr, under these
experimental conditions (Figure 3). Furthermore, apoptotic in-
duction in response to both Dex and MPA was observed, starting
at concentrations as low as 10 nM (Figure 3). The maximal
apoptotic response observed for both Dex and MPA was reached
at 100 nM, and the maximal response for MPA (,1.3-fold) at that
concentration was lower than for Dex (,2.3-fold) (Figure 3). Note
that the fold induction of apoptosis with MPA under these
conditions varies between experiments from about 1.3- to 1.7-fold
(Figures 1,2,3), most likely due to biological variability between
donors. Even though no dose-dependent significant trend for
changes in apoptosis was observed for NET-A or P4, a small
Figure 7. The GR is involved in MPA- and Vpr-mediated apoptosis in CD4+ T-cells. PBMCs were treated with vehicle (EtOH), 100 nM MPA,
1 mM RU486 or 100 nM MPA plus 1 mM RU486, in the absence (A) or presence (B) of 5 mM Vpr peptide for 24 hrs. Cells were stained and acquired by
flow cytometry as indicated in the methods. In A cells were not incubated with balanced isotonic glucose-HEPES buffer while in B, this buffer was
used and a tryptic BSA digest served as a control wherever Vpr peptide was not added, as described in Methods. The histograms show pooled results
from two independent experiments with samples from three donors. Statistical significance was determined by one-way ANOVA with Dunnett’s post-
test or a paired t-test, where *, **, and *** indicate p,0.05, 0.01 and 0.005 respectively. Error bars represent standard deviation.
doi:10.1371/journal.pone.0062895.g007
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response (,1.1-fold) appeared to occur for P4 at 1 mM. These
results are similar to dose-responses observed with these ligands for
transcriptional regulation via the GR, with Dex acting as a full
agonist and MPA as a partial agonist for the GR at concentrations
between 1–100 nM, but with NET-A showing no agonist activity
and P4 very weak to partial agonist activity in some contexts only
at micromolar concentrations [31,34]. Having established that
both Dex and MPA induce apoptosis in the CD4+ T-cells in a dose-
dependent manner, we next sought to determine if Dex and MPA
can enhance Vpr-mediated apoptosis.
Dex Enhances Vpr-mediated Apoptosis in a GR-
dependent Manner
It is well established that Vpr is a potent inducer of apoptosis in
a number of different cell lines and primary cells. Therefore, we
determined whether exogenous C-terminal Vpr peptide could
induce apoptosis via the GR in CD4+ T-cells. As expected, Vpr
peptide significantly induced apoptosis by approximately 1.8-fold
in the CD4+ T-cells (Figure 4). This apoptotic induction was
decreased in the presence of RU486, a potent GR antagonist,
indicating that the GR was involved in Vpr-mediated apoptosis
(Figure 4). We next determined whether Dex could enhance Vpr-
mediated apoptosis through the GR in CD4+ T-cells. Cells were
incubated with Vpr peptide in the absence and presence of Dex.
Vpr and Dex alone induced apoptosis in CD4+ T-cells, although
statistical significance could not be established, most likely due to
the small responses (Figure 5). Furthermore, when cells were
treated with Dex and Vpr in combination, a significant increase in
apoptosis was observed as compared to Vpr or Dex alone. To
establish whether the GR was involved in combined effects of Vpr-
and Dex-mediated apoptosis, cells were treated in the absence and
presence of RU486. RU486 alone had no effect on apoptosis
(Figures 4 and 5). Apoptosis by Dex and Vpr alone was decreased
in the presence of RU486, although statistical significance could
not be established. Importantly, the 3-fold increase in apoptosis
observed when cells were treated with Dex and Vpr in
combination was significantly decreased in the presence of
RU486 (Figure 5). Although RU486 is also a PR and MR
antagonist [29], our data discount a role for these receptors in
apoptosis in these cells (Figure 2). Taken together, the data suggest
that the GR is required for Vpr- and Dex-mediated apoptosis, and
suggests that the GR is required for Vpr enhancement of Dex-
mediated apoptosis.
MPA, but not NET-A or P4, Enhances Vpr-mediated
Apoptosis in a GR-dependent Fashion
Having shown that Dex treatment further increases Vpr-
mediated apoptosis in a GR-dependent fashion, we next sought to
investigate whether MPA, similarly to the full GR-agonist Dex, has
the capability to enhance Vpr-mediated apoptosis. Under the
experimental conditions used in figure 6, we observed statistically
significant [85] trends only for MPA (p= 0.012) in the presence of
Vpr, as well as for P4 in the absence of Vpr (p = 0.005), showing
increased apoptosis with increasing concentrations of ligand
(Figure 6A). Interestingly, a response was observed for MPA in
the presence of Vpr at concentrations as low as 1 nM. A maximal
increase of approximately 6-fold was obtained at a concentration
of 1 mM MPA (Figure 6A). This was in contrast to cells treated in
the absence of Vpr, where MPA appeared to have no dose-
dependent effect on apoptosis (Figure 6A). The lack of apoptotic
activity by MPA alone in these experiments compared to
figures 1,2,3 was likely due to the conditions required to treat
the cells with Vpr or control peptide, which masks the smaller
effects of MPA alone. The dose response results are consistent with
the results in Figure 6B, showing a statistically significant increase
in Vpr-mediated apoptosis with MPA, but not NET-A or P4, using
concentrations of ligands that nearly or fully saturate the GR.
Towards establishing a role for the GR in the MPA response,
further experiments were performed with RU486, in the absence
and presence of Vpr peptide (Figure 7). In the absence of prior
incubation with peptide buffer (see methods), MPA significantly
increased apoptosis compared to untreated CD4+ T-cells
(Figure 7A), as previously shown (Figures 1,2,3). Importantly,
although RU486 alone had no effect on apoptosis, this GR agonist
could reverse MPA-mediated apoptosis in the CD4+ T-cells
(Figure 7A) in a statistically significant manner. Vpr alone
significantly induced apoptosis in CD4+ T-cells, and this response
was decreased in the presence of RU486 (Figure 7A). Vpr and
MPA in combination enhanced apoptosis by about 3-fold in
a statistically significant manner, which was decreased by RU486
(Figure 7B). These results strongly suggest that MPA and Vpr
alone or in combination, enhance apoptosis in CD4+ T-cells via
a mechanism involving the GR. The lack of an effect by the
natural PR ligand P4 or the synthetic progestin NET-A on Vpr-
induced apoptosis is consistent with the requirement for GR
Figure 8. HIV-1-mediated apoptosis is enhanced in the
presence of Dex and MPA. PBMCs were activated in the presence
of PHA and rhIL-2 for 3 days at 37uC as described. Pseudotyped HIV-1
virus or control medium without virus was added to the cells, followed
by incubation for a further 3 days to allow infection. Cells were then
treated with vehicle (EtOH) or 100 nM Dex or MPA for an additional
24 hrs. Acquisition and analysis was carried out as described in the
methods. The histogram shows pooled results from two independent
experiments with samples from three donors. Statistical significance
was determined by one-way ANOVA with Dunnett’s post-test, where *,
**, and *** indicate p,0.05, 0.01 and 0.005 respectively. Error bars
represent standard deviation.
doi:10.1371/journal.pone.0062895.g008
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agonist or strong partial agonist activity of a ligand to modulate
Vpr-mediated apoptosis in CD4+ T-cells.
Dex and MPA Enhance HIV-1-mediated Apoptosis in
CD4+ T-cells
Having shown that Dex and MPA enhance Vpr-mediated
apoptosis using peptide studies, we next determined whether this
effect could be elicited by intact HIV-1 pseudovirus. PBMCs were
first activated with PHA and rhIL-2. Cells were then infected with
pseudotyped HIV-1 virus for 3 days before being treated with the
test compounds as indicated for an additional 24 hrs. The
apoptotic phenotype was detected by flow cytometry as described
above. However, we could not detect CD4+ T-cellsin this assay,
which was most likely owing to decreased expression of the CD4+
receptor following T-cell activation and subsequent infection [96].
Thus, the results are representative of the T-cell population that
was gated from the forward and side scatter plot. The responses
observed from this PBMC population most likely represent the T-
cell population only, because monocytes (which would scatter with
the T-cells) are resistant to ligand- and Vpr-mediated apoptosis
(data not shown; [97]). Consistent with results obtained in
figures 1,2,3 and 5,6,7, stimulation with Dex and MPA resulted
in a statistically significant increase in apoptosis (Figure 8). HIV-1
infection also increased apoptosis, which is consistent with results
obtained with Vpr peptide (Figures 4,5,6,7) and in the literature
[98–100]. Importantly, Dex and MPA stimulation further
enhanced HIV-1 mediated apoptosis. In summary the data
presented here indicate that Dex and MPA have the ability to
increase T-cell apoptosis in the presence of HIV-1.
Dex and Vpr Differentially Regulate Pro- and Anti-
apoptotic Genes
The mechanism of apoptotic induction by the GR and Vpr in
the presence of GR ligands most likely involves the transcriptional
regulation of pro- and anti-apoptotic genes [35,53]. To this end we
set out to identify key genes that could be regulated by both Vpr
and the GR. PBMCs were treated with or without 5 mM Vpr
peptide in the presence or absence of 100 nM Dex, MPA, NET-A
or P4 for 24 hrs (Figure 9 A and B). mRNA levels of potential
target genes were determined by using real time PCR with specific
primers to Bcl-2 or Bim. In the presence of Vpr alone or Vpr in
combination with Dex or MPA, mRNA expression of the anti-
apoptotic factor Bcl-2 was significantly repressed compared to
vehicle-treated cells, although Dex, MPA, NET-A or P4 had no
significant effect in the absence of Vpr (Figure 9A). However, Dex
and MPA alone significantly increased the expression of the pro-
apoptotic factor Bim by approximately 1.7-fold and 1.3-fold,
respectively, whereas Vpr alone had no significant effect
(Figure 9B). Both NET-A and P4 alone or in combination with
Vpr peptide had no effect on Bcl-2 or Bim mRNA levels (Figure 9A
and B). Additionally we found that Vpr and Dex alone or in
combination had no effect on the pro-apoptotic genes Bcl-2-
associated death promoter protein (Bad) and phorbol-12-myr-
istate-13-acetate-induced protein 1 (NOXA) (data not shown).
Figure 9. GC and Vpr differentially regulate key genes involved in apoptosis. PBMCs were treated with or without 5 mM Vpr peptide as
described previously and treated with or without 100 nM Dex, MPA, NET-A or P4 for 24 hrs. After treatment, RNA was extracted, reverse transcribed,
and Bcl-2 (A) or, Bim (B) mRNA expression was measured by real time PCR, normalising to GAPDH expression levels. The histogram shows pooled
results from two independent experiments with samples from three donors. Statistical significance was determined by one-way ANOVA with
Dunnett’s post-test, where *, **, and *** indicate p,0.05, 0.01 and 0.005 respectively. Error bars represent standard deviation.
doi:10.1371/journal.pone.0062895.g009
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Taken together the data suggest that Vpr regulates different genes
involved in the apoptotic pathway as compared to Dex and MPA,
with Dex/MPA up-regulating Bim gene expression and Vpr
decreasing Bcl-2 gene expression. Furthermore, the other steroid
receptor-selective agonists (Ald, E2, Mib and R5020) did not affect
expression of the genes investigated, indicating that the responses
were most likely mediated by the GR (data not shown).
Discussion
In this study we investigated the effects and molecular
mechanisms of the injectable progestin contraceptives, MPA and
NET-A, in CD4+ T-cells on apoptosis, in the absence and
presence of the HIV-1 protein Vpr. It has previously been shown
that GCs and Vpr induce apoptosis in T-cells [35,53], that Vpr
modulates GR function [70] and that MPA, but not NET-A, acts
as a partial agonist for the GR [33,34,95]. We thus hypothesized
that, similarly to GCs, MPA but not NET-A may also increase
apoptosis in CD4+ T-cells, which may be further enhanced in the
presence of Vpr. Consistent with this hypothesis, we show that the
GR agonists Dex and F, as well as MPA, but not NET-A or P4,
induce apoptosis in CD4+ T-cells. The predicted GR ligand
response profile, and the inability of other steroid receptor-
selective agonists to induce apoptosis in these cells, strongly
suggests that the GR is the predominant receptor eliciting this
effect. The relative responses by progestins are consistent with
a lack of involvement of the PR, since MPA, P4 and NET are all
potent PR agonists and hence apoptotic effects via the PR would
be expected to be similar for these ligands, contrary to what is
observed. On the other hand, MPA and NET-A have similar
partial agonist activity via the AR and thus AR-mediated
apoptotic effects via these ligands would be expected to be similar.
Further support for the role of the GR is the finding that only ER,
MR and GR mRNAs were detected in the PBMCs and only the
GR protein but no other steroid receptor proteins were detected
by Western blot analysis. MPA does not bind to and has no
activity via the ER [29], while it binds very weakly but has no
agonist activity on endogenous genes via the MR [101] and hence
the progestins are unlikely to exert any apoptotic effects via these
steroid receptors in PBMCs. Interestingly the AR, ER and MR
have been shown to inhibit apoptosis in skeletal cells, breast cancer
cells, neuronal cells and/or cardiomyocytes, when activated by
their receptor-selective agonists, an effect that is most likely cell-
specific [102,103–105]. Our results showing no detectable PR or
AR, but ER, MR and GR expression in PBMCs are consistent
with the literature [49,106,107]. Furthermore, MPA-induced
apoptosis could be inhibited in the presence of the GR antagonist
RU486. A role for the GR in mediating apoptosis by MPA and
not NET-A or P4 is consistent with the relative binding affinities,
potencies (concentration for half maximal response) and efficacies
(maximal response) for transcriptional regulation by these ligands
via the GR [31–34,95].
As expected, Vpr alone induced apoptosis in CD4+ T-cells,
which was further increased dose-dependently in the presence of
Dex or MPA. Remarkably, MPA appeared to enhance Vpr-
mediated apoptosis at a concentration as low as 1 nM (Figure 6A)
which is lower than the peak and plateau levels observed in the
serum of female patients using DMPA [87]. These findings suggest
that the presence of MPA during HIV-1 infection would further
potentiate the effects of Vpr on apoptosis in T-cells. As
hypothesized due to their weak GR activity, NET-A or P4 did
not induce apoptosis alone or in combination with Vpr. The
increase in apoptosis observed with MPA, Dex or Vpr alone or
Dex and MPA in combination with Vpr was decreased by the GR
antagonist RU486, indicating that the GR is required for these
effects. This is the first report to our knowledge showing that the
GR is required for Vpr-mediated apoptosis in primary T-cells.
The physiological significance of these findings with Vpr require
further investigation. From the literature, it is unclear at what
concentration Vpr occurs in the serum of infected individuals. One
report has detected Vpr in the serum of infected patients at the
same concentrations as circulating viremia [56], whereas another
suggests that Vpr is present at a concentration of 0.7 nM [108].
Higher concentrations of Vpr peptide as used in this study (5 mM)
and by others (1–10 mM) are required to induce apoptosis in vitro
[61,62,99,109]. The intracellular concentrations of Vpr protein
delivered and/or expressed in specific T-cells during chronic
infection are unknown and likely to be much higher than serum
concentrations reflecting Vpr diluted in the total volume of blood
in the body. Thus whether the concentrations of Vpr peptide used
in this study are physiologically relevant is not possible to ascertain
at present. Interestingly, it has been reported that low concentra-
tions of Vpr protect T-cells from apoptosis [110]. These authors
suggested that the levels of Vpr during infection may vary in
a manner that may be crucial to maintaining viral virulence and
increased pathogenesis. Thus, it is possible that the levels of Vpr
vary both in specific cellular environments and during different
stages of disease progression such that at low levels of Vpr,
apoptosis of T-cells does not occur to favour viral replication,
whereas at other stages of the disease, increased Vpr levels may
favour apoptosis and T-cell death.
To investigate whether the results with Vpr peptide are
consistent with a role for Vpr delivered in the context of the
whole virus we treated PBMCs with or without HIV-1
pseudotyped virus in the absence and presence of MPA and
Dex. The results showed that MPA and Dex increase apoptosis
induced by the HIV-1 pseudovirus particles. This result is
consistent with potentiation by GR ligands of apoptosis in the
presence of HIV-1 proteins. However, it does not exclude the
possibility that other proteins besides Vpr are involved in the
response in the context of HIV-1 pseudovirus particles.
Even though the literature suggests that Vpr directly targets the
mitochondria during apoptosis, there is evidence that Vpr is
predominately localized to the nucleus [66,111–113]. It is possible
that a small percentage of Vpr translocates to mitochondria, but
requires the transcription of pro-apoptotic genes in the nucleus to
fully commit to apoptosis. For this reason, Vpr may regulate host
gene expression to induce apoptosis. To determine which genes
are involved in Vpr-mediated apoptosis in the presence of GR
ligands we investigated key genes that have previously been shown
to be regulated by either GCs or Vpr. The anti-apoptotic factor
Bcl-2 was previously identified as a key mediator of apoptosis
because its overexpression in a murine lymphoma cell line
protected cells from GC-induced apoptosis [114]. Bcl-2 has been
shown to be down-regulated by Vpr in a human promonocytic cell
line [97,109]. Key genes that are upregulated by GCs include Bim
in human and murine leukaemia cell lines as well as primary
murine thymocytes [115]. As shown previously [109], the Vpr
peptide down-regulated the anti-apoptotic gene Bcl-2. In contrast,
we show that Dex and MPA, but not NET-A or P4, increased the
expression of the pro-apoptotic genes Bim. Both Vpr and Dex
alone or in combination had no effect on the pro-apoptotic genes
NOXA and Bad (data not shown). Furthermore, no other steroid
receptor-selective agonist enhanced or decreased expression of
Bim or Bcl-2, indicating that the GR was the only steroid receptor
that increased Bim expression (data not shown). Surprisingly Vpr
and Dex did not act in concert to regulate gene expression of any
genes tested. The evidence presented here suggests that the GR
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and Vpr differentially regulate either pro- or anti-apoptotic genes,
most likely resulting in a potent apoptotic response over
a prolonged period of time. In the absence of Vpr, apoptosis is
favoured by GCs or the progestin MPA, by induction of the pro-
apoptotic gene Bim, whereas in the absence of GCs or MPA but
the presence of Vpr, apoptosis is favoured by the repression of the
anti-apoptotic gene Bcl-2. It is likely that the differential regulation
of apoptotic genes by GCs/MPA and Vpr contributes to increased
pathogenicity of the virus and T-cell depletion. We cannot
however rule out the possibility that GCs/MPA and/or Vpr
regulate other genes involved in the apoptosis pathway, or that
Vpr induces apoptosis through direct interaction with the
mitochondrial membrane or that the extrinsic and intrinsic
pathways act together in inducing apoptosis in the CD4+ T-cells.
Taken together, these findings are consistent with a role for
MPA in repressing systemic immune function by increasing
apoptosis in CD4+ T-cells in the absence of HIV-1 infection, and
an increase in this effect in the presence of HIV-1 infection.
Furthermore the findings suggest that this occurs via a mechanism
involving the GC-like properties of MPA, via GR-mediated
changes in transcription of apoptotic genes, which are involved in
the intrinsic apoptotic pathway. The extent to which these
systemic immunosuppressive effects are physiologically relevant
requires further investigation in clinical models, but the dose
response results suggest that the apoptotic effects of MPA could
occur within the peak nanomolar physiological concentration
range measured in serum samples of women on DMPA.
Additionally, the results in Figure 6 suggest that even when the
MPA concentrations drop to about 2.6 nM a few weeks after
injection of DMPA, MPA could potentiate apoptotic effects of Vpr
in HIV-1 infected patients during chronic infection. The apoptotic
effects of MPA in the absence of HIV-1 infection could have a role
in acquisition of the virus owing to compromised immune
responses, whereas the effects of DMPA in the presence of HIV-
1 could have a role in disease progression and depletion of the T-
cell population. These results for MPA are consistent with results
showing a slower cellular immune response rate in DMPA-treated
animals [40] and decreased T-cell numbers in patients treated
with high concentrations of MPA for breast cancer [41].
There is not much information available regarding the effects of
DMPA contraceptive usage on T-cell populations in women.
Synthetic hormones in combined oral preparations, which usually
do not contain MPA, were found not to affect absolute numbers or
percentages of lymphocytes, T-cells and subsets of T-cells
[49,116], consistent with a lack of an effect of contraceptives
other than MPA on T-cell apoptosis. However, our results are
consistent with the findings showing accelerated loss of CD4+ T
cells and death rate in women on DMPA infected with HIV-1
compared to non-contraceptive users [12]. The results in this study
are also consistent with results for women using MPA in HRT,
who exhibited a decrease in total lymphocyte count [117], the
percentage of T-cells [117,118] and the percentage of T-helper
(Th) lymphocytes [117].
Our finding that NET-A does not exhibit these GR-mediated
apoptotic effects like MPA and F, suggests that choice of progestin
contraceptive could significantly affect susceptibility to and
progression of infectious diseases, such as HIV-1 and AIDS. The
finding that P4 at concentrations less than 1 mM does not induce
apoptosis in T-cells suggests that P4 concentrations in the luteal
phase of the menstrual cycle [29] are unlikely to affect immune
function via apoptosis of T-cells. These findings highlight the fact
that not all progestins are the same [29,31,33,119] and that choice
of progestin in hormonal therapy needs to be carefully considered.
The choice of progestin for contraception may be particularly
important for young women of child bearing age in the developing
world in high risk areas for HIV-1 infection, where MPA usage as
an injectable contraceptive is high [120].
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